Search for FDA Guidance Documents | FDA,,,,,,,,
Summary,Document,Issue Date,FDA Organization,Topic,Guidance Status,Open for Comment,Comment Closing Date on Draft,Docket Number
Bioanalytical Method Validation for Biomarkers,PDF (222.38 KB)PDF (222.38 KB) of Bioanalytical Method Validation for Biomarkers,01/21/2025,Center for Drug Evaluation and Research,,Final,No,,FDA-2017-D-6821
Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology,PDF (246.3 KB)PDF (246.3 KB) of Prevention and Treatment of Chemotherapy-Induced Peripheral Neuropathy: Developing Drug and Biological Products in Oncology,01/17/2025,Oncology Center of Excellence,,Draft,Yes,03/18/2025,FDA-2024-D-5663
Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Draft Guidance for Industry,PDF (335.94 KB)PDF (335.94 KB) of Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria: Draft Guidance for Industry,01/15/2025,Center for Biologics Evaluation and Research,"Blood, Blood Products",Draft,No,,FDA-2000-D-0187
Premarket Approval Application and Humanitarian Device Exemption Modular Review:  Guidance for Industry and FDA Staff,PDF (610.09 KB)PDF (610.09 KB) of Premarket Approval Application and Humanitarian Device Exemption Modular Review:  Guidance for Industry and FDA Staff,01/13/2025,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Final,No,,FDA-2024-D-5332
CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process,PDF (820.56 KB)PDF (820.56 KB) of CVM GFI #187B Heritable Intentional Genomic Alterations in Animals: The Approval Process,01/07/2025,Center for Veterinary Medicine,"Premarket, Biotechnology, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Final,No,07/31/2024,FDA-2019-D-2648
CVM GFI #294 - Animal Food Ingredient Consultation (AFIC),PDF (306.9 KB)PDF (306.9 KB) of CVM GFI #294 - Animal Food Ingredient Consultation (AFIC),01/07/2025,Center for Veterinary Medicine,"Premarket, Animal Food Additives, Labeling, Safety - Issues, Errors, and Problems",Final,No,09/09/2024,FDA-2024-D-2978
Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway,PDF (277.18 KB)PDF (277.18 KB) of Accelerated Approval and Considerations for Determining Whether a Confirmatory Trial is Underway,01/07/2025,Oncology Center of Excellence,,Draft,No,,FDA-2024-D-3334
Considerations for Including Tissue Biopsies in Clinical Trials,PDF (310.94 KB)PDF (310.94 KB) of Considerations for Including Tissue Biopsies in Clinical Trials,01/07/2025,Oncology Center of Excellence,,Draft,Yes,03/10/2025,FDA-2024-D-2402
CVM GFI #251 - Heritable Intentional Genomic Alterations in Animals of Food-Producing Species for Use as Models of Disease,PDF (321.79 KB)PDF (321.79 KB) of CVM GFI #251 - Heritable Intentional Genomic Alterations in Animals of Food-Producing Species for Use as Models of Disease,01/07/2025,Center for Veterinary Medicine,"Biotechnology, Cellular & Gene Therapy, Premarket, Animal Cell-Based Products",Draft,Yes,03/10/2025,FDA-2024-D-4778
CVM GFI #260 - Type VII Veterinary Master File for Research and Development and Risk Reviews,PDF (512.63 KB)PDF (512.63 KB) of CVM GFI #260 - Type VII Veterinary Master File for Research and Development and Risk Reviews,01/07/2025,Center for Veterinary Medicine,"Biotechnology, Cellular & Gene Therapy, Animal Cell-Based Products",Draft,Yes,03/10/2025,FDA-2024-D-5376
Developing Drugs for Optical Imaging,PDF (335.16 KB)PDF (335.16 KB) of Developing Drugs for Optical Imaging,01/07/2025,Center for Devices and Radiological HealthCenter for Drug Evaluation and Research,Clinical - Medical,Draft,Yes,04/08/2025,FDA-2024-D-3780
Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction,PDF (412.63 KB)PDF (412.63 KB) of Obesity and Overweight: Developing Drugs and Biological Products for Weight Reduction,01/07/2025,Center for Drug Evaluation and Research,Clinical - Medical,Draft,Yes,04/08/2025,FDA-2007-D-0435
"Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations: Draft Guidance for Industry and  Food and Drug Administration Staff","PDF (1.55 MB)PDF (1.55 MB) of Pulse Oximeters for Medical Purposes - Non-Clinical and Clinical Performance Testing, Labeling, and Premarket Submission Recommendations: Draft Guidance for Industry and  Food and Drug Administration Staff",01/07/2025,Center for Devices and Radiological Health,"Premarket,",Draft,Yes,03/10/2025,FDA-2023-N-4976
Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act:  Guidance for Industry and Food and Drug Administration Staff,PDF (626.22 KB)PDF (626.22 KB) of Notifying FDA of a Permanent Discontinuance or Interruption in Manufacturing of a Device Under Section 506J of the FD&C Act:  Guidance for Industry and Food and Drug Administration Staff,01/07/2025,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket,",Final,No,,FDA-2022-D-0053
Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (1.34 MB)PDF (1.34 MB) of Artificial Intelligence-Enabled Device Software Functions: Lifecycle Management and Marketing Submission Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,01/07/2025,Center for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Postmarket, Premarket, Digital Health",Draft,Yes,04/07/2025,FDA-2024-D-4488
Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry and Other Interested Parties,PDF (407.1 KB)PDF (407.1 KB) of Considerations for the Use of Artificial Intelligence To Support Regulatory Decision-Making for Drug and Biological Products: Draft Guidance for Industry and Other Interested Parties,01/07/2025,"Center for Veterinary MedicineOffice of Inspections and InvestigationsOncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of the Chief Medical Officer,Office of Combination Products",Artificial Intelligence,Draft,Yes,04/07/2025,FDA-2024-D-4689
Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers,PDF (418.56 KB)PDF (418.56 KB) of Communications From Firms to Health Care Providers Regarding Scientific Information on Unapproved Uses of Approved/Cleared Medical Products: Questions and Answers,01/06/2025,Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Administrative / Procedural,Final,No,,FDA-2008-D-0053
"Guidance for FDA Staff and Interested Parties: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act","PDF (606.53 KB)PDF (606.53 KB) of Guidance for FDA Staff and Interested Parties: Evaluating the Public Health Importance of Food Allergens Other Than the Major Food Allergens Listed in the Federal Food, Drug, and Cosmetic Act",01/06/2025,Human Foods Program,"Allergens, Labeling",Final,No,,FDA-2021-N-0553
Guidance for Industry: Action Levels for Lead in Processed Food Intended for Babies and Young Children,PDF (326.37 KB)PDF (326.37 KB) of Guidance for Industry: Action Levels for Lead in Processed Food Intended for Babies and Young Children,01/06/2025,Human Foods Program,"Infant Formula & Foods, Lead",Final,No,,FDA-2022-D-0278
Guidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5),PDF (1.28 MB)PDF (1.28 MB) of Guidance for Industry: Questions and Answers Regarding Food Allergen Labeling (Edition 5),01/06/2025,Human Foods Program,"Allergens, Labeling",Final,No,,FDA-2022-D-0099
"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act","PDF (333.04 KB)PDF (333.04 KB) of Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act",01/06/2025,Center for Drug Evaluation and Research,"Administrative / Procedural, Compounding",Final,No,01/08/2024,FDA-2015-D-3517
"Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act","PDF (301.2 KB)PDF (301.2 KB) of Interim Policy on Compounding Using Bulk Drug Substances Under Section 503B of the Federal Food, Drug, and Cosmetic Act",01/06/2025,Center for Drug Evaluation and Research,"Administrative / Procedural, Compounding",Final,No,,FDA-2015-D-3539
Validation and Verification of Analytical Testing Methods Used for Tobacco Products,PDF (473.47 KB)PDF (473.47 KB) of Validation and Verification of Analytical Testing Methods Used for Tobacco Products,01/06/2025,Center for Tobacco Products,,Final,No,,FDA-2021-D-0756
Considerations for Complying with 21 CFR 211.110,PDF (265.65 KB)PDF (265.65 KB) of Considerations for Complying with 21 CFR 211.110,01/06/2025,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Draft,Yes,04/07/2025,FDA-2024-D-5374
Draft Guidance for Industry: Establishing Sanitation Programs for Low-Moisture Ready-to-Eat Human Foods and Taking Corrective Actions Following a Pathogen Contamination Event,PDF (468.96 KB)PDF (468.96 KB) of Draft Guidance for Industry: Establishing Sanitation Programs for Low-Moisture Ready-to-Eat Human Foods and Taking Corrective Actions Following a Pathogen Contamination Event,01/06/2025,Human Foods Program,,Draft,Yes,05/07/2025,FDA-2024-D-2604
Draft Guidance for Industry: Labeling of Plant-Based Alternatives to Animal-Derived Foods,PDF (796.68 KB)PDF (796.68 KB) of Draft Guidance for Industry: Labeling of Plant-Based Alternatives to Animal-Derived Foods,01/06/2025,Human Foods Program,Labeling,Draft,Yes,05/07/2025,FDA-2022-D-1102
Study of Sex Differences in the Clinical Evaluation of Medical Products,PDF (365.87 KB)PDF (365.87 KB) of Study of Sex Differences in the Clinical Evaluation of Medical Products,01/06/2025,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,Clinical - Medical,Draft,Yes,04/07/2025,FDA-2024-D-4245
"Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry","PDF (301.77 KB)PDF (301.77 KB) of Recommendations to Reduce the Risk of Transmission of Disease Agents Associated with Sepsis by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",01/06/2025,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2024-D-3067
"Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry","PDF (413.29 KB)PDF (413.29 KB) of Recommendations to Reduce the Risk of Transmission of Mycobacterium tuberculosis (Mtb) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",01/06/2025,Center for Biologics Evaluation and Research,"Tuberculosis, Tissue",Final,No,,FDA-2024-D-3863
"Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry","PDF (943.06 KB)PDF (943.06 KB) of Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry",01/06/2025,Center for Biologics Evaluation and Research,Tissue,Draft,No,,FDA-2022-D-0464
"Recommendations to Reduce the Risk of Transmission of Hepatitis B Virus (HBV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry","PDF (336.66 KB)PDF (336.66 KB) of Recommendations to Reduce the Risk of Transmission of Hepatitis B Virus (HBV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry",01/06/2025,Center for Biologics Evaluation and Research,"Hepatitis B, Tissue",Draft,No,,FDA-2022-D-0465
"Recommendations to Reduce the Risk of Transmission of Hepatitis C Virus (HCV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry","PDF (329.08 KB)PDF (329.08 KB) of Recommendations to Reduce the Risk of Transmission of Hepatitis C Virus (HCV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry",01/06/2025,Center for Biologics Evaluation and Research,"Hepatitis C, Tissue",Draft,No,,FDA-2022-D-0466
"Recommendations to Reduce the Risk of Transmission of Human Immunodeficiency Virus (HIV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry","PDF (382.49 KB)PDF (382.49 KB) of Recommendations to Reduce the Risk of Transmission of Human Immunodeficiency Virus (HIV) by Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps): Draft Guidance for Industry",01/06/2025,Center for Biologics Evaluation and Research,"HIV/AIDS, Tissue",Draft,No,,FDA-2022-D-0467
Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (936.37 KB)PDF (936.37 KB) of Validation of Certain In Vitro Diagnostic Devices for Emerging Pathogens During a Section 564 Declared Emergency: Draft Guidance for Industry and Food and Drug Administration Staff,01/06/2025,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",IVDs (In Vitro Diagnostic Devices),Draft,Yes,03/07/2025,FDA-2024-D-2707
Advanced Manufacturing Technologies Designation Program,PDF (350.54 KB)PDF (350.54 KB) of Advanced Manufacturing Technologies Designation Program,12/31/2024,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2023-D-4974
E11A Pediatric Extrapolation,PDF (473.47 KB)PDF (473.47 KB) of E11A Pediatric Extrapolation,12/30/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"ICH-Efficacy, Pediatric Product Development",Final,No,,FDA-2022-D-1562
E6(R3) Good Clinical Practice: Annex 2,PDF (717.99 KB)PDF (717.99 KB) of E6(R3) Good Clinical Practice: Annex 2,12/30/2024,Center for Drug Evaluation and Research,ICH-Efficacy,Draft,Yes,02/28/2025,FDA-2024-D-5601
M15 General Principles for Model-Informed Drug Development,PDF (830.43 KB)PDF (830.43 KB) of M15 General Principles for Model-Informed Drug Development,12/30/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Draft,Yes,02/28/2025,FDA-2024-D-5580
"Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices","PDF (274.83 KB)PDF (274.83 KB) of Protocol Deviations for Clinical Investigations of Drugs, Biological Products, and Devices",12/30/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthOncology Center of Excellence,Clinical - Medical,Draft,Yes,02/28/2025,FDA-2023-D-5016
Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document,PDF (221.49 KB)PDF (221.49 KB) of Combined Food and Drug Administration and Sponsor Oncologic Drugs Advisory Committee Briefing Document,12/27/2024,Oncology Center of Excellence,"Prescription Drugs, Oncology",Draft,No,,FDA-2024-D-4490
Global Unique Device Identification Database (GUDID):  Guidance for Industry and Food and Drug Administration Staff,PDF (2.55 MB)PDF (2.55 MB) of Global Unique Device Identification Database (GUDID):  Guidance for Industry and Food and Drug Administration Staff,12/17/2024,Center for Devices and Radiological Health,"GUDID, Labeling, UDI",Final,No,,FDA-2013-D-0636
Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH):  Guidance for Industry Technical Specifications Document,PDF (573.44 KB)PDF (573.44 KB) of Technical Specifications for Submitting Clinical Trial Data Sets for Treatment of Noncirrhotic Nonalcoholic Steatohepatitis (NASH):  Guidance for Industry Technical Specifications Document,12/13/2024,Center for Drug Evaluation and Research,,Final,No,,FDA-2018-D-1216
Guidance for Industry:  Registration and Listing of Cosmetic Product Facilities and Products,PDF (382.42 KB)PDF (382.42 KB) of Guidance for Industry:  Registration and Listing of Cosmetic Product Facilities and Products,12/11/2024,"Office of the Commissioner,Office of the Chief Scientist",,Final,No,01/13/2025,FDA-2023-D-1716
Standardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions Guidance for Industry,PDF (275.84 KB)PDF (275.84 KB) of Standardized Format for Electronic Submission of NDA and BLA Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for CDER Submissions Guidance for Industry,12/06/2024,Center for Drug Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2018-D-0481
Accelerated Approval – Expedited Program for Serious Conditions,PDF (382.28 KB)PDF (382.28 KB) of Accelerated Approval – Expedited Program for Serious Conditions,12/05/2024,Center for Drug Evaluation and Research,,Draft,Yes,02/04/2025,FDA-2024-D-2033
CVM GFI #49 Evaluating Target Animal Safety and Effectiveness of Antibacterial New Animal Drugs for Bovine Mastitis,PDF (398.88 KB)PDF (398.88 KB) of CVM GFI #49 Evaluating Target Animal Safety and Effectiveness of Antibacterial New Animal Drugs for Bovine Mastitis,12/04/2024,Center for Veterinary Medicine,"Premarket, Animal Drugs, Clinical - Antimicrobial, Target Animal – Effectiveness, Target Animal – Safety, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Draft,Yes,02/03/2025,FDA-1993-D-0285
Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions:  Guidance for Industry and Food and Drug Administration Staff,PDF (678.22 KB)PDF (678.22 KB) of Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions:  Guidance for Industry and Food and Drug Administration Staff,12/04/2024,"Center for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","Premarket, Digital Health",Final,No,,FDA-2022-D-2628
Draft Guidance for Industry: Notifying FDA of a Permanent Discontinuance in the Manufacture or an Interruption of the Manufacture of an Infant Formula,PDF (246.02 KB)PDF (246.02 KB) of Draft Guidance for Industry: Notifying FDA of a Permanent Discontinuance in the Manufacture or an Interruption of the Manufacture of an Infant Formula,12/02/2024,Human Foods Program,Infant Formula & Foods,Draft,Yes,02/03/2025,FDA-2024-D-1334
Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Guidance for Industry; Availability,PDF (303.41 KB)PDF (303.41 KB) of Use of Circulating Tumor Deoxyribonucleic Acid for Early-Stage Solid Tumor Drug Development; Guidance for Industry; Availability,11/27/2024,Oncology Center of Excellence,,Final,No,,Docket No. FDA-2022-D-0084
Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects,PDF (592.48 KB)PDF (592.48 KB) of Recommended Followup Testing for an Ames-Positive Drug (Active Ingredient) or Metabolite To Support First-in-Human Clinical Trials With Healthy Subjects,11/27/2024,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Draft,Yes,02/25/2025,FDA-2024-D-4540
Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products,PDF (249.56 KB)PDF (249.56 KB) of Assessment of Ovarian Toxicity in Premenopausal Adults During Drug Development for Oncologic Products,11/26/2024,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Draft,No,,FDA-2024-D-4643
Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (483.14 KB)PDF (483.14 KB) of Transitional Enforcement Policy for Ethylene Oxide Sterilization Facility Changes for Class III Devices:  Guidance for Industry and Food and Drug Administration Staff,11/26/2024,Center for Devices and Radiological Health,"Premarket Approval (PMA), HUD/HDE",Final,No,,FDA-2024-D-2274
"Orthopedic Non-Spinal Bone Plates, Screws, and Washers - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff","PDF (766.28 KB)PDF (766.28 KB) of Orthopedic Non-Spinal Bone Plates, Screws, and Washers - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff",11/22/2024,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of Health Technology VI - Orthopedic Devices","Premarket, 510(k), Orthopedic",Final,No,,FDA-2023-D-0488
Orthopedic Non-Spinal Metallic Bone Screws and Washers - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (441.49 KB)PDF (441.49 KB) of Orthopedic Non-Spinal Metallic Bone Screws and Washers - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,11/22/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Orthopedic",Final,No,,FDA-2019-D-1652
"510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review:  Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations","PDF (600.95 KB)PDF (600.95 KB) of 510(k) Third Party Review Program and Third Party Emergency Use Authorization (EUA) Review:  Guidance for Industry, Food and Drug Administration Staff, and Third Party Review Organizations",11/21/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Administrative / Procedural",Final,No,,FDA-2016-D-2565
Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products,PDF (439.22 KB)PDF (439.22 KB) of Frequently Asked Questions — Developing Potential Cellular and Gene Therapy Products,11/18/2024,Center for Biologics Evaluation and Research,"Gene Therapy, Pediatric Product Development",Draft,No,,FDA-2024-D-4311
Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics,PDF (354.31 KB)PDF (354.31 KB) of Nonclinical Safety Assessment of Oligonucleotide-Based Therapeutics,11/15/2024,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Draft,No,01/14/2025,FDA-2024-D-4624
Guidance for Industry: FDA's Voluntary Qualified Importer Program,PDF (358.87 KB)PDF (358.87 KB) of Guidance for Industry: FDA's Voluntary Qualified Importer Program,11/14/2024,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,Import,Final,No,,FDA-2011-N-0144
CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products – Decomposition and Histamine (CPG 7108.24),PDF (402.44 KB)PDF (402.44 KB) of CPG Sec 540.525 Scombrotoxin (Histamine)-forming Fish and Fishery Products – Decomposition and Histamine (CPG 7108.24),11/01/2024,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,FDA-2021-D-0367
Study Data Technical Conformance Guide - Technical Specifications Document,PDF (1.36 MB)PDF (1.36 MB) of Study Data Technical Conformance Guide - Technical Specifications Document,10/31/2024,Center for Drug Evaluation and Research,,Final,No,05/07/2014,FDA-2014-D-0092
M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms,PDF (391.49 KB)PDF (391.49 KB) of M13A Bioequivalence for Immediate-Release Solid Oral Dosage Forms,10/30/2024,Center for Drug Evaluation and Research,ICH-Multidisciplinary,Final,No,04/03/2023,FDA-2023-D-0093
CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients,PDF (311.52 KB)PDF (311.52 KB) of CVM GFI #293 - FDA Enforcement Policy for AAFCO-Defined Animal Feed Ingredients,10/24/2024,Center for Veterinary Medicine,"Postmarket, Premarket, Animal Food Additives, Labeling",Final,No,09/09/2024,FDA-2024-D-2977
"Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination","PDF (295.45 KB)PDF (295.45 KB) of Guidance for Industry: Insanitary Conditions in the Preparation, Packing, and Holding of Tattoo Inks and the Risk of Microbial Contamination",10/22/2024,"Office of the Commissioner,Office of the Chief Scientist",Tattoos,Final,No,09/11/2023,FDA-2023-D-1083
Drug Interaction Information in Human Prescription Drug and Biological Product Labeling,PDF (548.42 KB)PDF (548.42 KB) of Drug Interaction Information in Human Prescription Drug and Biological Product Labeling,10/21/2024,Center for Drug Evaluation and Research,"Labeling, Clinical - Pharmacology",Draft,No,01/21/2025,FDA-2024-D-3903
Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA,PDF (272.69 KB)PDF (272.69 KB) of Review of Drug Master Files in Advance of Certain ANDA Submissions Under GDUFA,10/17/2024,Center for Drug Evaluation and Research,"User Fees, Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality, Drug Competition Action Plan",Final,No,,FDA-2022-D-2061
Postoperative Nausea and Vomiting: Developing Drugs for Prevention,PDF (256.27 KB)PDF (256.27 KB) of Postoperative Nausea and Vomiting: Developing Drugs for Prevention,10/17/2024,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,12/17/2024,FDA-2024-D-3993
"Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method","PDF (316.76 KB)PDF (316.76 KB) of Recommendations for the Development of Blood Collection, Processing, and Storage Systems for the Manufacture of Blood Components Using the Buffy Coat Method",10/17/2024,Center for Biologics Evaluation and Research,"Blood, Blood Products",Draft,No,,FDA-2024-D-2732
Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development:  Guidance for Industry,PDF (375.34 KB)PDF (375.34 KB) of Considerations for Long-Term Clinical Neurodevelopmental Safety Studies in Neonatal Product Development:  Guidance for Industry,10/17/2024,"Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of the Chief Medical Officer,Office of Pediatric Therapeutics","Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2022-D-0112
Core Patient-Reported Outcomes in Cancer Clinical Trials:  Guidance for Industry,PDF (288.64 KB)PDF (288.64 KB) of Core Patient-Reported Outcomes in Cancer Clinical Trials:  Guidance for Industry,10/17/2024,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Clinical Trials, Clinical - Medical",Final,No,08/09/2021,FDA-2020-D-2303
Requests for Reconsideration at the Division Level Under GDUFA,PDF (259.37 KB)PDF (259.37 KB) of Requests for Reconsideration at the Division Level Under GDUFA,10/16/2024,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Final,No,03/11/2024,FDA-2017-D-5868
CVM GFI #284 Using Relative Supersaturation to Support “Urinary Tract Health” Claims for Adult Maintenance Cat Food,PDF (629.36 KB)PDF (629.36 KB) of CVM GFI #284 Using Relative Supersaturation to Support “Urinary Tract Health” Claims for Adult Maintenance Cat Food,10/15/2024,Center for Veterinary Medicine,"Animal Feed, Labeling",Final,No,02/28/2024,FDA-2023-D-4095
Endosseous Dental Implants and Endosseous Dental Implant Abutments - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (490.46 KB)PDF (490.46 KB) of Endosseous Dental Implants and Endosseous Dental Implant Abutments - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,10/15/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Final,No,,FDA-2024-D-4409
Temporary Policies for Compounding Certain Parenteral Drug Products:  Guidance for Industry,PDF (133.59 KB)PDF (133.59 KB) of Temporary Policies for Compounding Certain Parenteral Drug Products:  Guidance for Industry,10/11/2024,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2024-D-4774
"Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations:  Questions and Answers","PDF (545.68 KB)PDF (545.68 KB) of Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations:  Questions and Answers",10/01/2024,"Center for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs",Administrative / Procedural,Final,No,05/15/2023,FDA-2017-D-1105
CVM GFI #116 (VICH GL23 (R2)) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2),PDF (429.95 KB)PDF (429.95 KB) of CVM GFI #116 (VICH GL23 (R2)) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Genotoxicity Testing (Revision 2),09/30/2024,Center for Veterinary Medicine,"Human Food Safety, VICH",Draft,No,11/29/2024,FDA-2000-D-0598
Air Powered Dental Handpieces and Air Motors - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (519.17 KB)PDF (519.17 KB) of Air Powered Dental Handpieces and Air Motors - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,09/30/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Final,No,,FDA-2024-D-4168
Dental Cements - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (528.42 KB)PDF (528.42 KB) of Dental Cements - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,09/30/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Final,No,,FDA-2024-D-4171
Dental Ceramics - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (450.79 KB)PDF (450.79 KB) of Dental Ceramics - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,09/30/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Final,No,,FDA-2024-D-4169
Dental Impression Materials - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (473.92 KB)PDF (473.92 KB) of Dental Impression Materials - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,09/30/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Final,No,,FDA-2024-D-4170
Clarification of Radiation Control Regulations For Manufacturers of Diagnostic X-Ray Equipment:  Guidance for Industry and Food and Drug Administration Staff,PDF (922.48 KB)PDF (922.48 KB) of Clarification of Radiation Control Regulations For Manufacturers of Diagnostic X-Ray Equipment:  Guidance for Industry and Food and Drug Administration Staff,09/27/2024,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","Export, Import, Labeling, Radiology",Final,No,,FDA-2018-D-4115
Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies,PDF (271.51 KB)PDF (271.51 KB) of Clinical Pharmacology Considerations for Human Radiolabeled Mass Balance Studies,09/26/2024,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,08/04/2022,FDA-2022-D-0113
"Small Entity Compliance Guide: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption","PDF (475.82 KB)PDF (475.82 KB) of Small Entity Compliance Guide: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",09/25/2024,Human Foods Program,Produce,Final,No,,FDA-2011-N-0921
An Acceptable Circular of Information for the Use of Human Blood and Blood Components:  Guidance for Industry,PDF (226.66 KB)PDF (226.66 KB) of An Acceptable Circular of Information for the Use of Human Blood and Blood Components:  Guidance for Industry,09/25/2024,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2002-D-0223
"Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff","PDF (657.84 KB)PDF (657.84 KB) of Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",09/23/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Draft,No,12/23/2024,FDA-2019-D-3805
"Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program : Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff","PDF (4.71 MB)PDF (4.71 MB) of Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Program : Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",09/23/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Draft,No,12/23/2024,FDA-2019-D-3805
"The Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff","PDF (1.42 MB)PDF (1.42 MB) of The Accreditation Scheme for Conformity Assessment (ASCA) Program: Draft Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",09/23/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Draft,No,12/23/2024,FDA-2019-D-3805
Chemical Analysis for Biocompatibility Assessment of Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (1002.96 KB)PDF (1002.96 KB) of Chemical Analysis for Biocompatibility Assessment of Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,09/20/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Chemistry, Manufacturing, and Controls (CMC)",Draft,No,12/19/2024,FDA-2024-D-4165
Conducting Clinical Trials With Decentralized Elements,PDF (528.44 KB)PDF (528.44 KB) of Conducting Clinical Trials With Decentralized Elements,09/18/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthOncology Center of Excellence,Clinical - Medical,Final,No,08/01/2023,FDA-2022-D-2870
Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry,PDF (320.1 KB)PDF (320.1 KB) of Integrating Randomized Controlled Trials for Drug and Biological Products Into Routine Clinical Practice: Draft Guidance for Industry,09/18/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,"Real World Data / Real World Evidence (RWD/RWE),",Draft,No,12/17/2024,FDA-2024-D-2052
"CVM GFI #227 Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies","PDF (311.11 KB)PDF (311.11 KB) of CVM GFI #227 Chemistry, Manufacturing, and Controls (CMC) Technical Section Filing Strategies",09/17/2024,Center for Veterinary Medicine,"Premarket, Animal Drugs, Chemistry, Manufacturing, and Controls (CMC), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Draft,No,11/18/2024,FDA-2014-D-1492
Data Standards Catalog,,09/16/2024,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchHuman Foods ProgramCenter for Veterinary Medicine,,Final,No,,
Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs,PDF (306.07 KB)PDF (306.07 KB) of Considerations for Generating Clinical Evidence from Oncology Multiregional Clinical Development Programs,09/16/2024,Oncology Center of Excellence,Clinical - Medical,Draft,No,11/18/2024,FDA-2024-D-3163
Enforcement Policy for Required Warnings for Cigarette Packages and Advertisements,PDF (131.88 KB)PDF (131.88 KB) of Enforcement Policy for Required Warnings for Cigarette Packages and Advertisements,09/13/2024,Center for Tobacco Products,,Final,No,,FDA-2024-D-3742
Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry,PDF (362.91 KB)PDF (362.91 KB) of Providing Regulatory Submissions in Electronic Format — Certain Human Pharmaceutical Product Applications and Related Submissions Using the eCTD Specifications Guidance for Industry,09/13/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2014-N-1006
Submission of Plans for Cigarette Packages and Cigarette Advertisements (Revised),PDF (539.45 KB)PDF (539.45 KB) of Submission of Plans for Cigarette Packages and Cigarette Advertisements (Revised),09/12/2024,Center for Tobacco Products,,Final,No,,FDA-2019-D-5364
Required Warnings for Cigarette Packages and Advertisements: Small Entity Compliance Guide (Revised):  Guidance for Industry,PDF (805.23 KB)PDF (805.23 KB) of Required Warnings for Cigarette Packages and Advertisements: Small Entity Compliance Guide (Revised):  Guidance for Industry,09/12/2024,Center for Tobacco Products,,Final,No,,FDA-2020-D-0988
ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA:  Guidance for Industry,PDF (400.85 KB)PDF (400.85 KB) of ANDA Submissions | Amendments to Abbreviated New Drug Applications Under GDUFA:  Guidance for Industry,09/11/2024,Center for Drug Evaluation and Research,"User Fees, Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2017-D-5670
"Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Referring Provider Notification Orders:  Guidance for Mammography Facilities and Food and Drug Administration Staff","PDF (335.19 KB)PDF (335.19 KB) of Appeal Options Available to Mammography Facilities Concerning Adverse Accreditation Decisions, Suspension/Revocation of Certificates, or Patient and Referring Provider Notification Orders:  Guidance for Mammography Facilities and Food and Drug Administration Staff",09/10/2024,Center for Devices and Radiological Health,"Investigation & Enforcement, Administrative / Procedural, Radiological Health, Radiology",Final,No,,FDA-2020-D-1317
Withdrawn Guidances (Biologics),,09/06/2024,Center for Biologics Evaluation and Research,,Final,No,,
"Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle: Draft Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties","PDF (887.62 KB)PDF (887.62 KB) of Incorporating Voluntary Patient Preference Information over the Total Product Life Cycle: Draft Guidance for Industry, Food and Drug Administration Staff, and Other Interested Parties",09/06/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,,Draft,No,12/05/2024,FDA-2015-D-1580
Control of Nitrosamine Impurities in Human Drugs:  Guidance for Industry,PDF (665 KB)PDF (665 KB) of Control of Nitrosamine Impurities in Human Drugs:  Guidance for Industry,09/05/2024,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2020-D-1530
Bioresearch Monitoring Technical Conformance Guide,PDF (581.57 KB)PDF (581.57 KB) of Bioresearch Monitoring Technical Conformance Guide,09/03/2024,Center for Drug Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2018-D-1216
Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers:  Guidance for Industry and Food and Drug Administration Staff,PDF (795.35 KB)PDF (795.35 KB) of Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers:  Guidance for Industry and Food and Drug Administration Staff,08/29/2024,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,,Final,No,,FDA-2022-D-2873
CVM GFI #63 (VICH GL1) Validation of Analytical Procedures: Definition and Terminology,PDF (373.12 KB)PDF (373.12 KB) of CVM GFI #63 (VICH GL1) Validation of Analytical Procedures: Definition and Terminology,08/28/2024,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-2021-D-0614
CVM GFI #64 (VICH  GL2) Validation of Analytical Procedures: Methodology,PDF (423.07 KB)PDF (423.07 KB) of CVM GFI #64 (VICH  GL2) Validation of Analytical Procedures: Methodology,08/28/2024,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-2021-D-0616
Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,PDF (864.29 KB)PDF (864.29 KB) of Mammography Quality Standards Act and Regulation Amendments: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,08/26/2024,Center for Devices and Radiological Health,,Final,No,,FDA-2013-N-0134
Electronic Submission Template for Medical Device De Novo Requests:  Guidance for Industry and Food and Drug Administration Staff,PDF (664.24 KB)PDF (664.24 KB) of Electronic Submission Template for Medical Device De Novo Requests:  Guidance for Industry and Food and Drug Administration Staff,08/23/2024,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, Electronic Submissions,",Final,No,,FDA-2023-D-3788
"FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff","PDF (553.88 KB)PDF (553.88 KB) of FDA and Industry Procedures for Section 513(g) Requests for Information under the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",08/23/2024,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, Administrative / Procedural, Labeling",Final,No,,FDA-2010-D-0153
Predetermined Change Control Plans for Medical Devices: Draft Guidance for Industry and FDA Staff,PDF (1.39 MB)PDF (1.39 MB) of Predetermined Change Control Plans for Medical Devices: Draft Guidance for Industry and FDA Staff,08/22/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Draft,No,11/20/2024,FDA-2024-D-2338
Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA:  Guidance for Industry,PDF (371.05 KB)PDF (371.05 KB) of Product-Specific Guidance Meetings Between FDA and ANDA Applicants Under GDUFA:  Guidance for Industry,08/20/2024,"Center for Drug Evaluation and Research,Office of Generic Drugs","Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2023-D-0044
Acceptable Media for Electronic Product User Manuals:  Guidance for Industry and FDA Staff,PDF (388.02 KB)PDF (388.02 KB) of Acceptable Media for Electronic Product User Manuals:  Guidance for Industry and FDA Staff,08/19/2024,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Draft Guidance for Industry: Voluntary Sodium Reduction Goals (Edition 2),PDF (529.93 KB)PDF (529.93 KB) of Draft Guidance for Industry: Voluntary Sodium Reduction Goals (Edition 2),08/15/2024,Human Foods Program,,Draft,No,01/13/2025,FDA-2014-D-0055
Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry,PDF (326.5 KB)PDF (326.5 KB) of Bacillus Calmette-Guérin-Unresponsive Nonmuscle Invasive Bladder Cancer: Developing Drugs and Biological Products for Treatment : Draft Guidance for Industry,08/08/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2018-D-0342
Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases:  Guidance for Industry; Availability,PDF (311.33 KB)PDF (311.33 KB) of Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases:  Guidance for Industry; Availability,08/08/2024,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Final,No,,FDA-2022-D-2827
M12 Drug Interaction Studies,PDF (824.34 KB)PDF (824.34 KB) of M12 Drug Interaction Studies,08/02/2024,"Center for Drug Evaluation and Research,Office of Regulatory PolicyCenter for Biologics Evaluation and Research",ICH-Multidisciplinary,Final,No,,FDA-2022-D-1527
M12 Drug Interaction Studies: Questions and Answers,PDF (258.44 KB)PDF (258.44 KB) of M12 Drug Interaction Studies: Questions and Answers,08/02/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2022-D-1527
FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products,PDF (466.88 KB)PDF (466.88 KB) of FDA Regional Implementation Guide for E2B(R3) Electronic Transmission of Individual Case Safety Reports for Drug and Biological Products,08/01/2024,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-2016-D-1280
"CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)","PDF (569.79 KB)PDF (569.79 KB) of CVM GFI #100 (VICH GL18 (R2)) Impurities: Residual Solvents in New Veterinary Medicinal Products, Active Substances and Excipients (Revision 2)",07/25/2024,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,09/16/2022,FDA-1999-D-2955
Providing Over-the-Counter Monograph Submissions in Electronic Format,PDF (269.74 KB)PDF (269.74 KB) of Providing Over-the-Counter Monograph Submissions in Electronic Format,07/25/2024,Center for Drug Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2022-D-2059
Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products:  Guidance for Industry,PDF (500.41 KB)PDF (500.41 KB) of Real-World Data: Assessing Electronic Health Records and Medical Claims Data To Support Regulatory Decision-Making for Drug and Biological Products:  Guidance for Industry,07/25/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,"Real World Data / Real World Evidence (RWD/RWE),",Final,No,,FDA-2020-D-2307
Container Closure System and Component Changes: Glass Vials and Stoppers,PDF (466.34 KB)PDF (466.34 KB) of Container Closure System and Component Changes: Glass Vials and Stoppers,07/24/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Final,No,,FDA-2017-D-6821
Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers,PDF (240.13 KB)PDF (240.13 KB) of Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products Questions and Answers,07/23/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Current Good Manufacturing Practice (CGMP),Draft,No,09/23/2024,FDA-2024-D-2581
Pediatric Inflammatory Bowel Disease:  Developing Drugs for Treatment,PDF (388.92 KB)PDF (388.92 KB) of Pediatric Inflammatory Bowel Disease:  Developing Drugs for Treatment,07/19/2024,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Draft,No,09/17/2024,FDA-2024-D-2682
Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma:  Guidance for Industry,PDF (299 KB)PDF (299 KB) of Recommendations for Investigational and Licensed COVID-19 Convalescent Plasma:  Guidance for Industry,07/19/2024,Center for Biologics Evaluation and Research,"Blood, Infectious Disease Treatment, Coronavirus, Blood Products",Final,No,,FDA-2024-D-2442
Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy:  Guidance for Industry,PDF (218.93 KB)PDF (218.93 KB) of Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy:  Guidance for Industry,07/17/2024,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2022-D-0362
Application User Fees for Combination Products:  Guidance for Industry and FDA Staff,PDF (314.74 KB)PDF (314.74 KB) of Application User Fees for Combination Products:  Guidance for Industry and FDA Staff,07/16/2024,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","User Fees, Combination Products, Pediatric Product Development",Final,No,,FDA-2004-D-0371
Drugs for the Treatment of Partial Onset Seizures: Extrapolation of Efficacy from Adults to Pediatric Patients  1 Month of Age and Older,PDF (200.85 KB)PDF (200.85 KB) of Drugs for the Treatment of Partial Onset Seizures: Extrapolation of Efficacy from Adults to Pediatric Patients  1 Month of Age and Older,07/15/2024,Center for Drug Evaluation and Research,"Clinical - Pharmacology, Pediatric Product Development",Final,No,,FDA-2018-D-0178
Dental Composite Resin Devices - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (532.96 KB)PDF (532.96 KB) of Dental Composite Resin Devices - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,07/12/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Draft,No,09/10/2024,FDA-2024-D-2511
Dental Curing Lights - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (511.87 KB)PDF (511.87 KB) of Dental Curing Lights - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,07/12/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Draft,No,09/10/2024,FDA-2024-D-2512
Clinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder:  Guidance for Industry and Food and Drug Administration Staff,PDF (538.76 KB)PDF (538.76 KB) of Clinical Considerations for Studies of Devices Intended to Treat Opioid Use Disorder:  Guidance for Industry and Food and Drug Administration Staff,07/11/2024,Center for Devices and Radiological Health,,Final,No,,FDA-2023-D-0466
Addressing Misinformation About Medical Devices and Prescription Drugs:  Questions and Answers,PDF (374.75 KB)PDF (374.75 KB) of Addressing Misinformation About Medical Devices and Prescription Drugs:  Questions and Answers,07/08/2024,Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,Advertising,Draft,No,,FDA-2014-D-0447
"Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products","PDF (324.44 KB)PDF (324.44 KB) of Purpose and Content of Use-Related Risk Analyses for Drugs, Biological Products, and Combination Products",07/08/2024,"Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",,Draft,No,09/09/2024,FDA-2024-D-2484
"M14 General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies That Utilize Real-World Data for Safety Assessment of Medicines","PDF (1.02 MB)PDF (1.02 MB) of M14 General Principles on Plan, Design, and Analysis of Pharmacoepidemiological Studies That Utilize Real-World Data for Safety Assessment of Medicines",07/05/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Draft,No,09/03/2024,FDA-2024-D-2754
Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry,PDF (552.4 KB)PDF (552.4 KB) of Essential Drug Delivery Outputs for Devices Intended to Deliver Drugs and Biological Products: Draft Guidance for Industry,06/28/2024,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research","Combination Products, Pediatric Product Development",Draft,No,09/30/2024,FDA-2024-D-2560
Diversity Action Plans to Improve Enrollment of Participants from Underrepresented Populations in Clinical Studies: Draft Guidance for Industry,,06/26/2024,"Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthOffice of the Commissioner,Office of Minority Health and Health EquityOffice of the Commissioner,Office of Women's Health",Pediatric Product Development,Draft,No,09/26/2024,FDA-2021-D-0789
CVM GFI #276 Effectiveness of Anthelmintics:  Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs,PDF (274.34 KB)PDF (274.34 KB) of CVM GFI #276 Effectiveness of Anthelmintics:  Specific Recommendations for Products Proposed for the Prevention of Heartworm Disease in Dogs,06/26/2024,Center for Veterinary Medicine,"Premarket, Anthelmintics, Investigational New Animal Drug (INAD), Target Animal – Effectiveness",Final,No,05/01/2023,FDA-2022-D-2899
CVM GFI #283 Priority Zoonotic Animal Drug Designation and Review Process,PDF (365.16 KB)PDF (365.16 KB) of CVM GFI #283 Priority Zoonotic Animal Drug Designation and Review Process,06/26/2024,Center for Veterinary Medicine,"Premarket, Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Final,No,02/16/2024,FDA-2023-D-3740
Laboratory Developed Tests: Small Entity Compliance Guide:  Guidance for Laboratory Manufacturers and Food and Drug Administration Staff,PDF (700.68 KB)PDF (700.68 KB) of Laboratory Developed Tests: Small Entity Compliance Guide:  Guidance for Laboratory Manufacturers and Food and Drug Administration Staff,06/25/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,IVDs (In Vitro Diagnostic Devices),Final,No,,FDA-2023-N-2177
"CVM GFI #288 Chemistry, Manufacturing, and Controls in Support of Recombinant Protein Products for Veterinary Medicinal Use","PDF (433.9 KB)PDF (433.9 KB) of CVM GFI #288 Chemistry, Manufacturing, and Controls in Support of Recombinant Protein Products for Veterinary Medicinal Use",06/24/2024,Center for Veterinary Medicine,"Premarket, Biotechnology, Chemistry, Manufacturing, and Controls (CMC), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Draft,No,08/23/2024,FDA-2024-D-1668
"CVM GFI #292 Chemistry, Manufacturing, and Controls Considerations for Type A Medicated Articles","PDF (332.33 KB)PDF (332.33 KB) of CVM GFI #292 Chemistry, Manufacturing, and Controls Considerations for Type A Medicated Articles",06/24/2024,Center for Veterinary Medicine,"Premarket, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Draft,No,08/23/2024,FDA-2024-D-1202
CVM GFI #278 Human User Safety in New and Abbreviated New Animal Drug Applications,PDF (359.66 KB)PDF (359.66 KB) of CVM GFI #278 Human User Safety in New and Abbreviated New Animal Drug Applications,06/21/2024,Center for Veterinary Medicine,"Premarket, Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Labeling, Safety - Issues, Errors, and Problems, Pharmacology/Toxicology",Final,No,06/05/2023,FDA-2023-D-0592
"CVM GFI #279 Demonstrating Bioequivalence for Type A Medicated Articles Containing Active Pharmaceutical Ingredient(s) Considered to be Poorly Soluble in Aqueous Media, That Exhibit Little to No Systemic Bioavailability, and Are Locally Acting","PDF (317.41 KB)PDF (317.41 KB) of CVM GFI #279 Demonstrating Bioequivalence for Type A Medicated Articles Containing Active Pharmaceutical Ingredient(s) Considered to be Poorly Soluble in Aqueous Media, That Exhibit Little to No Systemic Bioavailability, and Are Locally Acting",06/21/2024,Center for Veterinary Medicine,"Premarket, Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Final,No,10/16/2023,FDA-2023-D-1275
Considerations in Demonstrating Interchangeability With a Reference Product: Update,PDF (240.79 KB)PDF (240.79 KB) of Considerations in Demonstrating Interchangeability With a Reference Product: Update,06/21/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Biosimilars,Draft,No,08/20/2024,FDA-2017-D-0154
"Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection:  Guidance for Industry","PDF (341.74 KB)PDF (341.74 KB) of Circumstances that Constitute Delaying, Denying, Limiting, or Refusing a Drug or Device Inspection:  Guidance for Industry",06/20/2024,Office of Inspections and InvestigationsCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary MedicineCenter for Devices and Radiological Health,"Postmarket, Investigation & Enforcement,",Final,No,,FDA-2013-D-0710
Facility Readiness:  Goal Date Decisions Under GDUFA,PDF (252.05 KB)PDF (252.05 KB) of Facility Readiness:  Goal Date Decisions Under GDUFA,06/18/2024,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,FDA-2022-D-1981
Diabetic Foot Infections: Developing Drugs for Treatment,PDF (401.35 KB)PDF (401.35 KB) of Diabetic Foot Infections: Developing Drugs for Treatment,06/17/2024,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2023-D-4067
Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry,PDF (322.17 KB)PDF (322.17 KB) of Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics:  Guidance for Industry,06/14/2024,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,09/25/2022,FDA-2022-D-0235
Standardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center of Biologics Evaluation and Research Submissions,PDF (300.15 KB)PDF (300.15 KB) of Standardized Format for Electronic Submission for Marketing Applications Content for the Planning of Bioresearch Monitoring (BIMO) Inspections for Center of Biologics Evaluation and Research Submissions,06/05/2024,Center for Biologics Evaluation and Research,"Electronic Submissions,",Draft,No,08/05/2024,FDA-2024-D-2221
Processes and Practices Applicable to Bioresearch Monitoring Inspections: Draft Guidance for Industry,PDF (516.52 KB)PDF (516.52 KB) of Processes and Practices Applicable to Bioresearch Monitoring Inspections: Draft Guidance for Industry,06/05/2024,"Office of Inspections and InvestigationsOffice of the Commissioner,Office of Clinical Policy and ProgramsCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthHuman Foods ProgramCenter for Tobacco ProductsCenter for Veterinary Medicine","Clinical Trials, Compliance, Postmarket, Premarket, Investigation & Enforcement, Inspection, International, Administrative / Procedural, Bioequivalence, Biopharmaceutics, Biosimilars, Investigational New Drug Application (INDA), Food & Color Additives, Generic Drugs, HUD/HDE, Investigational Device Exemption (IDE), Premarket Approval (PMA), IVDs (In Vitro Diagnostic Devices), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Vaccines",Draft,No,08/05/2024,FDA-2023-D-5021
Platform Technology Designation Program for Drug Development,PDF (350.67 KB)PDF (350.67 KB) of Platform Technology Designation Program for Drug Development,05/28/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Draft,No,07/29/2024,FDA-2024-D-1829
CVM GFI #115 (VICH GL22) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Toxicity Testing (Revision 1),PDF (374.29 KB)PDF (374.29 KB) of CVM GFI #115 (VICH GL22) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Reproduction Toxicity Testing (Revision 1),05/23/2024,Center for Veterinary Medicine,"Human Food Safety, VICH",Draft,No,07/22/2024,FDA-2000-D-0784
"Remanufacturing of Medical Devices:  Guidance for Industry, Entities That Perform Servicing or Remanufacturing, and Food and Drug Administration Staff","PDF (748.47 KB)PDF (748.47 KB) of Remanufacturing of Medical Devices:  Guidance for Industry, Entities That Perform Servicing or Remanufacturing, and Food and Drug Administration Staff",05/10/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2018-N-3741
REMS Logic Model: A Framework to Link Program Design With Assessment,PDF (555.35 KB)PDF (555.35 KB) of REMS Logic Model: A Framework to Link Program Design With Assessment,05/07/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Safety - Issues, Errors, and Problems",Draft,No,08/05/2024,FDA-2024-D-1032
CVM GFI #290 (VICH GL61) – Pharmaceutical Development,PDF (910.11 KB)PDF (910.11 KB) of CVM GFI #290 (VICH GL61) – Pharmaceutical Development,05/06/2024,Center for Veterinary Medicine,"Premarket, Postmarket, Chemistry, Manufacturing, and Controls (CMC), Quality, Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), VICH",Draft,No,07/05/2024,FDA-2024-D-1133
Consideration of Enforcement Policies for Tests During a Section 564 Declared Emergency: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (422.3 KB)PDF (422.3 KB) of Consideration of Enforcement Policies for Tests During a Section 564 Declared Emergency: Draft Guidance for Industry and Food and Drug Administration Staff,05/06/2024,Center for Devices and Radiological Health,"Outbreak, IVDs (In Vitro Diagnostic Devices)",Draft,No,07/05/2024,FDA-2023-D-5365
Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration under Section 564: Draft Guidance for Laboratory Manufacturers and Food and Drug Administration Staff,PDF (457.29 KB)PDF (457.29 KB) of Enforcement Policy for Certain In Vitro Diagnostic Devices for Immediate Public Health Response in the Absence of a Declaration under Section 564: Draft Guidance for Laboratory Manufacturers and Food and Drug Administration Staff,05/06/2024,Center for Devices and Radiological Health,"Outbreak, IVDs (In Vitro Diagnostic Devices)",Draft,No,07/05/2024,FDA-2024-D-0083
CVM GFI #187A Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach,PDF (392.06 KB)PDF (392.06 KB) of CVM GFI #187A Heritable Intentional Genomic Alterations in Animals: Risk-Based Approach,05/02/2024,Center for Veterinary Medicine,"Biotechnology,",Final,No,04/19/2017,FDA-2008-D-0394
Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels:  Guidance for Industry,PDF (206.79 KB)PDF (206.79 KB) of Recognition and Use of a Standard for Uniform Blood and Blood Component Container Labels:  Guidance for Industry,04/30/2024,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-1998-D-0067
CVM GFI #120 Veterinary Feed Directive Regulation Questions and Answers,PDF (602.76 KB)PDF (602.76 KB) of CVM GFI #120 Veterinary Feed Directive Regulation Questions and Answers,04/29/2024,Center for Veterinary Medicine,Animal Feed,Final,No,05/28/2019,FDA-2010-N-0155
Small Entity Compliance Guide: Revocation of Uses of Partially Hydrogenated Oils in Foods,PDF (237.6 KB)PDF (237.6 KB) of Small Entity Compliance Guide: Revocation of Uses of Partially Hydrogenated Oils in Foods,04/29/2024,Human Foods Program,,Final,No,,FDA-2024-D-1669
Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products,PDF (319.89 KB)PDF (319.89 KB) of Considerations for the Use of Human-and Animal-Derived Materials in the Manufacture of Cell and Gene Therapy and Tissue-Engineered Medical Products,04/29/2024,Center for Biologics Evaluation and Research,"Gene Therapy, Tissue, Xenotransplantation",Draft,No,,FDA-2024-D-1244
Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs,PDF (406.3 KB)PDF (406.3 KB) of Content and Format of Composition Statement and Corresponding Statement of Ingredients in Labeling in NDAs and ANDAs,04/29/2024,Center for Drug Evaluation and Research,"Electronic Submissions, Drug Competition Action Plan, Generic Drugs",Draft,No,06/28/2024,FDA-2024-D-1461
CVM GFI #287 - Raw Data for Safety and Effectiveness Studies,PDF (238.4 KB)PDF (238.4 KB) of CVM GFI #287 - Raw Data for Safety and Effectiveness Studies,04/29/2024,Center for Veterinary Medicine,"Premarket, Environmental Safety, Human Food Safety, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal – Effectiveness, Target Animal – Safety",Draft,No,06/28/2024,FDA-2024-D-1613
Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products,PDF (289.31 KB)PDF (289.31 KB) of Safety Testing of Human Allogeneic Cells Expanded for Use in Cell-Based Medical Products,04/29/2024,Center for Biologics Evaluation and Research,Gene Therapy,Draft,No,,FDA-2024-D-1243
"Cancer Clinical Trial Eligibility Criteria: Laboratory Values: Draft Guidance for Industry, IRBs, and Clinical Investigators","PDF (267.91 KB)PDF (267.91 KB) of Cancer Clinical Trial Eligibility Criteria: Laboratory Values: Draft Guidance for Industry, IRBs, and Clinical Investigators",04/25/2024,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical Trials,",Draft,No,06/25/2024,FDA-2024-D-1402
"Cancer Clinical Trial Eligibility Criteria: Performance Status: Draft Guidance for Industry, IRBs, and Clinical Investigators","PDF (292.25 KB)PDF (292.25 KB) of Cancer Clinical Trial Eligibility Criteria: Performance Status: Draft Guidance for Industry, IRBs, and Clinical Investigators",04/25/2024,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical Trials,",Draft,No,06/25/2024,FDA-2024-D-1377
"Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications: Draft Guidance for Industry, IRBs, and Clinical Investigators","PDF (255.6 KB)PDF (255.6 KB) of Cancer Clinical Trial Eligibility Criteria: Washout Periods and Concomitant Medications: Draft Guidance for Industry, IRBs, and Clinical Investigators",04/25/2024,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical Trials,",Draft,No,06/25/2024,FDA-2024-D-1376
Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry,PDF (270.66 KB)PDF (270.66 KB) of Promotional Labeling and Advertising Considerations for Prescription Biological Reference and Biosimilar Products Questions and Answers Guidance for Industry,04/24/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Draft,No,06/25/2024,FDA-2019-D-5473
Data Integrity for In Vivo Bioavailability and Bioequivalence Studies,PDF (339.61 KB)PDF (339.61 KB) of Data Integrity for In Vivo Bioavailability and Bioequivalence Studies,04/03/2024,Center for Drug Evaluation and Research,Generic Drugs,Draft,No,07/03/2024,FDA-2024-D-1245
Draft Guidance for Industry: New Dietary Ingredient Notification Master Files for Dietary Supplements,PDF (282.89 KB)PDF (282.89 KB) of Draft Guidance for Industry: New Dietary Ingredient Notification Master Files for Dietary Supplements,04/03/2024,Human Foods Program,,Draft,No,06/03/2024,FDA-2024-D-0706
Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues,PDF (2.63 MB)PDF (2.63 MB) of Draft Guidance for Industry: New Dietary Ingredient Notifications and Related Issues,04/03/2024,Human Foods Program,,Draft,No,12/12/2016,FDA-2011-D-0376
Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry,PDF (256.74 KB)PDF (256.74 KB) of Electronic Submission of Expedited Safety Reports From IND-Exempt BA/BE Studies Guidance for Industry,04/01/2024,Center for Drug Evaluation and Research,"Electronic Submissions, Generic Drugs",Final,No,,FDA-2022-D-1173
Providing Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry,PDF (251.48 KB)PDF (251.48 KB) of Providing Regulatory Submissions in Electronic Format: IND Safety Reports Guidance for Industry,04/01/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,"Electronic Submissions,",Final,No,,FDA-2019-D-3953
Animal Studies for Dental Bone Grafting Material Devices - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (686.61 KB)PDF (686.61 KB) of Animal Studies for Dental Bone Grafting Material Devices - Premarket Notification (510(k)) Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,03/29/2024,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Draft,No,05/28/2024,FDA-2024-D-1242
Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry,PDF (309.45 KB)PDF (309.45 KB) of Handling and Retention of Bioavailability BA and Bioequivalence BE Testing Samples: Draft Guidance for Industry,03/27/2024,Center for Drug Evaluation and Research,"Generic Drugs, Good Clinical Practice (GCP)",Draft,No,05/28/2024,FDA-2002-D-0176
Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products,PDF (263.5 KB)PDF (263.5 KB) of Real-World Evidence: Considerations Regarding Non-Interventional Studies for Drug and Biological Products,03/21/2024,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Real World Data / Real World Evidence (RWD/RWE),",Draft,No,06/18/2024,FDA-2023-D-5470
Controlled Correspondence Related to Generic Drug Development,PDF (385.76 KB)PDF (385.76 KB) of Controlled Correspondence Related to Generic Drug Development,03/18/2024,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2014-D-1167
"CVM GFI #285 - Manufacture of Batches in Support of Original NADAs, ANADAs, and CNADAs","PDF (250.85 KB)PDF (250.85 KB) of CVM GFI #285 - Manufacture of Batches in Support of Original NADAs, ANADAs, and CNADAs",03/18/2024,Center for Veterinary Medicine,"Premarket, Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Generic Animal Drugs, New Animal Drug Application (NADA), Investigational New Animal Drug (INAD)",Draft,No,05/17/2024,FDA-2024-D-1054
"Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing","PDF (364.42 KB)PDF (364.42 KB) of Pharmacokinetics in Patients with Impaired Renal Function — Study Design, Data Analysis, and Impact on Dosing",03/15/2024,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,12/03/2020,FDA-2010-D-0133
Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program - Draft Guidance for Industry and Food and Drug Administration Staff,PDF (1.07 MB)PDF (1.07 MB) of Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program - Draft Guidance for Industry and Food and Drug Administration Staff,03/15/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Administrative / Procedural",Draft,No,05/14/2024,FDA-2018-D-1774
Evaluation of Thermal Effects of Medical Devices that Produce Tissue Heating and/or Cooling: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (604.7 KB)PDF (604.7 KB) of Evaluation of Thermal Effects of Medical Devices that Produce Tissue Heating and/or Cooling: Draft Guidance for Industry and Food and Drug Administration Staff,03/15/2024,Center for Devices and Radiological Health,,Draft,No,05/14/2024,FDA-2024-D-0664
Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products,PDF (276.49 KB)PDF (276.49 KB) of Annual Reportable Labeling Changes for New Drug Applications and Abbreviated New Drug Applications for Nonprescription Drug Products,03/13/2024,Center for Drug Evaluation and Research,Labeling,Draft,No,05/13/2024,FDA-2023-D-5616
E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports,PDF (444.11 KB)PDF (444.11 KB) of E2D(R1) Post-Approval Safety Data: Definitions and Standards for Management and Reporting of Individual Case Safety Reports,03/13/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Draft,No,,FDA-2024-D-0803
Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (649.66 KB)PDF (649.66 KB) of Select Updates for the Premarket Cybersecurity Guidance: Section 524B of the FD&C Act: Draft Guidance for Industry and Food and Drug Administration Staff,03/13/2024,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Draft,No,05/13/2024,FDA-2021-D-1158
Early Alzheimer’s Disease: Developing Drugs for Treatment,PDF (260.09 KB)PDF (260.09 KB) of Early Alzheimer’s Disease: Developing Drugs for Treatment,03/12/2024,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Draft,No,06/10/2024,FDA-2013-D-0077
Q14 Analytical Procedure Development,PDF (1.05 MB)PDF (1.05 MB) of Q14 Analytical Procedure Development,03/07/2024,"Center for Drug Evaluation and Research,Office of Regulatory PolicyCenter for Biologics Evaluation and Research",ICH-Quality,Final,No,,FDA-2022-D-1503
Q2(R2) Validation of Analytical Procedures,PDF (637.6 KB)PDF (637.6 KB) of Q2(R2) Validation of Analytical Procedures,03/06/2024,"Center for Drug Evaluation and Research,Office of Regulatory Policy",ICH-Quality,Final,No,,FDA-2022-D-1503
Guidance for Industry: New Dietary Ingredient Notification Procedures and Timeframes - Dietary Supplements,PDF (321.79 KB)PDF (321.79 KB) of Guidance for Industry: New Dietary Ingredient Notification Procedures and Timeframes - Dietary Supplements,03/05/2024,Human Foods Program,Ingredients,Final,No,,FDA-2023-D-5280
"Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards","PDF (435.04 KB)PDF (435.04 KB) of Key Information and Facilitating Understanding in Informed Consent Guidance for Sponsors, Investigators, and Institutional Review Boards",03/01/2024,"Center for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs",Administrative / Procedural,Draft,No,04/30/2024,FDA-2022-D-2997
Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry,PDF (320.72 KB)PDF (320.72 KB) of Clinical Pharmacology Considerations for Antibody-Drug Conjugates  Guidance for Industry:  Guidance for Industry,03/01/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Pharmacology,Final,No,,FDA-2021-D-1051
Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide:  Guidance for Industry,PDF (480.04 KB)PDF (480.04 KB) of Reporting Amount of Listed Drugs and Biological Products Technical Conformance Guide:  Guidance for Industry,02/26/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,Administrative / Procedural,Final,No,,FDA-2021-D-1031
Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment :  Guidance for Industry,PDF (303.02 KB)PDF (303.02 KB) of Assessing COVID-19-Related Symptoms in Outpatient Adult and Adolescent Subjects in Clinical Trials of Drugs and Biological Products for COVID-19 Prevention or Treatment :  Guidance for Industry,02/22/2024,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Infectious Disease, Coronavirus, Clinical - Medical",Final,No,,FDA-2020-D-1824
Select Updates for the Medical Device User Fee Small Business Qualification and Certification Guidance: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (547.72 KB)PDF (547.72 KB) of Select Updates for the Medical Device User Fee Small Business Qualification and Certification Guidance: Draft Guidance for Industry and Food and Drug Administration Staff,02/22/2024,Center for Devices and Radiological Health,"User Fees,",Draft,No,04/22/2024,FDA-2018-D-1873
Guidance for Industry: Foods Derived from Plants Produced Using Genome Editing,PDF (414.23 KB)PDF (414.23 KB) of Guidance for Industry: Foods Derived from Plants Produced Using Genome Editing,02/21/2024,Human Foods Program,Bioengineering / GMOs,Final,No,,FDA-2019-D-4658
Charging for Investigational Drugs Under an IND: Questions and Answers,PDF (266.07 KB)PDF (266.07 KB) of Charging for Investigational Drugs Under an IND: Questions and Answers,02/14/2024,Center for Drug Evaluation and Research,,Final,No,,FDA-2013-D-0447
Use of Data Monitoring Committees in Clinical Trials,PDF (402.09 KB)PDF (402.09 KB) of Use of Data Monitoring Committees in Clinical Trials,02/13/2024,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,Clinical - Medical,Draft,No,04/15/2024,FDA-2001-D-0219
Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act,PDF (316.88 KB)PDF (316.88 KB) of Notifying FDA of a Discontinuance or Interruption in Manufacturing of Finished Products or Active Pharmaceutical Ingredients Under Section 506C of the FD&C Act,02/06/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Draft,No,06/05/2023,FDA-2020-D-1057
Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act,PDF (577.54 KB)PDF (577.54 KB) of Reporting Amount of Listed Drugs and Biological Products Under Section 510(j)(3) of the FD&C Act,02/05/2024,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2021-D-1031
Draft Guidance for Industry: Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination (DWPE) and Removal of a Foreign Manufacturer’s Goods from DWPE,PDF (345.36 KB)PDF (345.36 KB) of Draft Guidance for Industry: Recommendations for Collecting Representative Samples for Food Testing Used as Evidence for Release of Certain Fish and Fishery Products Subject to Detention Without Physical Examination (DWPE) and Removal of a Foreign Manufacturer’s Goods from DWPE,02/05/2024,Human Foods Program,Seafood/Seafood Product,Draft,No,06/25/2024,FDA-2023-D-5303
Conducting Remote Regulatory Assessments Questions and Answers: Draft Guidance for Industry,PDF (550.17 KB)PDF (550.17 KB) of Conducting Remote Regulatory Assessments Questions and Answers: Draft Guidance for Industry,02/02/2024,Office of Inspections and Investigations,"Compliance, Investigation & Enforcement, Inspection, Electronic Submissions, Regulation, Administration, Records, Import",Draft,No,,FDA-2022-D-0810
Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products,PDF (516.23 KB)PDF (516.23 KB) of Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products,01/31/2024,Center for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmacology/Toxicology, Gene Therapy",Final,No,,FDA-2021-D-0404
CVM GFI #188 Data Elements for Submission of Veterinary Adverse Event Reports to the Center for Veterinary Medicine,PDF (581.3 KB)PDF (581.3 KB) of CVM GFI #188 Data Elements for Submission of Veterinary Adverse Event Reports to the Center for Veterinary Medicine,01/31/2024,Center for Veterinary Medicine,Adverse Event Reporting,Final,No,,FDA-2010-D-0241
CVM GFI #214 (VICH GL35) Pharmacovigilance of Veterinary Medicinal Products Electronic Standards for Transfer of Data,PDF (2.36 MB)PDF (2.36 MB) of CVM GFI #214 (VICH GL35) Pharmacovigilance of Veterinary Medicinal Products Electronic Standards for Transfer of Data,01/31/2024,Center for Veterinary Medicine,"Adverse Event Reporting, VICH",Final,No,,FDA-2011-D-0588
Collection of Race and Ethnicity Data in Clinical Trials and Clinical Studies for FDA-Regulated Medical Products,,01/30/2024,"Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of Minority Health and Health EquityOffice of the Commissioner,Office of Women's HealthOffice of the Commissioner,Office of Clinical Policy and ProgramsOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Pediatric Therapeutics","Clinical - Medical, Pediatric Product Development",Draft,No,04/29/2024,FDA-2016-D-3561
Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food,PDF (118 KB)PDF (118 KB) of Draft Guidance for Industry: Hazard Analysis and Risk-Based Preventive Controls for Human Food,01/30/2024,Human Foods Program,,Draft,No,08/02/2024,FDA-2016-D-2343
Human Gene Therapy Products Incorporating Human Genome Editing:  Guidance for Industry,PDF (458.17 KB)PDF (458.17 KB) of Human Gene Therapy Products Incorporating Human Genome Editing:  Guidance for Industry,01/29/2024,Center for Biologics Evaluation and Research,Gene Therapy,Final,No,,FDA-2021-D-0398
CVM GFI #286 (VICH GL60) - Good Manufacturing Practice for Active Pharmaceutical Ingredients Used in Veterinary Medicinal Products,PDF (634.23 KB)PDF (634.23 KB) of CVM GFI #286 (VICH GL60) - Good Manufacturing Practice for Active Pharmaceutical Ingredients Used in Veterinary Medicinal Products,01/25/2024,Center for Veterinary Medicine,"Postmarket, Premarket, Compliance, Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), VICH",Draft,No,03/25/2024,FDA-2023-D-4761
ANDA Submissions – Amendments and Requests for Final Approval to Tentatively Approved ANDAs:  Guidance for Industry,PDF (313.87 KB)PDF (313.87 KB) of ANDA Submissions – Amendments and Requests for Final Approval to Tentatively Approved ANDAs:  Guidance for Industry,01/24/2024,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2018-D-4726
Revising ANDA  Labeling Following  Revision of the RLD  Labeling Guidance for Industry:  Guidance for Industry,PDF (280.85 KB)PDF (280.85 KB) of Revising ANDA  Labeling Following  Revision of the RLD  Labeling Guidance for Industry:  Guidance for Industry,01/24/2024,Center for Drug Evaluation and Research,Generic Drugs,Final,No,03/25/2022,FDA-2022-D-0092
Characterization of Metallic Coatings and/or Calcium Phosphate Coatings on Orthopedic Devices: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (1003.88 KB)PDF (1003.88 KB) of Characterization of Metallic Coatings and/or Calcium Phosphate Coatings on Orthopedic Devices: Draft Guidance for Industry and Food and Drug Administration Staff,01/23/2024,Center for Devices and Radiological Health,"Premarket, Orthopedic",Draft,No,03/22/2024,FDA-2023-D-5430
Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin,PDF (661.29 KB)PDF (661.29 KB) of Q5A(R2) Viral Safety Evaluation of Biotechnology Products Derived from Cell Lines of Human or Animal Origin,01/10/2024,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2022-D-2512
Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile:  Guidance for Industry and Food and Drug Administration Staff,PDF (273.01 KB)PDF (273.01 KB) of Submission and Review of Sterility Information in Premarket Notification (510(k)) Submissions for Devices Labeled as Sterile:  Guidance for Industry and Food and Drug Administration Staff,01/08/2024,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2008-D-0611
Reformulating Drug Products That Contain Carbomers Manufactured With Benzene,PDF (293.9 KB)PDF (293.9 KB) of Reformulating Drug Products That Contain Carbomers Manufactured With Benzene,12/28/2023,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2023-D-5408
Potency Assurance for Cellular and Gene Therapy Products,PDF (364.34 KB)PDF (364.34 KB) of Potency Assurance for Cellular and Gene Therapy Products,12/27/2023,Center for Biologics Evaluation and Research,Gene Therapy,Draft,No,03/27/2024,FDA-2023-D-4299
Quality Considerations for Topical Ophthalmic Drug Products,PDF (361.23 KB)PDF (361.23 KB) of Quality Considerations for Topical Ophthalmic Drug Products,12/27/2023,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,02/26/2024,FDA-2023-D-4177
"Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers","PDF (254.05 KB)PDF (254.05 KB) of Direct-to-Consumer Prescription Drug Advertisements: Presentation of the Major Statement in a Clear, Conspicuous, and Neutral Manner in Advertisements in Television and Radio Format Final Rule Questions and Answers",12/26/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Advertising,Final,No,,FDA-2009-N-0582
Rare Diseases: Considerations for the Development of Drugs and Biological Products,PDF (409.38 KB)PDF (409.38 KB) of Rare Diseases: Considerations for the Development of Drugs and Biological Products,12/26/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Rare Diseases, Pediatric Product Development",Final,No,,FDA-2015-D-2818
"CVM GFI #61 Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species","PDF (766.14 KB)PDF (766.14 KB) of CVM GFI #61 Special Considerations, Incentives, and Programs to Support the Approval of New Animal Drugs for Minor Uses and for Minor Species",12/22/2023,Center for Veterinary Medicine,"Premarket, Aquaculture, Investigational New Animal Drug (INAD)",Final,No,01/11/2021,FDA-1997-D-0444
Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,PDF (459.63 KB)PDF (459.63 KB) of Digital Health Technologies for Remote Data Acquisition in Clinical Investigations,12/22/2023,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2021-D-1128
Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products,PDF (283.15 KB)PDF (283.15 KB) of Real-World Data: Assessing Registries To Support Regulatory Decision-Making for Drug and Biological Products,12/22/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,"Real World Data / Real World Evidence (RWD/RWE), Clinical - Medical",Final,No,,FDA-2021-D-1146
Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization,PDF (317.69 KB)PDF (317.69 KB) of Development of Monoclonal Antibody Products Targeting SARS-CoV-2 for Emergency Use Authorization,12/21/2023,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2020-D-1136
Master Protocols for Drug and Biological Product Development,PDF (563.04 KB)PDF (563.04 KB) of Master Protocols for Drug and Biological Product Development,12/21/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Draft,No,02/22/2024,FDA-2023-D-5259
Data Standards for Drug and Biological Product Submissions Containing Real-World Data:  Guidance for Industry,PDF (331.3 KB)PDF (331.3 KB) of Data Standards for Drug and Biological Product Submissions Containing Real-World Data:  Guidance for Industry,12/21/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Real World Data / Real World Evidence (RWD/RWE),",Final,No,01/21/2022,FDA-2021-D-0548
Clinical Pharmacology Considerations for Peptide Drug Products,PDF (308.77 KB)PDF (308.77 KB) of Clinical Pharmacology Considerations for Peptide Drug Products,12/14/2023,Center for Drug Evaluation and Research,Clinical - Pharmacology,Draft,No,12/11/2023,FDA-2023-D-3391
Draft: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (991.53 KB)PDF (991.53 KB) of Draft: Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff,12/14/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket, Real World Data / Real World Evidence (RWD/RWE), Premarket,",Draft,No,02/20/2024,FDA-2023-D-4395
Draft Guidance for Industry: Menu Labeling Supplemental Guidance (Edition 2),PDF (183.69 KB)PDF (183.69 KB) of Draft Guidance for Industry: Menu Labeling Supplemental Guidance (Edition 2),12/13/2023,Human Foods Program,"Labeling, Nutrition",Draft,No,02/12/2024,FDA-2011-F-0172
Presenting Quantitative Efficacy and Risk Information in  Direct-to-Consumer (DTC) Promotional Labeling and Advertisements,PDF (323.03 KB)PDF (323.03 KB) of Presenting Quantitative Efficacy and Risk Information in  Direct-to-Consumer (DTC) Promotional Labeling and Advertisements,12/12/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,Advertising,Final,No,,FDA-2018-D-2613
Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs:  Guidance for Industry,PDF (354.14 KB)PDF (354.14 KB) of Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs:  Guidance for Industry,12/07/2023,"Center for Drug Evaluation and Research,Office of Regulatory Policy",Administrative / Procedural,Final,No,,FDA-2018-D-3462
CVM GFI #199 Animal Generic Drug User Fees and Fee Waivers and Reductions,PDF (320.45 KB)PDF (320.45 KB) of CVM GFI #199 Animal Generic Drug User Fees and Fee Waivers and Reductions,12/04/2023,Center for Veterinary Medicine,"User Fees,",Final,No,,FDA-2009-D-0189
Small Entity Compliance Guide: Milk and Cream Products and Yogurt Products; Final Rule to Revoke the Standards for Lowfat Yogurt and Nonfat Yogurt and To Amend the Standard for Yogurt,PDF (555.79 KB)PDF (555.79 KB) of Small Entity Compliance Guide: Milk and Cream Products and Yogurt Products; Final Rule to Revoke the Standards for Lowfat Yogurt and Nonfat Yogurt and To Amend the Standard for Yogurt,11/27/2023,Human Foods Program,Dairy,Final,No,,FDA-2023-D-4722
COVID-19: Developing Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry,,11/24/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Infectious Disease, Coronavirus, Clinical - Medical",Final,No,,FDA-2020-D-1370
Translation of Good Laboratory Practice Study Reports: Questions and Answers,PDF (192.09 KB)PDF (192.09 KB) of Translation of Good Laboratory Practice Study Reports: Questions and Answers,11/21/2023,Center for Drug Evaluation and Research,,Draft,No,02/20/2024,FDA-2023-D-4719
Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (1.3 MB)PDF (1.3 MB) of Assessing the Credibility of Computational Modeling and Simulation in Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,11/17/2023,Center for Devices and Radiological Health,"Premarket, Digital Health",Final,No,03/24/2022,FDA-2021-D-0980
Guidance for Industry: Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing,PDF (217.95 KB)PDF (217.95 KB) of Guidance for Industry: Compliance Policy for Cosmetic Product Facility Registration and Cosmetic Product Listing,11/08/2023,"Office of the Commissioner,Office of the Chief Scientist",,Final,No,,FDA-2023-D-1716
Real-Time Oncology Review (RTOR) :  Guidance for Industry,PDF (257.79 KB)PDF (257.79 KB) of Real-Time Oncology Review (RTOR) :  Guidance for Industry,11/07/2023,Oncology Center of Excellence,,Final,No,,FDA-2022-D-0823
Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory,PDF (284.09 KB)PDF (284.09 KB) of Submitting Clinical Trial Datasets and Documentation for Clinical Outcome Assessments Using Item Response Theory,11/06/2023,Center for Drug Evaluation and Research,,Final,No,,FDA-2018-D-1216
Submitting Patient-Reported Outcome Data in Cancer Clinical Trials,PDF (851.69 KB)PDF (851.69 KB) of Submitting Patient-Reported Outcome Data in Cancer Clinical Trials,11/06/2023,Center for Drug Evaluation and ResearchOncology Center of Excellence,,Final,No,,FDA-2018-D-1216
Enforcement Policy for Clinical Electronic Thermometers:  Guidance for Industry and Food and Drug Administration Staff,PDF (627.51 KB)PDF (627.51 KB) of Enforcement Policy for Clinical Electronic Thermometers:  Guidance for Industry and Food and Drug Administration Staff,11/03/2023,Center for Devices and Radiological Health,"Premarket, Postmarket, Device & Drug Safety",Final,No,,FDA-2023-N-4372
Process to Request a Review of FDA's Decision Not to Issue Certain Export Certificates for Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (494.44 KB)PDF (494.44 KB) of Process to Request a Review of FDA's Decision Not to Issue Certain Export Certificates for Devices:  Guidance for Industry and Food and Drug Administration Staff,11/03/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket, Export, Import",Final,No,,FDA-2018-D-2310
Enforcement Policy for Certain Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (428.12 KB)PDF (428.12 KB) of Enforcement Policy for Certain Supplements for Approved Premarket Approval (PMA) or Humanitarian Device Exemption (HDE) Submissions:  Guidance for Industry and Food and Drug Administration Staff,11/02/2023,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"HUD/HDE, Premarket Approval (PMA)",Final,No,,FDA-2023-D-4595
Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities,PDF (310.2 KB)PDF (310.2 KB) of Remote Interactive Evaluations of Drug Manufacturing and Bioresearch Monitoring Facilities,10/26/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Draft,No,12/26/2023,FDA-2023-D-4416
Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence,PDF (526.26 KB)PDF (526.26 KB) of Topical Dermatologic Corticosteroids:  In Vivo Bioequivalence,10/24/2023,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Draft,No,,FDA-2022-D-2170
Development and Licensure of Vaccines to Prevent COVID-19:  Guidance for Industry,PDF (407.08 KB)PDF (407.08 KB) of Development and Licensure of Vaccines to Prevent COVID-19:  Guidance for Industry,10/19/2023,Center for Biologics Evaluation and Research,"Infectious Disease, Coronavirus, Vaccines",Final,No,,FDA-2020-D-1137
Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies:  Guidance for Industry,PDF (289.04 KB)PDF (289.04 KB) of Voluntary Consensus Standards Recognition Program for Regenerative Medicine Therapies:  Guidance for Industry,10/19/2023,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2022-D-0745
Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring:  Guidance for Industry and Food and Drug Administration Staff,PDF (562.96 KB)PDF (562.96 KB) of Enforcement Policy for Non-Invasive Remote Monitoring Devices Used to Support Patient Monitoring:  Guidance for Industry and Food and Drug Administration Staff,10/19/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Labeling",Final,No,,FDA-2023-D-4356
Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions (Revised):  Guidance for Industry,PDF (444.72 KB)PDF (444.72 KB) of Demonstrating the Substantial Equivalence of a New Tobacco Product: Responses to Frequently Asked Questions (Revised):  Guidance for Industry,10/18/2023,Center for Tobacco Products,,Final,No,,FDA-2011-D-0147
"Establishing That a Tobacco Product Was Commercially Marketed in the United States as of February 15, 2007 (Revised):  Guidance for Industry","PDF (295.64 KB)PDF (295.64 KB) of Establishing That a Tobacco Product Was Commercially Marketed in the United States as of February 15, 2007 (Revised):  Guidance for Industry",10/18/2023,Center for Tobacco Products,,Final,No,,FDA-2011-D-0125
Benefit-Risk Assessment for New Drug and Biological Products,PDF (398.36 KB)PDF (398.36 KB) of Benefit-Risk Assessment for New Drug and Biological Products,10/17/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2020-D-2316
"Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements:  Guidance for Industry","PDF (282.59 KB)PDF (282.59 KB) of Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements:  Guidance for Industry",10/17/2023,Center for Biologics Evaluation and Research,"Blood, Coronavirus, Blood Products",Final,No,,FDA-2022-D-0588
Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol:  Guidance for Industry,PDF (292.4 KB)PDF (292.4 KB) of Policy for Testing of Alcohol (Ethanol) and Isopropyl Alcohol for Methanol:  Guidance for Industry,10/17/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,Current Good Manufacturing Practice (CGMP),Final,No,,FDA-2020-D-2016
Guidance for Industry: Prior Notice of Imported Food Questions and Answers (Edition 4),PDF (538.12 KB)PDF (538.12 KB) of Guidance for Industry: Prior Notice of Imported Food Questions and Answers (Edition 4),10/13/2023,Human Foods ProgramOffice of Inspections and InvestigationsCenter for Veterinary Medicine,Import,Final,No,10/13/2023,FDA-2011-N-0179
Investigational COVID-19 Convalescent Plasma:  Guidance for Industry,PDF (320.57 KB)PDF (320.57 KB) of Investigational COVID-19 Convalescent Plasma:  Guidance for Industry,10/13/2023,Center for Biologics Evaluation and Research,"Blood, Infectious Disease, Coronavirus, Blood Products",Final,No,,FDA-2020-D-1825
Submission of Premarket Notifications for Magnetic Resonance Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (506.83 KB)PDF (506.83 KB) of Submission of Premarket Notifications for Magnetic Resonance Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,10/10/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Radiological Health, Radiology",Final,No,,FDA-2015-D-2148
Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment:  Guidance for Industry and Food and Drug Administration Staff,PDF (1.02 MB)PDF (1.02 MB) of Testing and Labeling Medical Devices for Safety in the Magnetic Resonance (MR) Environment:  Guidance for Industry and Food and Drug Administration Staff,10/10/2023,Center for Devices and Radiological Health,"Premarket, Labeling, Safety - Issues, Errors, and Problems",Final,No,,FDA-2019-D-2837
Stimulant Use Disorders: Developing Drugs for Treatment,PDF (279.31 KB)PDF (279.31 KB) of Stimulant Use Disorders: Developing Drugs for Treatment,10/05/2023,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,12/04/2023,FDA-2023-D-1848
Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”,PDF (261.22 KB)PDF (261.22 KB) of Human Prescription Drug and Biological Products--Labeling for Dosing Based on Weight or Body Surface Area for Ready-to-Use Containers--“Dose Banding”,10/02/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Labeling,Final,No,,FDA-2022-D-0219
Electronic Submission Template for Medical Device 510(k) Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (455.72 KB)PDF (455.72 KB) of Electronic Submission Template for Medical Device 510(k) Submissions:  Guidance for Industry and Food and Drug Administration Staff,10/02/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,,Final,No,,FDA-2021-D-0872
Antimicrobial Susceptibility Test (AST) System Devices – Updating Breakpoints in Device Labeling:  Guidance for Industry and Food and Drug Administration Staff,PDF (340.66 KB)PDF (340.66 KB) of Antimicrobial Susceptibility Test (AST) System Devices – Updating Breakpoints in Device Labeling:  Guidance for Industry and Food and Drug Administration Staff,09/29/2023,Center for Devices and Radiological Health,Antimicrobial Resistance,Final,No,,FDA-2023-D-4045
Technical Considerations for Medical Devices with Physiologic Closed-Loop Control Technology:  Guidance for Industry and Food and Drug Administration Staff,PDF (539.42 KB)PDF (539.42 KB) of Technical Considerations for Medical Devices with Physiologic Closed-Loop Control Technology:  Guidance for Industry and Food and Drug Administration Staff,09/29/2023,Center for Devices and Radiological Health,"Premarket, Combination Products, Clinical - Medical, Digital Health",Final,No,02/22/2022,FDA-2021-D-0996
"Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption","PDF (3.89 MB)PDF (3.89 MB) of Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption",09/28/2023,Human Foods Program,Produce,Final,No,,FDA-2017-D-0175
"Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption","PDF (698.43 KB)PDF (698.43 KB) of Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Sprouts for Human Consumption",09/28/2023,Human Foods Program,Vegetable Products,Draft,No,03/27/2024,FDA-2017-D-0175
"Graft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment","PDF (511.08 KB)PDF (511.08 KB) of Graft-versus-Host Diseases: Developing Drugs, Biological Products, and Certain Devices for Prevention or Treatment",09/28/2023,Oncology Center of Excellence,,Draft,No,11/28/2023,FDA-2023-D-3900
Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (674.46 KB)PDF (674.46 KB) of Cybersecurity in Medical Devices: Quality System Considerations and Content of Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,09/27/2023,Center for Devices and Radiological Health,"Premarket, Digital Health",Final,No,,FDA-2021-D-1158
CVM GFI #273 Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals,PDF (523.07 KB)PDF (523.07 KB) of CVM GFI #273 Defining Durations of Use for Approved Medically Important Antimicrobial Drugs Fed to Food-Producing Animals,09/26/2023,Center for Veterinary Medicine,"Premarket, Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)",Draft,No,01/05/2024,FDA-2023-D-2925
Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications,PDF (292.26 KB)PDF (292.26 KB) of Alternative Tools: Assessing Drug Manufacturing Facilities Identified in Pending Applications,09/22/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Draft,No,11/21/2023,FDA-2023-D-3031
Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products,PDF (388.31 KB)PDF (388.31 KB) of Formal Meetings Between the FDA and Sponsors or Applicants of PDUFA Products,09/22/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Draft,No,12/21/2023,FDA-2017-D-6530
Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies,PDF (470.23 KB)PDF (470.23 KB) of Considerations for the Conduct of Clinical Trials of Medical Products During Major Disruptions Due to Disasters and Public Health Emergencies,09/21/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthOncology Center of Excellence,"Emergencies,",Final,No,,FDA-2023-D-3550
Guidance for Industry: Returning Refrigerated Transport Vehicles and Refrigerated Storage Units to Food Uses After Using Them to  Preserve Human Remains,PDF (230.96 KB)PDF (230.96 KB) of Guidance for Industry: Returning Refrigerated Transport Vehicles and Refrigerated Storage Units to Food Uses After Using Them to  Preserve Human Remains,09/20/2023,Center for Veterinary MedicineHuman Foods Program,Transportation,Final,No,,FDA-2020-D-1139
Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence,PDF (308.11 KB)PDF (308.11 KB) of Demonstrating Substantial Evidence of Effectiveness With One Adequate and Well-Controlled Clinical Investigation and Confirmatory Evidence,09/19/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of ExcellenceOffice of the Commissioner,Clinical - Medical,Draft,No,12/18/2023,FDA-2023-D-2318
Regulatory Considerations for Prescription Drug Use-Related Software,PDF (341.64 KB)PDF (341.64 KB) of Regulatory Considerations for Prescription Drug Use-Related Software,09/19/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthOncology Center of Excellence,Labeling,Draft,No,12/18/2023,FDA-2023-D-2482
Labeling for Biosimilar and Interchangeable Biosimilar Products,PDF (359.65 KB)PDF (359.65 KB) of Labeling for Biosimilar and Interchangeable Biosimilar Products,09/18/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Biosimilars,Draft,No,11/17/2023,FDA-2016-D-0643
Biosimilarity and Interchangeability:  Additional Draft Q&As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry,PDF (310.57 KB)PDF (310.57 KB) of Biosimilarity and Interchangeability:  Additional Draft Q&As on Biosimilar Development and the BPCI Act (Revision 1): Draft Guidance for Industry,09/18/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Biosimilars, Prescription Drugs",Draft,No,,FDA-2011-D-0611
CVM GFI #282 Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals,PDF (323.88 KB)PDF (323.88 KB) of CVM GFI #282 Informed Consent Forms for Studies that Enroll Client-Owned Companion Animals,09/15/2023,Center for Veterinary Medicine,"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal – Effectiveness",Draft,No,11/14/2023,FDA-2023-D-2654
Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry:  Guidance for Industry,PDF (309.7 KB)PDF (309.7 KB) of Annual Status Report Information and Other Submissions for Postmarketing Requirements and Commitments: Using Forms FDA 3988 and FDA 3989 Guidance for Industry:  Guidance for Industry,09/15/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Final,No,,FDA-2018-N-3771
Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program:  Guidance for Industry and Food and Drug Administration Staff,PDF (584.86 KB)PDF (584.86 KB) of Fostering Medical Device Improvement: FDA Activities and Engagement with the Voluntary Improvement Program:  Guidance for Industry and Food and Drug Administration Staff,09/15/2023,Center for Devices and Radiological Health,"Postmarket, Current Good Manufacturing Practice (CGMP)",Final,No,,FDA-2022-D-0109
Medical Devices with Indications Associated with Weight Loss - Clinical Study and Benefit-Risk Considerations: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (1.37 MB)PDF (1.37 MB) of Medical Devices with Indications Associated with Weight Loss - Clinical Study and Benefit-Risk Considerations: Draft Guidance for Industry and Food and Drug Administration Staff,09/15/2023,Center for Devices and Radiological Health,"Premarket, Gastroenterology-Urology",Draft,No,11/14/2023,FDA-2019-N-4060
Medical Devices with Indications Associated with Weight Loss - Non-Clinical Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (922.81 KB)PDF (922.81 KB) of Medical Devices with Indications Associated with Weight Loss - Non-Clinical Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,09/15/2023,Center for Devices and Radiological Health,"Premarket, Gastroenterology-Urology",Draft,No,11/14/2023,FDA-2019-N-4060
Breakthrough Devices Program:  Guidance for Industry and Food and Drug Administration Staff,PDF (839.14 KB)PDF (839.14 KB) of Breakthrough Devices Program:  Guidance for Industry and Food and Drug Administration Staff,09/14/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,,Final,No,,FDA-2017-D-5966
Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products:   Guidance for IRBs and Clinical Investigators,PDF (152.78 KB)PDF (152.78 KB) of Institutional Review Board (IRB) Review of Individual Patient Expanded Access Submissions for Investigational Drugs and Biological Products:   Guidance for IRBs and Clinical Investigators,09/11/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,Good Clinical Practice (GCP),Final,No,,FDA-2023-D-3452
Endogenous Cushing’s Syndrome: Developing Drugs for Treatment,PDF (359.45 KB)PDF (359.45 KB) of Endogenous Cushing’s Syndrome: Developing Drugs for Treatment,09/08/2023,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,11/07/2023,FDA-2023-D-3518
"Use of International Standard ISO 10993-1, ""Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"" :  Guidance for Industry and Food and Drug Administration Staff","PDF (1.12 MB)PDF (1.12 MB) of Use of International Standard ISO 10993-1, ""Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process"" :  Guidance for Industry and Food and Drug Administration Staff",09/08/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD/HDE, Safety - Issues, Errors, and Problems",Final,No,,FDA-2013-D-0350
Application of Human Factors Engineering Principles for Combination Products: Questions and Answers:  Guidance for Industry and  FDA Staff,PDF (337.28 KB)PDF (337.28 KB) of Application of Human Factors Engineering Principles for Combination Products: Questions and Answers:  Guidance for Industry and  FDA Staff,09/07/2023,"Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Final,No,05/03/2016,FDA-2015-D-4848
Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (593.27 KB)PDF (593.27 KB) of Best Practices for Selecting a Predicate Device to Support a Premarket Notification [510(k)] Submission: Draft Guidance for Industry and Food and Drug Administration Staff,09/07/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k)",Draft,No,12/06/2023,FDA-2023-D-3134
Evidentiary Expectations for 510(k) Implant Devices: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (815.33 KB)PDF (815.33 KB) of Evidentiary Expectations for 510(k) Implant Devices: Draft Guidance for Industry and Food and Drug Administration Staff,09/07/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k)",Draft,No,12/06/2023,FDA-2023-D-3132
Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (561.13 KB)PDF (561.13 KB) of Recommendations for the Use of Clinical Data in Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,09/07/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k)",Draft,No,12/06/2023,FDA-2023-D-3133
"DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry","PDF (237.14 KB)PDF (237.14 KB) of DSCSA Standards for the Interoperable Exchange of Information for Tracing of Certain Human, Finished, Prescription Drugs Guidance for Industry",09/06/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2014-D-1981
Post-Warning Letter Meetings Under GDUFA,PDF (281.97 KB)PDF (281.97 KB) of Post-Warning Letter Meetings Under GDUFA,09/05/2023,Center for Drug Evaluation and Research,Generic Drugs,Draft,No,11/06/2023,FDA-2023-D-3370
Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex:  Developing Drugs for Treatment :  Guidance for Industry,PDF (257.24 KB)PDF (257.24 KB) of Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium avium Complex:  Developing Drugs for Treatment :  Guidance for Industry,09/05/2023,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2021-D-0544
Enforcement Policy for Face Masks and Barrier Face Coverings During the Coronavirus Disease (COVID-19) Public Health Emergency :  Guidance for Industry and Food and Drug Administration Staff,PDF (527.83 KB)PDF (527.83 KB) of Enforcement Policy for Face Masks and Barrier Face Coverings During the Coronavirus Disease (COVID-19) Public Health Emergency :  Guidance for Industry and Food and Drug Administration Staff,09/05/2023,Center for Devices and Radiological Health,"Premarket, Coronavirus, Labeling",Final,No,,FDA-2020-D-1138
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies,PDF (242 KB)PDF (242 KB) of Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies,09/01/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2019-D-4212
Civil Money Penalties and No-Tobacco-Sale Orders For Tobacco Retailers (*Revised):  Guidance for Industry,PDF (547.39 KB)PDF (547.39 KB) of Civil Money Penalties and No-Tobacco-Sale Orders For Tobacco Retailers (*Revised):  Guidance for Industry,08/31/2023,Center for Tobacco Products,No-tobacco-sale order (NTSO),Final,No,,FDA-2010-D-0431
Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products:  Guidance for Industry,PDF (218.37 KB)PDF (218.37 KB) of Considerations for the Use of Real-World Data and Real-World Evidence To Support Regulatory Decision-Making for Drug and Biological Products:  Guidance for Industry,08/30/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,"Real World Data / Real World Evidence (RWD/RWE), Clinical - Medical",Final,No,,FDA-2021-D-1214
Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act:  Guidance for Industry,PDF (430.51 KB)PDF (430.51 KB) of Enhanced Drug Distribution Security at the Package Level Under the Drug Supply Chain Security Act:  Guidance for Industry,08/30/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2020-D-2024
"Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies","PDF (259.61 KB)PDF (259.61 KB) of Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act--Compliance Policies",08/28/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2023-D-1909
Guidance for Industry: The Seafood List FDA’s Guide to Determine Acceptable Seafood Names,PDF (371.78 KB)PDF (371.78 KB) of Guidance for Industry: The Seafood List FDA’s Guide to Determine Acceptable Seafood Names,08/22/2023,Human Foods Program,Seafood/Seafood Product,Final,No,,FDA-1994-D-0221
"Informed Consent:  Guidance for IRBs, Clinical Investigators, and Sponsors","PDF (747.35 KB)PDF (747.35 KB) of Informed Consent:  Guidance for IRBs, Clinical Investigators, and Sponsors",08/15/2023,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Good Clinical Practice (GCP), Pediatric Product Development",Final,No,,FDA-2006-D-0031
Classification Categories for Certain Supplements Under BsUFA III,PDF (289.85 KB)PDF (289.85 KB) of Classification Categories for Certain Supplements Under BsUFA III,08/11/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Biosimilars,Draft,No,10/10/2023,FDA-2023-D-1954
Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry,PDF (348.41 KB)PDF (348.41 KB) of Formal Meetings Between the FDA and Sponsors or Applicants of BsUFA Products Guidance for Industry,08/11/2023,Center for Drug Evaluation and Research,"Administrative / Procedural, Biosimilars",Draft,No,10/10/2023,FDA-2018-D-1922
Off-The-Shelf Software Use in Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (524.43 KB)PDF (524.43 KB) of Off-The-Shelf Software Use in Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,08/11/2023,Center for Devices and Radiological Health,"Premarket, Digital Health",Final,No,,FDA-2019-D-3598
Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products,PDF (321.2 KB)PDF (321.2 KB) of Postmarketing Approaches to Obtain Data on Populations Underrepresented in Clinical Trials for Drugs and Biological Products,08/10/2023,Oncology Center of Excellence,Clinical - Medical,Draft,No,,FDA-2022-D-2629
QTc Information in Human Prescription Drug and Biological Product Labeling: Draft Guidance for Industry,PDF (336.55 KB)PDF (336.55 KB) of QTc Information in Human Prescription Drug and Biological Product Labeling: Draft Guidance for Industry,08/08/2023,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,10/10/2023,FDA-2023-D-2439
Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities,PDF (727.18 KB)PDF (727.18 KB) of Recommended Acceptable Intake Limits for Nitrosamine Drug Substance-Related Impurities,08/07/2023,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2020-D-1530
"Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act","PDF (296.22 KB)PDF (296.22 KB) of Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act",08/04/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2018-D-1434
"PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR","PDF (274.72 KB)PDF (274.72 KB) of PDUFA Waivers, Reductions, and Refunds for Fixed- Combinations and Single-Entity Versions of Previously Approved Antiretrovirals under PEPFAR",08/03/2023,Center for Drug Evaluation and Research,"User Fees,",Draft,No,10/02/2023,FDA-2018-D-1635
Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President’s Emergency Plan for Acquired Immunodeficiency Syndrome Relief,PDF (385.65 KB)PDF (385.65 KB) of Fixed-Combinations and Single-Entity Versions of Previously Approved Antiretrovirals for the Treatment or Prevention of Human Immunodeficiency Virus-One Under the President’s Emergency Plan for Acquired Immunodeficiency Syndrome Relief,08/01/2023,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,11/01/2023,FDA-2004-D-0301
Assessing User Fees Under the Biosimilar User Fee Amendments of 2022:  Guidance for Industry,PDF (366.77 KB)PDF (366.77 KB) of Assessing User Fees Under the Biosimilar User Fee Amendments of 2022:  Guidance for Industry,07/31/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"User Fees,",Final,No,,FDA-2017-D-6209
Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (671.09 KB)PDF (671.09 KB) of Hydrogen Peroxide-Based Contact Lens Care Products: Consumer Labeling Recommendations - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,07/27/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Labeling, Ophthalmic",Final,No,,FDA-2022-D-0986
CDER’s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality,PDF (273.53 KB)PDF (273.53 KB) of CDER’s Program for the Recognition of Voluntary Consensus Standards Related to Pharmaceutical Quality,07/26/2023,Center for Drug Evaluation and Research,"Administrative / Procedural, Drug Competition Action Plan",Final,No,,FDA-2018-D-4417
Guidance for Industry | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk,PDF (515.37 KB)PDF (515.37 KB) of Guidance for Industry | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk,07/25/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2022-D-0055
M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES:  Guidance for Industry,PDF (1.34 MB)PDF (1.34 MB) of M7(R2) ADDENDUM: APPLICATION OF THE PRINCIPLES OF THE ICH M7 GUIDELINE TO CALCULATION OF COMPOUND-SPECIFIC ACCEPTABLE INTAKES:  Guidance for Industry,07/25/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2022-D-0055
Questions and Answers | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk:  Guidance for Industry,PDF (291.4 KB)PDF (291.4 KB) of Questions and Answers | M7(R2) Assessment and Control of DNA Reactive (Mutagenic) Impurities in Pharmaceuticals To Limit Potential Carcinogenic Risk:  Guidance for Industry,07/25/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2020-N-1790
"Qualification of Medical Device Development Tools:  Guidance for Industry, Tool Developers, and Food and Drug Administration Staff","PDF (386.33 KB)PDF (386.33 KB) of Qualification of Medical Device Development Tools:  Guidance for Industry, Tool Developers, and Food and Drug Administration Staff",07/17/2023,Center for Devices and Radiological Health,"Premarket, Administrative / Procedural, Digital Health",Final,No,,FDA-2013-D-1279
"Postmarketing Studies and Clinical Trials:  Determining Good Cause for Noncompliance with Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry","PDF (301.83 KB)PDF (301.83 KB) of Postmarketing Studies and Clinical Trials:  Determining Good Cause for Noncompliance with Section 505(o)(3)(E)(ii) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry",07/14/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Draft,No,09/12/2023,FDA-2023-D-0559
Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products,PDF (426.13 KB)PDF (426.13 KB) of Manufacturing Changes and Comparability for Human Cellular and Gene Therapy Products,07/13/2023,Center for Biologics Evaluation and Research,Gene Therapy,Draft,No,11/13/2023,FDA-2023-D-2436
Temporary Policy Regarding Accredited Third-Party Certification Program Onsite Observation and Certificate Duration Requirements Due to COVID-19 :  Guidance for Industry,PDF (284.86 KB)PDF (284.86 KB) of Temporary Policy Regarding Accredited Third-Party Certification Program Onsite Observation and Certificate Duration Requirements Due to COVID-19 :  Guidance for Industry,07/13/2023,Human Foods ProgramCenter for Veterinary MedicineOffice of Inspections and Investigations,"Infectious Disease, Coronavirus,",Final,No,,FDA-2023-D-2827
Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements Due to COVID-19:  Guidance for Industry,PDF (265.9 KB)PDF (265.9 KB) of Temporary Policy Regarding Preventive Controls and FSVP Food Supplier Verification Onsite Audit Requirements Due to COVID-19:  Guidance for Industry,07/13/2023,Human Foods Program,"Infectious Disease, Coronavirus,",Final,No,,FDA-2023-D-2828
Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development: Draft Guidance for Industry,PDF (248.13 KB)PDF (248.13 KB) of Inborn Errors of Metabolism That Use Dietary Management: Considerations for Optimizing and Standardizing Diet in Clinical Trials for Drug Product Development: Draft Guidance for Industry,07/12/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Draft,No,09/11/2023,FDA-2018-D-2647
Chronic Rhinosinusitis with Nasal Polyps: Developing Drugs for Treatment :  Guidance for Industry,,06/28/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2021-D-1096
Patient-Matched Guides to Orthopedic Implants: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (455.47 KB)PDF (455.47 KB) of Patient-Matched Guides to Orthopedic Implants: Draft Guidance for Industry and Food and Drug Administration Staff,06/28/2023,Center for Devices and Radiological Health,"Premarket, Orthopedic",Draft,No,08/28/2023,FDA-2023-D-2370
"Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act","PDF (215.86 KB)PDF (215.86 KB) of Prohibition on Wholesaling Under Section 503B of the Federal Food, Drug, and Cosmetic Act",06/27/2023,Center for Drug Evaluation and Research,Compounding,Draft,No,08/28/2023,FDA-2023-D-0939
"Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act","PDF (370.78 KB)PDF (370.78 KB) of Formal Dispute Resolution and Administrative Hearings of Final Administrative Orders Under Section 505G of the Federal Food, Drug, and Cosmetic Act",06/23/2023,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,08/22/2023,FDA-2023-D-2204
Psychedelic Drugs: Considerations for Clinical Investigations,PDF (303.72 KB)PDF (303.72 KB) of Psychedelic Drugs: Considerations for Clinical Investigations,06/23/2023,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,08/25/2023,FDA-2023-D-1987
Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical:  Guidance for Industry,PDF (320.29 KB)PDF (320.29 KB) of Alternative Procedures for the Manufacture of Cold-Stored Platelets Intended for the Treatment of Active Bleeding when Conventional Platelets Are Not Available or Their Use Is Not Practical:  Guidance for Industry,06/23/2023,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2023-D-2034
Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry:  Guidance for Industry,PDF (358.31 KB)PDF (358.31 KB) of Drug-Drug Interaction Assessment for Therapeutic Proteins Guidance for Industry:  Guidance for Industry,06/22/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,11/09/2020,FDA-2020-D-1480
"Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program:  Guidance for Industry, Clinical Laboratories, and Food and Drug Administration Staff","PDF (279.32 KB)PDF (279.32 KB) of Oncology Drug Products Used with Certain In Vitro Diagnostic Tests: Pilot Program:  Guidance for Industry, Clinical Laboratories, and Food and Drug Administration Staff",06/20/2023,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Devices and Radiological Health,,Final,No,,FDA-2022-D-2275
CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered to Be Soluble in Aqueous Media,PDF (419.64 KB)PDF (419.64 KB) of CVM GFI #171 - Demonstrating Bioequivalence for Soluble Powder Oral Dosage Form Products and Type A Medicated Articles Containing Active Pharmaceutical Ingredients Considered to Be Soluble in Aqueous Media,06/16/2023,Center for Veterinary Medicine,"Premarket, Aquaculture, Generic Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Final,No,11/29/2019,FDA-2019-D-3764
Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma:  Guidance for Industry,PDF (230.2 KB)PDF (230.2 KB) of Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Source Plasma:  Guidance for Industry,06/14/2023,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2016-D-1342
Content of Premarket Submissions for Device Software Functions:  Guidance for Industry and Food and Drug Administration Staff,PDF (1.2 MB)PDF (1.2 MB) of Content of Premarket Submissions for Device Software Functions:  Guidance for Industry and Food and Drug Administration Staff,06/14/2023,"Center for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Drug Evaluation and Research","Premarket, Digital Health",Final,No,,FDA-2021-D-0775
Assessing User Fees Under the Generic Drug User Fee Amendments of 2022,PDF (550.06 KB)PDF (550.06 KB) of Assessing User Fees Under the Generic Drug User Fee Amendments of 2022,06/09/2023,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Final,No,,FDA-2012-D-0880
Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry:  Guidance for Industry,PDF (432.1 KB)PDF (432.1 KB) of Clinical Drug Interaction Studies With Combined Oral Contraceptives Guidance for Industry:  Guidance for Industry,06/08/2023,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,02/22/2021,FDA-2020-D-1848
E6(R3) GOOD CLINICAL PRACTICE (GCP),PDF (1.1 MB)PDF (1.1 MB) of E6(R3) GOOD CLINICAL PRACTICE (GCP),06/06/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Draft,No,09/05/2023,FDA-2023-D-1955
Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals,PDF (288.98 KB)PDF (288.98 KB) of Nonclinical Evaluation of the Immunotoxic Potential of Pharmaceuticals,06/05/2023,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2019-D-5607
Cover Letter Attachments for Controlled Correspondences and ANDA Submissions:  Guidance for Industry,PDF (333.78 KB)PDF (333.78 KB) of Cover Letter Attachments for Controlled Correspondences and ANDA Submissions:  Guidance for Industry,06/05/2023,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,FDA-2021-D-0861
Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment: Draft Guidance for Industry,PDF (295.3 KB)PDF (295.3 KB) of Interstitial Cystitis/Bladder Pain Syndrome: Establishing Drug Development Programs for Treatment: Draft Guidance for Industry,06/02/2023,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,08/04/2023,FDA-2019-D-4656
Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program:  Guidance for Industry and Food and Drug Administration Staff,PDF (756.54 KB)PDF (756.54 KB) of Requests for Feedback and Meetings for Medical Device Submissions: The Q-Submission Program:  Guidance for Industry and Food and Drug Administration Staff,06/02/2023,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Administrative / Procedural, Investigational Device Exemption (IDE)",Final,No,,FDA-2018-D-1774
Guidance for Industry: Action Level for Inorganic Arsenic in Apple Juice,PDF (322.08 KB)PDF (322.08 KB) of Guidance for Industry: Action Level for Inorganic Arsenic in Apple Juice,06/01/2023,Human Foods Program,"Arsenic, Juice",Final,No,,FDA-2012-D-0322
Migraine:  Developing Drugs for Preventive Treatment,PDF (278.4 KB)PDF (278.4 KB) of Migraine:  Developing Drugs for Preventive Treatment,06/01/2023,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,08/01/2023,FDA-2022-D-1729
Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products,PDF (357.25 KB)PDF (357.25 KB) of Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products,05/26/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Final,No,,FDA-2019-D-0934
Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures:  Guidance for Industry and Food and Drug Administration Staff,PDF (362.84 KB)PDF (362.84 KB) of Non-Clinical Performance Assessment of Tissue Containment Systems Used During Power Morcellation Procedures:  Guidance for Industry and Food and Drug Administration Staff,05/26/2023,Center for Devices and Radiological Health,"Premarket, Clinical - Medical, General & Plastic Surgery , Obstetrical & Gynecological",Final,No,,FDA-2022-D-0737
Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products,PDF (267.14 KB)PDF (267.14 KB) of Diabetes Mellitus: Efficacy Endpoints for Clinical Trials Investigating Antidiabetic Drugs and Biological Products,05/25/2023,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Draft,No,08/24/2023,FDA-2023-D-0625
Generally Accepted Scientific Knowledge in Applications for Drug and Biological Products:  Nonclinical Information,PDF (249.65 KB)PDF (249.65 KB) of Generally Accepted Scientific Knowledge in Applications for Drug and Biological Products:  Nonclinical Information,05/24/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Pharmacology/Toxicology,Draft,No,07/24/2023,FDA-2023-D-1618
Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers:  Guidance for Industry,PDF (124.61 KB)PDF (124.61 KB) of Use of Whole Slide Imaging in Nonclinical Toxicology Studies: Questions and Answers:  Guidance for Industry,05/24/2023,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,Pharmacology/Toxicology,Final,No,,FDA-2021-D-1268
Small Entity Compliance Guide: Requirements for Additional Traceability Records for Certain Foods: What You Need to Know About the FDA Regulation,PDF (457.97 KB)PDF (457.97 KB) of Small Entity Compliance Guide: Requirements for Additional Traceability Records for Certain Foods: What You Need to Know About the FDA Regulation,05/18/2023,Human Foods Program,,Final,No,,FDA-2023-D-1336
Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act:  Scientific Considerations,PDF (324.33 KB)PDF (324.33 KB) of Pediatric Drug Development Under the Pediatric Research Equity Act and the Best Pharmaceuticals for Children Act:  Scientific Considerations,05/17/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Pediatric Product Development",Draft,No,07/17/2023,FDA-2005-D-0460
Pediatric Drug Development:  Regulatory Considerations — Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act,PDF (515.66 KB)PDF (515.66 KB) of Pediatric Drug Development:  Regulatory Considerations — Complying With the Pediatric Research Equity Act and Qualifying for Pediatric Exclusivity Under the Best Pharmaceuticals for Children Act,05/17/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Pediatric Product Development",Draft,No,07/17/2023,FDA-2005-D-0460
CVM GFI #271 Reporting and Mitigating Animal Drug Shortages,PDF (262.94 KB)PDF (262.94 KB) of CVM GFI #271 Reporting and Mitigating Animal Drug Shortages,05/12/2023,Center for Veterinary Medicine,"Postmarket, Coronavirus, Animal Drugs, Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2020-D-1140
Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Blood and Blood Components:  Guidance for Industry,PDF (248.04 KB)PDF (248.04 KB) of Implementation of Acceptable Full-Length and Abbreviated Donor History Questionnaires and Accompanying Materials for Use in Screening Donors of Blood and Blood Components:  Guidance for Industry,05/11/2023,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2016-D-1342
Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products:  Guidance for Industry,PDF (299.43 KB)PDF (299.43 KB) of Recommendations for Evaluating Donor Eligibility Using Individual Risk-Based Questions to Reduce the Risk of Human Immunodeficiency Virus Transmission by Blood and Blood Products:  Guidance for Industry,05/11/2023,Center for Biologics Evaluation and Research,"Blood, Coronavirus, HIV/AIDS, Blood Products",Final,No,,FDA-2015-D-1211
CPG Sec 555.250 DRAFT: Major Food Allergen Labeling and Cross-contact,PDF (290.97 KB)PDF (290.97 KB) of CPG Sec 555.250 DRAFT: Major Food Allergen Labeling and Cross-contact,05/09/2023,Human Foods Program,"Investigation & Enforcement,",Draft,No,07/17/2023,FDA-2023-D-1103
"Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol","PDF (283.72 KB)PDF (283.72 KB) of Testing of Glycerin, Propylene Glycol, Maltitol Solution, Hydrogenated Starch Hydrolysate, Sorbitol Solution, and Other High-Risk Drug Components for Diethylene Glycol and Ethylene Glycol",05/08/2023,Center for Drug Evaluation and Research,"Compliance,",Final,No,,FDA-2023-D-1573
Q9(R1) Quality Risk Management,PDF (435.74 KB)PDF (435.74 KB) of Q9(R1) Quality Risk Management,05/03/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2022-D-0705
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022,PDF (386.18 KB)PDF (386.18 KB) of Assessing User Fees Under the Prescription Drug User Fee Amendments of 2022,05/01/2023,Center for Drug Evaluation and Research,"User Fees,",Final,No,,FDA-2017-D-6821
Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products,PDF (353.58 KB)PDF (353.58 KB) of Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products,05/01/2023,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2019-D-0297
S12 NONCLINICAL BIODISTRIBUTION CONSIDERATIONS FOR GENE THERAPY PRODUCTS:  Guidance for Industry,PDF (276.84 KB)PDF (276.84 KB) of S12 NONCLINICAL BIODISTRIBUTION CONSIDERATIONS FOR GENE THERAPY PRODUCTS:  Guidance for Industry,05/01/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2021-D-0875
CVM GFI #108 Registering with CVM’s Electronic Submission System,PDF (355.98 KB)PDF (355.98 KB) of CVM GFI #108 Registering with CVM’s Electronic Submission System,04/26/2023,Center for Veterinary Medicine,"Electronic Submissions,",Final,No,,FDA-1992-S-0039
Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment,PDF (313.75 KB)PDF (313.75 KB) of Acute Radiation Syndrome: Developing Drugs for Prevention and Treatment,04/19/2023,Center for Drug Evaluation and Research,"Animal Rule, Pediatric Product Development",Draft,No,07/19/2023,FDA-2023-D-1146
"Guidance for Industry: Transition from Temporary Policy During the COVID-19 Public Health Emergency Regarding the Qualified Exemption from the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption","PDF (201.29 KB)PDF (201.29 KB) of Guidance for Industry: Transition from Temporary Policy During the COVID-19 Public Health Emergency Regarding the Qualified Exemption from the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",04/14/2023,Human Foods Program,Produce,Final,No,,FDA-2023-D-1031
Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (767.94 KB)PDF (767.94 KB) of Peripheral Percutaneous Transluminal Angioplasty (PTA) and Specialty Catheters - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,04/14/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Cardiovascular , Labeling",Final,No,,FDA-2019-D-5422
CVM GFI #170 Animal Drug User Fees and Fee Waivers and Reductions,PDF (673.08 KB)PDF (673.08 KB) of CVM GFI #170 Animal Drug User Fees and Fee Waivers and Reductions,04/13/2023,Center for Veterinary Medicine,"User Fees,",Final,No,01/03/2017,FDA-2004-D-0369
Over-the-Counter Monograph Order Requests: Format and Content,PDF (334.61 KB)PDF (334.61 KB) of Over-the-Counter Monograph Order Requests: Format and Content,04/13/2023,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Draft,No,06/12/2023,FDA-2023-D-1188
Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry,PDF (409.31 KB)PDF (409.31 KB) of Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs: Draft Guidance for Industry,04/13/2023,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Draft,No,06/12/2023,FDA-2018-D-3546
Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry,PDF (370.85 KB)PDF (370.85 KB) of Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs Draft Guidance for Industry,04/12/2023,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Draft,No,06/12/2023,FDA-2016-D-1254
A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers:  Guidance for Industry,PDF (265.71 KB)PDF (265.71 KB) of A Risk-Based Approach to Monitoring of Clinical Investigations Questions and Answers:  Guidance for Industry,04/12/2023,"Office of Inspections and InvestigationsCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Administrative / Procedural,Final,No,,FDA-2019-D-0362
Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making,PDF (739.7 KB)PDF (739.7 KB) of Patient-Focused Drug Development: Incorporating Clinical Outcome Assessments Into Endpoints for Regulatory Decision-Making,04/05/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,Administrative / Procedural,Draft,No,07/05/2023,FDA-2023-D-0026
Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration,PDF (263.13 KB)PDF (263.13 KB) of Guidance for Industry: Labeling of Certain Beers Subject to the Labeling Jurisdiction of the Food and Drug Administration,04/04/2023,Human Foods Program,Labeling,Final,No,,FDA-2009-D-0268
CVM GFI #281 Infectious Otitis Externa Drugs for Topical Use in Dogs,PDF (312.66 KB)PDF (312.66 KB) of CVM GFI #281 Infectious Otitis Externa Drugs for Topical Use in Dogs,03/31/2023,Center for Veterinary Medicine,"Premarket, Animal Drugs, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal – Effectiveness, Target Animal – Safety, Labeling",Draft,No,05/30/2023,FDA-2023-D-0606
Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments:  Guidance for Industry,PDF (672.53 KB)PDF (672.53 KB) of Registration and Product Listing for Owners and Operators of Domestic Tobacco Product Establishments:  Guidance for Industry,03/31/2023,Center for Tobacco Products,,Final,No,04/07/2014,FDA-2009-D-0508
Tobacco Health Document Submission (Revised):  Guidance for Industry,PDF (424.12 KB)PDF (424.12 KB) of Tobacco Health Document Submission (Revised):  Guidance for Industry,03/31/2023,Center for Tobacco Products,Tobacco Health documents,Final,No,04/20/2010,FDA-2009-D-0600
Identification of Medicinal Products —  Implementation and Use,PDF (285.67 KB)PDF (285.67 KB) of Identification of Medicinal Products —  Implementation and Use,03/30/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2023-D-0266
"Research Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research Protections: Draft Guidance for Institutional Review Boards, Investigators, and Sponsors","PDF (400.45 KB)PDF (400.45 KB) of Research Involving Children as Subjects and Not Otherwise Approvable by an Institutional Review Board: Process for Referrals to Food and Drug Administration and Office for Human Research Protections: Draft Guidance for Institutional Review Boards, Investigators, and Sponsors",03/30/2023,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Pediatric Therapeutics",Pediatric Product Development,Draft,No,05/30/2023,FDA-2022-D-0142
General Considerations for Animal Studies Intended to Evaluate Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (684.66 KB)PDF (684.66 KB) of General Considerations for Animal Studies Intended to Evaluate Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,03/28/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD/HDE",Final,No,,FDA-2015-D-3419
Soft (Hydrophilic) Daily Wear Contact Lenses - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (565.55 KB)PDF (565.55 KB) of Soft (Hydrophilic) Daily Wear Contact Lenses - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,03/28/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Ophthalmic",Final,No,,FDA-2019-D-4843
"Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19):  Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff","PDF (607.88 KB)PDF (607.88 KB) of Transition Plan for Medical Devices Issued Emergency Use Authorizations (EUAs) Related to Coronavirus Disease 2019 (COVID-19):  Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff",03/27/2023,Center for Devices and Radiological Health,"Premarket, Postmarket, Coronavirus,",Final,No,,FDA-2021-D-1149
"Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency:  Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff","PDF (528.07 KB)PDF (528.07 KB) of Transition Plan for Medical Devices That Fall Within Enforcement Policies Issued During the Coronavirus Disease 2019 (COVID-19) Public Health Emergency:  Guidance for Industry, Other Stakeholders, and Food and Drug Administration Staff",03/27/2023,Center for Devices and Radiological Health,"Premarket, Postmarket, Coronavirus,",Final,No,,FDA-2021-D-1118
Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics,PDF (311.67 KB)PDF (311.67 KB) of Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics,03/24/2023,Oncology Center of Excellence,,Draft,No,05/26/2023,FDA-2023-D-0110
Draft Guidance for Industry: Questions and Answers About Dietary Guidance Statements in Food Labeling,PDF (1.87 MB)PDF (1.87 MB) of Draft Guidance for Industry: Questions and Answers About Dietary Guidance Statements in Food Labeling,03/24/2023,Human Foods Program,"Labeling, Nutrition",Draft,No,09/25/2023,FDA-2023-D-1027
Pharmacogenomic Data Submissions,PDF (306.62 KB)PDF (306.62 KB) of Pharmacogenomic Data Submissions,03/17/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Draft,No,06/20/2023,FDA-2022-D-2856
"FDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements:  Guidance for Industry","PDF (857.04 KB)PDF (857.04 KB) of FDA Deems Certain Tobacco Products Subject to FDA Authority, Sales and Distribution Restrictions, and Health Warning Requirements for Packages and Advertisements:  Guidance for Industry",03/17/2023,Center for Tobacco Products,,Final,No,,FDA-2014-N-0189
Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products - Small Entity Compliance Guide:  Guidance for Industry,PDF (269.7 KB)PDF (269.7 KB) of Further Amendments to General Regulations of the Food and Drug Administration to Incorporate Tobacco Products - Small Entity Compliance Guide:  Guidance for Industry,03/17/2023,Center for Tobacco Products,,Final,No,03/28/2012,FDA-2011-N-0121
"Interpretation of and Compliance Policy for Certain Label Requirement; Applicability of Certain Federal Food, Drug, and Cosmetic Act Requirements to Vape Shops:  Guidance for Industry","PDF (345.39 KB)PDF (345.39 KB) of Interpretation of and Compliance Policy for Certain Label Requirement; Applicability of Certain Federal Food, Drug, and Cosmetic Act Requirements to Vape Shops:  Guidance for Industry",03/17/2023,Center for Tobacco Products,Labeling,Final,No,,FDA-2017-D-0120
Listing of Ingredients in Tobacco Products:  Guidance for Industry,PDF (459.45 KB)PDF (459.45 KB) of Listing of Ingredients in Tobacco Products:  Guidance for Industry,03/17/2023,Center for Tobacco Products,,Final,No,12/01/2009,FDA-2009-D-0524
Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS):  Guidance for Industry,PDF (662.12 KB)PDF (662.12 KB) of Premarket Tobacco Product Applications for Electronic Nicotine Delivery Systems (ENDS):  Guidance for Industry,03/17/2023,Center for Tobacco Products,"Electronic Nicotine Delivery Systems (ENDS), Product Application and Review",Final,No,,FDA-2015-D-2496
Prohibition of Distributing Free Samples of Tobacco Products:  Guidance for Industry,PDF (269.44 KB)PDF (269.44 KB) of Prohibition of Distributing Free Samples of Tobacco Products:  Guidance for Industry,03/17/2023,Center for Tobacco Products,Free samples,Final,No,,FDA-2017-D-0113
Determination of the Period Covered by a No-Tobacco-Sale Order and Compliance With an Order:  Guidance for Tobacco Retailers,PDF (268.96 KB)PDF (268.96 KB) of Determination of the Period Covered by a No-Tobacco-Sale Order and Compliance With an Order:  Guidance for Tobacco Retailers,03/17/2023,Center for Tobacco Products,No-tobacco-sale order (NTSO),Final,No,,FDA-2015-D-0404
CVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals,PDF (494.35 KB)PDF (494.35 KB) of CVM GFI #106 The Use of Published Literature in Support of New Animal Drug Approvals,03/16/2023,Center for Veterinary Medicine,"Premarket, Chemistry, Manufacturing, and Controls (CMC), Clinical - Antimicrobial, Clinical - Pharmacology, Safety - Issues, Errors, and Problems, Antimicrobial Resistance, New Animal Drug Application (NADA), Target Animal – Effectiveness, Target Animal – Safety, Investigational New Animal Drug (INAD), Minor Use/ Minor Species (MUMS)",Final,No,06/21/2022,FDA-2021-D-1155
Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act Guidance for Industry:  Guidance for Industry,PDF (240.02 KB)PDF (240.02 KB) of Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act Guidance for Industry:  Guidance for Industry,03/16/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2018-D-0338
Guidance for Industry: Frequently Asked Questions About Medical Foods - Third Edition,PDF (307.15 KB)PDF (307.15 KB) of Guidance for Industry: Frequently Asked Questions About Medical Foods - Third Edition,03/15/2023,Human Foods Program,Labeling,Final,No,,FDA-2013-D-0880
Development of Local Anesthetic Drug Products With Prolonged Duration of Effect,PDF (299.5 KB)PDF (299.5 KB) of Development of Local Anesthetic Drug Products With Prolonged Duration of Effect,03/15/2023,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,06/14/2023,FDA-2023-D-0608
"Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications  Guidance for Industry:  Guidance for Industry","PDF (428.9 KB)PDF (428.9 KB) of Evaluation of Gastric pH-Dependent Drug Interactions With Acid-Reducing Agents: Study Design, Data Analysis, and Clinical Implications  Guidance for Industry:  Guidance for Industry",03/10/2023,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,02/26/2021,FDA-2020-D-1794
Guidance for Industry: Labeling of Infant Formula,PDF (281.28 KB)PDF (281.28 KB) of Guidance for Industry: Labeling of Infant Formula,03/06/2023,Human Foods Program,"Infant Formula & Foods, Labeling",Final,No,,FDA-2013-S-0610
Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens,PDF (315.61 KB)PDF (315.61 KB) of Potency Assay Considerations for Monoclonal Antibodies and Other Therapeutic Proteins Targeting Viral Pathogens,03/01/2023,"Center for Drug Evaluation and Research,Office of Pharmaceutical Quality","Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,05/01/2023,FDA-2023-D-0202
Q13 Continuous Manufacturing of Drug Substances and Drug Products:  Guidance for Industry,PDF (1.15 MB)PDF (1.15 MB) of Q13 Continuous Manufacturing of Drug Substances and Drug Products:  Guidance for Industry,03/01/2023,Center for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2021-D-1047
Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment,PDF (238.91 KB)PDF (238.91 KB) of Neovascular Age-Related Macular Degeneration: Developing Drugs for Treatment,02/24/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Draft,No,05/30/2023,FDA-2022-D-0073
Guidance for Industry and Food and Drug Administration Staff - Assembler's Guide to Diagnostic X-Ray Equipment,PDF (681.97 KB)PDF (681.97 KB) of Guidance for Industry and Food and Drug Administration Staff - Assembler's Guide to Diagnostic X-Ray Equipment,02/21/2023,Center for Devices and Radiological Health,,Final,No,,FDA-2018-D-4115
"Performance Standard for Diagnostic X-Ray Systems and Their Major Components (21CFR 1020.30, 1020.31, 1020.32, 1020.33); Small Entity Compliance Guide","PDF (371.39 KB)PDF (371.39 KB) of Performance Standard for Diagnostic X-Ray Systems and Their Major Components (21CFR 1020.30, 1020.31, 1020.32, 1020.33); Small Entity Compliance Guide",02/21/2023,Center for Devices and Radiological Health,Radiology,Final,No,,FDA-2001-N-0178
Laser Products - Conformance with IEC 60825-1 Ed. 3 and IEC 60601-2-22 Ed. 3.1 (Laser Notice No. 56):  Guidance for Industry and Food and Drug Administration Staff,PDF (379.78 KB)PDF (379.78 KB) of Laser Products - Conformance with IEC 60825-1 Ed. 3 and IEC 60601-2-22 Ed. 3.1 (Laser Notice No. 56):  Guidance for Industry and Food and Drug Administration Staff,02/21/2023,Center for Devices and Radiological Health,"Export, Import, Laser Notice, Radiological Health, Radiology",Final,No,,FDA-2017-D-7011
Marketing Clearance of Diagnostic Ultrasound Systems and Transducers :  Guidance for Industry and Food and Drug Administration Staff,PDF (898.34 KB)PDF (898.34 KB) of Marketing Clearance of Diagnostic Ultrasound Systems and Transducers :  Guidance for Industry and Food and Drug Administration Staff,02/21/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Radiological Health, Radiology",Final,No,,FDA-2017-D-5372
Medical X-Ray Imaging Devices Conformance with IEC Standards:  Guidance for Industry and Food and Drug Administration Staff,PDF (535.82 KB)PDF (535.82 KB) of Medical X-Ray Imaging Devices Conformance with IEC Standards:  Guidance for Industry and Food and Drug Administration Staff,02/21/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Radiological Health, Radiology",Final,No,,FDA-2016-D-2049
Policy Clarification and Premarket Notification [510(k)] Submissions for Ultrasonic Diathermy Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (545.39 KB)PDF (545.39 KB) of Policy Clarification and Premarket Notification [510(k)] Submissions for Ultrasonic Diathermy Devices:  Guidance for Industry and Food and Drug Administration Staff,02/21/2023,Center for Devices and Radiological Health,"Premarket, 510(k), Physical Medicine",Final,No,10/30/2017,FDA-2017-D-4764
Draft Guidance for Industry: Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements,PDF (971.3 KB)PDF (971.3 KB) of Draft Guidance for Industry: Labeling of Plant-Based Milk Alternatives and Voluntary Nutrient Statements,02/10/2023,Human Foods Program,"Labeling, Nutrition",Draft,No,07/31/2023,FDA-2023-D-0451
"Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act","PDF (382.05 KB)PDF (382.05 KB) of Compounding Certain Ibuprofen Oral Suspension Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act",02/09/2023,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2023-D-0169
Draft Guidance for Industry:  Protein Efficiency Ratio (PER) Rat Bioassay Studies to Demonstrate that a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein,PDF (741.54 KB)PDF (741.54 KB) of Draft Guidance for Industry:  Protein Efficiency Ratio (PER) Rat Bioassay Studies to Demonstrate that a New Infant Formula Supports the Quality Factor of Sufficient Biological Quality of Protein,02/09/2023,Human Foods Program,Infant Formula & Foods,Draft,No,05/11/2023,FDA-2022-D-2424
Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products,PDF (336.1 KB)PDF (336.1 KB) of Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products,02/01/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,"Real World Data / Real World Evidence (RWD/RWE),",Draft,No,05/02/2023,FDA-2022-D-2983
Early Lyme Disease as Manifested by Erythema Migrans:  Developing Drugs for Treatment,PDF (335.78 KB)PDF (335.78 KB) of Early Lyme Disease as Manifested by Erythema Migrans:  Developing Drugs for Treatment,01/31/2023,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Draft,No,04/03/2023,FDA-2022-D-2315
"Surveying, Leveling, and Alignment Laser Products:  Guidance for Industry and Food and Drug Administration Staff","PDF (618.11 KB)PDF (618.11 KB) of Surveying, Leveling, and Alignment Laser Products:  Guidance for Industry and Food and Drug Administration Staff",01/31/2023,Center for Devices and Radiological Health,"Laser Notice, Radiological Health",Final,No,,FDA-2014-D-0435
Acromegaly:  Developing Drugs for Treatment,,01/30/2023,Center for Drug Evaluation and Research,Clinical - Pharmacology,Draft,No,03/31/2023,FDA-2022-D-2658
CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover,PDF (262.79 KB)PDF (262.79 KB) of CVM GFI #272 Practices to Prevent Unsafe Contamination of Animal Feed from Drug Carryover,01/30/2023,Center for Veterinary Medicine,"Animal Feed, Current Good Manufacturing Practice (CGMP), Safety - Issues, Errors, and Problems",Final,No,08/08/2022,FDA-2022-D-0173
CVM GFI #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern,PDF (618.14 KB)PDF (618.14 KB) of CVM GFI #152 Evaluating the Safety of Antimicrobial New Animal Drugs with Regard to Their Microbiological Effects on Bacteria of Human Health Concern,01/27/2023,Center for Veterinary Medicine,"Antimicrobial Resistance, Human Food Safety",Draft,No,05/19/2023,FDA-1998-D-0038
Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry:  Guidance for Industry,PDF (383.62 KB)PDF (383.62 KB) of Cannabis and Cannabis-Derived Compounds: Quality Considerations for Clinical Research Guidance for Industry:  Guidance for Industry,01/23/2023,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2020-D-1079
Mpox: Development of Drugs and Biological Products; Guidance for Industry,PDF (259.22 KB)PDF (259.22 KB) of Mpox: Development of Drugs and Biological Products; Guidance for Industry,01/19/2023,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,03/21/2023,FDA-2022-D-2395
Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,PDF (560.74 KB)PDF (560.74 KB) of Dosage and Administration Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,01/12/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,03/14/2023,FDA-2007-D-0201
Policy for Coronavirus Disease-2019 Tests (Revised):  Guidance for Developers and Food and Drug Administration Staff,PDF (372.44 KB)PDF (372.44 KB) of Policy for Coronavirus Disease-2019 Tests (Revised):  Guidance for Developers and Food and Drug Administration Staff,01/12/2023,Center for Devices and Radiological Health,"Premarket, Coronavirus, CLIA (Clinical Laboratory Improvement Amendments), Immunology & Microbiology , IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2020-D-0987
Photobiomodulation (PBM) Devices - Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (900.03 KB)PDF (900.03 KB) of Photobiomodulation (PBM) Devices - Premarket Notification [510(k)] Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,01/12/2023,Center for Devices and Radiological Health,,Draft,No,03/13/2023,FDA-2022-D-3116
Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests (Revised):  Guidance for Test Developers and Food and Drug Administration Staff,PDF (430.26 KB)PDF (430.26 KB) of Policy for Evaluating Impact of Viral Mutations on COVID-19 Tests (Revised):  Guidance for Test Developers and Food and Drug Administration Staff,01/12/2023,Center for Devices and Radiological Health,"Premarket, Coronavirus, IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2020-D-0987
Guidance for Industry: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals,PDF (1.19 MB)PDF (1.19 MB) of Guidance for Industry: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals,01/10/2023,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,Import,Final,No,,FDA-2017-D-5225
Format and Content of a REMS Document Guidance for Industry,PDF (331.56 KB)PDF (331.56 KB) of Format and Content of a REMS Document Guidance for Industry,01/04/2023,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,12/11/2017,FDA-2009-D-0461
REMS Document Technical Conformance Guide,PDF (545.79 KB)PDF (545.79 KB) of REMS Document Technical Conformance Guide,01/04/2023,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,
M11 Clinical Electronic Structured Harmonised Protocol,PDF (350.38 KB)PDF (350.38 KB) of M11 Clinical Electronic Structured Harmonised Protocol,12/21/2022,"Center for Drug Evaluation and Research,Office of Regulatory Policy",ICH-Multidisciplinary,Draft,No,02/21/2023,FDA-2022-D-3054
M11 Technical Specification: Clinical Electronic Structured Harmonised Protocol,PDF (3.05 MB)PDF (3.05 MB) of M11 Technical Specification: Clinical Electronic Structured Harmonised Protocol,12/21/2022,"Center for Drug Evaluation and Research,Office of Regulatory Policy",ICH-Multidisciplinary,Draft,No,,FDA-2022-D-3054
M11 Template: Clinical Electronic Structured Harmonised Protocol,PDF (695.38 KB)PDF (695.38 KB) of M11 Template: Clinical Electronic Structured Harmonised Protocol,12/21/2022,"Center for Drug Evaluation and Research,Office of Regulatory Policy",ICH-Multidisciplinary,Draft,No,,FDA-2022-D-3054
Guidance for Industry: Best Practices for Convening a GRAS Panel,PDF (665.74 KB)PDF (665.74 KB) of Guidance for Industry: Best Practices for Convening a GRAS Panel,12/20/2022,Center for Veterinary MedicineHuman Foods Program,GRAS,Final,No,05/15/2018,FDA-2017-D-0085
Pulmonary Tuberculosis: Developing Drugs for Treatment,PDF (380.11 KB)PDF (380.11 KB) of Pulmonary Tuberculosis: Developing Drugs for Treatment,12/14/2022,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Draft,No,02/13/2023,FDA-2013-D-1319
Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry:  Guidance for Industry,PDF (280.99 KB)PDF (280.99 KB) of Failure to Respond to an ANDA Complete Response Letter Within the Regulatory Timeframe Guidance for Industry:  Guidance for Industry,12/14/2022,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"User Fees, Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2020-D-1548
Content of Human Factors Information in Medical Device Marketing Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (916.09 KB)PDF (916.09 KB) of Content of Human Factors Information in Medical Device Marketing Submissions: Draft Guidance for Industry and Food and Drug Administration Staff,12/09/2022,Center for Devices and Radiological Health,,Draft,No,03/09/2023,FDA-2015-D-4599
Homeopathic Drug Products Guidance for FDA Staff and Industry,PDF (283.97 KB)PDF (283.97 KB) of Homeopathic Drug Products Guidance for FDA Staff and Industry,12/07/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Compliance, Administrative / Procedural",Final,No,,FDA-2017-D-6580
Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria:  Guidance for Industry,PDF (311.41 KB)PDF (311.41 KB) of Recommendations to Reduce the Risk of Transfusion-Transmitted Malaria:  Guidance for Industry,12/07/2022,Center for Biologics Evaluation and Research,"Laboratory Methods, Blood, Infectious Disease, Coronavirus, Blood Products",Final,No,,FDA-2000-D-0187
Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations,PDF (446.92 KB)PDF (446.92 KB) of Small Volume Parenteral Drug Products and Pharmacy Bulk Packages for Parenteral Nutrition: Aluminum Content and Labeling Recommendations,12/06/2022,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,02/06/2023,FDA-2022-D-2301
Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer:  Guidance for Industry,PDF (230.43 KB)PDF (230.43 KB) of Pharmacokinetic-Based Criteria for Supporting Alternative Dosing Regimens of Programmed Cell Death Receptor-1 (PD-1) or Programmed Cell Death-Ligand 1 (PD-L1) Blocking Antibodies for Treatment of Patients with Cancer:  Guidance for Industry,12/06/2022,Oncology Center of ExcellenceCenter for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,,FDA-2021-D-0691
E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials,PDF (273.95 KB)PDF (273.95 KB) of E19 A Selective Approach to Safety Data Collection in Specific Late-Stage Pre-Approval or Post-Approval Clinical Trials,12/05/2022,Center for Drug Evaluation and Research,,Final,No,,FDA-2019-D-1828
ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions,PDF (351.65 KB)PDF (351.65 KB) of ANDAs: Pre-Submission Facility Correspondence Related to Prioritized Generic Drug Submissions,12/02/2022,"Center for Drug Evaluation and Research,Office of Pharmaceutical Quality",,Draft,No,,FDA-2017-D-3101
Statistical Approaches to Establishing Bioequivalence,PDF (592.56 KB)PDF (592.56 KB) of Statistical Approaches to Establishing Bioequivalence,12/02/2022,Center for Drug Evaluation and Research,"Biopharmaceutics, Generic Drugs",Draft,No,,FDA-2001-D-0197
"Clinical Investigator Administrative Actions - Disqualification:  Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors","PDF (277.99 KB)PDF (277.99 KB) of Clinical Investigator Administrative Actions - Disqualification:  Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors",12/01/2022,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,FDA-2010-D-0265
Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies:  Guidance for Industry,PDF (224.27 KB)PDF (224.27 KB) of Enforcement Policy Regarding Investigational New Drug Requirements for Use of Fecal Microbiota for Transplantation to Treat Clostridium difficile Infection Not Responsive to Standard Therapies:  Guidance for Industry,11/28/2022,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-2013-D-0811
Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act,PDF (233.57 KB)PDF (233.57 KB) of Compounding Certain Beta-Lactam Products in Shortage Under Section 503A of the Federal Food Drug and Cosmetic Act,11/18/2022,Center for Drug Evaluation and Research,,Final,No,,FDA-2022-D-2922
"Referencing the Definition of ""Device"" in the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents, Communications, and Other Public Documents:  Guidance for Industry and Food and Drug Administration Staff","PDF (501.85 KB)PDF (501.85 KB) of Referencing the Definition of ""Device"" in the Federal Food, Drug, and Cosmetic Act in Guidance, Regulatory Documents, Communications, and Other Public Documents:  Guidance for Industry and Food and Drug Administration Staff",11/14/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,,Final,No,,FDA-2021-D-0997
Sameness Evaluations in an ANDA — Active Ingredients,PDF (378.63 KB)PDF (378.63 KB) of Sameness Evaluations in an ANDA — Active Ingredients,11/08/2022,"Center for Drug Evaluation and Research,Office of Generic Drugs","Drug Competition Action Plan, Generic Drugs",Draft,No,01/08/2023,FDA-2022-D-0697
M10 Bioanalytical Method Validation and Study Sample Analysis,PDF (616.57 KB)PDF (616.57 KB) of M10 Bioanalytical Method Validation and Study Sample Analysis,11/04/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, ICH-Multidisciplinary",Final,No,,FDA-2019-D-1469
Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial:  Guidance for Industry,PDF (346.16 KB)PDF (346.16 KB) of Studying Multiple Versions of a Cellular or Gene Therapy Product in an Early-Phase Clinical Trial:  Guidance for Industry,11/04/2022,Center for Biologics Evaluation and Research,"Clinical Trials, Gene Therapy",Final,No,,FDA-2021-D-0776
Cross Labeling Oncology Drugs in Combination Regimens,PDF (240.89 KB)PDF (240.89 KB) of Cross Labeling Oncology Drugs in Combination Regimens,11/02/2022,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2020-D-2107
S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals:  Guidance for Industry,PDF (791.15 KB)PDF (791.15 KB) of S1B(R1) Addendum to S1B Testing for Carcinogenicity of Pharmaceuticals:  Guidance for Industry,11/02/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2021-D-0669
Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program,PDF (360.98 KB)PDF (360.98 KB) of Assessing User Fees Under the Over-the-Counter Monograph Drug User Fee Program,11/01/2022,Center for Drug Evaluation and Research,"User Fees,",Draft,No,,2021-709
Expanded Access to Investigational Drugs for Treatment Use:  Questions and Answers,PDF (476.18 KB)PDF (476.18 KB) of Expanded Access to Investigational Drugs for Treatment Use:  Questions and Answers,11/01/2022,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,01/03/2023,FDA-2013-D-0446
"Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Small Entity Compliance Guide:  Guidance for Industry","PDF (354.33 KB)PDF (354.33 KB) of Regulation of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) - Small Entity Compliance Guide:  Guidance for Industry",11/01/2022,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2022-D-0563
Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability,PDF (291.6 KB)PDF (291.6 KB) of Measuring Growth and Evaluating Pubertal Development in Pediatric Clinical Trials; Draft Guidance for Industry; Availability,10/31/2022,"Center for Drug Evaluation and Research,Office of New DrugsCenter for Biologics Evaluation and Research","Clinical - Medical, Pediatric Product Development",Draft,No,01/03/2023,FDA-2022-D-0760
"Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention","PDF (285.69 KB)PDF (285.69 KB) of Clostridioides difficile Infection: Developing Drugs for Treatment, Reduction of Recurrence, and Prevention",10/27/2022,"Center for Drug Evaluation and Research,Office of New Drugs",Clinical - Antimicrobial,Draft,No,12/27/2022,FDA-2022-D-1261
Developing and Responding to Deficiencies in Accordance with the Least Burdensome Provisions:  Guidance for Industry and Food and Drug Administration Staff,PDF (426.19 KB)PDF (426.19 KB) of Developing and Responding to Deficiencies in Accordance with the Least Burdensome Provisions:  Guidance for Industry and Food and Drug Administration Staff,10/26/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Premarket Approval (PMA)",Final,No,,FDA-2017-D-5711
In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs,PDF (689.03 KB)PDF (689.03 KB) of In Vitro Permeation Test Studies for Topical Drug Products Submitted in ANDAs,10/21/2022,"Center for Drug Evaluation and Research,Office of Regulatory Policy",Generic Drugs,Draft,No,,FDA-2022-D-1862
In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs,PDF (252.01 KB)PDF (252.01 KB) of In Vitro Release Test Studies for Topical Drug Products Submitted in ANDAs,10/21/2022,"Center for Drug Evaluation and Research,Office of Regulatory Policy",Generic Drugs,Draft,No,,FDA-2022-D-1859
Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs,PDF (469.4 KB)PDF (469.4 KB) of Physicochemical and Structural (Q3) Characterization of Topical Drug Products Submitted in ANDAs,10/21/2022,"Center for Drug Evaluation and Research,Office of Regulatory Policy",Generic Drugs,Draft,No,,FDA-2022-D-1864
Human Gene Therapy for Neurodegenerative Diseases:  Guidance for Industry,PDF (310.87 KB)PDF (310.87 KB) of Human Gene Therapy for Neurodegenerative Diseases:  Guidance for Industry,10/21/2022,Center for Biologics Evaluation and Research,"Gene Therapy, Pediatric Product Development",Final,No,,FDA-2020-D-2101
Multiple Endpoints in Clinical Trials:  Guidance for Industry,PDF (317.1 KB)PDF (317.1 KB) of Multiple Endpoints in Clinical Trials:  Guidance for Industry,10/21/2022,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2016-D-4460
"CVM GFI #253 Current Good Manufacturing Practice for Animal Cells, Tissues, and Cell- and Tissue-Based Products","PDF (471.34 KB)PDF (471.34 KB) of CVM GFI #253 Current Good Manufacturing Practice for Animal Cells, Tissues, and Cell- and Tissue-Based Products",10/20/2022,Center for Veterinary Medicine,"Premarket, Animal Cell-Based Products, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Final,No,11/22/2021,FDA-2021-D-0399
"CVM GFI #254 Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products","PDF (337.84 KB)PDF (337.84 KB) of CVM GFI #254 Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products",10/20/2022,Center for Veterinary Medicine,"Premarket, Animal Cell-Based Products, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Final,No,11/22/2021,FDA-2021-D-0401
Guidance for Industry: Refusal of Inspection by a Foreign Food Establishment or Foreign Government,PDF (404.26 KB)PDF (404.26 KB) of Guidance for Industry: Refusal of Inspection by a Foreign Food Establishment or Foreign Government,10/20/2022,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,"Inspection,",Final,No,,FDA-2017-D-6528
"CVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds","PDF (197.32 KB)PDF (197.32 KB) of CVM GFI #258 Use of Tracers in Animal Food, Type A Medicated Articles, and Medicated Feeds",10/19/2022,Center for Veterinary Medicine,"Animal Food Additives, Chemistry, Manufacturing, and Controls (CMC), Labeling, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA)",Final,No,05/02/2022,FDA-2021-D-1246
Small Entity Compliance Guide: Laboratory Accreditation for Analyses of Foods - What You Need to Know,PDF (505.15 KB)PDF (505.15 KB) of Small Entity Compliance Guide: Laboratory Accreditation for Analyses of Foods - What You Need to Know,10/19/2022,Human Foods ProgramCenter for Veterinary MedicineOffice of Inspections and Investigations,,Final,No,,FDA-2022-D-1126
Tissue Agnostic Drug Development in Oncology: Draft Guidance for Industry,,10/17/2022,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,,Draft,No,,FDA-2022-D-0286
Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment:  Guidance for Industry; Availability,PDF (463.91 KB)PDF (463.91 KB) of Acute Myeloid Leukemia: Developing Drugs and Biological Products for Treatment:  Guidance for Industry; Availability,10/17/2022,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Pediatric Product Development,Final,No,,FDA-2020-D-1298
"Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability","PDF (301.07 KB)PDF (301.07 KB) of Characterizing, Collecting, and Reporting Immune-Mediated Adverse Reactions in Cancer Immunotherapeutic Clinical Trials: Draft Guidance for Industry; Availability",10/17/2022,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,,Draft,No,,FDA-2022-D-1744
ANDA Submissions – Prior Approval Supplements Under GDUFA:  Guidance for Industry,PDF (347 KB)PDF (347 KB) of ANDA Submissions – Prior Approval Supplements Under GDUFA:  Guidance for Industry,10/14/2022,Center for Drug Evaluation and Research,"User Fees, Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2014-D-0901
"Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA","PDF (459.7 KB)PDF (459.7 KB) of Comparability Protocols for Postapproval Changes to the Chemistry, Manufacturing, and Controls Information in an NDA, ANDA, or BLA",10/13/2022,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2016-D-0973
"Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff","PDF (630.67 KB)PDF (630.67 KB) of Postmarket Surveillance Under Section 522 of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",10/07/2022,Center for Devices and Radiological Health,,Final,No,,FDA-2011-D-0514
Procedures for Handling Post-Approval Studies Imposed by PMA Order:  Guidance for Industry and Food and Drug Administration Staff,PDF (438.61 KB)PDF (438.61 KB) of Procedures for Handling Post-Approval Studies Imposed by PMA Order:  Guidance for Industry and Food and Drug Administration Staff,10/07/2022,Center for Devices and Radiological Health,,Final,No,,FDA-2005-D-0027
Competitive Generic Therapies,PDF (396.05 KB)PDF (396.05 KB) of Competitive Generic Therapies,10/05/2022,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2019-D-0065
Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry,PDF (489.27 KB)PDF (489.27 KB) of Formal Meetings Between FDA and ANDA Applicants of Complex Products Under GDUFA Guidance for Industry,10/05/2022,Center for Drug Evaluation and Research,"User Fees, Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2017-D-5739
Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA Guidance for Industry,PDF (321.03 KB)PDF (321.03 KB) of Post-Complete Response Letter Clarification Teleconferences Between FDA and ANDA Applicants Under GDUFA Guidance for Industry,10/05/2022,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Final,No,,FDA-2017-D-5928
Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry,PDF (253.33 KB)PDF (253.33 KB) of Information Requests and Discipline Review Letters Under the Generic Drug User Fee Amendments:  Guidance for Industry,10/05/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"User Fees, Generic Drugs",Final,No,,FDA-2017-D-6752
User Fees and Refunds for De Novo Classification Requests :  Guidance for Industry and Food and Drug Administration Staff,PDF (498.87 KB)PDF (498.87 KB) of User Fees and Refunds for De Novo Classification Requests :  Guidance for Industry and Food and Drug Administration Staff,10/05/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, User Fees, Administrative / Procedural",Final,No,,FDA-2017-D-5713
User Fees and Refunds for Premarket Approval Applications and Device Biologics License Applications:  Guidance for Industry and Food and Drug Administration Staff,PDF (417.84 KB)PDF (417.84 KB) of User Fees and Refunds for Premarket Approval Applications and Device Biologics License Applications:  Guidance for Industry and Food and Drug Administration Staff,10/05/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, User Fees,",Final,No,,FDA-2009-D-0051
User Fees and Refunds for Premarket Notification Submissions (510(k)s):  Guidance for Industry and Food and Drug Administration Staff,PDF (523.75 KB)PDF (523.75 KB) of User Fees and Refunds for Premarket Notification Submissions (510(k)s):  Guidance for Industry and Food and Drug Administration Staff,10/05/2022,Center for Devices and Radiological Health,"Premarket, User Fees, 510(k)",Final,No,,FDA-2003-D-0198
User Fees for 513(g) Requests for Information:  Guidance for Industry and Food and Drug Administration Staff,PDF (322.37 KB)PDF (322.37 KB) of User Fees for 513(g) Requests for Information:  Guidance for Industry and Food and Drug Administration Staff,10/05/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, User Fees,",Final,No,,FDA-2010-D-0144
"Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules","PDF (303.31 KB)PDF (303.31 KB) of Size, Shape, and Other Physical Attributes of Generic Tablets and Capsules",10/03/2022,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2013-N-1434
FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,PDF (436.19 KB)PDF (436.19 KB) of FDA and Industry Actions on De Novo Classification Requests: Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,10/03/2022,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, Administrative / Procedural",Final,No,,FDA-2017-D-5712
FDA and Industry Actions on Premarket Approval Applications (PMAs): Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,PDF (471.95 KB)PDF (471.95 KB) of FDA and Industry Actions on Premarket Approval Applications (PMAs): Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,10/03/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Premarket Approval (PMA)",Final,No,,FDA-2003-D-0378
FDA and Industry Actions on Premarket Notification (510(k)) Submissions: Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,PDF (516.34 KB)PDF (516.34 KB) of FDA and Industry Actions on Premarket Notification (510(k)) Submissions: Effect on FDA Review Clock and Goals:  Guidance for Industry and Food and Drug Administration Staff,10/03/2022,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2003-D-0033
Guidance for Industry: Infant Formula Transition Plan for Exercise of Enforcement Discretion,PDF (349.71 KB)PDF (349.71 KB) of Guidance for Industry: Infant Formula Transition Plan for Exercise of Enforcement Discretion,09/29/2022,Human Foods Program,Infant Formula & Foods,Final,No,,FDA-2022-D-0814
Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions:  Guidance for Industry and FDA Staff,PDF (499.67 KB)PDF (499.67 KB) of Clinical Performance Assessment: Considerations for Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data in Premarket Notification (510(k)) Submissions:  Guidance for Industry and FDA Staff,09/28/2022,Center for Devices and Radiological Health,"Premarket, 510(k), Digital Health, Radiology, Labeling",Final,No,,FDA-2009-D-0503
Clinical Decision Support Software:  Guidance for Industry and Food and Drug Administration Staff,PDF (690.26 KB)PDF (690.26 KB) of Clinical Decision Support Software:  Guidance for Industry and Food and Drug Administration Staff,09/28/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Administrative / Procedural, Digital Health",Final,No,,FDA-2017-D-6569
Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data - Premarket Notification [510(k)] Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (589.83 KB)PDF (589.83 KB) of Computer-Assisted Detection Devices Applied to Radiology Images and Radiology Device Data - Premarket Notification [510(k)] Submissions:  Guidance for Industry and Food and Drug Administration Staff,09/28/2022,Center for Devices and Radiological Health,"Premarket, Radiology",Final,No,,FDA-2009-D-0503
Display Devices for Diagnostic Radiology:  Guidance for Industry and Food and Drug Administration Staff,PDF (449.06 KB)PDF (449.06 KB) of Display Devices for Diagnostic Radiology:  Guidance for Industry and Food and Drug Administration Staff,09/28/2022,Center for Devices and Radiological Health,"Premarket, 510(k), Labeling, Radiological Health, Radiology",Final,No,,FDA-2016-D-0270
"Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices:  Guidance for Industry and Food and Drug Administration Staff","PDF (371.78 KB)PDF (371.78 KB) of Medical Device Data Systems, Medical Image Storage Devices, and Medical Image Communications Devices:  Guidance for Industry and Food and Drug Administration Staff",09/28/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Digital Health,Final,No,,FDA-2014-D-0798
Policy for Device Software Functions and Mobile Medical Applications:  Guidance for Industry and Food and Drug Administration Staff,PDF (676.74 KB)PDF (676.74 KB) of Policy for Device Software Functions and Mobile Medical Applications:  Guidance for Industry and Food and Drug Administration Staff,09/28/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Digital Health",Final,No,,FDA-2011-D-0530
"Ethical Considerations for Clinical Investigations of Medical Products Involving Children: Draft Guidance for Industry, Sponsors, and IRBs","PDF (433.98 KB)PDF (433.98 KB) of Ethical Considerations for Clinical Investigations of Medical Products Involving Children: Draft Guidance for Industry, Sponsors, and IRBs",09/26/2022,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Pediatric TherapeuticsCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research","Clinical - Medical, Pediatric Product Development",Draft,No,,FDA-2022-D-0738
Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry,PDF (185.47 KB)PDF (185.47 KB) of Exemption and Exclusion From Certain Requirements of the Drug Supply Chain Security Act for the Distribution of FDA-Approved Naloxone Products During the Opioid Public Health Emergency Guidance for Industry,09/22/2022,"Center for Drug Evaluation and Research,Office of Regulatory Policy",Administrative / Procedural,Final,No,,FDA-2022-D-1847
How To Obtain a Covered Product Authorization,PDF (340.48 KB)PDF (340.48 KB) of How To Obtain a Covered Product Authorization,09/21/2022,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,11/21/2022,FDA-2022-D-1358
Q3D(R2) – Guideline for Elemental Impurities:  International Council for Harmonisation; Draft Guidance for Industry,PDF (968.57 KB)PDF (968.57 KB) of Q3D(R2) – Guideline for Elemental Impurities:  International Council for Harmonisation; Draft Guidance for Industry,09/14/2022,Center for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2013-D-1156
Computer Software Assurance for Production and Quality System Software: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (798.33 KB)PDF (798.33 KB) of Computer Software Assurance for Production and Quality System Software: Draft Guidance for Industry and Food and Drug Administration Staff,09/13/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket, Current Good Manufacturing Practice (CGMP), Digital Health",Draft,No,11/14/2022,FDA-2022-D-0795
Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products,PDF (244.63 KB)PDF (244.63 KB) of Submitting Documents Using Real-World Data and Real-World Evidence to FDA for Drug and Biological Products,09/09/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Real World Data / Real World Evidence (RWD/RWE), Administrative / Procedural",Final,No,,FDA-2019-D-1263
"Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products","PDF (266.67 KB)PDF (266.67 KB) of Quantitative Labeling of Sodium, Potassium, and Phosphorus for Human Over-the-Counter and Prescription Drug Products",09/08/2022,Center for Drug Evaluation and Research,Labeling,Draft,No,11/08/2022,FDA-2021-D-0528
Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products,PDF (266.17 KB)PDF (266.17 KB) of Statement of Identity and Strength — Content and Format of Labeling for Human Nonprescription Drug Products,09/08/2022,"Center for Drug Evaluation and Research,Office of New Drugs",Labeling,Draft,No,11/08/2022,FDA-2022-D-1837
"General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products","PDF (426.03 KB)PDF (426.03 KB) of General Clinical Pharmacology Considerations for Pediatric Studies of Drugs, Including Biological Products",09/07/2022,Center for Drug Evaluation and Research,"Clinical - Pharmacology, Pediatric Product Development",Draft,No,12/07/2022,FDA-2013-D-1275
Meetings with Industry and Investigators on the Research and Development of Tobacco Products (Revised):  Guidance for Industry and Investigators,PDF (342.75 KB)PDF (342.75 KB) of Meetings with Industry and Investigators on the Research and Development of Tobacco Products (Revised):  Guidance for Industry and Investigators,09/07/2022,Center for Tobacco Products,,Final,No,,FDA-2012-D-0429
"Policy for Monkeypox Tests to Address the Public Health Emergency:  Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff","PDF (599.02 KB)PDF (599.02 KB) of Policy for Monkeypox Tests to Address the Public Health Emergency:  Guidance for Laboratories, Commercial Manufacturers and Food and Drug Administration Staff",09/07/2022,Center for Devices and Radiological Health,,Final,No,,FDA-2022-D-1908
E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers :  Guidance for Industry,PDF (430.5 KB)PDF (430.5 KB) of E14 and S7B Clinical and Nonclinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential--Questions and Answers :  Guidance for Industry,08/26/2022,Center for Drug Evaluation and Research,"ICH-Efficacy, ICH-Safety",Final,No,,FDA-2020-D-1791
Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies,PDF (448.17 KB)PDF (448.17 KB) of Tobacco Products: Principles for Designing and Conducting Tobacco Product Perception and Intention Studies,08/23/2022,Center for Tobacco Products,,Final,No,,FDA-2019-D-4188
Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff,PDF (930.94 KB)PDF (930.94 KB) of Replacement Reagent and Instrument Family Policy for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff,08/17/2022,Center for Devices and Radiological Health,Laboratory Tests,Final,No,,FDA-2017-D-6765
Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products:  Guidance for Industry and Food and Drug Administration Staff,PDF (462.66 KB)PDF (462.66 KB) of Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products:  Guidance for Industry and Food and Drug Administration Staff,08/17/2022,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-1380
CVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines,PDF (399.36 KB)PDF (399.36 KB) of CVM GFI #109 (VICH GL15) Effectiveness of Anthelmintics: Specific Recommendations for Equines,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness, VICH",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines,PDF (406.47 KB)PDF (406.47 KB) of CVM GFI #110 (VICH GL16) Effectiveness of Anthelmintics: Specific Recommendations for Porcines,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness, VICH",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines,PDF (388.68 KB)PDF (388.68 KB) of CVM GFI #111 (VICH GL19) Effectiveness of Anthelmintics: Specific Recommendations for Canines,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness, VICH",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines,PDF (381.45 KB)PDF (381.45 KB) of CVM GFI #113 (VICH GL20) Effectiveness of Anthelmintics: Specific Recommendations for Felines,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness, VICH",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus,PDF (392.36 KB)PDF (392.36 KB) of CVM GFI #114 (VICH GL21) Effectiveness of Anthelmintics: Specific Recommendations for Chickens Gallus gallus,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations,PDF (587.39 KB)PDF (587.39 KB) of CVM GFI #90 (VICH GL7) Effectiveness of Anthelmintics: General Recommendations,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness, VICH",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics:  Specific Recommendations for Bovines,PDF (403.5 KB)PDF (403.5 KB) of CVM GFI #95 (VICH GL12) Effectiveness of Anthelmintics:  Specific Recommendations for Bovines,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness, VICH",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics:  Specific Recommendations for Ovines,PDF (378.2 KB)PDF (378.2 KB) of CVM GFI #96 (VICH GL13) Effectiveness of Anthelmintics:  Specific Recommendations for Ovines,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness, VICH",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics:  Specific Recommendations for Caprines,PDF (427.6 KB)PDF (427.6 KB) of CVM GFI #97 (VICH GL14) Effectiveness of Anthelmintics:  Specific Recommendations for Caprines,08/12/2022,Center for Veterinary Medicine,"Anthelmintics, Target Animal – Effectiveness, VICH",Draft,No,10/11/2022,FDA-2022-D-1494
CVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances,PDF (404.91 KB)PDF (404.91 KB) of CVM GFI #256 - Compounding Animal Drugs from Bulk Drug Substances,08/10/2022,Center for Veterinary Medicine,Compounding,Final,No,10/15/2020,FDA-2018-D-4533
"Guidance for Industry: Questions and Answers Regarding the Final Rule on Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)","PDF (550.78 KB)PDF (550.78 KB) of Guidance for Industry: Questions and Answers Regarding the Final Rule on Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation (Layers with Access to Areas Outside the Poultry House)",08/10/2022,Human Foods Program,"Egg/Egg Product, Transportation",Final,No,09/23/2013,FDA-2000-N-0190
Guidance for Industry: Policy Regarding N-acetyl-L-cysteine,PDF (219.41 KB)PDF (219.41 KB) of Guidance for Industry: Policy Regarding N-acetyl-L-cysteine,08/01/2022,Human Foods Program,,Final,No,,FDA-2022-D-0490
Changes to Disposable Manufacturing Materials:  Questions and Answers Guidance for Industry,PDF (296.49 KB)PDF (296.49 KB) of Changes to Disposable Manufacturing Materials:  Questions and Answers Guidance for Industry,07/29/2022,Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Pharmaceutical Quality,Final,No,,FDA-2017-D-6821
Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (765.68 KB)PDF (765.68 KB) of Laser-Assisted In Situ Keratomileusis (LASIK) Lasers - Patient Labeling Recommendations: Draft Guidance for Industry and Food and Drug Administration Staff,07/28/2022,Center for Devices and Radiological Health,"Labeling, Ophthalmic, Premarket Approval (PMA)",Draft,No,11/25/2022,FDA-2022-D-1253
General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry,PDF (385.7 KB)PDF (385.7 KB) of General Clinical Pharmacology Considerations for Neonatal Studies for Drugs and Biological Products Guidance for Industry,07/27/2022,Center for Drug Evaluation and Research,"Clinical - Pharmacology, Pediatric Product Development",Final,No,,FDA-2019-D-3132
Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings:  Guidance for Industry,PDF (243.71 KB)PDF (243.71 KB) of Cancer Clinical Trial Eligibility Criteria: Available Therapy in Non-Curative Settings:  Guidance for Industry,07/27/2022,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Clinical Trials, Clinical - Medical",Final,No,08/24/2021,FDA-2020-D-1802
"Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices:  Guidance for Industry and Food and Drug Administration Staff","PDF (558.76 KB)PDF (558.76 KB) of Unique Device Identification: Policy Regarding Compliance Dates for Class I and Unclassified Devices, Direct Marking, and Global Unique Device Identification Database Requirements for Certain Devices:  Guidance for Industry and Food and Drug Administration Staff",07/25/2022,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Labeling, UDI",Final,No,,FDA-2017-D-6841
Orange Book Questions and Answers Guidance for Industry:  Guidance for Industry,PDF (365.98 KB)PDF (365.98 KB) of Orange Book Questions and Answers Guidance for Industry:  Guidance for Industry,07/22/2022,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,FDA-2020-D-1068
Evaluation of Therapeutic Equivalence,PDF (353.44 KB)PDF (353.44 KB) of Evaluation of Therapeutic Equivalence,07/21/2022,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Draft,No,09/19/2022,FDA-2022-D-0528
Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products — Content and Format,PDF (392.19 KB)PDF (392.19 KB) of Instructions for Use — Patient Labeling for Human Prescription Drug and Biological Products — Content and Format,07/15/2022,Center for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2019-D-1615
CVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals,PDF (1.04 MB)PDF (1.04 MB) of CVM GFI #245 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals,07/08/2022,Center for Veterinary Medicine,Animal Feed,Final,No,07/23/2018,FDA-2018-D-0388
Identifying Trading Partners Under the Drug Supply Chain Security Act,PDF (308.96 KB)PDF (308.96 KB) of Identifying Trading Partners Under the Drug Supply Chain Security Act,07/05/2022,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,09/05/2022,FDA-2017-D-1956
"Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments","PDF (2.26 MB)PDF (2.26 MB) of Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments",06/29/2022,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,09/28/2022,FDA-2022-D-1385
Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry,PDF (310.11 KB)PDF (310.11 KB) of Bladder Cancer: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry,06/28/2022,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Premarket, Clinical - Medical",Final,No,12/01/2020,FDA-2020-D-1497
Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry,PDF (256.94 KB)PDF (256.94 KB) of Renal Cell Carcinoma: Developing Drugs and Biologics for Adjuvant Treatment:  Guidance for Industry,06/27/2022,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Premarket, Clinical - Medical",Final,No,12/01/2020,FDA-2020-D-1496
Considerations for Rescinding Breakthrough Therapy Designation,PDF (251.13 KB)PDF (251.13 KB) of Considerations for Rescinding Breakthrough Therapy Designation,06/24/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,Administrative / Procedural,Draft,No,08/23/2022,FDA-2021-D-1152
Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry,PDF (264.37 KB)PDF (264.37 KB) of Providing Regulatory Submissions in Alternate Electronic Format Guidance for Industry:  Guidance for Industry,06/24/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2020-D-0420
Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry,PDF (461.3 KB)PDF (461.3 KB) of Non-Penicillin Beta-Lactam Drugs:  A CGMP Framework for Preventing Cross-Contamination: Draft Guidance for Industry,06/24/2022,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Draft,No,08/23/2022,FDA-2011-D-0104
Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations,PDF (557.2 KB)PDF (557.2 KB) of Assessing the Effects of Food on Drugs in INDs and NDAs – Clinical Pharmacology Considerations,06/23/2022,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,,FDA-2018-D-4368
FDA Oversight of Food Covered by Systems Recognition Arrangements,PDF (237.45 KB)PDF (237.45 KB) of FDA Oversight of Food Covered by Systems Recognition Arrangements,06/21/2022,Office of Inspections and InvestigationsHuman Foods Program,"Export, Import, Investigational Use",Final,No,,FDA-2019-D-1997
Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (570.33 KB)PDF (570.33 KB) of Technical Performance Assessment of Quantitative Imaging in Radiological Device Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,06/16/2022,Center for Devices and Radiological Health,"Premarket, Radiological Health",Final,No,,FDA-2019-D-1470
Electromagnetic Compatibility (EMC) of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (532.25 KB)PDF (532.25 KB) of Electromagnetic Compatibility (EMC) of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,06/06/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Investigational Device Exemption (IDE), Radiological Health, Radiology, Safety - Issues, Errors, and Problems",Final,No,,FDA-2015-D-3787
Guidance for Industry: Fish and Fishery Products Hazards and Controls,,06/01/2022,Human Foods Program,Seafood/Seafood Product,Final,No,,FDA-2011-D-0287
Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry:  Clinical/Medical,PDF (271.21 KB)PDF (271.21 KB) of Advanced Prostate Cancer: Developing Gonadotropin-Releasing Hormone Analogues Guidance for Industry:  Clinical/Medical,05/27/2022,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2019-D-2808
Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide,PDF (232.73 KB)PDF (232.73 KB) of Importation of Prescription Drugs Final Rule Questions and Answers; Small Entity Compliance Guide,05/25/2022,Center for Drug Evaluation and Research,Import,Final,No,,FDA-2021-D-0958
Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases – Questions and Answers (Revision 1),PDF (328.41 KB)PDF (328.41 KB) of Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases – Questions and Answers (Revision 1),05/24/2022,"Center for Drug Evaluation and Research,Office of New Drugs",Clinical - Antimicrobial,Draft,No,07/24/2022,FDA-2013-D-0744
Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components:  Guidance for Industry,PDF (284.19 KB)PDF (284.19 KB) of Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components:  Guidance for Industry,05/23/2022,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2012-D-0307
Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification,PDF (233.96 KB)PDF (233.96 KB) of Draft Guidance for Industry: Policy Regarding Certain New Dietary Ingredients and Dietary Supplements Subject to the Requirement for Pre-market Notification,05/19/2022,Human Foods Program,,Draft,No,07/19/2022,FDA-2022-D-0281
Risk Management Plans to Mitigate the Potential for Drug Shortages,PDF (375.4 KB)PDF (375.4 KB) of Risk Management Plans to Mitigate the Potential for Drug Shortages,05/19/2022,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Draft,No,07/19/2022,FDA-2022-D-0277
Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors,PDF (570.23 KB)PDF (570.23 KB) of Safety Considerations for Container Labels and Carton Labeling Design to Minimize Medication Errors,05/18/2022,Center for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,FDA-2013-D-0401
Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision:  Guidance for Industry,PDF (268.95 KB)PDF (268.95 KB) of Investigating Out-of-Specification (OOS) Test Results for Pharmaceutical Production - Level 2 revision:  Guidance for Industry,05/16/2022,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-1998-D-0019
Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting,PDF (283.7 KB)PDF (283.7 KB) of Guidance for Industry: Reducing Microbial Food Safety Hazards in the Production of Seed for Sprouting,05/13/2022,Human Foods Program,Produce,Final,No,08/26/2019,FDA-2018-D-4534
CVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals,PDF (639.65 KB)PDF (639.65 KB) of CVM GFI #3 General Principles for Evaluating the Human Food Safety of New Animal Drugs Used In Food-Producing Animals,05/10/2022,Center for Veterinary Medicine,Human Food Safety,Final,No,09/19/2016,FDA-2005-D-0155
Benefit-Risk Considerations for Product Quality Assessments,PDF (317.92 KB)PDF (317.92 KB) of Benefit-Risk Considerations for Product Quality Assessments,05/09/2022,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,07/10/2022,FDA-2022-D-0168
Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus:  Guidance for Industry and Food and Drug Administration Staff,PDF (562.39 KB)PDF (562.39 KB) of Feasibility and Early Feasibility Clinical Studies for Certain Medical Devices Intended to Therapeutically Improve Glycemic Control in Patients with Type 2 Diabetes Mellitus:  Guidance for Industry and Food and Drug Administration Staff,05/06/2022,Center for Devices and Radiological Health,"Premarket, Gastroenterology-Urology , Investigational Device Exemption (IDE)",Final,No,,FDA-2021-D-0131
Guidance for Industry: Infant Formula Enforcement Discretion Policy,PDF (272.43 KB)PDF (272.43 KB) of Guidance for Industry: Infant Formula Enforcement Discretion Policy,05/01/2022,Human Foods Program,Infant Formula & Foods,Final,No,,FDA-2022-D-0814
E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility,PDF (1.65 MB)PDF (1.65 MB) of E2B(R3) Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification; and Appendix to the Implementation Guide — Backwards and Forwards Compatibility,04/29/2022,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2011-D-0720
E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide —Appendix to the Implementation Guide — Backwards and Forwards Compatibility,PDF (597.38 KB)PDF (597.38 KB) of E2B(R3) The Electronic Transmission of Individual Case Safety Reports Implementation Guide —Appendix to the Implementation Guide — Backwards and Forwards Compatibility,04/29/2022,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-2011-D-0720
Electronic Submission of IND Safety Reports Technical Conformance Guide :  Guidance for Industry,PDF (326.93 KB)PDF (326.93 KB) of Electronic Submission of IND Safety Reports Technical Conformance Guide :  Guidance for Industry,04/29/2022,Center for Drug Evaluation and ResearchOncology Center of ExcellenceCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2018-D-1216
Crohn’s Disease:  Developing Drugs for Treatment,PDF (305.09 KB)PDF (305.09 KB) of Crohn’s Disease:  Developing Drugs for Treatment,04/28/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Draft,No,06/28/2022,FDA-2022-D-0091
Draft Guidance for Industry: Questions and Answers on the Accredited Third-Party Certification Program,PDF (442.68 KB)PDF (442.68 KB) of Draft Guidance for Industry: Questions and Answers on the Accredited Third-Party Certification Program,04/28/2022,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,Import,Draft,No,07/28/2022,FDA-2022-D-0370
Ulcerative Colitis:  Developing Drugs for Treatment,PDF (321.54 KB)PDF (321.54 KB) of Ulcerative Colitis:  Developing Drugs for Treatment,04/28/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Draft,No,06/28/2022,FDA-2022-D-0140
Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation,PDF (264.54 KB)PDF (264.54 KB) of Guidance for Industry: Compliance with Providing an Acceptable Unique Facility Identifier for the Foreign Supplier Verification Programs for Food Importers Regulation,04/27/2022,Center for Veterinary MedicineHuman Foods Program,Import,Final,No,,FDA-2011-N-0143
Providing Submissions in Electronic Format — Postmarketing Safety Reports,PDF (327.01 KB)PDF (327.01 KB) of Providing Submissions in Electronic Format — Postmarketing Safety Reports,04/27/2022,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2001-D-0067
Draft Guidance for Industry: Action Levels for Lead in Juice,PDF (283.96 KB)PDF (283.96 KB) of Draft Guidance for Industry: Action Levels for Lead in Juice,04/27/2022,Human Foods Program,"Juice, Lead",Draft,No,06/28/2022,FDA-2019-D-5609
"Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry","PDF (458.28 KB)PDF (458.28 KB) of Drug Products, Including Biological Products, that Contain Nanomaterials - Guidance for Industry",04/21/2022,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,03/13/2018,FDA-2017-D-0759
Refuse to Accept Policy for 510(k)s:  Guidance for Industry and Food and Drug Administration Staff,PDF (1.41 MB)PDF (1.41 MB) of Refuse to Accept Policy for 510(k)s:  Guidance for Industry and Food and Drug Administration Staff,04/21/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k), Administrative / Procedural",Final,No,,FDA-2012-D-0523
Bioavailability Studies Submitted in NDAs or INDs – General Considerations,PDF (472.59 KB)PDF (472.59 KB) of Bioavailability Studies Submitted in NDAs or INDs – General Considerations,04/15/2022,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,05/28/2019,FDA-2018-D-4367
Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet,PDF (296.08 KB)PDF (296.08 KB) of Celiac Disease: Developing Drugs for Adjunctive Treatment to a Gluten-Free Diet,04/15/2022,"Center for Drug Evaluation and Research,Office of New DrugsCenter for Biologics Evaluation and Research",Clinical - Medical,Draft,No,06/14/2022,FDA-2021-D-1238
"Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Draft Guidance for Industry","PDF (359.66 KB)PDF (359.66 KB) of Considerations for Waiver Requests for pH Adjusters in Generic Drug Products Intended for Parenteral, Ophthalmic, or Otic Use: Draft Guidance for Industry",04/14/2022,Center for Drug Evaluation and Research,Generic Drugs,Draft,No,,FDA-2022-D-0108
Guidance for Industry: Reconditioning of Fish and Fishery Products by Segregation,PDF (313.35 KB)PDF (313.35 KB) of Guidance for Industry: Reconditioning of Fish and Fishery Products by Segregation,04/13/2022,Human Foods Program,Seafood/Seafood Product,Final,No,,FDA-2019-D-3324
Denture Base Resins - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (486.03 KB)PDF (486.03 KB) of Denture Base Resins - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,04/13/2022,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2021-D-0603
Facet Screw Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (618.36 KB)PDF (618.36 KB) of Facet Screw Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,04/13/2022,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2021-D-0604
Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs,PDF (463.59 KB)PDF (463.59 KB) of Providing Regulatory Submissions in Electronic and Non-Electronic Format—Promotional Labeling and Advertising Materials for Human Prescription Drugs,04/11/2022,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2015-D-1163
Orthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (447.92 KB)PDF (447.92 KB) of Orthopedic Fracture Fixation Plates - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,04/11/2022,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2022-D-0552
Surgical Sutures - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (395.53 KB)PDF (395.53 KB) of Surgical Sutures - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,04/11/2022,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2022-D-0552
E8(R1) General Considerations for Clinical Studies,PDF (376.69 KB)PDF (376.69 KB) of E8(R1) General Considerations for Clinical Studies,04/08/2022,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2019-D-3049
Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment,PDF (387.62 KB)PDF (387.62 KB) of Chronic Hepatitis B Virus Infection: Developing Drugs for Treatment,04/07/2022,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2018-D-3903
Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4  Guidance for Industry:  Guidance for Industry,PDF (239 KB)PDF (239 KB) of Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR Part 4  Guidance for Industry:  Guidance for Industry,03/22/2022,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,Combination Products,Final,No,,FDA-2022-D-0192
"Guidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions","PDF (307.88 KB)PDF (307.88 KB) of Guidance for Industry: Current Good Manufacturing Practice and Preventive Controls, Foreign Supplier Verification Programs, Intentional Adulteration, and Produce Safety Regulations: Enforcement Policy Regarding Certain Provisions",03/11/2022,Human Foods ProgramCenter for Veterinary MedicineOffice of Inspections and Investigations,,Final,No,,FDA-2021-D-0563
"Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C:  Guidance for Industry and FDA Staff","PDF (355.26 KB)PDF (355.26 KB) of Initiation of Voluntary Recalls Under 21 CFR Part 7, Subpart C:  Guidance for Industry and FDA Staff",03/04/2022,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods ProgramCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchCenter for Tobacco Products,"Recalls, Investigation & Enforcement,",Final,No,,FDA-2018-D-2074
Inclusion of Older Adults in Cancer Clinical Trials:  Guidance for Industry,PDF (299.75 KB)PDF (299.75 KB) of Inclusion of Older Adults in Cancer Clinical Trials:  Guidance for Industry,03/02/2022,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2019-D-5572
Center for Devices and Radiological Health (CDRH) Appeals Processes:  Guidance for Industry and Food and Drug Administration Staff,PDF (657.39 KB)PDF (657.39 KB) of Center for Devices and Radiological Health (CDRH) Appeals Processes:  Guidance for Industry and Food and Drug Administration Staff,03/02/2022,Center for Devices and Radiological Health,Administrative / Procedural,Final,No,,FDA-2011-D-0893
Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry,PDF (146.86 KB)PDF (146.86 KB) of Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry,03/01/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOncology Center of Excellence,"Administrative / Procedural, Biosimilars",Final,No,,FDA-2018-D-2777
Master Protocols:  Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry,PDF (518.2 KB)PDF (518.2 KB) of Master Protocols:  Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics Guidance for Industry:  Guidance for Industry,03/01/2022,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Administrative / Procedural, Pediatric Product Development, Biosimilars",Final,No,11/30/2018,FDA-2018-D-3292
Pre-Launch Activities Importation Requests (PLAIR):  Guidance for Industry,PDF (226.44 KB)PDF (226.44 KB) of Pre-Launch Activities Importation Requests (PLAIR):  Guidance for Industry,03/01/2022,Office of the CommissionerCenter for Drug Evaluation and Research,"Administrative / Procedural, Biosimilars",Final,No,,FDA-2013-D-0836
"Patient-Focused Drug Development: Methods to Identify What Is Important to Patients:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders","PDF (305.39 KB)PDF (305.39 KB) of Patient-Focused Drug Development: Methods to Identify What Is Important to Patients:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",02/25/2022,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,12/30/2019,FDA-2019-D-4247
Guidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits,PDF (367.35 KB)PDF (367.35 KB) of Guidance for Industry and FDA Staff: Model Accreditation Standards for Third-Party Certification Body Accreditation for Food Safety Audits,02/24/2022,Human Foods Program,Import,Final,No,,FDA-2011-N-0146
Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry: Draft Guidance for Industry,PDF (106.21 KB)PDF (106.21 KB) of Development of Non-Opioid Analgesics for Acute Pain; Draft Guidance for Industry: Draft Guidance for Industry,02/09/2022,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,04/11/2022,FDA-2021-N-0556
Drug Product Tracing: The Effect of Section 585 of the FD&C Act,PDF (144.3 KB)PDF (144.3 KB) of Drug Product Tracing: The Effect of Section 585 of the FD&C Act,02/03/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2014-D-1411
Population Pharmacokinetics:  Guidance for Industry,PDF (229.72 KB)PDF (229.72 KB) of Population Pharmacokinetics:  Guidance for Industry,02/03/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Pharmacology,Final,No,,FDA-2019-D-2398
Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry,PDF (183.44 KB)PDF (183.44 KB) of Assessment of Pressor Effects of Drugs Guidance for Industry: Draft Guidance for Industry,02/03/2022,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2018-D-1636
Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry,PDF (143.76 KB)PDF (143.76 KB) of Immunogenicity Information in Human Prescription Therapeutic Protein and Select Drug Product Labeling--Content and Format: Draft Guidance for Industry,02/03/2022,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,04/05/2022,FDA-2021-D-1041
Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs,PDF (140.77 KB)PDF (140.77 KB) of Formal Meetings Between the Food and Drug Administration and Sponsors or Requestors of Over-the-Counter Monograph Drugs,02/01/2022,"Center for Drug Evaluation and Research,Office of New Drugs",Administrative / Procedural,Draft,No,,FDA-2022-D-0080
Good ANDA Submission Practices Guidance for Industry,PDF (247.39 KB)PDF (247.39 KB) of Good ANDA Submission Practices Guidance for Industry,01/26/2022,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2017-D-6854
Principles of Premarket Pathways for Combination Products:  Guidance for Industry and FDA Staff,PDF (397.22 KB)PDF (397.22 KB) of Principles of Premarket Pathways for Combination Products:  Guidance for Industry and FDA Staff,01/26/2022,"Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Final,No,05/07/2019,FDA-2019-D-0078
"Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation:  Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders","PDF (436.61 KB)PDF (436.61 KB) of Principles for Selecting, Developing, Modifying, and Adapting Patient-Reported Outcome Instruments for Use in Medical Device Evaluation:  Guidance for Industry and Food and Drug Administration Staff, And Other Stakeholders",01/26/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Postmarket,",Final,No,,FDA-2020-D-1564
"Patient Engagement in the Design and Conduct of Medical Device Clinical Studies:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders","PDF (308.26 KB)PDF (308.26 KB) of Patient Engagement in the Design and Conduct of Medical Device Clinical Studies:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",01/26/2022,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Good Clinical Practice (GCP)",Final,No,,FDA-2019-D-3846
CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI,PDF (870.05 KB)PDF (870.05 KB) of CVM GFI #159 (VICH GL36) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish a Microbiological ADI,01/21/2022,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2003-D-0433
Collecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry,PDF (315.09 KB)PDF (315.09 KB) of Collecting and Providing 702(b) Portions of FDA Official Samples: Draft Guidance for Industry,01/01/2022,Center for Drug Evaluation and ResearchCenter for Veterinary MedicineOffice of Inspections and InvestigationsCenter for Biologics Evaluation and ResearchHuman Foods Program,"Allergenics, Blood Products, Allergens, Animal Feed, Combination Products, Current Good Manufacturing Practice (CGMP), Chemistry, Manufacturing, and Controls (CMC), Human Food Safety",Draft,No,,FDA-2021-D-0593
Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers,PDF (193.76 KB)PDF (193.76 KB) of Pathology Peer Review in Nonclinical Toxicology Studies: Questions and Answers,12/27/2021,Center for Biologics Evaluation and ResearchCenter for Veterinary MedicineCenter for Devices and Radiological HealthHuman Foods ProgramCenter for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2019-D-2330
Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH):  Guidance for Industry and Food and Drug Administration Staff,PDF (559.79 KB)PDF (559.79 KB) of Non-Clinical and Clinical Investigation of Devices Used for the Treatment of Benign Prostatic Hyperplasia (BPH):  Guidance for Industry and Food and Drug Administration Staff,12/27/2021,Center for Devices and Radiological Health,"Premarket, Gastroenterology-Urology , Good Clinical Practice (GCP)",Final,No,,FDA-2020-D-1118
Arthroscopy Pump Tubing Sets Intended for Multiple Patient Use - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (488.26 KB)PDF (488.26 KB) of Arthroscopy Pump Tubing Sets Intended for Multiple Patient Use - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,12/23/2021,Center for Devices and Radiological Health,"Premarket, 510(k), Orthopedic",Final,No,,FDA-2019-D-5606
Guidance for Industry: Juice HACCP and the FDA Food Safety Modernization Act,PDF (432.99 KB)PDF (432.99 KB) of Guidance for Industry: Juice HACCP and the FDA Food Safety Modernization Act,12/21/2021,Human Foods Program,"HACCP, Juice",Final,No,,FDA-2017-D-3716
Guidance for Industry: Low-Acid Foods Packaged in Hermetically Sealed Containers (LACF) Regulation and the FDA Food Safety Modernization Act,PDF (329.54 KB)PDF (329.54 KB) of Guidance for Industry: Low-Acid Foods Packaged in Hermetically Sealed Containers (LACF) Regulation and the FDA Food Safety Modernization Act,12/21/2021,Human Foods Program,Canned Foods,Final,No,,FDA-2017-D-3716
Guidance for Industry: Seafood HACCP and the FDA Food Safety Modernization Act,PDF (348.75 KB)PDF (348.75 KB) of Guidance for Industry: Seafood HACCP and the FDA Food Safety Modernization Act,12/21/2021,Human Foods Program,"HACCP, Seafood/Seafood Product",Final,No,,FDA-2017-D-3716
Inspection of Injectable Products for Visible Particulates: Draft Guidance for Industry,PDF (192.36 KB)PDF (192.36 KB) of Inspection of Injectable Products for Visible Particulates: Draft Guidance for Industry,12/16/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,02/15/2022,FDA-2021-D-0241
Q3C(R8) Impurities: Guidance for Residual Solvents   Guidance for Industry:  Guidance for Industry,PDF (213.55 KB)PDF (213.55 KB) of Q3C(R8) Impurities: Guidance for Residual Solvents   Guidance for Industry:  Guidance for Industry,12/10/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2020-D-1301
Bowel Cleansing for Colonoscopy:  Efficacy and Safety Considerations for Developing New Products : Draft Guidance for Industry,PDF (98.37 KB)PDF (98.37 KB) of Bowel Cleansing for Colonoscopy:  Efficacy and Safety Considerations for Developing New Products : Draft Guidance for Industry,12/10/2021,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,02/10/2022,FDA-2021-D-0406
CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports,PDF (96.67 KB)PDF (96.67 KB) of CMC Postapproval Manufacturing Changes for Specified Biological Products To Be Documented in Annual Reports,12/09/2021,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2017-D-2802
Development of Anti-Infective Drug Products for the Pediatric Population :  Guidance for Industry,PDF (91.93 KB)PDF (91.93 KB) of Development of Anti-Infective Drug Products for the Pediatric Population :  Guidance for Industry,12/09/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2020-D-1518
Tobacco Product User Fees: Responses to Frequently Asked Questions,PDF (233.19 KB)PDF (233.19 KB) of Tobacco Product User Fees: Responses to Frequently Asked Questions,12/08/2021,Center for Tobacco Products,,Final,No,,FDA-2021-D-0373
IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry,PDF (92.5 KB)PDF (92.5 KB) of IND Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases: Clinical Recommendations: Draft Guidance for Industry,12/08/2021,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,02/07/2022,FDA-2021-D-1140
"Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases:  Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators : Draft Guidance for Industry","PDF (149.36 KB)PDF (149.36 KB) of Investigational New Drug Application Submissions for Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases:  Chemistry, Manufacturing, and Controls Recommendations, Guidance for Sponsor-Investigators : Draft Guidance for Industry",12/07/2021,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC)",Draft,No,02/07/2022,FDA-2021-D-1139
Manufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers:  Guidance for Industry,PDF (334 KB)PDF (334 KB) of Manufacture of Blood Components Using a Pathogen Reduction Device in Blood Establishments: Questions and Answers:  Guidance for Industry,11/03/2021,Center for Biologics Evaluation and Research,"Blood, Blood Products, Product Safety",Final,No,,FDA-2017-D-6784
Guidance for Industry: Temporary Permits for Interstate Shipment of Experimental Packs of Food Varying from the Requirements of Definitions and Standards of Identity,PDF (244.21 KB)PDF (244.21 KB) of Guidance for Industry: Temporary Permits for Interstate Shipment of Experimental Packs of Food Varying from the Requirements of Definitions and Standards of Identity,11/01/2021,Human Foods Program,Labeling,Final,No,,FDA-2016-D-4484
Guidance for Industry: Preparation of Food Contact Substance Notifications (Toxicology Recommendations),PDF (329.6 KB)PDF (329.6 KB) of Guidance for Industry: Preparation of Food Contact Substance Notifications (Toxicology Recommendations),10/20/2021,Human Foods Program,"Food & Color Additives, Food Contact Substances (FCS), Ingredients",Final,No,,FDA-1999-D-0062
Guidance for Industry:  Preparation of Food Contact  Substance Notifications (Administrative),PDF (307.86 KB)PDF (307.86 KB) of Guidance for Industry:  Preparation of Food Contact  Substance Notifications (Administrative),10/18/2021,Human Foods Program,"Food & Color Additives, Food Contact Substances (FCS), Ingredients",Final,No,,FDA-2000-D-0138
"Guidance for Industry: Voluntary Sodium Reduction Goals:  Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods","PDF (35.76 KB)PDF (35.76 KB) of Guidance for Industry: Voluntary Sodium Reduction Goals:  Target Mean and Upper Bound Concentrations for Sodium in Commercially Processed, Packaged, and Prepared Foods",10/13/2021,Human Foods Program,Nutrition,Final,No,,FDA-2014-D-0055
Surgical Staplers and Staples for Internal Use - Labeling Recommendations:  Guidance for Industry and Food and Drug Administration Staff,PDF (345.34 KB)PDF (345.34 KB) of Surgical Staplers and Staples for Internal Use - Labeling Recommendations:  Guidance for Industry and Food and Drug Administration Staff,10/08/2021,Center for Devices and Radiological Health,"Device & Drug Safety, General & Plastic Surgery , Labeling, Device & Drug Safety",Final,No,,FDA-2019-D-1262
CVM GFI #265 Use of Data from Foreign Investigational Studies to Support Effectiveness of New Animal Drugs,PDF (334.06 KB)PDF (334.06 KB) of CVM GFI #265 Use of Data from Foreign Investigational Studies to Support Effectiveness of New Animal Drugs,10/06/2021,Center for Veterinary Medicine,"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal – Effectiveness",Final,No,10/13/2020,FDA-2020-D-1396
CVM GFI #266 Use of Real-World Data and Real-World Evidence to Support Effectiveness of New Animal Drugs,PDF (376.32 KB)PDF (376.32 KB) of CVM GFI #266 Use of Real-World Data and Real-World Evidence to Support Effectiveness of New Animal Drugs,10/06/2021,Center for Veterinary Medicine,"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal – Effectiveness",Final,No,10/13/2020,FDA-2020-D-1400
CVM GFI #267 Biomarkers and Surrogate Endpoints in Clinical Studies to Support Effectiveness of New Animal Drugs,PDF (367.79 KB)PDF (367.79 KB) of CVM GFI #267 Biomarkers and Surrogate Endpoints in Clinical Studies to Support Effectiveness of New Animal Drugs,10/06/2021,Center for Veterinary Medicine,"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal – Effectiveness",Final,No,10/13/2020,FDA-2020-D-1402
CVM GFI #268 Adaptive and Other Innovative Designs for Effectiveness Studies of New Animal Drugs,PDF (402.22 KB)PDF (402.22 KB) of CVM GFI #268 Adaptive and Other Innovative Designs for Effectiveness Studies of New Animal Drugs,10/06/2021,Center for Veterinary Medicine,"Premarket, Investigational New Animal Drug (INAD), New Animal Drug Application (NADA), Target Animal – Effectiveness",Final,No,10/13/2020,FDA-2020-D-1401
"Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry","PDF (122.11 KB)PDF (122.11 KB) of Hospital and Health System Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",10/06/2021,Center for Drug Evaluation and Research,Compounding,Draft,No,,FDA-2016-D-0271
Acceptance Review for De Novo Classification Requests:  Guidance for Industry and Food and Drug Administration Staff,PDF (893.39 KB)PDF (893.39 KB) of Acceptance Review for De Novo Classification Requests:  Guidance for Industry and Food and Drug Administration Staff,10/05/2021,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Final,No,,FDA-2017-D-6069
De Novo Classification Process (Evaluation of Automatic Class III Designation):  Guidance for Industry and Food and Drug Administration Staff,PDF (683.56 KB)PDF (683.56 KB) of De Novo Classification Process (Evaluation of Automatic Class III Designation):  Guidance for Industry and Food and Drug Administration Staff,10/05/2021,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Administrative / Procedural",Final,No,,FDA-2011-D-0689
Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations:  Guidance for Industry,PDF (222.06 KB)PDF (222.06 KB) of Interpreting Sameness of Gene Therapy Products Under the Orphan Drug Regulations:  Guidance for Industry,09/29/2021,"Center for Biologics Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development",Gene Therapy,Final,No,07/28/2020,FDA-2019-D-5392
Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices: Draft Guidance for Industry,PDF (117.55 KB)PDF (117.55 KB) of Investigator Responsibilities – Safety Reporting for Investigational Drugs and Devices: Draft Guidance for Industry,09/29/2021,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,Device & Drug Safety,Draft,No,11/29/2021,FDA-2021-D-0368
Microbiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry,PDF (283.29 KB)PDF (283.29 KB) of Microbiological Quality Considerations in Non-Sterile Drug Manufacturing: Draft Guidance for Industry,09/29/2021,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,12/29/2021,FDA-2021-D-0432
Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry:  Guidance for Industry,PDF (114.24 KB)PDF (114.24 KB) of Questions and Answers on Quality Related Controlled Correspondence Guidance for Industry:  Guidance for Industry,09/20/2021,Center for Drug Evaluation and Research,Pharmaceutical Quality,Final,No,,FDA-2017-D-6821
Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry:  Guidance for Industry,PDF (184.85 KB)PDF (184.85 KB) of Questions and Answers on Biosimilar Development and the BPCI Act Guidance for Industry:  Guidance for Industry,09/17/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Biosimilars,Final,No,,FDA-2011-D-0611
New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3): Draft New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3).”,PDF (94.67 KB)PDF (94.67 KB) of New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3): Draft New and Revised Draft Q&As on Biosimilar Development and the BPCI Act (Revision 3).”,09/17/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Biosimilars,Draft,No,11/17/2021,FDA-2011-D-0611
Q2(R1) Validation of Analytical Procedures: Text and Methodology  Guidance for Industry:  Guidance for Industry,PDF (209.53 KB)PDF (209.53 KB) of Q2(R1) Validation of Analytical Procedures: Text and Methodology  Guidance for Industry:  Guidance for Industry,09/16/2021,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,,Final,No,,FDA-2017-D-6821
Withdrawn CDER Product Specific Guidances,PDF (83.18 KB)PDF (83.18 KB) of Withdrawn CDER Product Specific Guidances,09/09/2021,Center for Drug Evaluation and Research,"Generic Drugs, Labeling",Final,No,,FDA-2007-D-0369
Guidance for Industry: Microbiological Considerations for Antimicrobial Agents Used in Food Applications,PDF (378.85 KB)PDF (378.85 KB) of Guidance for Industry: Microbiological Considerations for Antimicrobial Agents Used in Food Applications,09/01/2021,Human Foods Program,Food & Color Additives,Final,No,,FDA-2007-D-0207
Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application,PDF (388.32 KB)PDF (388.32 KB) of Bioequivalence Studies With Pharmacokinetic Endpoints for Drugs Submitted Under an Abbreviated New Drug Application,08/20/2021,Center for Drug Evaluation and Research,"Biopharmaceutics, Generic Drugs",Draft,No,,FDA-2013-D-1464
FDA Export Certification:  Guidance for Industry,PDF (344.56 KB)PDF (344.56 KB) of FDA Export Certification:  Guidance for Industry,08/20/2021,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthHuman Foods ProgramCenter for Veterinary Medicine,"Export, Import",Final,No,,
Notifying FDA of Fatalities Related to Blood Collection or Transfusion:  Guidance for Industry,PDF (141.35 KB)PDF (141.35 KB) of Notifying FDA of Fatalities Related to Blood Collection or Transfusion:  Guidance for Industry,08/20/2021,Center for Biologics Evaluation and Research,"Application & Approvals, Blood Products",Final,No,,FDA-2002-D-0010
Development and Submission of Near Infrared Analytical Procedures,PDF (236.73 KB)PDF (236.73 KB) of Development and Submission of Near Infrared Analytical Procedures,08/06/2021,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2015-D-0868
Nonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials,PDF (73.73 KB)PDF (73.73 KB) of Nonmetastatic Castration-Resistant Prostate Cancer: Considerations for Metastasis-Free Survival Endpoint in Clinical Trials,08/06/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2018-D-3931
Rabies:  Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry,PDF (208.66 KB)PDF (208.66 KB) of Rabies:  Developing Monoclonal Antibody Cocktails for the Passive Immunization Component of Post-Exposure Prophylaxis Guidance for Industry: Draft Guidance for Industry,07/28/2021,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Draft,No,10/27/2021,FDA-2021-D-0519
Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry,PDF (113.59 KB)PDF (113.59 KB) of Field Alert Report Submission: Questions and Answers Guidance for Industry:  Guidance for Industry,07/22/2021,Office of Inspections and InvestigationsCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Investigation & Enforcement, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2018-D-2326
Guidance for Industry: Use of Recycled Plastics in Food Packaging (Chemistry Considerations),PDF (338.92 KB)PDF (338.92 KB) of Guidance for Industry: Use of Recycled Plastics in Food Packaging (Chemistry Considerations),07/15/2021,Human Foods Program,"Food & Color Additives, Food Contact Substances (FCS)",Final,No,,FDA-2020-D-1456
CVM GFI #261 - Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs,PDF (266.69 KB)PDF (266.69 KB) of CVM GFI #261 - Eligibility Criteria for Expanded Conditional Approval of New Animal Drugs,07/14/2021,Center for Veterinary Medicine,"Premarket, User Fees, Antimicrobial Resistance, New Animal Drug Application (NADA), Target Animal – Effectiveness",Final,No,01/28/2020,FDA-2019-D-3361
Technical Considerations for Non-Clinical Assessment of Medical Devices Containing Nitinol:  Guidance for Industry and Food and Drug Administration Staff,PDF (560.51 KB)PDF (560.51 KB) of Technical Considerations for Non-Clinical Assessment of Medical Devices Containing Nitinol:  Guidance for Industry and Food and Drug Administration Staff,07/09/2021,Center for Devices and Radiological Health,"Premarket, Animal Cell-Based Products",Final,No,,FDA-2019-D-1261
Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI):  Guidance for Industry and Food and Drug Administration Staff,PDF (478.28 KB)PDF (478.28 KB) of Unique Device Identification System: Form and Content of the Unique Device Identifier (UDI):  Guidance for Industry and Food and Drug Administration Staff,07/07/2021,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Labeling, UDI",Final,No,,FDA-2016-D-1853
Evaluating Cancer Drugs in Patients with Central Nervous System Metastases:  Guidance for Industry,PDF (319.18 KB)PDF (319.18 KB) of Evaluating Cancer Drugs in Patients with Central Nervous System Metastases:  Guidance for Industry,07/01/2021,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchOffice of the Commissioner,Clinical - Medical,Final,No,10/26/2020,FDA-2020-D-0938
Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications : Draft Guidance for Industry,PDF (186.49 KB)PDF (186.49 KB) of Assessment of Adhesion for Topical and Transdermal Systems Submitted in New Drug Applications : Draft Guidance for Industry,07/01/2021,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2020-D-2323
Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies: Draft Guidance for Industry,PDF (519.77 KB)PDF (519.77 KB) of Sponsor Responsibilities - Safety Reporting Requirements and Safety Assessment for IND and Bioavailability/Bioequivalence Studies: Draft Guidance for Industry,06/25/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Device & Drug Safety, Safety - Issues, Errors, and Problems",Draft,No,09/24/2021,FDA-2020-D-2099
Providing Regulatory Submissions in Electronic Format -- Standardized Study Data,PDF (161.89 KB)PDF (161.89 KB) of Providing Regulatory Submissions in Electronic Format -- Standardized Study Data,06/22/2021,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2012-D-0097
"Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products:  Guidance for Industry","PDF (480.03 KB)PDF (480.03 KB) of Chemistry, Manufacturing, and Controls Changes to an Approved Application: Certain Biological Products:  Guidance for Industry",06/21/2021,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,,Final,No,,FDA-1995-D-0288
Premenopausal Women with Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry,PDF (250.02 KB)PDF (250.02 KB) of Premenopausal Women with Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry,06/17/2021,Oncology Center of ExcellenceCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,12/07/2020,FDA-2020-D-1553
CVM GFI #263 Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter,PDF (310.55 KB)PDF (310.55 KB) of CVM GFI #263 Recommendations for Sponsors of Medically Important Antimicrobial Drugs Approved for Use in Animals to Voluntarily Bring Under Veterinary Oversight All Products That Continue to be Available Over-the-Counter,06/11/2021,Center for Veterinary Medicine,"Premarket, Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)",Final,No,12/24/2019,FDA-2019-D-3614
Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry,PDF (139.74 KB)PDF (139.74 KB) of Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification Guidance for Industry,06/03/2021,Office of Inspections and InvestigationsCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2014-D-0609
Product Identifiers under the Drug Supply Chain Security Act - Questions and Answers:  Guidance for Industry,PDF (216.35 KB)PDF (216.35 KB) of Product Identifiers under the Drug Supply Chain Security Act - Questions and Answers:  Guidance for Industry,06/03/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2018-D-3175
Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry,PDF (180.48 KB)PDF (180.48 KB) of Oral Drug Products Administered Via Enteral Feeding Tube: In Vitro Testing and Labeling Recommendations: Draft Guidance for Industry,06/02/2021,Center for Drug Evaluation and ResearchCenter for Devices and Radiological Health,"Chemistry, Manufacturing, and Controls (CMC), Labeling, Pharmaceutical Quality",Draft,No,08/02/2021,FDA-2021-D-0391
CPG Sec 555.400 Aflatoxins in Human Food,PDF (153.15 KB)PDF (153.15 KB) of CPG Sec 555.400 Aflatoxins in Human Food,06/01/2021,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,FDA-2021-D-0242
CPG Sec 570.200 Aflatoxins in Brazil Nuts,PDF (157.4 KB)PDF (157.4 KB) of CPG Sec 570.200 Aflatoxins in Brazil Nuts,06/01/2021,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,FDA-2021-D-0243
CPG Sec 570.375 Aflatoxins in Peanuts and Peanut Products,PDF (165.53 KB)PDF (165.53 KB) of CPG Sec 570.375 Aflatoxins in Peanuts and Peanut Products,06/01/2021,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,FDA-2021-D-0244
CPG Sec 570.500 Aflatoxins in Pistachio Nuts,PDF (156.26 KB)PDF (156.26 KB) of CPG Sec 570.500 Aflatoxins in Pistachio Nuts,06/01/2021,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,FDA-2021-D-0245
Bispecific Antibody Development Programs Guidance for Industry,PDF (83.98 KB)PDF (83.98 KB) of Bispecific Antibody Development Programs Guidance for Industry,05/24/2021,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2019-D-0621
FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act:  Guidance for Industry,PDF (154.18 KB)PDF (154.18 KB) of FDARA Implementation Guidance for Pediatric Studies of Molecularly Targeted Oncology Drugs: Amendments to Sec. 505B of the FD&C Act:  Guidance for Industry,05/24/2021,Oncology Center of ExcellenceCenter for Drug Evaluation and Research,"Clinical Trials, Administrative / Procedural, Pediatric Product Development",Final,No,02/12/2020,FDA-2019-D-4751
ICH Q12: Implementation Considerations for FDA-Regulated Products: Draft Guidance for Industry,PDF (173.68 KB)PDF (173.68 KB) of ICH Q12: Implementation Considerations for FDA-Regulated Products: Draft Guidance for Industry,05/20/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,10/12/2021,FDA-2021-D-0166
Implanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation - Non-clinical Testing and Clinical Considerations:  Guidance for Industry and Food and Drug Administration Staff,PDF (640.22 KB)PDF (640.22 KB) of Implanted Brain-Computer Interface (BCI) Devices for Patients with Paralysis or Amputation - Non-clinical Testing and Clinical Considerations:  Guidance for Industry and Food and Drug Administration Staff,05/20/2021,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE), Neurological",Final,No,,FDA-2014-N-1130
Peripheral Vascular Atherectomy Devices - Premarket Notification [510(k)] Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (652.12 KB)PDF (652.12 KB) of Peripheral Vascular Atherectomy Devices - Premarket Notification [510(k)] Submissions:  Guidance for Industry and Food and Drug Administration Staff,05/20/2021,Center for Devices and Radiological Health,"Premarket, 510(k), Cardiovascular , Labeling",Final,No,,FDA-2018-D-2494
ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry:  Guidance for Industry,PDF (152.82 KB)PDF (152.82 KB) of ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin Guidance for Industry:  Guidance for Industry,05/19/2021,Center for Drug Evaluation and Research,"User Fees, Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2017-D-5767
Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry: Draft Guidance for Industry,PDF (113.5 KB)PDF (113.5 KB) of Chemotherapy-Induced Nausea and Vomiting: Developing Drugs for Prevention Guidance for Industry: Draft Guidance for Industry,05/19/2021,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,07/19/2021,FDA-2021-D-0351
"Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs  Frequently Asked Questions  Statement of Investigator  (Form FDA 1572) (Revision 1): Draft Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs  Frequently Asked Questions  Statement of Investigator  (Form FDA 1572) (Revision 1)","PDF (96.64 KB)PDF (96.64 KB) of Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs  Frequently Asked Questions  Statement of Investigator  (Form FDA 1572) (Revision 1): Draft Information Sheet Guidance for Sponsors, Clinical Investigators, and IRBs  Frequently Asked Questions  Statement of Investigator  (Form FDA 1572) (Revision 1)",05/19/2021,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Draft,No,07/15/2021,FDA-2008-D-0406
COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry,PDF (309.55 KB)PDF (309.55 KB) of COVID-19: Master Protocols Evaluating Drugs and Biological Products for Treatment or Prevention:  Guidance for Industry,05/17/2021,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,,Final,No,,FDA-2021-D-0409
M9 Biopharmaceutics Classification System-Based Biowaivers,PDF (288.16 KB)PDF (288.16 KB) of M9 Biopharmaceutics Classification System-Based Biowaivers,05/11/2021,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2018-D-3614
Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex,PDF (237.14 KB)PDF (237.14 KB) of Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Annex,05/11/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2018-D-1609
E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials:  Guidance for Industry,PDF (235.63 KB)PDF (235.63 KB) of E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials:  Guidance for Industry,05/11/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2017-D-6113
Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry:  Guidance for Industry,PDF (359.57 KB)PDF (359.57 KB) of Q12 Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Guidance for Industry:  Guidance for Industry,05/11/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2018-D-1609
S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals :  Guidance for Industry,PDF (817.76 KB)PDF (817.76 KB) of S5(R3) Detection of Reproductive and Developmental Toxicity for Human Pharmaceuticals :  Guidance for Industry,05/11/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2017-D-5138
Qualified Infectious Disease Product Designation Questions and Answers:  Guidance for Industy,PDF (122.83 KB)PDF (122.83 KB) of Qualified Infectious Disease Product Designation Questions and Answers:  Guidance for Industy,05/11/2021,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2017-D-7001
S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals :  International Council for Harmonisation; Draft Guidance for Industry,PDF (502.03 KB)PDF (502.03 KB) of S11 Nonclinical Safety Testing In Support of Development of Pediatric Pharmaceuticals :  International Council for Harmonisation; Draft Guidance for Industry,05/11/2021,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"ICH-Safety, Pediatric Product Development",Final,No,,FDA-2018-D-4524
Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals,PDF (330.1 KB)PDF (330.1 KB) of Submitting Nonclinical Datasets for Evaluation of Rodent Carcinogenicity Studies of Pharmaceuticals,05/01/2021,Center for Drug Evaluation and Research,,Final,No,,
Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators,PDF (85.72 KB)PDF (85.72 KB) of Nonclinical Testing of Individualized Antisense Oligonucleotide Drug Products for Severely Debilitating or Life-Threatening Diseases Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators,04/26/2021,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Draft,No,,FDA-2021-D-0320
Guidance for Industry: Enforcement Policy for Providing an Acceptable Unique Facility Identifier (UFI) for the 2020 Food Facility Registration Biennial Renewal Period,PDF (60.7 KB)PDF (60.7 KB) of Guidance for Industry: Enforcement Policy for Providing an Acceptable Unique Facility Identifier (UFI) for the 2020 Food Facility Registration Biennial Renewal Period,03/30/2021,Human Foods Program,"Registration,",Final,No,,FDA-2012-D-1002
Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency:  Guidance for Industry,PDF (162.02 KB)PDF (162.02 KB) of Manufacturing Considerations for Licensed and Investigational Cellular and Gene Therapy Products During COVID-19 Public Health Emergency:  Guidance for Industry,01/19/2021,Center for Biologics Evaluation and Research,"Coronavirus, Gene Therapy",Final,No,,FDA-2020-D-1137
Safer Technologies Program for Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (250.61 KB)PDF (250.61 KB) of Safer Technologies Program for Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,01/06/2021,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k), Premarket Approval (PMA)",Final,No,,FDA-2019-D-4048
Mouse Embryo Assay for Assisted Reproduction Technology Devices,PDF (325.49 KB)PDF (325.49 KB) of Mouse Embryo Assay for Assisted Reproduction Technology Devices,01/05/2021,Center for Devices and Radiological Health,"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Obstetrical & Gynecological",Final,No,,FDA-2019-D-2105
IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators,PDF (95.13 KB)PDF (95.13 KB) of IND Submissions for Individualized Antisense Oligonucleotide Drug Products: Administrative and Procedural Recommendations Guidance for Sponsor-Investigators: Draft Guidance for Sponsor-Investigators,01/04/2021,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,03/04/2021,FDA-2020-D-2199
Consumer Antiseptic  Rub Final Rule Questions and Answers Guidance for Industry:  Guidance for Industry,PDF (146.36 KB)PDF (146.36 KB) of Consumer Antiseptic  Rub Final Rule Questions and Answers Guidance for Industry:  Guidance for Industry,12/30/2020,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2016-N-0124
Product Labeling for Laparoscopic Power Morcellators:  Guidance for Industry and Food and Drug Administration Staff,PDF (325.39 KB)PDF (325.39 KB) of Product Labeling for Laparoscopic Power Morcellators:  Guidance for Industry and Food and Drug Administration Staff,12/30/2020,Center for Devices and Radiological Health,"Postmarket, Premarket, 510(k), Labeling, Safety - Issues, Errors, and Problems, Obstetrical & Gynecological, General & Plastic Surgery",Final,No,,FDA-2014-D-1804
Providing Regulatory Submissions in Electronic Format --Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling:  Guidance for Industry,PDF (144.06 KB)PDF (144.06 KB) of Providing Regulatory Submissions in Electronic Format --Content of the Risk Evaluation and Mitigation Strategies Document Using Structured Product Labeling:  Guidance for Industry,12/23/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions, Generic Drugs",Final,No,,FDA-2017-D-4303
Guidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling,PDF (75.25 KB)PDF (75.25 KB) of Guidance for Industry: The Use of an Alternate Name for Potassium Chloride in Food Labeling,12/17/2020,Human Foods Program,Labeling,Final,No,,FDA-2019-D-0892
Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion:  Guidance for Industry,PDF (371.3 KB)PDF (371.3 KB) of Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion:  Guidance for Industry,12/17/2020,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2014-D-1814
Dry Eye: Developing Drugs for Treatment Guidance for Industry,PDF (234.58 KB)PDF (234.58 KB) of Dry Eye: Developing Drugs for Treatment Guidance for Industry,12/16/2020,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,03/17/2021,FDA-2020-D-2214
Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products:  Guidance for Industry,PDF (126.2 KB)PDF (126.2 KB) of Interacting with the FDA on Complex Innovative Trial Designs for Drugs and Biological Products:  Guidance for Industry,12/16/2020,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2019-D-3679
CVM GFI #262 Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices,PDF (194.72 KB)PDF (194.72 KB) of CVM GFI #262 Pre-Submission Consultation Process for Animal Food Additive Petitions or Generally Recognized as Safe (GRAS) Notices,12/11/2020,Center for Veterinary Medicine,"Animal Food Additives, Generally Recognized as Safe (GRAS)",Final,No,04/13/2020,FDA-2020-D-0064
Magnetic Resonance (MR) Receive-only Coil - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (446.23 KB)PDF (446.23 KB) of Magnetic Resonance (MR) Receive-only Coil - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,12/11/2020,Center for Devices and Radiological Health,"Premarket, 510(k), Radiology",Final,No,,FDA-2019-D-1650
Spinal Plating Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (463.16 KB)PDF (463.16 KB) of Spinal Plating Systems - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,12/11/2020,Center for Devices and Radiological Health,"Premarket, 510(k), Orthopedic",Final,No,,FDA-2019-D-1647
Best Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry:  Guidance for Industry,PDF (346.09 KB)PDF (346.09 KB) of Best Practices in Developing Proprietary Names for Human Prescription Drug Products; Guidance for Industry:  Guidance for Industry,12/08/2020,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,FDA-2014-D-0622
Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry,PDF (219.59 KB)PDF (219.59 KB) of Best Practices in Developing Proprietary Names for Human Nonprescription Drug Products; Draft Guidance for Industry: Draft Guidance for Industry,12/08/2020,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Draft,No,02/08/2021,FDA-2020-D-0770
Requesting FDA Feedback on Combination Products :  Guidance for Industry and FDA Staff,PDF (595.72 KB)PDF (595.72 KB) of Requesting FDA Feedback on Combination Products :  Guidance for Industry and FDA Staff,12/04/2020,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and ResearchCenter for Devices and Radiological Health","Combination Products, Over-the-Counter Drugs",Final,No,02/24/2020,FDA-2019-D-4739
"Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis:  Guidance for Industry","PDF (1.07 MB)PDF (1.07 MB) of Recommendations for Screening, Testing, and Management of Blood Donors and Blood and Blood Components Based on Screening Tests for Syphilis:  Guidance for Industry",12/02/2020,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2003-D-0128
Compliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff,PDF (75.88 KB)PDF (75.88 KB) of Compliance Policy Guide CPG Sec. 110.650 Weekly Entry Filing Guidance for Industry and FDA Staff,11/30/2020,Office of Inspections and Investigations,"Compliance, Export, Import",Final,No,,FDA-2019-D-3904
CVM GFI #242 In-Use Stability Studies and Associated Labeling Statements for Multiple-Dose Injectable Animal Drug Products,PDF (141.27 KB)PDF (141.27 KB) of CVM GFI #242 In-Use Stability Studies and Associated Labeling Statements for Multiple-Dose Injectable Animal Drug Products,11/27/2020,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), New Animal Drug Application (NADA), Investigational New Animal Drug (INAD)",Final,No,03/06/2017,FDA-2016-D-4437
Qualification Process for Drug Development Tools Guidance for Industry and FDA Staff,PDF (167.65 KB)PDF (167.65 KB) of Qualification Process for Drug Development Tools Guidance for Industry and FDA Staff,11/24/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Clinical - Medical, Drug Development Tools",Final,No,,FDA-2010-D-0529
CVM GFI #255 Elemental Impurities in Animal Drug Products Questions and Answers,PDF (152.19 KB)PDF (152.19 KB) of CVM GFI #255 Elemental Impurities in Animal Drug Products Questions and Answers,11/23/2020,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,05/29/2018,FDA-2018-D-0943
Public Availability of Lists of Retail Consignees to Effectuate Certain Human and Animal Food Recalls:  Guidance for Industry and FDA Staff,PDF (54.69 KB)PDF (54.69 KB) of Public Availability of Lists of Retail Consignees to Effectuate Certain Human and Animal Food Recalls:  Guidance for Industry and FDA Staff,11/20/2020,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,"Recalls, Retail Food Protection",Final,No,11/26/2018,FDA-2018-D-1752
CVM GFI #197 Documenting Electronic Data Files and Statistical Analysis Programs,PDF (130.84 KB)PDF (130.84 KB) of CVM GFI #197 Documenting Electronic Data Files and Statistical Analysis Programs,11/13/2020,Center for Veterinary Medicine,"Target Animal – Effectiveness, Target Animal – Safety, Investigational New Animal Drug (INAD)",Final,No,07/20/2018,FDA-2009-D-0052
"Certificates of Confidentiality:  Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff","PDF (167 KB)PDF (167 KB) of Certificates of Confidentiality:  Guidance for Sponsors, Sponsor-Investigators, Researchers, Industry, and Food and Drug Administration Staff",11/13/2020,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of PolicyCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Tobacco ProductsHuman Foods ProgramCenter for Veterinary MedicineOffice of the Commissioner,Office of the Chief Scientist","Research, Good Clinical Practice (GCP)",Final,No,01/08/2020,FDA-2019-D-3592
Draft Guidance for Industry: Voluntary Disclosure of Sesame as an Allergen,PDF (94.6 KB)PDF (94.6 KB) of Draft Guidance for Industry: Voluntary Disclosure of Sesame as an Allergen,11/10/2020,Human Foods Program,Allergens,Draft,No,02/25/2021,FDA-2020-D-0530
Regulatory Considerations for Microneedling Products:  Guidance for Industry and Food and Drug Administration Staff,PDF (380.45 KB)PDF (380.45 KB) of Regulatory Considerations for Microneedling Products:  Guidance for Industry and Food and Drug Administration Staff,11/10/2020,Center for Devices and Radiological Health,"Premarket, General & Plastic Surgery",Final,No,,FDA-2017-D-4792
"Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry","PDF (152.64 KB)PDF (152.64 KB) of Enhancing the Diversity of Clinical Trial Populations — Eligibility Criteria, Enrollment Practices, and Trial Designs Guidance for Industry",11/09/2020,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2019-D-1264
Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry:  Guidance for Industry,PDF (224.28 KB)PDF (224.28 KB) of Assessing User Fees Under the Prescription Drug User Fee Amendments of 2017 Guidance for Industry:  Guidance for Industry,11/09/2020,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"User Fees,",Final,No,,FDA-2017-D-5913
Insanitary Conditions at Compounding Facilities Guidance for Industry,PDF (123.19 KB)PDF (123.19 KB) of Insanitary Conditions at Compounding Facilities Guidance for Industry,11/06/2020,Center for Drug Evaluation and Research,"Administrative / Procedural, Compounding",Final,No,,FDA-2016-D-2268
Guidance for Industry: Prior Notice of Imported Food Contingency Plan for System Outages,PDF (84.82 KB)PDF (84.82 KB) of Guidance for Industry: Prior Notice of Imported Food Contingency Plan for System Outages,11/01/2020,Office of Inspections and Investigations,Import,Final,No,,FDA-2004-D-0042
Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products Guidance for Industry,PDF (117.92 KB)PDF (117.92 KB) of Nonclinical Testing of Orally Inhaled Nicotine-Containing Drug Products Guidance for Industry,10/28/2020,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2018-D-2583
Referencing Approved Drug Products in ANDA Submissions Guidance for Industry,PDF (154.94 KB)PDF (154.94 KB) of Referencing Approved Drug Products in ANDA Submissions Guidance for Industry,10/27/2020,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,FDA-2017-D-0114
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies,PDF (237 KB)PDF (237 KB) of Wholesale Distributor Verification Requirement for Saleable Returned Drug Product and Dispenser Verification Requirements When Investigating a Suspect or Illegitimate Product—Compliance Policies,10/22/2020,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2019-D-4212.
Guidance for Industry: The Declaration of Allulose and Calories from Allulose on Nutrition and Supplement Facts Labels,PDF (108.49 KB)PDF (108.49 KB) of Guidance for Industry: The Declaration of Allulose and Calories from Allulose on Nutrition and Supplement Facts Labels,10/16/2020,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2019-D-0725
Guidance for Industry: U.S. Agent Voluntary Identification System (VIS) for Food Facility Registration,PDF (133.08 KB)PDF (133.08 KB) of Guidance for Industry: U.S. Agent Voluntary Identification System (VIS) for Food Facility Registration,10/16/2020,Human Foods Program,"Registration,",Final,No,,FDA-2012-D-1002
Testing for Biotin Interference in In Vitro Diagnostic Devices:  Guidance for Industry,PDF (90.06 KB)PDF (90.06 KB) of Testing for Biotin Interference in In Vitro Diagnostic Devices:  Guidance for Industry,10/16/2020,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Blood, Blood Products, IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2019-D-1876
Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry,PDF (53.23 KB)PDF (53.23 KB) of Opioid Use Disorder: Endpoints for Demonstrating Effectiveness of Drugs for Treatment Guidance for Industry,10/01/2020,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2018-D-2382
"Importation of Certain FDA- Approved Human Prescription Drugs, Including Biological Products, and Combination Products under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry","PDF (340.57 KB)PDF (340.57 KB) of Importation of Certain FDA- Approved Human Prescription Drugs, Including Biological Products, and Combination Products under Section 801(d)(1)(B) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry",10/01/2020,"Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and ResearchOffice of Inspections and InvestigationsOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","Investigation & Enforcement, Labeling, Chemistry, Manufacturing, and Controls (CMC), Combination Products, Pharmaceutical Quality",Final,No,02/21/2020,FDA-2019-D-5743
"The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls : Draft Guidance for Industry","PDF (223.33 KB)PDF (223.33 KB) of The Use of Physiologically Based Pharmacokinetic Analyses — Biopharmaceutics Applications for Oral Drug Product Development, Manufacturing Changes, and Controls : Draft Guidance for Industry",09/30/2020,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,11/30/2020,FDA-2020-D-1517
"Saline, Silicone Gel, and Alternative Breast Implants:  Guidance for Industry and FDA Staff","PDF (452.04 KB)PDF (452.04 KB) of Saline, Silicone Gel, and Alternative Breast Implants:  Guidance for Industry and FDA Staff",09/29/2020,Center for Devices and Radiological Health,"Premarket, General & Plastic Surgery , Labeling",Final,No,,FDA-2004-D-0124
Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use:  Guidance for Industry and Food and Drug Administration Staff,PDF (899.61 KB)PDF (899.61 KB) of Blood Glucose Monitoring Test Systems for Prescription Point-of-Care Use:  Guidance for Industry and Food and Drug Administration Staff,09/29/2020,Center for Devices and Radiological Health,"Premarket, CLIA (Clinical Laboratory Improvement Amendments), IVDs (In Vitro Diagnostic Devices), General Hospital & Personal Use , Clinical Chemistry & Clinical Toxicology",Final,No,,FDA-2013-D-1445
Breast Implants - Certain Labeling Recommendations to Improve Patient Communication:  Guidance for Industry and Food and Drug Administration Staff,PDF (459.48 KB)PDF (459.48 KB) of Breast Implants - Certain Labeling Recommendations to Improve Patient Communication:  Guidance for Industry and Food and Drug Administration Staff,09/29/2020,Center for Devices and Radiological Health,"Premarket, General & Plastic Surgery , Labeling",Final,No,12/23/2019,FDA-2019-D-4467
Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use:  Guidance for Industry and Food and Drug Administration Staff,PDF (827.21 KB)PDF (827.21 KB) of Self-Monitoring Blood Glucose Test Systems for Over-the-Counter Use:  Guidance for Industry and Food and Drug Administration Staff,09/29/2020,Center for Devices and Radiological Health,"Premarket, 510(k), Clinical Chemistry & Clinical Toxicology , Over-the-Counter Drugs",Final,No,,FDA-2013-D-1446
"Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff","PDF (607.78 KB)PDF (607.78 KB) of Basic Safety and Essential Performance of Medical Electrical Equipment, Medical Electrical Systems, and Laboratory Medical Equipment - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",09/25/2020,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2019-D-3805
"Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff","PDF (871.63 KB)PDF (871.63 KB) of Biocompatibility Testing of Medical Devices - Standards Specific Information for the Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",09/25/2020,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2019-D-3805
"The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff","PDF (867.5 KB)PDF (867.5 KB) of The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program:  Guidance for Industry, Accreditation Bodies, Testing Laboratories, and Food and Drug Administration Staff",09/25/2020,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2019-D-3805
Eosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry,PDF (271.07 KB)PDF (271.07 KB) of Eosinophilic Esophagitis: Developing Drugs for Treatment Guidance for Industry,09/15/2020,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2019-D-0177
Geriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Industry: Draft Guidance for Industry,PDF (348.12 KB)PDF (348.12 KB) of Geriatric Information in Human Prescription Drug and Biological Product Labeling Guidance for Industry: Draft Guidance for Industry,09/15/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,11/16/2020,FDA-2020-D-1621
Recognition and Withdrawal of Voluntary Consensus Standards:  Guidance for Industry and Food and Drug Administration Staff,PDF (559.96 KB)PDF (559.96 KB) of Recognition and Withdrawal of Voluntary Consensus Standards:  Guidance for Industry and Food and Drug Administration Staff,09/15/2020,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,Administrative / Procedural,Final,No,,FDA-2018-D-2936
CVM GFI #191 Changes to Approved NADAs - New NADAs vs. Category II Supplemental NADAs,PDF (266.41 KB)PDF (266.41 KB) of CVM GFI #191 Changes to Approved NADAs - New NADAs vs. Category II Supplemental NADAs,08/27/2020,Center for Veterinary Medicine,New Animal Drug Application (NADA),Final,No,,FDA-2008-D-0614
Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry,PDF (262.91 KB)PDF (262.91 KB) of Acute Myeloid Leukemia:  Developing Drugs and Biological Products for Treatment: Draft Guidance for Industry,08/17/2020,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Draft,No,10/13/2020,FDA-2020-D-1298
Conventional Foley Catheters - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (94.14 KB)PDF (94.14 KB) of Conventional Foley Catheters - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,08/14/2020,Center for Devices and Radiological Health,"Premarket, 510(k), Gastroenterology-Urology",Final,No,,FDA-2019-D-1651
Cutaneous Electrodes for Recording Purposes - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,PDF (79.43 KB)PDF (79.43 KB) of Cutaneous Electrodes for Recording Purposes - Performance Criteria for Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration Staff,08/14/2020,Center for Devices and Radiological Health,"Premarket, 510(k), Neurological",Final,No,,FDA-2019-D-1649
"Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank:  Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to FDA, and FDA Staff","PDF (93.08 KB)PDF (93.08 KB) of Civil Money Penalties Relating to the ClinicalTrials.gov Data Bank:  Guidance for Responsible Parties, Submitters of Certain Applications and Submissions to FDA, and FDA Staff",08/14/2020,"Office of Inspections and InvestigationsOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Investigation & Enforcement, Good Clinical Practice (GCP)",Final,No,,FDA-2018-D-0787
Male Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry,PDF (59.99 KB)PDF (59.99 KB) of Male Breast Cancer: Developing Drugs for Treatment:  Guidance for Industry,08/12/2020,Oncology Center of ExcellenceCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,10/28/2019,FDA-2019-D-2966
"Marketing Status Notifications Under Section 506I of the Federal Food, Drug, and Cosmetic Act","PDF (84.56 KB)PDF (84.56 KB) of Marketing Status Notifications Under Section 506I of the Federal Food, Drug, and Cosmetic Act",08/10/2020,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2018-D-4615
Limited Population Pathway for Antibacterial and Antifungal Drugs Guidance for Industry,PDF (285.08 KB)PDF (285.08 KB) of Limited Population Pathway for Antibacterial and Antifungal Drugs Guidance for Industry,08/05/2020,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2018-D-2032
Guidance for Industry: Action Level for Inorganic Arsenic in Rice Cereals for Infants,PDF (124.11 KB)PDF (124.11 KB) of Guidance for Industry: Action Level for Inorganic Arsenic in Rice Cereals for Infants,08/04/2020,Human Foods Program,"Arsenic, Infant Formula & Foods",Final,No,,FDA-2016-D-1099
CPG Sec. 280.100 -  Stability Requirements -  Licensed In Vitro Diagnostic Products,PDF (73.86 KB)PDF (73.86 KB) of CPG Sec. 280.100 -  Stability Requirements -  Licensed In Vitro Diagnostic Products,07/31/2020,Center for Biologics Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 280.110-  Microbiological Control Requirements-Licensed Anti-Human Globulin and Blood Grouping Reagents,PDF (53.39 KB)PDF (53.39 KB) of CPG Sec. 280.110-  Microbiological Control Requirements-Licensed Anti-Human Globulin and Blood Grouping Reagents,07/31/2020,Center for Biologics Evaluation and Research,"Investigation & Enforcement,",Final,No,,
Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans,PDF (369.14 KB)PDF (369.14 KB) of Pediatric Study Plans: Content of and Process for Submitting Initial Pediatric Study Plans and Amended Initial Pediatric Study Plans,07/31/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Pediatric Product Development",Final,No,,FDA-2013-D-0814
Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval,PDF (241.24 KB)PDF (241.24 KB) of Pathological Complete Response in Neoadjuvant Treatment of High-Risk Early-Stage Breast Cancer: Use as an Endpoint to Support Accelerated Approval,07/29/2020,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2012-D-0432
Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products:  Guidance for Industry,PDF (69.76 KB)PDF (69.76 KB) of Expiration Dating of Unit-Dose Repackaged Solid Oral Dosage Form Drug Products:  Guidance for Industry,07/29/2020,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2017-D-0829
"Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products-Content and Format: Draft Guidance for Industry","PDF (410.23 KB)PDF (410.23 KB) of Pregnancy, Lactation, and Reproductive Potential: Labeling for Human Prescription Drug and Biological Products-Content and Format: Draft Guidance for Industry",07/29/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,09/29/2020,FDA-2014-D-1551
Multiple Function Device Products: Policy and Considerations:  Guidance for Industry and Food and Drug Administration,PDF (631.95 KB)PDF (631.95 KB) of Multiple Function Device Products: Policy and Considerations:  Guidance for Industry and Food and Drug Administration,07/29/2020,"Center for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Drug Evaluation and Research","Postmarket, Premarket, Combination Products, Digital Health",Final,No,,FDA-2018-D-1339
Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry,PDF (79.5 KB)PDF (79.5 KB) of Setting Endotoxin Limits During Development of Investigational Oncology Drugs and Biological Products Guidance for Industry: Draft Guidance for Industry,07/28/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,10/28/2020,FDA-2020-D-1294
"Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use:  Guidance for Industry and Food and Drug Administration Staff","PDF (225.48 KB)PDF (225.48 KB) of Regulatory Considerations for Human Cells, Tissues, and Cellular and Tissue-Based Products: Minimal Manipulation and Homologous Use:  Guidance for Industry and Food and Drug Administration Staff",07/20/2020,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Cellular & Gene Therapy, Tissue",Final,No,,FDA-2017-D-6146
Clinical Investigations for Prostate Tissue Ablation Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (352.13 KB)PDF (352.13 KB) of Clinical Investigations for Prostate Tissue Ablation Devices:  Guidance for Industry and Food and Drug Administration Staff,07/15/2020,Center for Devices and Radiological Health,"Premarket, 510(k), Investigational Device Exemption (IDE), Gastroenterology-Urology , Good Clinical Practice (GCP)",Final,No,,FDA-2019-D-2223
"Providing Regulatory Submissions for Medical Devices in Electronic Format - Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff","PDF (385.46 KB)PDF (385.46 KB) of Providing Regulatory Submissions for Medical Devices in Electronic Format - Submissions Under Section 745A(b) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and Food and Drug Administration Staff",07/15/2020,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2019-D-3769
CPG Sec 540.750 - Use of The Seafood List to Determine Acceptable Seafood Names,PDF (85.59 KB)PDF (85.59 KB) of CPG Sec 540.750 - Use of The Seafood List to Determine Acceptable Seafood Names,07/13/2020,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,FDA-2016-D-3004
Cancer Clinical Trial Eligibility Criteria: Brain Metastases,PDF (117.81 KB)PDF (117.81 KB) of Cancer Clinical Trial Eligibility Criteria: Brain Metastases,07/10/2020,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2019-D-0357
Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients,PDF (133.3 KB)PDF (133.3 KB) of Cancer Clinical Trial Eligibility Criteria: Minimum Age Considerations for Inclusion of Pediatric Patients,07/10/2020,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2019-D-0358
"Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections","PDF (185.88 KB)PDF (185.88 KB) of Cancer Clinical Trial Eligibility Criteria: Patients with HIV, Hepatitis B Virus, or Hepatitis C Virus Infections",07/10/2020,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2019-D-0363
Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies,PDF (154.93 KB)PDF (154.93 KB) of Cancer Clinical Trial Eligibility Criteria: Patients with Organ Dysfunction or Prior or Concurrent Malignancies,07/10/2020,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2019-D-0359
Review and Update of Device Establishment Inspection Processes and Standards:  Guidance for Industry,PDF (51.51 KB)PDF (51.51 KB) of Review and Update of Device Establishment Inspection Processes and Standards:  Guidance for Industry,06/29/2020,Office of Inspections and InvestigationsCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,06/26/2020,FDA-2019-D-0914
CVM GFI #240 Proprietary Names for New Animal Drugs,PDF (175.72 KB)PDF (175.72 KB) of CVM GFI #240 Proprietary Names for New Animal Drugs,06/01/2020,Center for Veterinary Medicine,"Administrative / Procedural, Advertising, Labeling, New Animal Drug Application (NADA)",Final,No,05/11/2018,FDA-2018-D-0626
Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic,PDF (394.46 KB)PDF (394.46 KB) of Postmarketing Adverse Event Reporting for Medical Products and Dietary Supplements During a Pandemic,05/11/2020,Human Foods ProgramCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,FDA-2008-D-0610
Classification of Posterior Cervical Screw Systems: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,PDF (58.41 KB)PDF (58.41 KB) of Classification of Posterior Cervical Screw Systems: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,05/04/2020,Center for Devices and Radiological Health,"Orthopedic, Premarket Approval (PMA)",Final,No,,FDA-2015-N-3785
Enforcement Priorities for Electronic Nicotine Delivery System (ENDS) and Other Deemed Products on the Market Without Premarket Authorization:  Guidance for Industry,PDF (872.13 KB)PDF (872.13 KB) of Enforcement Priorities for Electronic Nicotine Delivery System (ENDS) and Other Deemed Products on the Market Without Premarket Authorization:  Guidance for Industry,04/29/2020,Center for Tobacco Products,"Electronic Nicotine Delivery Systems (ENDS), Product Application and Review",Final,No,04/15/2019,FDA-2019-D-0661
eCopy Program for Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (566.73 KB)PDF (566.73 KB) of eCopy Program for Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,04/27/2020,Center for Devices and Radiological Health,"Premarket, User Fees, Administrative / Procedural, Investigational Device Exemption (IDE)",Final,No,,FDA-2018-N-0628
Nonbinding Feedback After Certain FDA Inspections of Device Establishments:  Guidance for Industry and Food and Drug Administration Staff,PDF (338.73 KB)PDF (338.73 KB) of Nonbinding Feedback After Certain FDA Inspections of Device Establishments:  Guidance for Industry and Food and Drug Administration Staff,04/22/2020,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket,",Final,No,04/20/2019,FDA-2018-D-4711
"Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA: Draft Guidance for Industry and Food and Drug Administration Staff","PDF (451.26 KB)PDF (451.26 KB) of Technical Considerations for Demonstrating Reliability of Emergency-Use Injectors Submitted under a BLA, NDA or ANDA: Draft Guidance for Industry and Food and Drug Administration Staff",04/21/2020,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological Health",Combination Products,Draft,No,06/22/2020,FDA-2019-D-5573
CVM GFI #259 (VICH GL58) Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV,PDF (200.75 KB)PDF (200.75 KB) of CVM GFI #259 (VICH GL58) Stability Testing of New Veterinary Drug Substances and Medicinal Products in Climatic Zones III and IV,04/14/2020,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,02/26/2019,FDA-2018-D-4662
Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products:  Guidance for Industry,PDF (323.18 KB)PDF (323.18 KB) of Developing and Labeling In vitro Companion Diagnostic Devices for a Specific Group of Oncology Therapeutic Products:  Guidance for Industry,04/13/2020,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOncology Center of Excellence,"Premarket, Labeling",Final,No,02/05/2019,FDA-2018-D-3380
Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act,PDF (172.27 KB)PDF (172.27 KB) of Fees for Human Drug Compounding Outsourcing Facilities Under Sections 503B and 744K of the FD&C Act,04/03/2020,Center for Drug Evaluation and Research,"User Fees, Compounding",Final,No,,FDA-2014-D-0329
Center for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers About 517A:  Guidance for Industry and Food and Drug Administration Staff,PDF (329.57 KB)PDF (329.57 KB) of Center for Devices and Radiological Health (CDRH) Appeals Processes: Questions and Answers About 517A:  Guidance for Industry and Food and Drug Administration Staff,03/27/2020,Center for Devices and Radiological Health,"510(k), Premarket Approval (PMA), Administrative / Procedural",Final,No,,FDA-2013-D-0501
CPG Section 110.800 Post Detention Sampling Guidance for Industry,PDF (46.48 KB)PDF (46.48 KB) of CPG Section 110.800 Post Detention Sampling Guidance for Industry,03/24/2020,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
Restricted Delivery Systems: Flow Restrictors for Oral Liquid Drug Products Guidance for Industry,PDF (143.43 KB)PDF (143.43 KB) of Restricted Delivery Systems: Flow Restrictors for Oral Liquid Drug Products Guidance for Industry,03/17/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,Device & Drug Safety,Draft,No,05/18/2020,FDA-2020-D-0567
Biological Product Deviation Reporting for Blood and Plasma Establishments:  Guidance for Industry,PDF (547.39 KB)PDF (547.39 KB) of  Biological Product Deviation Reporting for Blood and Plasma Establishments:  Guidance for Industry,03/12/2020,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2001-D-0007
Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry,PDF (222.39 KB)PDF (222.39 KB) of Type 2 Diabetes Mellitus: Evaluating the Safety of New Drugs for Improving Glycemic Control Guidance for Industry,03/10/2020,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,06/08/2020,FDA-2019-N-6084
Premarket Notification (510(k)) Submissions for Electrosurgical Devices for General Surgery:  Guidance for Industry and Food and Drug Administration Staff,PDF (587.09 KB)PDF (587.09 KB) of Premarket Notification (510(k)) Submissions for Electrosurgical Devices for General Surgery:  Guidance for Industry and Food and Drug Administration Staff,03/09/2020,Center for Devices and Radiological Health,"Premarket, 510(k), Clinical - Medical, Good Clinical Practice (GCP), Labeling, General & Plastic Surgery",Final,No,,FDA-2014-D-0217
Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment Guidance for Industry,PDF (55.51 KB)PDF (55.51 KB) of Contact Dermatitis From Topical Drug Products for Cutaneous Application: Human Safety Assessment Guidance for Industry,03/06/2020,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,05/08/2020,FDA-2020-D-0043
The “Deemed to be a License” Provision of the BPCI Act: Questions and Answers :  Guidance for Industry,PDF (319.91 KB)PDF (319.91 KB) of The “Deemed to be a License” Provision of the BPCI Act: Questions and Answers :  Guidance for Industry,03/04/2020,"Center for Drug Evaluation and Research,Office of Regulatory PolicyCenter for Biologics Evaluation and Research",Administrative / Procedural,Final,No,,FDA-2015-D-4750.
Bone Anchors - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (503.42 KB)PDF (503.42 KB) of Bone Anchors - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,03/03/2020,Center for Devices and Radiological Health,"Premarket, 510(k), Orthopedic",Final,No,,FDA-2016-D-4436
"Product Recalls, Including Removals and Corrections:  Guidance for Industry","PDF (133.7 KB)PDF (133.7 KB) of Product Recalls, Including Removals and Corrections:  Guidance for Industry",03/02/2020,Center for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and ResearchHuman Foods ProgramCenter for Tobacco ProductsCenter for Veterinary Medicine,"Recalls,",Final,No,,
CVM GFI #264 Standardized Medicated Feed Assay Limits,PDF (85.07 KB)PDF (85.07 KB) of CVM GFI #264 Standardized Medicated Feed Assay Limits,02/27/2020,Center for Veterinary Medicine,"Animal Feed, Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Target Animal – Safety, Target Animal – Effectiveness, Human Food Safety, Investigational New Animal Drug (INAD)",Draft,No,06/26/2020,FDA-2019-D-5664
Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (596.03 KB)PDF (596.03 KB) of Recommendations for Clinical Laboratory Improvement Amendments of 1988 (CLIA) Waiver Applications for Manufacturers of In Vitro Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,02/26/2020,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,CLIA (Clinical Laboratory Improvement Amendments),Final,No,,FDA-2017-D-5570
Recommendations for Dual 510(k) and CLIA Waiver by Application Studies:  Guidance for Industry and Food and Drug Administration Staff,PDF (392.56 KB)PDF (392.56 KB) of Recommendations for Dual 510(k) and CLIA Waiver by Application Studies:  Guidance for Industry and Food and Drug Administration Staff,02/26/2020,Center for Devices and Radiological Health,"Premarket, Postmarket, CLIA (Clinical Laboratory Improvement Amendments), 510(k)",Final,No,,FDA-2017-D-5625
Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments,PDF (313.86 KB)PDF (313.86 KB) of Specifications for Preparing and Submitting Electronic ICSRs and ICSR Attachments,02/14/2020,Center for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,None found
Supplemental Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration,PDF (459.08 KB)PDF (459.08 KB) of Supplemental Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration,02/13/2020,Human Foods Program,,Draft,No,,FDA-2018-D-1398
Biosimilars and Interchangeable Biosimilars:  Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed Guidance for Industry: Draft Guidance for Industry,PDF (378.7 KB)PDF (378.7 KB) of Biosimilars and Interchangeable Biosimilars:  Licensure for Fewer Than All Conditions of Use for Which the Reference Product Has Been Licensed Guidance for Industry: Draft Guidance for Industry,02/07/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Biosimilars,Draft,No,04/06/2020,FDA-2019-D-5270
Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II):  Guidance for Industry,PDF (781.67 KB)PDF (781.67 KB) of Use of Serological Tests to Reduce the Risk of Transfusion-Transmitted Human T-Lymphotropic Virus Types I and II (HTLV-I/II):  Guidance for Industry,02/05/2020,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2018-D-3324
Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy,PDF (242.58 KB)PDF (242.58 KB) of Mucopolysaccharidosis Type III (Sanfilippo Syndrome): Developing Drugs for Treatment Guidance for Industry: Draft Guidance for Industy,02/04/2020,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Draft,No,05/05/2020,FDA-2019-D-5404
Small Entity Compliance Guide: Revision of the Nutrition and Supplement Facts Labels,PDF (1.05 MB)PDF (1.05 MB) of Small Entity Compliance Guide: Revision of the Nutrition and Supplement Facts Labels,02/03/2020,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2012-N-1210
Long Term Follow-up After Administration of Human Gene Therapy Products:   Guidance for Industry,PDF (508.09 KB)PDF (508.09 KB) of Long Term Follow-up After Administration of Human Gene Therapy Products:   Guidance for Industry,01/28/2020,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy,",Final,No,10/10/2018,FDA-2018-D-2173
"Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs):  Guidance for Industry","PDF (466.7 KB)PDF (466.7 KB) of Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs):  Guidance for Industry",01/28/2020,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,10/10/2018,2008-D-0205
Human Gene Therapy for Hemophilia:  Guidance for Industry,PDF (260.41 KB)PDF (260.41 KB) of Human Gene Therapy for Hemophilia:  Guidance for Industry,01/28/2020,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,10/18/2018,FDA 2018-D-2238
Human Gene Therapy for Rare Diseases:  Guidance for Industry,PDF (240.96 KB)PDF (240.96 KB) of Human Gene Therapy for Rare Diseases:  Guidance for Industry,01/28/2020,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy, Pediatric Product Development",Final,No,10/10/2018,FDA-2018-D-2258
Human Gene Therapy for Retinal Disorders:  Guidance for Industry,PDF (107.86 KB)PDF (107.86 KB) of Human Gene Therapy for Retinal Disorders:  Guidance for Industry,01/28/2020,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy, Pediatric Product Development",Final,No,10/10/2018,FDA-2018-D-2236
Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up:  Guidance for Industry,PDF (227.35 KB)PDF (227.35 KB) of Testing of Retroviral Vector-Based Human Gene Therapy Products for Replication Competent Retrovirus During Product Manufacture and Patient Follow-up:  Guidance for Industry,01/28/2020,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,10/10/2018,FDA-1999-D-0081
Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry,PDF (153.92 KB)PDF (153.92 KB) of Hematologic Malignancies: Regulatory Considerations for Use of Minimal Residual Disease in Development of Drug and Biological Products for Treatment:  Guidance for Industry,01/24/2020,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2018-D-3090
Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry: Draft Guidance for Industry,PDF (484.69 KB)PDF (484.69 KB) of Current Good Manufacturing Practice—Guidance for Human Drug Compounding Outsourcing Facilities Under Section 503B of the FD&C Act Guidance for Industry: Draft Guidance for Industry,01/22/2020,Center for Drug Evaluation and Research,"Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)",Draft,No,02/11/2019,FDA-2014-D-0779
"Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics","PDF (327.33 KB)PDF (327.33 KB) of Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion, Reference Amounts Customarily Consumed, Serving Size-Related Issues, Dual-Column Labeling, and Miscellaneous Topics",12/30/2019,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2018-D-1459
Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products: Draft Guidance for Industry,PDF (367.32 KB)PDF (367.32 KB) of Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products: Draft Guidance for Industry,12/20/2019,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Draft,No,03/19/2020,FDA-2019-D-4964
Recommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (383.76 KB)PDF (383.76 KB) of Recommended Content and Format of Non-Clinical Bench Performance Testing Information in Premarket Submissions:  Guidance for Industry and Food and Drug Administration Staff,12/20/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Final,No,,FDA-2018-D-1329
Submitting Study Datasets for Vaccines to the Office of Vaccines Research and Review:  Guidance for Industry; Technical Specifications Document,PDF (259.57 KB)PDF (259.57 KB) of Submitting Study Datasets for Vaccines to the Office of Vaccines Research and Review:  Guidance for Industry; Technical Specifications Document,12/20/2019,Center for Biologics Evaluation and Research,"Electronic Submissions, Administrative / Procedural",Final,No,,FDA-2018-D-1216
Considerations for the Development of Dried Plasma Products Intended for Transfusion:   Guidance for Industry,PDF (119.37 KB)PDF (119.37 KB) of Considerations for the Development of Dried Plasma Products Intended for Transfusion:   Guidance for Industry,12/19/2019,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,01/28/2019,FDA-2018-D-3759
Bridging for Drug-Device and Biologic-Device Combination Products: Draft  Guidance for Industry,PDF (323.45 KB)PDF (323.45 KB) of Bridging for Drug-Device and Biologic-Device Combination Products: Draft  Guidance for Industry,12/19/2019,"Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Draft,No,02/18/2020,FDA-2019-D-5585
"Guidance for Industry: Nutrition and Supplement Facts Labels Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals","PDF (179.14 KB)PDF (179.14 KB) of Guidance for Industry: Nutrition and Supplement Facts Labels Questions and Answers Related to the Compliance Date, Added Sugars, and Declaration of Quantitative Amounts of Vitamins and Minerals",12/16/2019,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2016-D-4414
"30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes:  Guidance for Industry and FDA Staff","PDF (215.75 KB)PDF (215.75 KB) of 30-Day Notices, 135-Day Premarket Approval (PMA) Supplements and 75-Day Humanitarian Device Exemption (HDE) Supplements for Manufacturing Method or Process Changes:  Guidance for Industry and FDA Staff",12/16/2019,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, Administrative / Procedural, Device & Drug Safety, HUD/HDE, Premarket Approval (PMA)",Final,No,,FDA-1998-D-0281
Real-Time Premarket Approval Application (PMA) Supplements:  Guidance for Industry and FDA Staff,PDF (122.66 KB)PDF (122.66 KB) of Real-Time Premarket Approval Application (PMA) Supplements:  Guidance for Industry and FDA Staff,12/16/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Administrative / Procedural, Device & Drug Safety, Premarket Approval (PMA)",Final,No,,FDA-2017-D-5971
Acceptance and Filing Reviews for Premarket Approval Applications (PMAs):  Guidance for Industry and Food and Drug Administration Staff,PDF (777.39 KB)PDF (777.39 KB) of Acceptance and Filing Reviews for Premarket Approval Applications (PMAs):  Guidance for Industry and Food and Drug Administration Staff,12/16/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Administrative / Procedural, Premarket Approval (PMA)",Final,No,,FDA-2012-D-0524
Annual Reports for Approved Premarket Approval Applications (PMA) :  Guidance for Industry and Food and Drug Administration Staff,PDF (146.07 KB)PDF (146.07 KB) of Annual Reports for Approved Premarket Approval Applications (PMA) :  Guidance for Industry and Food and Drug Administration Staff,12/16/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Administrative / Procedural, Device & Drug Safety, Premarket Approval (PMA)",Final,No,,FDA-2006-D-0039
Chapter 2 - Biologics,,12/13/2019,Center for Biologics Evaluation and Research,"Investigation & Enforcement,",Final,No,,
Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated with Internal or External Hemorrhoids Guidance for Industry: Draft Guidance for Industry,PDF (94.79 KB)PDF (94.79 KB) of Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated with Internal or External Hemorrhoids Guidance for Industry: Draft Guidance for Industry,12/09/2019,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,02/07/2020,FDA-2019-D-4433
Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry,PDF (306.43 KB)PDF (306.43 KB) of Adaptive Design Clinical Trials for Drugs and Biologics Guidance for Industry,12/02/2019,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Biostatistics, Clinical - Medical",Final,No,,FDA-2018-D-3124
"CPG Sec. 230.150 Blood Donor Classification Statement, Paid or Volunteer Donor","PDF (72.09 KB)PDF (72.09 KB) of CPG Sec. 230.150 Blood Donor Classification Statement, Paid or Volunteer Donor",12/01/2019,Office of Regulatory Affairs,"Investigation & Enforcement, Blood Products",Final,No,,
Compliance Policy for Limited Modifications to Certain Marketed Tobacco Products:  Guidance for Industry,PDF (283.2 KB)PDF (283.2 KB) of Compliance Policy for Limited Modifications to Certain Marketed Tobacco Products:  Guidance for Industry,11/26/2019,Center for Tobacco Products,"Compliance,",Final,No,,FDA-2019-D-5324
Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products,PDF (165.86 KB)PDF (165.86 KB) of Clinical Immunogenicity Considerations for Biosimilar and Interchangeable Insulin Products,11/25/2019,Center for Drug Evaluation and Research,Biosimilars,Draft,No,01/28/2020,FDA-2019-D-5255
Transdermal and Topical Delivery Systems - Product Development and Quality Considerations,PDF (355.79 KB)PDF (355.79 KB) of Transdermal and Topical Delivery Systems - Product Development and Quality Considerations,11/21/2019,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality, Drug Competition Action Plan",Draft,No,02/19/2020,FDA-2019-D-4447
Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry,PDF (127.18 KB)PDF (127.18 KB) of Smallpox (Variola Virus) Infection: Developing Drugs for Treatment or Prevention Guidance for Industry,11/18/2019,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2018-D-1835
Drug Master Files Guidance for Industry,PDF (195.14 KB)PDF (195.14 KB) of Drug Master Files Guidance for Industry,11/15/2019,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,12/20/2019,FDA-2019-D-3989
Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment  Guidance for Industry,PDF (323.63 KB)PDF (323.63 KB) of Chronic Hepatitis D Virus Infection: Developing Drugs for Treatment  Guidance for Industry,11/01/2019,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Draft,No,01/01/2020,FDA-2019-D-4042
Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or Software Guidance for Industry,PDF (145.25 KB)PDF (145.25 KB) of Type V DMFs for CDER-Led Combination Products Using Device Constituent Parts With Electronics or Software Guidance for Industry,10/29/2019,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,12/30/2019,FDA-2019-D-4258
"Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry: Draft Guidance for Industry","PDF (372.7 KB)PDF (372.7 KB) of Postmarketing Studies and Clinical Trials—Implementation of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry: Draft Guidance for Industry",10/25/2019,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Draft,No,,FDA-2009-D-0283
Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers,PDF (279 KB)PDF (279 KB) of Identification of Manufacturing Establishments in Applications Submitted to CBER and CDER Questions and Answers,10/22/2019,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2017-D-6821
"Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry","PDF (514.8 KB)PDF (514.8 KB) of Prescription Drug User Fee Act Waivers, Reductions, and Refunds for Drug and Biological Products Guidance for Industry",10/17/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"User Fees,",Final,No,,2019-22690
Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination Guidance for Industry,PDF (83.67 KB)PDF (83.67 KB) of Investigational In Vitro Diagnostics in Oncology Trials: Streamlined Submission Process for Study Risk Determination Guidance for Industry,10/10/2019,Center for Drug Evaluation and ResearchCenter for Devices and Radiological Health,Administrative / Procedural,Final,No,,FDA-2018-D-0944
"Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling:  Guidance for Industry and Food and Drug Administration Staff","PDF (527.16 KB)PDF (527.16 KB) of Coronary, Peripheral, and Neurovascular Guidewires - Performance Tests and Recommended Labeling:  Guidance for Industry and Food and Drug Administration Staff",10/10/2019,Center for Devices and Radiological Health,"Premarket, 510(k), Cardiovascular , Neurological",Final,No,,FDA-2018-D-1775
"Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations:  Guidance for Industry and Food and Drug Administration Staff","PDF (371.46 KB)PDF (371.46 KB) of Intravascular Catheters, Wires, and Delivery Systems with Lubricious Coatings - Labeling Considerations:  Guidance for Industry and Food and Drug Administration Staff",10/10/2019,Center for Devices and Radiological Health,"510(k), Premarket Approval (PMA), Labeling, Neurological, Cardiovascular",Final,No,,FDA-2018-D-1788
Investigational Enzyme Replacement Therapy Products:  Nonclinical Assessment:  Guidance for Industry,PDF (95.62 KB)PDF (95.62 KB) of Investigational Enzyme Replacement Therapy Products:  Nonclinical Assessment:  Guidance for Industry,10/03/2019,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,01/02/2020,FDA-2015-D-1246
Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus:  Guidance for Industry,PDF (109.92 KB)PDF (109.92 KB) of Further Testing of Donations that are Reactive on a Licensed Donor Screening Test for Antibodies to Hepatitis C Virus:  Guidance for Industry,10/02/2019,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,12/24/2018,FDA-2018-D-3197
Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act:  Guidance for Industry and Food and Drug Administration Staff,PDF (660.31 KB)PDF (660.31 KB) of Changes to Existing Medical Software Policies Resulting from Section 3060 of the 21st Century Cures Act:  Guidance for Industry and Food and Drug Administration Staff,09/27/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket, Premarket, Digital Health",Final,No,,FDA-2017-D-6294
General Wellness: Policy for Low Risk Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (364.4 KB)PDF (364.4 KB) of General Wellness: Policy for Low Risk Devices:  Guidance for Industry and Food and Drug Administration Staff,09/27/2019,Center for Devices and Radiological Health,"Premarket, Digital Health",Final,No,,FDA-2014-N-1039
Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry:  Guidance for Industry,PDF (228.24 KB)PDF (228.24 KB) of Amyotrophic Lateral Sclerosis: Developing Drugs for Treatment Guidance for Industry:  Guidance for Industry,09/24/2019,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2013-N-0035
Wholesale Distributor Verification Requirement for Saleable Returned Drug Product—Compliance Policy Guidance for Industry:  Guidance for Industry,PDF (68.96 KB)PDF (68.96 KB) of Wholesale Distributor Verification Requirement for Saleable Returned Drug Product—Compliance Policy Guidance for Industry:  Guidance for Industry,09/20/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOffice of Regulatory Affairs,Administrative / Procedural,Final,No,,FDA-2019-D-4212
Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration,PDF (358.91 KB)PDF (358.91 KB) of Safety and Performance Based Pathway:  Guidance for Industry and Food and Drug Administration,09/20/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k)",Final,No,,FDA-2018-D-1387
"Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry","PDF (202.28 KB)PDF (202.28 KB) of Citizen Petitions and Petitions for Stay of Action Subject to Section 505(q) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry",09/19/2019,Center for Drug Evaluation and Research,"Administrative / Procedural, Drug Competition Action Plan",Final,No,,FDA-2009-D-0008
The Abbreviated 510(k) Program:  Guidance for Industry and Food and Drug Administration Staff,PDF (282.19 KB)PDF (282.19 KB) of The Abbreviated 510(k) Program:  Guidance for Industry and Food and Drug Administration Staff,09/13/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k)",Final,No,,FDA-2019-D-4015
The Special 510(k) Program:  Guidance for Industry and Food and Drug Administration Staff,PDF (672.44 KB)PDF (672.44 KB) of The Special 510(k) Program:  Guidance for Industry and Food and Drug Administration Staff,09/13/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k), Administrative / Procedural",Final,No,,FDA-2018-D-3304
Humanitarian Device Exemption (HDE) Program:  Guidance for Industry and Food and Drug Administration Staff,PDF (957.02 KB)PDF (957.02 KB) of Humanitarian Device Exemption (HDE) Program:  Guidance for Industry and Food and Drug Administration Staff,09/06/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Good Clinical Practice (GCP), HUD/HDE, Premarket Approval (PMA)",Final,No,,FDA-2014-D-0223
Humanitarian Use Device (HUD) Designations :  Guidance for Industry and Food and Drug Administration Staff,PDF (349.8 KB)PDF (349.8 KB) of Humanitarian Use Device (HUD) Designations :  Guidance for Industry and Food and Drug Administration Staff,09/05/2019,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP)",Final,No,,FDA-2014-D-0223
Evaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers,PDF (117.32 KB)PDF (117.32 KB) of Evaluation of Internal Standard Responses During Chromatographic Bioanalysis: Questions and Answers,09/04/2019,Center for Drug Evaluation and Research,Biopharmaceutics,Final,No,,FDA-2009-D-0008
Guidance for Industry: Policy Related to Cranberry Products with Added Flavorings,PDF (291.77 KB)PDF (291.77 KB) of Guidance for Industry: Policy Related to Cranberry Products with Added Flavorings,08/30/2019,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2018-D-0075
"Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions:  Guidance for Industry and Food and Drug Administration Staff","PDF (510.27 KB)PDF (510.27 KB) of Consideration of Uncertainty in Making Benefit-Risk Determinations in Medical Device Premarket Approvals, De Novo Classifications, and Humanitarian Device Exemptions:  Guidance for Industry and Food and Drug Administration Staff",08/30/2019,Center for Devices and Radiological Health,"Postmarket, Premarket Approval (PMA), HUD/HDE",Final,No,,FDA-2018-D-3130
Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications:  Guidance for Industry and Food and Drug Administration Staff,PDF (642.92 KB)PDF (642.92 KB) of Factors to Consider When Making Benefit-Risk Determinations in Medical Device Premarket Approval and De Novo Classifications:  Guidance for Industry and Food and Drug Administration Staff,08/30/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Premarket Approval (PMA)",Final,No,,FDA-2011-D-0577
Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry,PDF (69.75 KB)PDF (69.75 KB) of Placebos and Blinding in Randomized Controlled Cancer Clinical Trials for Drug and Biological Products Guidance for Industry,08/29/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2018-D-3092
CVM GFI #257 (VICH GL57) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Marker Residue Depletion Studies to Establish Product Withdrawal Periods in Aquatic Species,PDF (152.79 KB)PDF (152.79 KB) of CVM GFI #257 (VICH GL57) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Marker Residue Depletion Studies to Establish Product Withdrawal Periods in Aquatic Species,08/19/2019,Center for Veterinary Medicine,"Human Food Safety, VICH, Minor Use/ Minor Species (MUMS)",Final,No,09/24/2018,FDA-2018-D-2354
"Guidance for Industry: Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels","PDF (247.1 KB)PDF (247.1 KB) of Guidance for Industry: Converting Units of Measure for Folate, Niacin, and Vitamins A, D, and E on the Nutrition and Supplement Facts Labels",08/15/2019,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2016-D-4484
Osteoporosis:  Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry:  Guidance for Industry,PDF (94.69 KB)PDF (94.69 KB) of Osteoporosis:  Nonclinical Evaluation of Drugs Intended for Treatment Guidance for Industry:  Guidance for Industry,08/15/2019,Center for Drug Evaluation and Research,"Clinical - Medical, Pharmacology/Toxicology",Final,No,,FDA-2016-D-1273
Child-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry,PDF (97.52 KB)PDF (97.52 KB) of Child-Resistant Packaging Statements in Drug Product Labeling Guidance for Industry,08/13/2019,Center for Drug Evaluation and Research,Labeling,Final,No,,FDA-2017-D-2163
Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry,PDF (99.88 KB)PDF (99.88 KB) of Gastroparesis: Clinical Evaluation of Drugs for Treatment Guidance for Industry,08/13/2019,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,10/14/2019,FDA-2015-D-2479
Fabry Disease: Developing Drugs for Treatment Guidance for Industry,PDF (285.28 KB)PDF (285.28 KB) of Fabry Disease: Developing Drugs for Treatment Guidance for Industry,08/07/2019,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,11/06/2019,FDA-2019-D-2973
Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry,PDF (167.51 KB)PDF (167.51 KB) of Oncology Therapeutic Radiopharmaceuticals: Nonclinical Studies and Labeling Recommendations Guidance for Industry,08/02/2019,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2018-D-1772
Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry,PDF (269.89 KB)PDF (269.89 KB) of Bacterial Vaginosis: Developing Drugs for Treatment Guidance for Industry,08/01/2019,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2016-D-1659
Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry,PDF (301.3 KB)PDF (301.3 KB) of Uncomplicated Urinary Tract Infections: Developing Drugs for Treatment Guidance for Industry,08/01/2019,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2018-D-1562
Vulvovaginal Candidiasis:  Developing Drugs for Treatment,PDF (91.37 KB)PDF (91.37 KB) of Vulvovaginal Candidiasis:  Developing Drugs for Treatment,08/01/2019,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2016-D-1662
Rare Pediatric Disease Priority Review Vouchers: Draft Guidance for Industry,PDF (306.41 KB)PDF (306.41 KB) of Rare Pediatric Disease Priority Review Vouchers: Draft Guidance for Industry,07/30/2019,"Center for Biologics Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development","Rare Diseases, Administrative / Procedural, Pediatric Product Development",Draft,No,09/28/2019,FDA-2014-D-1461
Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention Guidance for Industry,PDF (277.36 KB)PDF (277.36 KB) of Delayed Graft Function in Kidney Transplantation: Developing Drugs for Prevention Guidance for Industry,07/29/2019,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2017-D-0198
Metal Expandable Biliary Stents - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (369.7 KB)PDF (369.7 KB) of Metal Expandable Biliary Stents - Premarket Notification (510(k)) Submissions:  Guidance for Industry and Food and Drug Administration Staff,07/26/2019,Center for Devices and Radiological Health,"Premarket, 510(k), Gastroenterology-Urology",Final,No,,FDA-2018-D-1771
Providing Regulatory Submissions in Electronic Format--Submission of Manufacturing Establishment Information Guidance for Industry,,07/23/2019,Center for Drug Evaluation and Research,,Draft,No,,
CVM GFI #181 Blue Bird Medicated Feed Labels,PDF (146.78 KB)PDF (146.78 KB) of CVM GFI #181 Blue Bird Medicated Feed Labels,07/23/2019,Center for Veterinary Medicine,"Animal Feed, Labeling",Final,No,,FDA-2008-D-0165
Postmarketing Safety Reporting for Combination Products:  Guidance for Industry and FDA Staff,PDF (620.95 KB)PDF (620.95 KB) of Postmarketing Safety Reporting for Combination Products:  Guidance for Industry and FDA Staff,07/22/2019,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research",Combination Products,Final,No,06/19/2018,FDA-2008-N-0424
Submitting Next Generation Sequencing Data to the Division of Antiviral Products Guidance for Industry Technical Specifications Document,PDF (250.51 KB)PDF (250.51 KB) of Submitting Next Generation Sequencing Data to the Division of Antiviral Products Guidance for Industry Technical Specifications Document,07/18/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,Clinical - Antimicrobial,Final,No,,FDA-2017-D-6821
Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry,PDF (133.02 KB)PDF (133.02 KB) of Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy Guidance for Industry,07/12/2019,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,09/11/2019,FDA-2019-D-2153
Using the Inactive Ingredient Database Guidance for Industry,PDF (121.68 KB)PDF (121.68 KB) of Using the Inactive Ingredient Database Guidance for Industry,07/11/2019,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Drug Competition Action Plan, Pharmaceutical Quality",Draft,No,10/09/2019,FDA-2019-D-2397
"Live Case Presentations During Investigational Device Exemption (IDE) Clinical Trials:  Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff","PDF (345.35 KB)PDF (345.35 KB) of Live Case Presentations During Investigational Device Exemption (IDE) Clinical Trials:  Guidance for Institutional Review Boards, Industry, Clinical Investigators, and Food and Drug Administration Staff",07/11/2019,Center for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP), Pediatric Product Development, Investigational Device Exemption (IDE)",Final,No,,FDA-2014-D-0331
Harmonizing Compendial Standards With Drug Application Approval Using the USP Pending Monograph Process Guidance for Industry,PDF (176.07 KB)PDF (176.07 KB) of Harmonizing Compendial Standards With Drug Application Approval Using the USP Pending Monograph Process Guidance for Industry,07/10/2019,Center for Drug Evaluation and ResearchCenter for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality, Drug Competition Action Plan",Draft,No,09/10/2019,FDA-2019-D-1768
Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry,PDF (371.97 KB)PDF (371.97 KB) of Risk Evaluation and Mitigation Strategies: Modifications and Revisions Guidance for Industry,07/09/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Device & Drug Safety,Final,No,,FDA-2014-D-1747
Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry,PDF (77.61 KB)PDF (77.61 KB) of Compliance Policy for Certain Compounding of Oral Oxitriptan (5-HTP) Drug Products for Patients With Tetrahydrobiopterin (BH4) Deficiency Immediately in Effect Guidance for Industry,07/08/2019,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2019-D-2733
Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products —  Content and Format   Guidance for Industry,PDF (130.14 KB)PDF (130.14 KB) of Drug Abuse and Dependence Section of Labeling for Human Prescription Drug and Biological Products —  Content and Format   Guidance for Industry,07/01/2019,Center for Drug Evaluation and Research,Labeling,Draft,No,09/02/2019,FDA-2019-D-1917
Epidermolysis Bullosa:  Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry,PDF (259.75 KB)PDF (259.75 KB) of Epidermolysis Bullosa:  Developing Drugs for Treatment of Cutaneous Manifestations; Guidance for Industry,06/28/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2018-D-2016
Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry,PDF (86.02 KB)PDF (86.02 KB) of Treatment for Heart Failure: Endpoints for Drug Development Guidance for Industry,06/28/2019,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Draft,No,08/27/2019,FDA-2019-D-2314
E19 OPTIMISATION OF SAFETY DATA COLLECTION,PDF (188.94 KB)PDF (188.94 KB) of E19 OPTIMISATION OF SAFETY DATA COLLECTION,06/27/2019,Center for Drug Evaluation and Research,ICH-Efficacy,Draft,No,08/26/2019,FDA-2019-D-1828
M10 BIOANALYTICAL METHOD VALIDATION,PDF (620.74 KB)PDF (620.74 KB) of M10 BIOANALYTICAL METHOD VALIDATION,06/26/2019,Center for Drug Evaluation and Research,"Clinical - Medical, ICH-Multidisciplinary",Draft,No,08/26/2019,FDA-2019-D-1469
Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry,PDF (280.65 KB)PDF (280.65 KB) of Opioid Analgesic Drugs: Considerations for Benefit-Risk Assessment Framework Guidance for Industry,06/20/2019,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,08/20/2019,FDA-2019-D-1536
ANDA Submissions — Content and Format of Abbreviated New Drug Applications:  Guidance for Industry,PDF (308.01 KB)PDF (308.01 KB) of ANDA Submissions — Content and Format of Abbreviated New Drug Applications:  Guidance for Industry,06/20/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"User Fees, Generic Drugs",Final,No,,FDA-2014-D-0725
Guidance for Industry: Determining the Number of Employees for Purposes of the “Small Business” Definition in Parts 117 and 507,PDF (163.46 KB)PDF (163.46 KB) of Guidance for Industry: Determining the Number of Employees for Purposes of the “Small Business” Definition in Parts 117 and 507,06/19/2019,Center for Veterinary MedicineHuman Foods Program,,Final,No,,FDA-2018-D-0671
"Guidance for Industry: Declaration of Added Sugars on Honey, Maple Syrup, Other Single-Ingredient Sugars and Syrups, and Certain Cranberry Products","PDF (408.53 KB)PDF (408.53 KB) of Guidance for Industry: Declaration of Added Sugars on Honey, Maple Syrup, Other Single-Ingredient Sugars and Syrups, and Certain Cranberry Products",06/18/2019,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2018-D-0075
Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry,PDF (231 KB)PDF (231 KB) of Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment Guidance for Industry,06/07/2019,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,08/06/2019,FDA-2019-D-1516
"Draft Guidance for Industry: Evaluating Alternate Curricula for the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption","PDF (398.38 KB)PDF (398.38 KB) of Draft Guidance for Industry: Evaluating Alternate Curricula for the Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",06/03/2019,Human Foods Program,Produce,Draft,No,10/02/2019,FDA-2019-D-2131
CPG Sec. 651.100  Ethylenediamine Dihydroiodide (EDDI),PDF (43.63 KB)PDF (43.63 KB) of CPG Sec. 651.100  Ethylenediamine Dihydroiodide (EDDI),06/01/2019,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,FDA-2021-D-0628
Formal Dispute Resolution: Sponsor Appeals Above the Division Level Guidance for Industry and Review Staff,PDF (297.56 KB)PDF (297.56 KB) of Formal Dispute Resolution: Sponsor Appeals Above the Division Level Guidance for Industry and Review Staff,05/30/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2013-D-0221
Section 503A Bulks List Final Rule Questions and Answers; Small Entity Compliance Guide;:  Guidance for Industry,PDF (68.34 KB)PDF (68.34 KB) of Section 503A Bulks List Final Rule Questions and Answers; Small Entity Compliance Guide;:  Guidance for Industry,05/24/2019,Center for Drug Evaluation and Research,"Administrative / Procedural, Compounding",Final,No,,FDA-2019-D-2011
Development of Therapeutic Protein Biosimilars:  Comparative Analytical Assessment and Other Quality-Related Considerations   Guidance for Industry,PDF (260.18 KB)PDF (260.18 KB) of Development of Therapeutic Protein Biosimilars:  Comparative Analytical Assessment and Other Quality-Related Considerations   Guidance for Industry,05/22/2019,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Biosimilars,Draft,No,,FDA-2019-D-2102
Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry,PDF (448.98 KB)PDF (448.98 KB) of Considerations in Demonstrating Interchangeability With a Reference Product Guidance for Industry,05/14/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Biosimilars,Final,No,,FDA-2017-D-0154
Determining Whether to Submit an ANDA or a 505(b)(2) Application,PDF (149.99 KB)PDF (149.99 KB) of Determining Whether to Submit an ANDA or a 505(b)(2) Application,05/10/2019,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2017-D-5974
Maximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-The-Counter Monograph: Study Elements and Considerations,PDF (156 KB)PDF (156 KB) of Maximal Usage Trials for Topically Applied Active Ingredients Being Considered for Inclusion in an Over-The-Counter Monograph: Study Elements and Considerations,05/10/2019,Center for Drug Evaluation and Research,"Clinical - Pharmacology, Pediatric Product Development, Over-the-Counter Drugs",Final,No,,FDA-2018-D-1456
Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry:  Guidance for Industry,PDF (118.32 KB)PDF (118.32 KB) of Oncology Pharmaceuticals: Reproductive Toxicity Testing and Labeling Recommendations Guidance for Industry:  Guidance for Industry,05/10/2019,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2017-D-2165
Clinical Lactation Studies: Considerations for Study Design,PDF (329.81 KB)PDF (329.81 KB) of Clinical Lactation Studies: Considerations for Study Design,05/09/2019,Center for Drug Evaluation and Research,"Clinical - Medical, Clinical - Pharmacology",Draft,No,,FDA-2018-D-4525.
Postapproval Pregnancy Safety Studies Guidance for Industry,PDF (403.33 KB)PDF (403.33 KB) of Postapproval Pregnancy Safety Studies Guidance for Industry,05/09/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Draft,No,07/08/2019,FDA-2018-D-4693
Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis:  Guidance for Industry,PDF (115.46 KB)PDF (115.46 KB) of Recommendations for Reducing the Risk of Transfusion-Transmitted Babesiosis:  Guidance for Industry,05/09/2019,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2018-D-2478
Guidance for Industry: Preparation of Food Contact Notifications for Food Contact Substances in Contact with Infant Formula and/or Human Milk,PDF (371.8 KB)PDF (371.8 KB) of Guidance for Industry: Preparation of Food Contact Notifications for Food Contact Substances in Contact with Infant Formula and/or Human Milk,05/08/2019,Human Foods Program,"Milk/Milk Product, Food & Color Additives, Infant Formula & Foods",Final,No,,FDA-2016-D-1814
Classification and Requirements for Laser Illuminated Projectors (LIPs) (Laser Notice No. 57):  Guidance for Industry and Food and Drug Administration,PDF (368.73 KB)PDF (368.73 KB) of Classification and Requirements for Laser Illuminated Projectors (LIPs) (Laser Notice No. 57):  Guidance for Industry and Food and Drug Administration,05/08/2019,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2014-D-2245
Policy Clarification for Certain Fluoroscopic Equipment Requirements:  Guidance for Industry and Food and Drug Administration Staff,PDF (336.85 KB)PDF (336.85 KB) of Policy Clarification for Certain Fluoroscopic Equipment Requirements:  Guidance for Industry and Food and Drug Administration Staff,05/08/2019,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2014-D-1344
Utilizing Animal Studies to Evaluate Organ Preservation Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (175.89 KB)PDF (175.89 KB) of Utilizing Animal Studies to Evaluate Organ Preservation Devices:  Guidance for Industry and Food and Drug Administration Staff,05/08/2019,Center for Devices and Radiological Health,"Premarket, 510(k), Gastroenterology-Urology",Final,No,,FDA-2017-D-4886
Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry,PDF (247.83 KB)PDF (247.83 KB) of Attention Deficit Hyperactivity Disorder: Developing Stimulant Drugs for Treatment Guidance for Industry,05/06/2019,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development, Over-the-Counter Drugs",Draft,No,07/03/2019,FDA-2019-D-0849
Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (519.76 KB)PDF (519.76 KB) of Characterization of Ultrahigh Molecular Weight Polyethylene (UHMWPE) Used in Orthopedic Devices:  Guidance for Industry and Food and Drug Administration Staff,04/26/2019,Center for Devices and Radiological Health,"510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Orthopedic",Final,No,05/12/2016,FDA-2016-D-0363
Unique Device Identification: Convenience Kits :  Guidance for Industry and Food and Drug Administration Staff,PDF (364.59 KB)PDF (364.59 KB) of Unique Device Identification: Convenience Kits :  Guidance for Industry and Food and Drug Administration Staff,04/26/2019,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Labeling, UDI",Final,No,04/05/2016,FDA-2015-D-4048
Extending Expiration Dates of Doxycycline Tablets and Capsules in Strategic Stockpiles :  Guidance for Government Public Health and Emergency Response Stakeholders,PDF (209.17 KB)PDF (209.17 KB) of Extending Expiration Dates of Doxycycline Tablets and Capsules in Strategic Stockpiles :  Guidance for Government Public Health and Emergency Response Stakeholders,04/24/2019,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,2019-08349
Compliance Policy for Combination Product Postmarketing Safety Reporting:  Immediately in Effect Guidance for Industry and Food and Drug Administration Staff,PDF (57.6 KB)PDF (57.6 KB) of Compliance Policy for Combination Product Postmarketing Safety Reporting:  Immediately in Effect Guidance for Industry and Food and Drug Administration Staff,04/20/2019,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research",Combination Products,Final,No,,FDA-2008-N-0424
REMS: FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary Guidance for Industry,PDF (110.01 KB)PDF (110.01 KB) of  REMS: FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary Guidance for Industry,04/04/2019,Center for Drug Evaluation and Research,,Final,No,,2019-06663
FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary,PDF (110.01 KB)PDF (110.01 KB) of FDA’s Application of Statutory Factors in Determining When a REMS Is Necessary,04/04/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,FDA-2016-D-2730
Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling Good Review Practice,PDF (315.2 KB)PDF (315.2 KB) of Pediatric Information Incorporated Into Human Prescription Drug and Biological Products Labeling Good Review Practice,03/28/2019,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Labeling, Pediatric Product Development",Final,No,,FDA-2013-D-0169
"Guidance for Industry: Enforcement Policy for Entities Growing, Harvesting, Packing, or Holding Hops, Wine Grapes, Pulse Crops, and Almonds","PDF (95.49 KB)PDF (95.49 KB) of Guidance for Industry: Enforcement Policy for Entities Growing, Harvesting, Packing, or Holding Hops, Wine Grapes, Pulse Crops, and Almonds",03/27/2019,Human Foods Program,,Final,No,,FDA-2019-D-1266
Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research:  Guidance for Industry,PDF (133.3 KB)PDF (133.3 KB) of Standards Development and the Use of Standards in Regulatory Submissions Reviewed in the Center for Biologics Evaluation and Research:  Guidance for Industry,03/25/2019,Center for Biologics Evaluation and Research,"Compliance, Administrative / Procedural",Final,No,,FDA-2017-D-6535
Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry,PDF (354.85 KB)PDF (354.85 KB) of Rare Diseases: Natural History Studies for Drug Development: Draft Guidance for Industry,03/25/2019,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products DevelopmentCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research","Diseases & Conditions, Rare Diseases,",Draft,No,05/24/2019,FDA-2019-D-0481
Pediatric HIV Infection: Drug Development for Treatment,PDF (70.68 KB)PDF (70.68 KB) of Pediatric HIV Infection: Drug Development for Treatment,03/20/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2018-D-1638
Human Immunodeficiency Virus-1 Infection:  Developing Systemic Drug Products for Pre-Exposure Prophylaxis,PDF (90.91 KB)PDF (90.91 KB) of Human Immunodeficiency Virus-1 Infection:  Developing Systemic Drug Products for Pre-Exposure Prophylaxis,03/18/2019,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2018-D-1918
Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry,PDF (121.8 KB)PDF (121.8 KB) of Severely Debilitating or Life-Threatening Hematologic Disorders: Nonclinical Development of Pharmaceuticals Guidance for Industry,03/15/2019,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2018-D-1328
Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products:  Guidance for Industry,PDF (576.03 KB)PDF (576.03 KB) of Enrichment Strategies for Clinical Trials to Support Approval of Human Drugs and Biological Products:  Guidance for Industry,03/15/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,FDA-2012-D-1145
Medical Devices Containing Materials Derived from Animal Sources (Except for In Vitro Diagnostic Devices):  Guidance for Industry and Food and Drug Administration Staff,PDF (602.81 KB)PDF (602.81 KB) of Medical Devices Containing Materials Derived from Animal Sources (Except for In Vitro Diagnostic Devices):  Guidance for Industry and Food and Drug Administration Staff,03/15/2019,Center for Devices and Radiological Health,"Premarket, Laboratory Tests",Final,No,,FDA-2013-D-1574
Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials,PDF (87.34 KB)PDF (87.34 KB) of Considerations for the Inclusion of Adolescent Patients in Adult Oncology Clinical Trials,03/13/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOffice of the Commissioner,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2018-D-1540
"Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act","PDF (323.4 KB)PDF (323.4 KB) of Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act",03/13/2019,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2018-D-1067
Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or Have Not Been Derived from Genetically Engineered Plants,PDF (137.72 KB)PDF (137.72 KB) of Guidance for Industry: Voluntary Labeling Indicating Whether Foods Have or Have Not Been Derived from Genetically Engineered Plants,03/11/2019,Human Foods Program,"Bioengineering / GMOs, Labeling",Final,No,,FDA-2000-D-0075
Draft Guidance for Industry: Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon,PDF (102.78 KB)PDF (102.78 KB) of Draft Guidance for Industry: Voluntary Labeling Indicating Whether Food Has or Has Not Been Derived From Genetically Engineered Atlantic Salmon,03/11/2019,Center for Veterinary MedicineHuman Foods Program,"Bioengineering / GMOs, Labeling",Draft,No,01/25/2016,FDA-2015-D-4272
Nonproprietary Naming of Biological Products: Update Guidance for Industry,PDF (322.39 KB)PDF (322.39 KB) of Nonproprietary Naming of Biological Products: Update Guidance for Industry,03/08/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,05/07/2019,FDA-2013-D-1543
Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration,PDF (995.91 KB)PDF (995.91 KB) of Draft Guidance for Industry: Mitigation Strategies to Protect Food Against Intentional Adulteration,03/06/2019,Human Foods Program,,Draft,No,08/14/2020,FDA-2018-D-1398
CPG Sec. 608.200  Prescription Use of Certain Injectable Animal Drugs,PDF (24.7 KB)PDF (24.7 KB) of CPG Sec. 608.200  Prescription Use of Certain Injectable Animal Drugs,03/01/2019,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec. 635.100  Large Volume Parenterals (LVPs) for Animal Use,PDF (29.64 KB)PDF (29.64 KB) of CPG Sec. 635.100  Large Volume Parenterals (LVPs) for Animal Use,03/01/2019,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec. 653.100  Animal Grooming Aids,PDF (23.15 KB)PDF (23.15 KB) of CPG Sec. 653.100  Animal Grooming Aids,03/01/2019,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 665.300 Use of Type A Medicated Article Proprietary Names in the Names of Medicated Feeds,PDF (47.62 KB)PDF (47.62 KB) of CPG Sec. 665.300 Use of Type A Medicated Article Proprietary Names in the Names of Medicated Feeds,03/01/2019,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Labeling, Medicated Feed",Final,No,,
CPG Sec. 666.100  Alternate Feeding of Different Medicated Feeds,PDF (22.87 KB)PDF (22.87 KB) of CPG Sec. 666.100  Alternate Feeding of Different Medicated Feeds,03/01/2019,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Medicated Feed",Final,No,,
CPG Sec. 683.100  Action Levels for Aflatoxins in Animal Feeds,PDF (38.81 KB)PDF (38.81 KB) of CPG Sec. 683.100  Action Levels for Aflatoxins in Animal Feeds,03/01/2019,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,
Release of ORA Laboratory Analytical Results to the Responsible Party:  Guidance for Food and Drug Administration Staff,PDF (69.02 KB)PDF (69.02 KB) of Release of ORA Laboratory Analytical Results to the Responsible Party:  Guidance for Food and Drug Administration Staff,03/01/2019,Center for Veterinary MedicineHuman Foods ProgramOffice of Inspections and InvestigationsCenter for Devices and Radiological HealthCenter for Tobacco Products,"Investigation & Enforcement, Administrative / Procedural",Final,No,,FDA-2019-D-1163
Enforcement Policy for Certain Marketed Tobacco Products: Draft Guidance for Industry,PDF (74.91 KB)PDF (74.91 KB) of Enforcement Policy for Certain Marketed Tobacco Products: Draft Guidance for Industry,02/28/2019,Center for Tobacco Products,,Draft,No,04/30/2019,FDA-2018-D-3244
Providing Lot Release Protocol Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format:  Guidance for Industry,PDF (220.05 KB)PDF (220.05 KB) of Providing Lot Release Protocol Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format:  Guidance for Industry,02/22/2019,Center for Biologics Evaluation and Research,"Premarket, Administrative / Procedural",Final,No,,FDA-1998-D-0095
Use of Investigational Tobacco Products: Draft Guidance for Industry and Investigators,PDF (734.03 KB)PDF (734.03 KB) of Use of Investigational Tobacco Products: Draft Guidance for Industry and Investigators,02/20/2019,Center for Tobacco Products,,Draft,No,04/21/2019,FDA-2014-D-1939
Evaluation of Devices Used with Regenerative Medicine Advanced Therapies:  Guidance for Industry,PDF (193.57 KB)PDF (193.57 KB) of Evaluation of Devices Used with Regenerative Medicine Advanced Therapies:  Guidance for Industry,02/15/2019,"Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","Combination Products, Gene Therapy",Final,No,02/15/2018,FDA-2017-D-6154
Expedited Programs for Regenerative Medicine Therapies for Serious Conditions:  Guidance for Industry,PDF (219.2 KB)PDF (219.2 KB) of Expedited Programs for Regenerative Medicine Therapies for Serious Conditions:  Guidance for Industry,02/15/2019,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,02/15/2018,FDA-2017-D-6159
"Public Warning-Notification of Recalls Under 21 CFR Part 7, Subpart C :  Guidance for Industry and FDA Staff","PDF (441.33 KB)PDF (441.33 KB) of Public Warning-Notification of Recalls Under 21 CFR Part 7, Subpart C :  Guidance for Industry and FDA Staff",02/08/2019,Office of Regulatory AffairsCenter for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Tobacco Products,"Recalls, Investigation & Enforcement,",Final,No,02/08/2020,FDA-2016-D-3548
Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements:  Guidance for Industry and Food and Drug Administration Staff,PDF (240.59 KB)PDF (240.59 KB) of Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements:  Guidance for Industry and Food and Drug Administration Staff,02/08/2019,Center for Devices and Radiological Health,"Premarket, 510(k), Anesthesiology , Physical Medicine, Orthopedic, Ophthalmic, Obstetrical & Gynecological, Neurological, Cardiovascular , General Hospital & Personal Use , General & Plastic Surgery , Gastroenterology-Urology , Ear, Nose & Throat , Dental",Final,No,,FDA-2014-D-0967
Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment,PDF (262.09 KB)PDF (262.09 KB) of Opioid Use Disorder: Developing Depot Buprenorphine Products for Treatment,02/07/2019,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2018-D-1334
The Least Burdensome Provisions: Concept and Principles:  Guidance for Industry and FDA Staff,PDF (483.29 KB)PDF (483.29 KB) of The Least Burdensome Provisions: Concept and Principles:  Guidance for Industry and FDA Staff,02/05/2019,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Final,No,,FDA-2017-D-6702
Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway,PDF (84.95 KB)PDF (84.95 KB) of Labeling for Human Prescription Drug and Biological Products Approved Under the Accelerated Approval Regulatory Pathway,02/04/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2014-D-0250
Immunogenicity Testing of Therapeutic Protein Products —Developing and Validating Assays for Anti-Drug Antibody Detection,PDF (371.72 KB)PDF (371.72 KB) of Immunogenicity Testing of Therapeutic Protein Products —Developing and Validating Assays for Anti-Drug Antibody Detection,02/01/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2009-D-0539
REMS Assessment: Planning and Reporting,PDF (590.24 KB)PDF (590.24 KB) of REMS Assessment: Planning and Reporting,02/01/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Draft,No,04/02/2019,FDA-2018-D-4628
Survey Methodologies to Assess REMS Goals That Relate to Knowledge,PDF (462.82 KB)PDF (462.82 KB) of Survey Methodologies to Assess REMS Goals That Relate to Knowledge,02/01/2019,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Draft,No,,FDA-2018-D-4629
Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (580.43 KB)PDF (580.43 KB) of Coordinated Development of Antimicrobial Drugs and Antimicrobial Susceptibility Test Devices:  Guidance for Industry and Food and Drug Administration Staff,02/01/2019,Center for Devices and Radiological Health,"IVDs (In Vitro Diagnostic Devices), Premarket Approval (PMA), Testing",Final,No,,FDA-2016-D-2561
Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data,PDF (137.82 KB)PDF (137.82 KB) of Developing and Submitting Proposed Draft Guidance Relating to Patient Experience Data,12/21/2018,"Center for Drug Evaluation and Research,Office of Regulatory PolicyCenter for Biologics Evaluation and Research","Administrative / Procedural, Generic Drugs",Draft,No,03/21/2019,FDA-2018-D-4455
Labeling of Red Blood Cell Units with Historical Antigen Typing Results:  Guidance for Industry,PDF (135.21 KB)PDF (135.21 KB) of Labeling of Red Blood Cell Units with Historical Antigen Typing Results:  Guidance for Industry,12/20/2018,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2016-D-4308
Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics:  Guidance for Industry,PDF (145.97 KB)PDF (145.97 KB) of Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics:  Guidance for Industry,12/19/2018,Oncology Center of ExcellenceCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2005-D-0225
Manufacturing Site Change Supplements: Content and Submission:  Guidance for Industry and Food and Drug Administration Staff,PDF (264.12 KB)PDF (264.12 KB) of Manufacturing Site Change Supplements: Content and Submission:  Guidance for Industry and Food and Drug Administration Staff,12/17/2018,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Postmarket, Premarket Approval (PMA)",Final,No,,FDA-2015-N-3454
Data Integrity and Compliance With Drug CGMP: Questions and Answers:  Guidance for Industry,PDF (127.11 KB)PDF (127.11 KB) of Data Integrity and Compliance With Drug CGMP: Questions and Answers:  Guidance for Industry,12/13/2018,"Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Office of Regulatory Policy","Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2018-D-3984
Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition and Innovation Act of 2009 :  Guidance for Industry,PDF (410.32 KB)PDF (410.32 KB) of Interpretation of the “Deemed to be a License” Provision of the Biologics Price Competition and Innovation Act of 2009 :  Guidance for Industry,12/12/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2015-D-4750
Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff,PDF (346.05 KB)PDF (346.05 KB) of Biomarker Qualification: Evidentiary Framework: Draft Guidance for Industry and FDA Staff,12/12/2018,Center for Drug Evaluation and Research,Drug Development Tools,Draft,No,02/11/2019,FDA-2018-D-4267
Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment,PDF (97.63 KB)PDF (97.63 KB) of Noncirrhotic Nonalcoholic Steatohepatitis With Liver Fibrosis: Developing Drugs for Treatment,12/04/2018,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,02/04/2019,FDA-2018-D-3632
Guidance for Industry and FDA: Establishing and Maintaining a List of U.S. Dairy Product Manufacturers/Processors with Interest in Exporting to Chile,PDF (64.85 KB)PDF (64.85 KB) of Guidance for Industry and FDA: Establishing and Maintaining a List of U.S. Dairy Product Manufacturers/Processors with Interest in Exporting to Chile,11/27/2018,Human Foods Program,Export,Final,No,,FDA-2006-N-0183
"Guidance for Industry: Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers/Processors with Interest in Exporting to China","PDF (52.84 KB)PDF (52.84 KB) of Guidance for Industry: Establishing and Maintaining a List of U.S. Milk and Milk Product, Seafood, Infant Formula, and Formula for Young Children Manufacturers/Processors with Interest in Exporting to China",11/27/2018,Human Foods Program,"Export, Seafood/Seafood Product, Milk/Milk Product, Infant Formula & Foods",Final,No,,FDA-2016-D-4484
CVM GFI #243 (VICH GL56) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing Maximum Residue Limits and Withdrawal Periods,PDF (202.44 KB)PDF (202.44 KB) of CVM GFI #243 (VICH GL56) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Species: Study Design Recommendations for Residue Studies in Honey for Establishing Maximum Residue Limits and Withdrawal Periods,11/14/2018,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,03/06/2017,FDA-2016-D-4461
Hypertension: Developing Fixed-Dose Combination Drugs for Treatment,PDF (95.73 KB)PDF (95.73 KB) of Hypertension: Developing Fixed-Dose Combination Drugs for Treatment,11/07/2018,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,01/26/2019,FDA-2018-D-3860
Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products,PDF (227.44 KB)PDF (227.44 KB) of Meta-Analyses of Randomized Controlled Clinical Trials to Evaluate the Safety of Human Drugs or Biological Products,11/07/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Device & Drug Safety",Draft,No,01/07/2019,FDA-2018-D-3710
Guidance for Industry and FDA Staff: Questions and Answers Regarding Mandatory Food Recalls,PDF (113.13 KB)PDF (113.13 KB) of Guidance for Industry and FDA Staff: Questions and Answers Regarding Mandatory Food Recalls,11/06/2018,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,"Recalls,",Final,No,,FDA-2015-D-0138
Testicular Toxicity: Evaluation During Drug Development,PDF (180.41 KB)PDF (180.41 KB) of Testicular Toxicity: Evaluation During Drug Development,10/25/2018,Center for Drug Evaluation and Research,"Clinical - Medical, Pharmacology/Toxicology",Final,No,,FDA-2015-D-2306
Draft Guidance for Industry: Guide to Minimize Food Safety Hazards of Fresh-cut Produce,PDF (446.91 KB)PDF (446.91 KB) of Draft Guidance for Industry: Guide to Minimize Food Safety Hazards of Fresh-cut Produce,10/22/2018,Human Foods Program,"Fruit/Fruit Product , Vegetable Products",Draft,No,04/22/2019,FDA-2018-D-3583
"Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption","PDF (1.72 MB)PDF (1.72 MB) of Draft Guidance for Industry: Standards for the Growing, Harvesting, Packing, and Holding of Produce for Human Consumption",10/22/2018,Human Foods Program,"Fruit/Fruit Product , Vegetable Products",Draft,No,04/22/2019,FDA-2018-D-3631
Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease,PDF (90.9 KB)PDF (90.9 KB) of Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease,10/16/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Pharmacology,Final,No,,FDA-2017-D-6617
Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry,PDF (131.81 KB)PDF (131.81 KB) of Rare Diseases: Early Drug Development and the Role of Pre-IND Meetings : Draft Guidance for Industry,10/16/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Rare Diseases, Pediatric Product Development",Draft,No,12/17/2018,FDA-2018-D-3268
"Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations:  Guidance for Sponsors, Investigators, and Institutional Review Boards","PDF (135.4 KB)PDF (135.4 KB) of Impact of Certain Provisions of the Revised Common Rule on FDA-Regulated Clinical Investigations:  Guidance for Sponsors, Investigators, and Institutional Review Boards",10/11/2018,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,FDA-2018-D-3551
Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs,PDF (70.95 KB)PDF (70.95 KB) of Atopic Dermatitis: Timing of Pediatric Studies During Development of Systemic Drugs,10/03/2018,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2018-D-1175
"Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use:  Guidance for Industry","PDF (166.88 KB)PDF (166.88 KB) of Selection of the Appropriate Package Type Terms and Recommendations for Labeling Injectable Medical Products Packaged in Multiple-Dose, Single-Dose, and Single-Patient-Use Containers for Human Use:  Guidance for Industry",10/03/2018,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Chemistry, Manufacturing, and Controls (CMC), Combination Products, Pharmaceutical Quality",Final,No,,FDA-2015-D-3438
Contents of a Complete Submission for Threshold Analyses and Human Factors Submissions to Drug and Biologic Applications,PDF (457.33 KB)PDF (457.33 KB) of Contents of a Complete Submission for Threshold Analyses and Human Factors Submissions to Drug and Biologic Applications,10/01/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-2018-D-3275
Compliance Policy Guides Index,PDF (396.94 KB)PDF (396.94 KB) of Compliance Policy Guides Index,09/28/2018,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
Compounding and Repackaging of Radiopharmaceuticals By Outsourcing Facilities Guidance for Industry,PDF (324.37 KB)PDF (324.37 KB) of Compounding and Repackaging of Radiopharmaceuticals By Outsourcing Facilities Guidance for Industry,09/26/2018,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2016-D-4317
Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies and Federal Facilities Guidance for Industry,PDF (306.64 KB)PDF (306.64 KB) of Compounding and Repackaging of Radiopharmaceuticals by State-Licensed Nuclear Pharmacies and Federal Facilities Guidance for Industry,09/26/2018,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2016-D-4318
Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics:  Guidance for Industry and Food and Drug Administration Staff,PDF (537.58 KB)PDF (537.58 KB) of Benefit-Risk Factors to Consider When Determining Substantial Equivalence in Premarket Notifications (510(k)) with Different Technological Characteristics:  Guidance for Industry and Food and Drug Administration Staff,09/25/2018,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,510(k),Final,No,,FDA-2014-D-0900
Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications: Draft Guidance for Industry and Review Staff,PDF (98.25 KB)PDF (98.25 KB) of Good Review Management Principles and Practices for New Drug Applications and Biologics License Applications: Draft Guidance for Industry and Review Staff,09/25/2018,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Draft,No,11/23/2018,FDA-2018-D-3103
Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy Guidance for Industry,PDF (249.15 KB)PDF (249.15 KB) of Product Identifier Requirements Under the Drug Supply Chain Security Act – Compliance Policy Guidance for Industry,09/20/2018,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing:  Guidance for Industry and Food and Drug Administration Staff,PDF (345.46 KB)PDF (345.46 KB) of Heparin-Containing Medical Devices and Combination Products: Recommendations for Labeling and Safety Testing:  Guidance for Industry and Food and Drug Administration Staff,09/20/2018,Center for Devices and Radiological Health,"Premarket, 510(k), Premarket Approval (PMA), HUD/HDE, Combination Products",Final,No,,FDA-2015-D-2167
Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier,PDF (319.01 KB)PDF (319.01 KB) of Grandfathering Policy for Packages and Homogenous Cases of Product Without a Product Identifier,09/19/2018,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
Guía para la industria: Evaluación de la inocuidad de los cultivos alimentarios para el consumo humano afectados por las inundaciones,,09/17/2018,Human Foods Program,,Final,No,,FDA-2011-D-0733
Guidance for Industry: Determination of Status as a Qualified Facility,PDF (236.61 KB)PDF (236.61 KB) of Guidance for Industry: Determination of Status as a Qualified Facility,09/17/2018,Center for Veterinary MedicineHuman Foods Program,,Final,No,,FDA-2016-D-1164
Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (400.61 KB)PDF (400.61 KB) of Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,09/14/2018,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket, Premarket, Administrative / Procedural",Final,No,,FDA-2014-D-0456
Postapproval Changes to Drug Substances Guidance for Industry,PDF (392.75 KB)PDF (392.75 KB) of Postapproval Changes to Drug Substances Guidance for Industry,09/11/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Draft,No,11/09/2018,FDA-2018-D-3151
Draft Guidance for Industry: Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials,PDF (116.62 KB)PDF (116.62 KB) of Draft Guidance for Industry: Policy Regarding Quantitative Labeling of Dietary Supplements Containing Live Microbials,09/07/2018,Human Foods Program,,Draft,No,11/06/2018,FDA-2011-D-0376
Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry,PDF (120.43 KB)PDF (120.43 KB) of Allergic Rhinitis: Developing Drug Products for Treatment Guidance for Industry,09/06/2018,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2000-D-0277
Nonallergic Rhinitis:  Developing Drug Products for Treatment,PDF (75.16 KB)PDF (75.16 KB) of Nonallergic Rhinitis:  Developing Drug Products for Treatment,09/06/2018,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2016-D-0236
Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry,PDF (87.1 KB)PDF (87.1 KB) of Physiologically Based Pharmacokinetic Analyses — Format and Content Guidance for Industry,09/04/2018,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,,FDA-2016-D-3969
Osteoarthritis: Structural Endpoints for the Development of Drugs,PDF (59.55 KB)PDF (59.55 KB) of Osteoarthritis: Structural Endpoints for the Development of Drugs,08/23/2018,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,Clinical - Medical,Draft,No,11/22/2018,FDA-2018-D-2896
Quality Attribute Considerations for Chewable Tablets Guidance for Industry,PDF (169.2 KB)PDF (169.2 KB) of Quality Attribute Considerations for Chewable Tablets Guidance for Industry,08/21/2018,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2016-D-1490
Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations:  Guidance for Industry,PDF (83.23 KB)PDF (83.23 KB) of Microdose Radiopharmaceutical Diagnostic Drugs: Nonclinical Study Recommendations:  Guidance for Industry,08/21/2018,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2017-D-5297
Guidance for Industry: Questions and Answers Regarding Food Facility Registration (Seventh Edition),PDF (463.59 KB)PDF (463.59 KB) of Guidance for Industry: Questions and Answers Regarding Food Facility Registration (Seventh Edition),08/20/2018,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,"Registration,",Final,No,,FDA-2012-D-1002
Draft Guidance for Industry: Supplemental Questions and Answers Regarding Food Facility Registration,PDF (65.8 KB)PDF (65.8 KB) of Draft Guidance for Industry: Supplemental Questions and Answers Regarding Food Facility Registration,08/20/2018,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,"Registration,",Draft,No,10/19/2018,FDA-2012-D-1002
Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry,PDF (103.25 KB)PDF (103.25 KB) of Dissolution Testing and Acceptance Criteria for Immediate-Release Solid Oral Dosage Form Drug Products Containing High Solubility Drug Substances Guidance for Industry,08/09/2018,Center for Drug Evaluation and Research,Biopharmaceutics,Final,No,,FDA-2018-D-2614
Compliance Policy for Certain Labeling and Warning Statement Requirements for Cigars and Pipe Tobacco:  Guidance for Industry,PDF (122.48 KB)PDF (122.48 KB) of Compliance Policy for Certain Labeling and Warning Statement Requirements for Cigars and Pipe Tobacco:  Guidance for Industry,08/09/2018,Center for Tobacco Products,"Cigars, Cigarillos, Little Filtered Cigars, Pipe, Labeling",Final,No,,FDA-2018-D-3047
Compliance Policy for Required Warning Statements on Small-Packaged Cigars:  Guidance for Industry,PDF (289.81 KB)PDF (289.81 KB) of Compliance Policy for Required Warning Statements on Small-Packaged Cigars:  Guidance for Industry,08/09/2018,Center for Tobacco Products,"Cigars, Cigarillos, Little Filtered Cigars, Labeling",Final,No,,FDA-2017-D-0121
Submission of Warning Plans for Cigars:  Guidance for Industry,PDF (527.27 KB)PDF (527.27 KB) of Submission of Warning Plans for Cigars:  Guidance for Industry,08/09/2018,Center for Tobacco Products,"Cigars, Cigarillos, Little Filtered Cigars, Labeling",Final,No,,FDA-2016-D-2495
Tobacco Retailer Training Programs:  Guidance for Industry,PDF (229.9 KB)PDF (229.9 KB) of Tobacco Retailer Training Programs:  Guidance for Industry,08/09/2018,Center for Tobacco Products,"Training & Education,",Final,No,08/16/2019,FDA-2010-D-0350
Elemental Impurities in Drug Products Guidance for Industry,PDF (91.65 KB)PDF (91.65 KB) of Elemental Impurities in Drug Products Guidance for Industry,08/08/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2016-D-1692
Q3C Tables and List Rev. 4,PDF (255.6 KB)PDF (255.6 KB) of Q3C Tables and List Rev. 4,08/01/2018,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,
"Medical Device User Fee Small Business Qualification and Certification:  Guidance for Industry, Food and Drug Administration Staff and Foreign Governments","PDF (748.18 KB)PDF (748.18 KB) of Medical Device User Fee Small Business Qualification and Certification:  Guidance for Industry, Food and Drug Administration Staff and Foreign Governments",08/01/2018,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"User Fees, Administrative / Procedural",Final,No,,FDA-2018-D-1873
"Slowly Progressive, Low-Prevalence Rare Diseases with Substrate Deposition That Results from Single Enzyme Defects: Providing Evidence of Effectiveness for Replacement or Corrective Therapies Guidance for Industry:  Guidance for Industry","PDF (116.37 KB)PDF (116.37 KB) of Slowly Progressive, Low-Prevalence Rare Diseases with Substrate Deposition That Results from Single Enzyme Defects: Providing Evidence of Effectiveness for Replacement or Corrective Therapies Guidance for Industry:  Guidance for Industry",07/27/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Rare Diseases, Pediatric Product Development",Final,No,,FDA-2018-D-2456
Use of Liquids and/or Soft Foods as Vehicles for Drug Administration:  General Considerations for Selection and In Vitro Methods for Product Quality Assessments,PDF (410.15 KB)PDF (410.15 KB) of Use of Liquids and/or Soft Foods as Vehicles for Drug Administration:  General Considerations for Selection and In Vitro Methods for Product Quality Assessments,07/25/2018,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,10/24/2018,FDA-2018-D-2544
E17 General Principles for Planning and Design of Multi-Regional Clinical Trials,PDF (403.56 KB)PDF (403.56 KB) of E17 General Principles for Planning and Design of Multi-Regional Clinical Trials,07/19/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,11/08/2016,2018-15395
Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry,PDF (327.2 KB)PDF (327.2 KB) of Use of Electronic Health Record Data in Clinical Investigations Guidance for Industry,07/19/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,Administrative / Procedural,Final,No,,FDA-2016-D-1224
Real World Data / Real World Evidence RWD/RWE,,07/18/2018,Center for Drug Evaluation and Research,"Real World Data / Real World Evidence (RWD/RWE),",Final,No,,
Labeling for Biosimilar Products Guidance for Industry,PDF (284.71 KB)PDF (284.71 KB) of Labeling for Biosimilar Products Guidance for Industry,07/18/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,10/18/2018,FDA-2016-D-0643
Innovative Approaches for Nonprescription Drug Products,PDF (246.74 KB)PDF (246.74 KB) of Innovative Approaches for Nonprescription Drug Products,07/18/2018,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Draft,No,10/17/2018,FDA-2018-D-2281
Hypertension: Conducting Studies of Drugs to Treat Patients on a Background of Multiple Antihypertensive Drugs Guidance for Industry,PDF (56.96 KB)PDF (56.96 KB) of Hypertension: Conducting Studies of Drugs to Treat Patients on a Background of Multiple Antihypertensive Drugs Guidance for Industry,07/13/2018,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,10/12/2018,FDA-2018-D-2515
Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry,PDF (480.52 KB)PDF (480.52 KB) of Indications and Usage Section of Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry,07/06/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,10/05/2018,FDA-2018-D-1895
CVM GFI #252 Small Entity Compliance Guide Antimicrobial Animal Drug Sales and Distribution Reporting,PDF (34.08 KB)PDF (34.08 KB) of CVM GFI #252 Small Entity Compliance Guide Antimicrobial Animal Drug Sales and Distribution Reporting,06/29/2018,Center for Veterinary Medicine,"Administrative / Procedural, Antimicrobial Resistance",Final,No,,FDA-2012-N-0447
Major Depressive Disorder:  Developing Drugs for Treatment,PDF (291.28 KB)PDF (291.28 KB) of Major Depressive Disorder:  Developing Drugs for Treatment,06/21/2018,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,09/20/2018,FDA-2018-D-1919
Guidance for Industry: The Declaration of Certain Isolated or Synthetic Non-Digestible Carbohydrates as Dietary Fiber on Nutrition and Supplement Facts Labels,PDF (94.84 KB)PDF (94.84 KB) of Guidance for Industry: The Declaration of Certain Isolated or Synthetic Non-Digestible Carbohydrates as Dietary Fiber on Nutrition and Supplement Facts Labels,06/15/2018,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2018-D-1323
CVM GFI #246 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply-Chain Program,PDF (301.2 KB)PDF (301.2 KB) of CVM GFI #246 Hazard Analysis and Risk-Based Preventive Controls for Food for Animals: Supply-Chain Program,06/15/2018,Center for Veterinary Medicine,"Administrative / Procedural, Animal Feed",Draft,No,12/12/2018,FDA-2018-D-1861
Logical Observation Identifiers Names and Codes for In Vitro Diagnostic Tests :  Guidance for Industry and Food and Drug Administration Staff,PDF (322.78 KB)PDF (322.78 KB) of Logical Observation Identifiers Names and Codes for In Vitro Diagnostic Tests :  Guidance for Industry and Food and Drug Administration Staff,06/15/2018,Center for Devices and Radiological Health,"Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Digital Health",Final,No,,FDA-2017-D-6982
Patient-Focused Drug Development:  Collecting Comprehensive and Representative Input,PDF (641.35 KB)PDF (641.35 KB) of Patient-Focused Drug Development:  Collecting Comprehensive and Representative Input,06/13/2018,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,09/12/2018,FDA-2018-D-1893
Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers :  Guidance for Industry,PDF (328.9 KB)PDF (328.9 KB) of Medical Product Communications That Are Consistent With the FDA-Required Labeling — Questions and Answers :  Guidance for Industry,06/13/2018,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchOffice of the Commissioner,Administrative / Procedural,Final,No,,FDA-2016-D-2285
"Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers:  Guidance for Industry and Review Staff","PDF (463.63 KB)PDF (463.63 KB) of Drug and Device Manufacturer Communications With Payors, Formulary Committees, and Similar Entities – Questions and Answers:  Guidance for Industry and Review Staff",06/13/2018,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Administrative / Procedural,Final,No,,FDA-2016-D-1307
Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President’s Emergency Plan for AIDS Relief: Draft Guidance for Industry,PDF (331.85 KB)PDF (331.85 KB) of Prescription Drug User Fee Act Waivers for Fixed-Combination Antiretroviral Drugs for the President’s Emergency Plan for AIDS Relief: Draft Guidance for Industry,06/07/2018,Center for Drug Evaluation and Research,"User Fees,",Draft,No,08/06/2018,FDA-2018-D-1635
Complicated Urinary Tract Infections:  Developing Drugs for Treatment,PDF (380.96 KB)PDF (380.96 KB) of Complicated Urinary Tract Infections:  Developing Drugs for Treatment,06/01/2018,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2012-D-0148
Development of a Shared System REMS Guidance for Industry,PDF (98.62 KB)PDF (98.62 KB) of Development of a Shared System REMS Guidance for Industry,06/01/2018,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Safety - Issues, Errors, and Problems",Draft,No,07/31/2018,FDA-2018-D-1041
Small Entity Compliance Guide: Registration of Food Facilities,PDF (361.57 KB)PDF (361.57 KB) of Small Entity Compliance Guide: Registration of Food Facilities,05/29/2018,Center for Veterinary MedicineHuman Foods Program,"Registration,",Final,No,,FDA-2012-D-1003
Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry,PDF (116.35 KB)PDF (116.35 KB) of Anthrax: Developing Drugs for Prophylaxis of Inhalational Anthrax Guidance for Industry,05/24/2018,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2016-D-0412
CVM GFI #132 Administrative Applications and the Phased Review Process,PDF (85.62 KB)PDF (85.62 KB) of CVM GFI #132 Administrative Applications and the Phased Review Process,05/23/2018,Center for Veterinary Medicine,New Animal Drug Application (NADA),Final,No,,FDA-2002-D-0147
Acne Vulgaris:  Establishing Effectiveness of Drugs Intended for Treatment,PDF (84.75 KB)PDF (84.75 KB) of Acne Vulgaris:  Establishing Effectiveness of Drugs Intended for Treatment,05/22/2018,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2005-D-0461
Bioanalytical Method Validation Guidance for Industry,PDF (385.62 KB)PDF (385.62 KB) of Bioanalytical Method Validation Guidance for Industry,05/22/2018,Center for Drug Evaluation and ResearchCenter for Veterinary Medicine,Biopharmaceutics,Final,No,,FDA-2013-D-1020
Cytomegalovirus in Transplantation:  Developing Drugs to Treat or Prevent Disease,PDF (219.48 KB)PDF (219.48 KB) of Cytomegalovirus in Transplantation:  Developing Drugs to Treat or Prevent Disease,05/21/2018,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,07/17/2018,FDA-2018-D-1711
Establishing Effectiveness for Drugs Intended to Treat Male Hypogonadotropic Hypogonadism Attributed to Nonstructural Disorders Guidance for Industry,PDF (65.97 KB)PDF (65.97 KB) of Establishing Effectiveness for Drugs Intended to Treat Male Hypogonadotropic Hypogonadism Attributed to Nonstructural Disorders Guidance for Industry,05/18/2018,,Clinical - Medical,Final,No,,
Institutional Review Board (IRB) Written Procedures:  Guidance for Institutions and IRBs,PDF (346.16 KB)PDF (346.16 KB) of Institutional Review Board (IRB) Written Procedures:  Guidance for Institutions and IRBs,05/17/2018,"Office of Inspections and InvestigationsOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Investigation & Enforcement, Good Clinical Practice (GCP)",Final,No,09/30/2016,FDA-2016-D-1605
Small Entity Compliance Guide: Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules of the FDA Food Safety Modernization Act,PDF (36.51 KB)PDF (36.51 KB) of Small Entity Compliance Guide: Extension and Clarification of Compliance Dates for Certain Provisions of Four Implementing Rules of the FDA Food Safety Modernization Act,05/14/2018,Center for Veterinary MedicineHuman Foods Program,,Final,No,,FDA-2018-D-1378
"Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act","PDF (86.66 KB)PDF (86.66 KB) of Facility Definition Under Section 503B of the Federal Food, Drug, and Cosmetic Act",05/10/2018,Center for Drug Evaluation and Research,Compounding,Final,No,,
S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling,PDF (148.76 KB)PDF (148.76 KB) of S3A Guidance: Note for Guidance on Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies: Focus on Microsampling,05/09/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2016-D-2513
Complicated Intra-Abdominal Infections: Developing Drugs for Treatment,PDF (129.97 KB)PDF (129.97 KB) of Complicated Intra-Abdominal Infections: Developing Drugs for Treatment,05/01/2018,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2012-D-0973
Guidance for Industry: Menu Labeling Supplemental Guidance,PDF (3.62 MB)PDF (3.62 MB) of Guidance for Industry: Menu Labeling Supplemental Guidance,05/01/2018,Human Foods Program,"Labeling, Nutrition",Final,No,,FDA-2011-F-0172
Clinical Trial Imaging Endpoint Process Standards Guidance for Industry,PDF (186.17 KB)PDF (186.17 KB) of Clinical Trial Imaging Endpoint Process Standards Guidance for Industry,04/27/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2011-D-0586
Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Questions and Answers Guidance for Industry,PDF (218.22 KB)PDF (218.22 KB) of Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Questions and Answers Guidance for Industry,04/20/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2018-D-1176
Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products--Quality Considerations,PDF (449.28 KB)PDF (449.28 KB) of Metered Dose Inhaler (MDI) and Dry Powder Inhaler (DPI) Drug Products--Quality Considerations,04/19/2018,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,,FDA-2018-D-1098
Guidance for Industry: Highly Concentrated Caffeine in Dietary Supplements,PDF (132.05 KB)PDF (132.05 KB) of Guidance for Industry: Highly Concentrated Caffeine in Dietary Supplements,04/16/2018,Human Foods Program,,Final,No,,FDA–2018–D–1189
Special Protocol Assessment Guidance for Industry,PDF (387.82 KB)PDF (387.82 KB) of Special Protocol Assessment Guidance for Industry,04/16/2018,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2016-D-1174
"Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) - Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases:  Guidance for Stakeholders and Food and Drug Administration Staff","PDF (868.7 KB)PDF (868.7 KB) of Considerations for Design, Development, and Analytical Validation of Next Generation Sequencing (NGS) - Based In Vitro Diagnostics (IVDs) Intended to Aid in the Diagnosis of Suspected Germline Diseases:  Guidance for Stakeholders and Food and Drug Administration Staff",04/13/2018,Center for Devices and Radiological Health,,Final,No,,FDA-2016-D-1270
Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics :  Guidance for Stakeholders and Food and Drug Administration Staff,PDF (593.15 KB)PDF (593.15 KB) of Use of Public Human Genetic Variant Databases to Support Clinical Validity for Genetic and Genomic-Based In Vitro Diagnostics :  Guidance for Stakeholders and Food and Drug Administration Staff,04/13/2018,Center for Devices and Radiological Health,"Premarket, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Molecular and Clinical Genetics",Final,No,,FDA-2016-D-1233
E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population,PDF (354.33 KB)PDF (354.33 KB) of E11(R1) Addendum: Clinical Investigation of Medicinal Products in the Pediatric Population,04/11/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"ICH-Efficacy, Pediatric Product Development",Final,No,,FDA-2016-D-3848
Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials,PDF (116.6 KB)PDF (116.6 KB) of Pregnant Women: Scientific and Ethical Considerations for Inclusion in Clinical Trials,04/09/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2018-D-1201
"Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation","PDF (120.22 KB)PDF (120.22 KB) of Liposome Drug Products: Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation",04/05/2018,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2016-D-2817
Questions and Answers on Current Good Manufacturing Practices for Drugs,,03/30/2018,Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2017-D-6821
Chronic Obstructive Pulmonary Disease: Use of the St. George’s Respiratory Questionnaire as a PRO Assessment Tool Guidance for Industry,PDF (69.43 KB)PDF (69.43 KB) of Chronic Obstructive Pulmonary Disease: Use of the St. George’s Respiratory Questionnaire as a PRO Assessment Tool Guidance for Industry,03/26/2018,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2017-D-6821
Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to the Importation of Live Animals,PDF (69.36 KB)PDF (69.36 KB) of Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to the Importation of Live Animals,03/22/2018,Human Foods Program,Import,Final,No,,FDA-2018-D-0721
E18 Genomic Sampling and Management of Genomic Data Guidance for Industry,PDF (97.94 KB)PDF (97.94 KB) of E18 Genomic Sampling and Management of Genomic Data Guidance for Industry,03/02/2018,Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2016-D-1255
Guidance for Industry: Proper Labeling of Honey and Honey Products,PDF (70.21 KB)PDF (70.21 KB) of Guidance for Industry: Proper Labeling of Honey and Honey Products,03/02/2018,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2006-P-0207
Guidance for Industry: Reference Amounts Customarily Consumed (List of Products for Each Product Category),PDF (289.34 KB)PDF (289.34 KB) of Guidance for Industry: Reference Amounts Customarily Consumed (List of Products for Each Product Category),03/02/2018,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2016-D-4098
Guidance for Industry: Scientific Evaluation of the Evidence on the Beneficial Physiological Effects of Isolated or Synthetic Non-Digestible Carbohydrates Submitted as a Citizen Petition (21 CFR 10.30),PDF (283.85 KB)PDF (283.85 KB) of Guidance for Industry: Scientific Evaluation of the Evidence on the Beneficial Physiological Effects of Isolated or Synthetic Non-Digestible Carbohydrates Submitted as a Citizen Petition (21 CFR 10.30),03/02/2018,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2016-D-3401
"Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion; Dual-Column Labeling; Updating, Modifying, and Establishing Certain Reference Amounts Customarily Consumed; Serving Size for Breath Mints","PDF (762.08 KB)PDF (762.08 KB) of Guidance for Industry: Serving Sizes of Foods That Can Reasonably Be Consumed At One Eating Occasion; Dual-Column Labeling; Updating, Modifying, and Establishing Certain Reference Amounts Customarily Consumed; Serving Size for Breath Mints",03/02/2018,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2004-N-0258
Standardization of Data and Documentation Practices for Product Tracing Guidance for Industry,PDF (170.08 KB)PDF (170.08 KB) of Standardization of Data and Documentation Practices for Product Tracing Guidance for Industry,03/02/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,Administrative / Procedural,Draft,No,05/01/2018,FDA-2018-D-0688
E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1),PDF (698.11 KB)PDF (698.11 KB) of E6(R2) Good Clinical Practice: Integrated Addendum to ICH E6(R1),03/01/2018,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2018-D-0719
Q11 Development and Manufacture of Drug Substances--Questions and Answers (Chemical Entities and Biotechnological/Biological Entities),PDF (843.18 KB)PDF (843.18 KB) of Q11 Development and Manufacture of Drug Substances--Questions and Answers (Chemical Entities and Biotechnological/Biological Entities),02/26/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2011-D-0436
Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions:  Guidance for Industry and Food and Drug Administration Staff,PDF (484.51 KB)PDF (484.51 KB) of Acceptance of Clinical Data to Support Medical Device Applications and Submissions: Frequently Asked Questions:  Guidance for Industry and Food and Drug Administration Staff,02/21/2018,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP), Investigational Device Exemption (IDE)",Final,No,,FDA-2013-N-0080
Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry,PDF (118.81 KB)PDF (118.81 KB) of Duchenne Muscular Dystrophy and Related Dystrophinopathies: Developing Drugs for Treatment Guidance for Industry,02/16/2018,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2015-D-1884
Migraine: Developing Drugs for Acute Treatment,PDF (115.42 KB)PDF (115.42 KB) of Migraine: Developing Drugs for Acute Treatment,02/16/2018,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2014-D-1540
Regulatory Classification of Pharmaceutical Co-Crystals,PDF (86.7 KB)PDF (86.7 KB) of Regulatory Classification of Pharmaceutical Co-Crystals,02/15/2018,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2011-D-0800
How to Prepare a Pre-Request for Designation (Pre-RFD):  Guidance for Industry,PDF (342.72 KB)PDF (342.72 KB) of How to Prepare a Pre-Request for Designation (Pre-RFD):  Guidance for Industry,02/14/2018,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Final,No,04/13/2017,FDA-2017-D-0040
"Microbiological Data for Systemic Antibacterial Drug Products — Development, Analysis, and Presentation","PDF (162.12 KB)PDF (162.12 KB) of Microbiological Data for Systemic Antibacterial Drug Products — Development, Analysis, and Presentation",02/07/2018,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2009-D-0408
Payment and Reimbursement to Research Subjects:  Guidance for Institutional Review Boards and Clinical Investigators,,01/29/2018,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to Importers of Grain Raw Agricultural Commodities,PDF (72.31 KB)PDF (72.31 KB) of Guidance for Industry: Application of the Foreign Supplier Verification Program Regulation to Importers of Grain Raw Agricultural Commodities,01/25/2018,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,Import,Final,No,,FDA-2017-D-6592
Small Entity Compliance Guide: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals,PDF (142.45 KB)PDF (142.45 KB) of Small Entity Compliance Guide: Foreign Supplier Verification Programs for Importers of Food for Humans and Animals,01/25/2018,Human Foods Program,Import,Final,No,,FDA-2011-N-0143
Draft Guidance for Industry: Considerations for Determining Whether a Measure Provides the Same Level of Public Health Protection as the Corresponding Requirement in 21 CFR part 112 or the Preventive Controls Requirements in part 117 or 507,PDF (112.96 KB)PDF (112.96 KB) of Draft Guidance for Industry: Considerations for Determining Whether a Measure Provides the Same Level of Public Health Protection as the Corresponding Requirement in 21 CFR part 112 or the Preventive Controls Requirements in part 117 or 507,01/25/2018,Human Foods Program,,Draft,No,05/25/2018,FDA-2017-D-0397
"Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry","PDF (552.95 KB)PDF (552.95 KB) of Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",01/19/2018,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2016-D-1309
"Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry","PDF (468.33 KB)PDF (468.33 KB) of Compounded Drug Products That Are Essentially Copies of Approved Drug Products Under Section 503B of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",01/19/2018,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2016-D-1267
Product Title and Initial U.S. Approval in the Highlights of Prescribing Information for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry,PDF (679.86 KB)PDF (679.86 KB) of Product Title and Initial U.S. Approval in the Highlights of Prescribing Information for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry,01/19/2018,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,03/19/2018,FDA-2017-D-6969
Material Threat Medical Countermeasure Priority Review Vouchers  - Draft Guidance for Industry: Draft Guidance for Industry,PDF (148.16 KB)PDF (148.16 KB) of Material Threat Medical Countermeasure Priority Review Vouchers  - Draft Guidance for Industry: Draft Guidance for Industry,01/19/2018,"Office of the Commissioner,Office of the Chief Scientist,Office of Counterterrorism and Emerging Threats","Emergencies,",Draft,No,03/20/2018,FDA-2017-D-6880
"Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application:  Guidance for Industry","PDF (555.69 KB)PDF (555.69 KB) of Mixing, Diluting, or Repackaging Biological Products Outside the Scope of an Approved Biologics License Application:  Guidance for Industry",01/18/2018,Center for Drug Evaluation and Research,"Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)",Final,No,03/13/2017,
"Guidance for Industry: Policy Regarding Certain Entities Subject to the Current Good Manufacturing Practice and Preventive Controls, Produce Safety, and/or Foreign Supplier Verification Programs","PDF (228.05 KB)PDF (228.05 KB) of Guidance for Industry: Policy Regarding Certain Entities Subject to the Current Good Manufacturing Practice and Preventive Controls, Produce Safety, and/or Foreign Supplier Verification Programs",01/05/2018,Center for Veterinary MedicineHuman Foods Program,,Final,No,,FDA-2017-N-6908
Labeling for Combined Hormonal Contraceptives Guidance for Industry,PDF (436.92 KB)PDF (436.92 KB) of Labeling for Combined Hormonal Contraceptives Guidance for Industry,01/02/2018,Center for Drug Evaluation and Research,Labeling,Draft,No,02/28/2018,FDA-2017-D-1846
Best Practices for Communication Between IND Sponsors and FDA During Drug Development,PDF (191.28 KB)PDF (191.28 KB) of Best Practices for Communication Between IND Sponsors and FDA During Drug Development,12/29/2017,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2017-D-6564
"Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry:  Guidance for Industry","PDF (219.18 KB)PDF (219.18 KB) of Nucleic Acid Testing (NAT) for Human Immunodeficiency Virus Type 1 (HIV-1) and Hepatitis C Virus (HCV): Testing, Product Disposition, and Donor Deferral and Reentry:  Guidance for Industry",12/28/2017,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2005-D-0140
Medical Device Accessories - Describing Accessories and Classification Pathways:   Guidance for Industry and FDA Staff,PDF (442.1 KB)PDF (442.1 KB) of Medical Device Accessories - Describing Accessories and Classification Pathways:   Guidance for Industry and FDA Staff,12/20/2017,Center for Biologics Evaluation and Research,"Premarket, Administrative / Procedural, Digital Health",Final,No,04/10/2015,FDA-2015-D-0025
Clarification of Orphan Designation of Drugs and  Biologics for Pediatric Subpopulations of Common Diseases:  Guidance for Industry,PDF (81.03 KB)PDF (81.03 KB) of Clarification of Orphan Designation of Drugs and  Biologics for Pediatric Subpopulations of Common Diseases:  Guidance for Industry,12/19/2017,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development","Premarket, Pediatric Product Development",Final,No,07/27/2018,FDA-2017-D-6380.
"Investigational IVDs Used in Clinical Investigations of Therapeutic Products: Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards","PDF (730.53 KB)PDF (730.53 KB) of Investigational IVDs Used in Clinical Investigations of Therapeutic Products: Draft Guidance for Industry, Food and Drug Administration Staff, Sponsors, and Institutional Review Boards",12/18/2017,Center for Devices and Radiological Health,"Good Clinical Practice (GCP), Labeling, Investigational Device Exemption (IDE), Investigational New Drug Application (INDA), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Draft,No,03/19/2018,FDA-2017-N-6356
Systemic Antibacterial and Antifungal Drugs:  Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs,PDF (92 KB)PDF (92 KB) of Systemic Antibacterial and Antifungal Drugs:  Susceptibility Test Interpretive Criteria Labeling for NDAs and ANDAs,12/13/2017,Center for Drug Evaluation and Research,Labeling,Final,No,,FDA-2017-N-5925
Refuse to File: NDA and BLA Submissions to CDER Guidance for Industry,PDF (109.48 KB)PDF (109.48 KB) of Refuse to File: NDA and BLA Submissions to CDER Guidance for Industry,12/13/2017,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,03/12/2018,FDA-2017-D-6554
"Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling-Final","PDF (111.38 KB)PDF (111.38 KB) of Product Name Placement, Size, and Prominence in Advertising and Promotional Labeling-Final",12/12/2017,Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Advertising,Final,No,,FDA-1999-D-4079
Gluten in Drug Products and Associated Labeling Recommendations; Draft Guidance for Industry,PDF (135.93 KB)PDF (135.93 KB) of Gluten in Drug Products and Associated Labeling Recommendations; Draft Guidance for Industry,12/12/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Draft,No,03/12/2018,FDA-2017-D-6352
Software as a Medical Device (SAMD): Clinical Evaluation:  Guidance for Industry and Food and Drug Administration Staff,PDF (1.23 MB)PDF (1.23 MB) of Software as a Medical Device (SAMD): Clinical Evaluation:  Guidance for Industry and Food and Drug Administration Staff,12/08/2017,Center for Devices and Radiological Health,"Premarket, International,",Final,No,,FDA-2016-D-2483
Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry,PDF (262.2 KB)PDF (262.2 KB) of Pediatric Rare Diseases--A Collaborative Approach for Drug Development Using Gaucher Disease as a Model; Draft Guidance for Industry: Draft Guidance for Industry,12/07/2017,Center for Drug Evaluation and Research,"Rare Diseases, Pediatric Product Development",Draft,No,03/06/2018,FDA-2017-N-6476
Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components:  Guidance for Industry,PDF (159.72 KB)PDF (159.72 KB) of Use of Serological Tests to Reduce the Risk of Transmission of Trypanosoma cruzi Infection in Blood and Blood Components:  Guidance for Industry,12/05/2017,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,12/06/2017,FDA-2009-D-0137
Technical Considerations for Additive Manufactured Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (802.88 KB)PDF (802.88 KB) of Technical Considerations for Additive Manufactured Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,12/05/2017,Center for Devices and Radiological Health,"Premarket, Biotechnology, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD/HDE, Orthopedic, Tissue",Final,No,08/08/2016,FDA-2016-D-1210
"FDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Services (CMS) with Coverage Decisions:  Guidance for Sponsors, Clinical Investigators, Industry, Institutional Review Boards, and Food and Drug Administration Staff","PDF (572.88 KB)PDF (572.88 KB) of FDA Categorization of Investigational Device Exemption (IDE) Devices to Assist the Centers for Medicare and Medicaid Services (CMS) with Coverage Decisions:  Guidance for Sponsors, Clinical Investigators, Industry, Institutional Review Boards, and Food and Drug Administration Staff",12/05/2017,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Investigational Device Exemption (IDE),Final,No,,FDA-2016-D-1159
Pediatric Information for X-ray Imaging Device Premarket Notifications:  Guidance for Industry and Food and Drug Administration Staff,PDF (671.92 KB)PDF (671.92 KB) of Pediatric Information for X-ray Imaging Device Premarket Notifications:  Guidance for Industry and Food and Drug Administration Staff,11/28/2017,Center for Devices and Radiological Health,"Premarket, 510(k), Pediatric Product Development, Radiology",Final,No,,FDA-2012-D-0384
Small Entity Compliance Guide: Sanitary Transportation of Human and Animal Food - What You Need to Know About the FDA Regulation,PDF (131.42 KB)PDF (131.42 KB) of Small Entity Compliance Guide: Sanitary Transportation of Human and Animal Food - What You Need to Know About the FDA Regulation,11/22/2017,Human Foods Program,Transportation,Final,No,,FDA-2013-N-0013
General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry,PDF (520.34 KB)PDF (520.34 KB) of General Principles for Evaluating the Abuse Deterrence of Generic Solid Oral Opioid Drug Products Guidance for Industry,11/21/2017,Center for Drug Evaluation and Research,"Drug Competition Action Plan, Generic Drugs",Final,No,,FDA-2016-D-0785
Unique Device Identification: Direct Marking of Devices :  Guidance for Industry and Food and Drug Administration Staff,PDF (586.68 KB)PDF (586.68 KB) of Unique Device Identification: Direct Marking of Devices :  Guidance for Industry and Food and Drug Administration Staff,11/17/2017,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Labeling, UDI",Final,No,09/24/2015,FDA-2015-D-2245
Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception,PDF (79.29 KB)PDF (79.29 KB) of Same Surgical Procedure Exception under 21 CFR 1271.15(b): Questions and Answers Regarding the Scope of the Exception,11/16/2017,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Tissue",Final,No,,FDA-2014-D-1584
Guidance for Industry: Use of the Terms “Brown King Crab” and “Golden King Crab” in the Labeling of Human Food Products,PDF (34.76 KB)PDF (34.76 KB) of Guidance for Industry: Use of the Terms “Brown King Crab” and “Golden King Crab” in the Labeling of Human Food Products,11/15/2017,Human Foods Program,"Labeling, Seafood/Seafood Product",Final,No,,
Use of a Drug Master File for Shared System REMS Submissions Guidance for Industry,PDF (102.63 KB)PDF (102.63 KB) of Use of a Drug Master File for Shared System REMS Submissions Guidance for Industry,11/09/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Drug Competition Action Plan",Draft,No,,FDA-2017-D-6231
Evaluating Drug Effects on the Ability to Operate a Motor Vehicle,PDF (104.38 KB)PDF (104.38 KB) of Evaluating Drug Effects on the Ability to Operate a Motor Vehicle,11/08/2017,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
Recurrent Herpes Labialis:  Developing Drugs for Treatment and Prevention,PDF (153.47 KB)PDF (153.47 KB) of Recurrent Herpes Labialis:  Developing Drugs for Treatment and Prevention,11/08/2017,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2016-D-1504
Chronic Hepatitis C Virus Infection:  Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry,PDF (257.59 KB)PDF (257.59 KB) of Chronic Hepatitis C Virus Infection:  Developing Direct-Acting Antiviral Drugs for Treatment Guidance for Industry,11/07/2017,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2013-D-1170
Recommended Statement for Over-the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery Guidance for Industry,PDF (192.74 KB)PDF (192.74 KB) of Recommended Statement for Over-the-Counter Aspirin-Containing Drug Products Labeled With Cardiovascular Related Imagery Guidance for Industry,11/07/2017,Center for Drug Evaluation and Research,"Compliance,",Final,No,,FDA-2012-D-0529
Guidance for Industry: Supply-Chain Program Requirements and Co-Manufacturer Supplier Approval and Verification for Human Food and Animal Food,PDF (84.49 KB)PDF (84.49 KB) of Guidance for Industry: Supply-Chain Program Requirements and Co-Manufacturer Supplier Approval and Verification for Human Food and Animal Food,11/06/2017,Center for Veterinary MedicineHuman Foods Program,,Final,No,,FDA-2017-D-5996
ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence) Guidance for Industry,PDF (151.29 KB)PDF (151.29 KB) of ANDAs: Pre-Submission of Facility Information Related to Prioritized Generic Drug Applications (Pre-Submission Facility Correspondence) Guidance for Industry,11/03/2017,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality, Drug Competition Action Plan",Draft,No,02/02/2018,FDA-2017-D-3101
"Guidance for Industry: Regulatory Framework for Substances Intended for Use in Human Food or Animal Food on the Basis of the Generally Recognized as Safe (GRAS) Provision of the Federal Food, Drug, and Cosmetic Act","PDF (176.65 KB)PDF (176.65 KB) of Guidance for Industry: Regulatory Framework for Substances Intended for Use in Human Food or Animal Food on the Basis of the Generally Recognized as Safe (GRAS) Provision of the Federal Food, Drug, and Cosmetic Act",11/01/2017,Center for Veterinary MedicineHuman Foods Program,GRAS,Final,No,,FDA-2016-D-4484
Recommendations for the Submission of LOINC® Codes in Regulatory Applications to the U.S. Food and Drug Administration:  Guidance for Industry,PDF (235.85 KB)PDF (235.85 KB) of Recommendations for the Submission of LOINC® Codes in Regulatory Applications to the U.S. Food and Drug Administration:  Guidance for Industry,11/01/2017,Center for Drug Evaluation and Research,,Final,No,,FDA-2017-D-6982
Assessing User Fees Under the Generic Drug User Fee Amendments of 2017 Guidance for Industry,,10/30/2017,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Draft,No,,FDA-2012-D-0880
Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request:  Guidance for Industry and Food and Drug Administration Staff,PDF (268.93 KB)PDF (268.93 KB) of Manufacturers Sharing Patient-Specific Information from Medical Devices with Patients Upon Request:  Guidance for Industry and Food and Drug Administration Staff,10/30/2017,Center for Devices and Radiological Health,"Postmarket,",Final,No,08/09/2016,FDA-2016-D-1264
Product Labeling for Certain Ultrasonic Surgical Aspirator Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (273 KB)PDF (273 KB) of Product Labeling for Certain Ultrasonic Surgical Aspirator Devices:  Guidance for Industry and Food and Drug Administration Staff,10/30/2017,Center for Devices and Radiological Health,"Premarket, 510(k), Labeling, Safety - Issues, Errors, and Problems, Obstetrical & Gynecological, General & Plastic Surgery",Final,No,01/09/2017,FDA-2016-D-3275
Pediatric Gastroesophageal Reflux Disease: Developing Drugs for Treatment Guidance for Industry,PDF (310.68 KB)PDF (310.68 KB) of Pediatric Gastroesophageal Reflux Disease: Developing Drugs for Treatment Guidance for Industry,10/26/2017,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Draft,No,01/26/2018,FDA-2017-D-5912
Deciding When to Submit a 510(k) for a Change to an Existing Device:  Guidance for Industry and Food and Drug Administration Staff,PDF (1.04 MB)PDF (1.04 MB) of Deciding When to Submit a 510(k) for a Change to an Existing Device:  Guidance for Industry and Food and Drug Administration Staff,10/25/2017,Center for Devices and Radiological Health,"Premarket, 510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Final,No,11/06/2016,FDA-2011-D-0453
Deciding When to Submit a 510(k) for a Software Change to an Existing Device:  Guidance for Industry and Food and Drug Administration Staff,PDF (585.18 KB)PDF (585.18 KB) of Deciding When to Submit a 510(k) for a Software Change to an Existing Device:  Guidance for Industry and Food and Drug Administration Staff,10/25/2017,Center for Devices and Radiological Health,"Premarket, 510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Digital Health",Final,No,11/06/2016,FDA-2016-D-2021
CVM GFI #235 Current Good Manufacturing Practice Requirements for Food for Animals,PDF (361.86 KB)PDF (361.86 KB) of CVM GFI #235 Current Good Manufacturing Practice Requirements for Food for Animals,10/20/2017,Center for Veterinary Medicine,"Animal Feed, Current Good Manufacturing Practice (CGMP)",Final,No,11/23/2016,FDA-2016-D-1229
Draft Guidance for Industry: Application of the “Solely Engaged” Exemptions in Parts 117 and 507,PDF (97.61 KB)PDF (97.61 KB) of Draft Guidance for Industry: Application of the “Solely Engaged” Exemptions in Parts 117 and 507,10/20/2017,Center for Veterinary MedicineHuman Foods Program,"Registration,",Draft,No,04/18/2018,FDA-2017-D-6133
Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry,PDF (179.49 KB)PDF (179.49 KB) of Respiratory Syncytial Virus Infection: Developing Antiviral Drugs for Prophylaxis and Treatment Guidance for Industry,10/11/2017,Center for Drug Evaluation and Research,"Clinical - Antimicrobial, Pediatric Product Development",Draft,No,12/11/2017,
Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry:  Guidance for Industry,PDF (379.2 KB)PDF (379.2 KB) of Completeness Assessments for Type II API DMFs Under GDUFA Guidance for Industry:  Guidance for Industry,10/11/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"User Fees, Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality",Final,No,,None found
CVM GFI #236 Clarification of FDA and EPA Jurisdiction Over Mosquito-Related Products,PDF (85.08 KB)PDF (85.08 KB) of CVM GFI #236 Clarification of FDA and EPA Jurisdiction Over Mosquito-Related Products,10/05/2017,Center for Veterinary Medicine,New Animal Drug Application (NADA),Final,No,02/21/2017,FDA-2016-D-4482
Individual Patient Expanded Access Applications: Form FDA 3926,PDF (271.83 KB)PDF (271.83 KB) of Individual Patient Expanded Access Applications: Form FDA 3926,10/03/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2015-D-0268
M4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use Guidance for Industry,PDF (269.33 KB)PDF (269.33 KB) of M4 Organization of the Common Technical Document for the Registration of Pharmaceuticals for Human Use Guidance for Industry,10/03/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2017-D-5139
ANDA Submissions - Refuse-to-Receive Standards: Questions and Answers Guidance for Industry,PDF (153.07 KB)PDF (153.07 KB) of ANDA Submissions - Refuse-to-Receive Standards: Questions and Answers Guidance for Industry,10/03/2017,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Draft,No,01/02/2018,FDA-2017-D-5846
"Waiver of IRB Requirements for Drug and Biological Product Studies:  Guidance For Sponsors, Clinical Investigators, and IRBs","PDF (87.28 KB)PDF (87.28 KB) of Waiver of IRB Requirements for Drug and Biological Product Studies:  Guidance For Sponsors, Clinical Investigators, and IRBs",10/03/2017,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Administrative Procedures for CLIA Categorization:  Guidance for Industry and Food and Drug Administration Staff,PDF (124.22 KB)PDF (124.22 KB) of Administrative Procedures for CLIA Categorization:  Guidance for Industry and Food and Drug Administration Staff,10/02/2017,Center for Devices and Radiological Health,"User Fees, Administrative / Procedural, CLIA (Clinical Laboratory Improvement Amendments)",Final,No,,FDA-2008-D-0228
Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization Guidance for Industry,PDF (71.22 KB)PDF (71.22 KB) of Advancement of Emerging Technology Applications for Pharmaceutical Innovation and Modernization Guidance for Industry,09/29/2017,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2015-D-4644
Classification of Products as Drugs and Devices and Additional Product Classification Issues:  Guidance for Industry and FDA Staff,PDF (86.73 KB)PDF (86.73 KB) of Classification of Products as Drugs and Devices and Additional Product Classification Issues:  Guidance for Industry and FDA Staff,09/25/2017,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Final,No,09/01/2011,FDA-2011-D-0429
Minutes of Institutional Review Board (IRB) Meetings:  Guidance for Institutions and IRBs,PDF (117.59 KB)PDF (117.59 KB) of Minutes of Institutional Review Board (IRB) Meetings:  Guidance for Institutions and IRBs,09/25/2017,"Office of Inspections and InvestigationsOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Investigation & Enforcement, Good Clinical Practice (GCP), Pediatric Product Development",Final,No,01/04/2016,FDA-2015-D-3638
Q4B Annex 2: Test for Extractable Volume of Parenteral Preparations General Chapter,PDF (69.05 KB)PDF (69.05 KB) of Q4B Annex 2: Test for Extractable Volume of Parenteral Preparations General Chapter,09/18/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2008-D-0081
Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses:  Guidance for Industry and Food and Drug Administration Staff,PDF (785.66 KB)PDF (785.66 KB) of Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Human Papillomaviruses:  Guidance for Industry and Food and Drug Administration Staff,09/15/2017,Center for Devices and Radiological Health,"Premarket, Microbiology, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Premarket Approval (PMA)",Final,No,11/12/2015,FDA-2009-D-0386
"Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies:  Guidance for Industry and Food and Drug Administration Staff","PDF (1.1 MB)PDF (1.1 MB) of Evaluation and Reporting of Age-, Race-, and Ethnicity-Specific Data in Medical Device Clinical Studies:  Guidance for Industry and Food and Drug Administration Staff",09/12/2017,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD/HDE, Clinical - Medical, Good Clinical Practice (GCP), Labeling, Pediatric Product Development, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Physical Medicine, Orthopedic, Ophthalmic, Obstetrical & Gynecological, Neurological, Molecular and Clinical Genetics, Immunology & Microbiology , Cardiovascular , Hematology & Pathology , General Hospital & Personal Use , General & Plastic Surgery , Gastroenterology-Urology , Ear, Nose & Throat , Dental , Clinical Chemistry & Clinical Toxicology , Radiology, Radiological Health",Final,No,09/18/2016,FDA-2016-D-0734
"Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271:  Guidance for Industry","PDF (157.07 KB)PDF (157.07 KB) of Deviation Reporting for Human Cells, Tissues, and Cellular and Tissue-Based Products Regulated Solely Under Section 361 of the Public Health Service Act and 21 CFR Part 1271:  Guidance for Industry",09/06/2017,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Tissue",Final,No,,FDA-2015-D-4386
Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (421.33 KB)PDF (421.33 KB) of Design Considerations and Pre-market Submission Recommendations for Interoperable Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,09/06/2017,Center for Devices and Radiological Health,"510(k), Anesthesiology , Neurological, Cardiovascular , General Hospital & Personal Use , Digital Health, Dental , Radiological Health",Final,No,04/28/2016,FDA-2015-D-4852
Requalification of Donors Previously Deferred for a History of Viral Hepatitis after the 11th Birthday:  Guidance for Industry,PDF (77.49 KB)PDF (77.49 KB) of Requalification of Donors Previously Deferred for a History of Viral Hepatitis after the 11th Birthday:  Guidance for Industry,09/01/2017,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2017-D-5152
Procedures for Meetings of the Medical Devices Advisory Committee:  Guidance for Industry and Food and Drug Administration Staff,PDF (443.17 KB)PDF (443.17 KB) of Procedures for Meetings of the Medical Devices Advisory Committee:  Guidance for Industry and Food and Drug Administration Staff,09/01/2017,Center for Devices and Radiological Health,"Premarket, Advisory Committees, 510(k), Premarket Approval (PMA), HUD/HDE, Administrative / Procedural, Labeling, Safety - Issues, Errors, and Problems, Anesthesiology , Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Physical Medicine, Orthopedic, Ophthalmic, Obstetrical & Gynecological, Neurological, Molecular and Clinical Genetics, Immunology & Microbiology , Cardiovascular , Hematology & Pathology , General Hospital & Personal Use , General & Plastic Surgery , Gastroenterology-Urology , Ear, Nose & Throat , Dental , Clinical Chemistry & Clinical Toxicology , Radiology, Laser Notice",Final,No,05/29/2015,FDA-2015-D-0838
Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices :   Guidance for Industry and Food and Drug Administration Staff,PDF (537.22 KB)PDF (537.22 KB) of Use of Real-World Evidence to Support Regulatory Decision-Making for Medical Devices :   Guidance for Industry and Food and Drug Administration Staff,08/31/2017,Center for Devices and Radiological Health,"Postmarket, Biostatistics, Adverse Event Reporting System (FAERS), Real World Data / Real World Evidence (RWD/RWE), Adverse Event Reporting, Antimicrobial Resistance, Anesthesiology , Physical Medicine, Orthopedic, Ophthalmic, Obstetrical & Gynecological, Neurological, Molecular and Clinical Genetics, Immunology & Microbiology , Cardiovascular",Final,No,10/25/2016,FDA-2016-D-2153
Small Entity Compliance Guide: Mitigation Strategies to Protect Food Against Intentional Adulteration,PDF (128.82 KB)PDF (128.82 KB) of Small Entity Compliance Guide: Mitigation Strategies to Protect Food Against Intentional Adulteration,08/25/2017,Human Foods Program,Defense & Security,Final,No,,FDA-2013-N-1425
CVM GFI #232 (VICH GL54) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish an Acute Reference Dose (ARfD),PDF (99.89 KB)PDF (99.89 KB) of CVM GFI #232 (VICH GL54) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Establish an Acute Reference Dose (ARfD),08/23/2017,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,07/31/2015,FDA-2015-D-1804
CVM GFI #237 Oncology Drugs for Companion Animals,PDF (198.25 KB)PDF (198.25 KB) of CVM GFI #237 Oncology Drugs for Companion Animals,08/23/2017,Center for Veterinary Medicine,Investigational New Animal Drug (INAD),Final,No,08/09/2016,FDA-2016-D-1248
Identifying Trading Partners Under the Drug Supply Chain Security Act Guidance for Industry,PDF (180.61 KB)PDF (180.61 KB) of Identifying Trading Partners Under the Drug Supply Chain Security Act Guidance for Industry,08/18/2017,,Administrative / Procedural,Draft,No,10/18/2017,
Guidance for Industry: Ultrafiltered Milk in the Production of Standardized Cheeses and Related Cheese Products,PDF (38.08 KB)PDF (38.08 KB) of Guidance for Industry: Ultrafiltered Milk in the Production of Standardized Cheeses and Related Cheese Products,08/14/2017,Human Foods Program,Cheese/Cheese Product,Final,No,,FDA-2017-D-4713
Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases,PDF (148.81 KB)PDF (148.81 KB) of Antibacterial Therapies for Patients With an Unmet Medical Need for the Treatment of Serious Bacterial Diseases,08/02/2017,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2013-D-0744
Guidance for Industry: Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule,PDF (37.42 KB)PDF (37.42 KB) of Guidance for Industry: Clarification on Food Establishment Waiver from Requirements of the Sanitary Transportation of Human and Animal Food Rule,08/01/2017,Center for Veterinary MedicineHuman Foods Program,"Sanitation, Transportation",Final,No,,FDA-2013-N-0013
Consumer Antiseptic Wash Final Rule Questions and Answers:  Guidance for Industry,PDF (91.76 KB)PDF (91.76 KB) of Consumer Antiseptic Wash Final Rule Questions and Answers:  Guidance for Industry,07/26/2017,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2017-D-3906
ICH Q3C Maintenance Procedures for the Guidance for Industry Q3C Impurities: Residual Solvents,,07/25/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2010-N-0327 (Cumene) FDA-2015-D-3474 (Triethylamine/Methylisobutylketone)  4 Guidances listed under this Document:Triethylamine/Methylisobutylketone - pdf on web Tetrahydrofuran (THF) - pdf ON web; Docket #2001B-0431 N-Methylpyrrolidone (NMP) - pdf ON
PDEs for Triethylamine and for Methylisobutylketone,PDF (129.02 KB)PDF (129.02 KB) of PDEs for Triethylamine and for Methylisobutylketone,07/25/2017,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,
M4E(R2):  The CTD – Efficacy,PDF (470.31 KB)PDF (470.31 KB) of M4E(R2):  The CTD – Efficacy,07/24/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2015-D-3235
Q3C Maintenance Procedures,PDF (94.02 KB)PDF (94.02 KB) of Q3C Maintenance Procedures,07/24/2017,Center for Drug Evaluation and Research,ICH-Quality,Final,No,,
Current Good Manufacturing Practice for Medical Gases: Draft Guidance for Industry,PDF (218.85 KB)PDF (218.85 KB) of Current Good Manufacturing Practice for Medical Gases: Draft Guidance for Industry,06/29/2017,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Draft,No,09/28/2017,FDA-2003-D-0431
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry,PDF (117.17 KB)PDF (117.17 KB) of E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs Questions and Answers (R3) Guidance for Industry,06/28/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2004-D-0241
"Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions:  Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff","PDF (51.64 KB)PDF (51.64 KB) of Form FDA 3674 - Certifications To Accompany Drug, Biological Product, and Device Applications/Submissions:  Guidance for Sponsors, Industry, Researchers, Investigators, and Food and Drug Administration Staff",06/07/2017,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","Premarket,",Final,No,,
Guidance for Industry: Recognition of Acceptable Unique Facility Identifier (UFI) for the Foreign Supplier Verification Programs Regulation,PDF (81.38 KB)PDF (81.38 KB) of Guidance for Industry: Recognition of Acceptable Unique Facility Identifier (UFI) for the Foreign Supplier Verification Programs Regulation,03/13/2017,Center for Veterinary MedicineHuman Foods Program,Import,Final,No,,FDA-2011-N-0143
Assessment of Abuse Potential of Drugs,PDF (285.09 KB)PDF (285.09 KB) of Assessment of Abuse Potential of Drugs,01/18/2017,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2010-D-0026
Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry,PDF (199.81 KB)PDF (199.81 KB) of Comparative Analyses and Related Comparative Use Human Factors Studies for a Drug-Device Combination Product Submitted in an ANDA: Draft Guidance for Industry,01/17/2017,Center for Drug Evaluation and Research,Generic Drugs,Draft,No,03/13/2017,FDA-2016-D-4412
Draft Guidance for Industry: Control of Listeria monocytogenes in Ready-To-Eat Foods,PDF (852.17 KB)PDF (852.17 KB) of Draft Guidance for Industry: Control of Listeria monocytogenes in Ready-To-Eat Foods,01/17/2017,Human Foods Program,Listeria,Draft,No,07/26/2017,FDA-2008-D-0096
2016 Medical Gas Container-Closure Rule Questions and Answers Guidance for Industry:  Guidance for Industry,PDF (81.54 KB)PDF (81.54 KB) of 2016 Medical Gas Container-Closure Rule Questions and Answers Guidance for Industry:  Guidance for Industry,01/17/2017,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Labeling",Final,No,,
Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities:  Guidance for Industry,PDF (645.92 KB)PDF (645.92 KB) of Repackaging of Certain Human Drug Products by Pharmacies and Outsourcing Facilities:  Guidance for Industry,01/13/2017,Center for Drug Evaluation and Research,"Compliance, Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)",Final,No,,FDA-2014-D-1524
Emergency Use Authorization of Medical Products and Related Authorities:  Guidance for Industry and Other Stakeholders,PDF (364.64 KB)PDF (364.64 KB) of Emergency Use Authorization of Medical Products and Related Authorities:  Guidance for Industry and Other Stakeholders,01/13/2017,"Office of the Commissioner,Office of the Chief Scientist,Office of Counterterrorism and Emerging Threats","Premarket, Emergencies,",Final,No,06/04/2016,FDA-2016-D-1025
"Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions:  Guidance for Investigational Device Exemption Sponsors, Sponsor-Investigators and Food and Drug Administration Staff","PDF (748.9 KB)PDF (748.9 KB) of Factors to Consider When Making Benefit-Risk Determinations for Medical Device Investigational Device Exemptions:  Guidance for Investigational Device Exemption Sponsors, Sponsor-Investigators and Food and Drug Administration Staff",01/13/2017,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Clinical - Medical, Investigational Device Exemption (IDE)",Final,No,09/16/2015,FDA-2015-D-1777
Nonproprietary Naming of Biological Products Guidance for Industry,PDF (114.73 KB)PDF (114.73 KB) of Nonproprietary Naming of Biological Products Guidance for Industry,01/12/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2013-D-1543
Guidance for Industry 180-Day Exclusivity: Questions and Answers,PDF (239.52 KB)PDF (239.52 KB) of Guidance for Industry 180-Day Exclusivity: Questions and Answers,01/12/2017,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Generic Drugs,Draft,No,03/12/2017,FDA-2016-D-4645
Recommended Warning for Over-the-Counter Acetaminophen-Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions,PDF (89.49 KB)PDF (89.49 KB) of Recommended Warning for Over-the-Counter Acetaminophen-Containing Drug Products and Labeling Statements Regarding Serious Skin Reactions,01/11/2017,Center for Drug Evaluation and Research,"Compliance, Current Good Manufacturing Practice (CGMP), Over-the-Counter Drugs",Final,No,,FDA-2014-D-1862
Current Good Manufacturing Practice Requirements for Combination Products:  Guidance for Industry and FDA Staff,PDF (555.16 KB)PDF (555.16 KB) of Current Good Manufacturing Practice Requirements for Combination Products:  Guidance for Industry and FDA Staff,01/11/2017,"Office of Inspections and InvestigationsOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Investigation & Enforcement, Compounding, Pharmaceutical Quality, Current Good Manufacturing Practice (CGMP)",Final,No,03/30/2015,FDA-2015-D-0198
Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers: Questions and Answers Guidance for Industry,PDF (111.44 KB)PDF (111.44 KB) of Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers: Questions and Answers Guidance for Industry,01/10/2017,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-2016-D-4646
"Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus:  Guidance for Industry","PDF (99.42 KB)PDF (99.42 KB) of Recommendations for Assessment of Blood Donor Eligibility, Donor Deferral and Blood Product Management in Response to Ebola Virus:  Guidance for Industry",01/10/2017,Center for Biologics Evaluation and Research,"Blood, Ebola, Blood Products",Final,No,,FDA-2014-D-2175
"Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act.”","PDF (190.66 KB)PDF (190.66 KB) of Electronic Drug Product Reporting for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act.”",01/03/2017,Center for Drug Evaluation and Research,"Administrative / Procedural, Compounding",Final,No,,FDA-2013-N-1428
Botanical Drug Development: Guidance for Industry,PDF (221.35 KB)PDF (221.35 KB) of Botanical Drug Development: Guidance for Industry,12/29/2016,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2000-D-0103
Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference  Product,PDF (149.89 KB)PDF (149.89 KB) of Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a Reference  Product,12/29/2016,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Biosimilars, Clinical - Pharmacology",Final,No,,FDA-2014-D-0234
"Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry","PDF (348.92 KB)PDF (348.92 KB) of Prescription Requirement Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",12/29/2016,Center for Drug Evaluation and Research,Compounding,Final,No,,FDA-2016-D-0269
ANDA Submissions -- Refuse-to-Receive Standards Rev.2,PDF (198.75 KB)PDF (198.75 KB) of ANDA Submissions -- Refuse-to-Receive Standards Rev.2,12/28/2016,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Final,No,,FDA-2013-D-1120
Postmarket Management of Cybersecurity in Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (1.23 MB)PDF (1.23 MB) of Postmarket Management of Cybersecurity in Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,12/28/2016,Center for Devices and Radiological Health,"Postmarket, Premarket, 510(k), Premarket Approval (PMA), Digital Health, Labeling, Safety - Issues, Errors, and Problems",Final,No,,FDA-2015-D-5105
"Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions:  Guidance for Industry and Food and Drug Administration Staff","PDF (870.11 KB)PDF (870.11 KB) of Factors to Consider Regarding Benefit-Risk in Medical Device Product Availability, Compliance, and Enforcement Decisions:  Guidance for Industry and Food and Drug Administration Staff",12/27/2016,Center for Devices and Radiological Health,"Postmarket, Recalls, Adverse Event Reporting System (FAERS), 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD/HDE, Adverse Event Reporting, Combination Products, Safety - Issues, Errors, and Problems, Laser Notice",Final,No,09/14/2016,FDA-2016-D-1495
Draft Guidance for Industry: Lead in Cosmetic Lip Products and Externally Applied Cosmetics: Recommended Maximum Level,PDF (115.52 KB)PDF (115.52 KB) of Draft Guidance for Industry: Lead in Cosmetic Lip Products and Externally Applied Cosmetics: Recommended Maximum Level,12/22/2016,"Office of the Commissioner,Office of the Chief Scientist",,Draft,No,02/21/2017,FDA-2014-D-2275
"CVM GFI #234 Question-Based Review for the Chemistry, Manufacturing, and Controls Technical Section of Animal Drug Applications","PDF (614.22 KB)PDF (614.22 KB) of CVM GFI #234 Question-Based Review for the Chemistry, Manufacturing, and Controls Technical Section of Animal Drug Applications",12/20/2016,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,05/17/2016,FDA-2016-D-0620
CVM GFI #224 (VICH GL52) Bioequivalence: Blood Level Bioequivalence Study,PDF (282.71 KB)PDF (282.71 KB) of CVM GFI #224 (VICH GL52) Bioequivalence: Blood Level Bioequivalence Study,12/16/2016,Center for Veterinary Medicine,"Generic Animal Drugs, Generic Drugs, New Animal Drug Application (NADA), VICH",Final,No,11/24/2014,FDA-2014-D-1352
Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Responses to Frequently Asked Questions (*Revised):  Guidance for Industry,PDF (185.39 KB)PDF (185.39 KB) of Civil Money Penalties and No-Tobacco-Sale Orders for Tobacco Retailers Responses to Frequently Asked Questions (*Revised):  Guidance for Industry,12/16/2016,Center for Tobacco Products,No-tobacco-sale order (NTSO),Final,No,,FDA-2012-D-1083
Gifts to FDA: Evaluation and Acceptance:  Guidance for the Public and FDA Staff,PDF (95.02 KB)PDF (95.02 KB) of Gifts to FDA: Evaluation and Acceptance:  Guidance for the Public and FDA Staff,12/16/2016,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy",,Final,No,09/12/2016,FDA-2015-D-4361
"Use of Electronic Informed Consent in Clinical Investigations – Questions and Answers:  Guidance for Institutional Review Boards, Investigators, and Sponsors","PDF (230.82 KB)PDF (230.82 KB) of Use of Electronic Informed Consent in Clinical Investigations – Questions and Answers:  Guidance for Institutional Review Boards, Investigators, and Sponsors",12/15/2016,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research",Administrative / Procedural,Final,No,,FDA-2015-D-0390
"Public Notification of Emerging Postmarket Medical Device Signals (""Emerging Signals""):  Guidance for Industry and Food and Drug Administration Staff","PDF (127.96 KB)PDF (127.96 KB) of Public Notification of Emerging Postmarket Medical Device Signals (""Emerging Signals""):  Guidance for Industry and Food and Drug Administration Staff",12/14/2016,Center for Devices and Radiological Health,"Postmarket, Safety - Issues, Errors, and Problems",Final,No,,FDA-2015-D-4803
"Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans:  Guidance for Industry","PDF (294.51 KB)PDF (294.51 KB) of Source Animal, Product, Preclinical, and Clinical Issues Concerning the Use of Xenotransplantation Products in Humans:  Guidance for Industry",12/13/2016,Center for Biologics Evaluation and Research,Xenotransplantation,Final,No,,FDA-2000-D-0129
Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format,PDF (143.76 KB)PDF (143.76 KB) of Clinical Pharmacology Labeling for Human Prescription Drug and Biological Products — Content and Format,12/05/2016,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2009-D-0095
CPG Sec 615.115 Extralabel Use of Medicated Feeds for Minor Species,PDF (101.75 KB)PDF (101.75 KB) of CPG Sec 615.115 Extralabel Use of Medicated Feeds for Minor Species,12/01/2016,Center for Veterinary Medicine,"Investigation & Enforcement, Medicated Feed, Minor Use/ Minor Species (MUMS)",Final,No,,
Providing Postmarket Periodic Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report),PDF (300.03 KB)PDF (300.03 KB) of Providing Postmarket Periodic Safety Reports in the ICH E2C(R2) Format (Periodic Benefit-Risk Evaluation Report),11/29/2016,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,FDA-2013-D-0349
Mitigating the Risk of Cross-Contamination from Valves and Accessories Used for Irrigation Through Flexible Gastrointestinal Endoscopes:  Guidance for Industry and Food and Drug Administration Staff,PDF (445.11 KB)PDF (445.11 KB) of Mitigating the Risk of Cross-Contamination from Valves and Accessories Used for Irrigation Through Flexible Gastrointestinal Endoscopes:  Guidance for Industry and Food and Drug Administration Staff,11/29/2016,Center for Devices and Radiological Health,"Premarket, Gastroenterology-Urology",Final,No,,FDA-2014-D-2153
Submission of Quality Metrics Data Guidance for Industry,PDF (339.64 KB)PDF (339.64 KB) of Submission of Quality Metrics Data Guidance for Industry,11/25/2016,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Draft,No,01/23/2017,FDA-2015-D-2537
Nonprescription Sunscreen Drug Products – Format and Content of Data Submissions,PDF (116.77 KB)PDF (116.77 KB) of Nonprescription Sunscreen Drug Products – Format and Content of Data Submissions,11/23/2016,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2015-D-4033
Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry:  Guidance for Industry,PDF (122.79 KB)PDF (122.79 KB) of Contract Manufacturing Arrangements for Drugs: Quality Agreements Guidance for Industry:  Guidance for Industry,11/23/2016,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Compliance, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2013-D-0558
Nonprescription Sunscreen Drug Products – Safety and Effectiveness Data,PDF (140.4 KB)PDF (140.4 KB) of Nonprescription Sunscreen Drug Products – Safety and Effectiveness Data,11/22/2016,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2015-D-4021
Safety Testing of Drug Metabolites,PDF (107.85 KB)PDF (107.85 KB) of Safety Testing of Drug Metabolites,11/22/2016,Center for Drug Evaluation and Research,"Device & Drug Safety, Pharmacology/Toxicology",Final,No,,FDA-2008-D-0065
Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments:  Guidance for Industry,PDF (221.68 KB)PDF (221.68 KB) of Generic Drug User Fee Amendments of 2012: Questions and Answers Related to User Fee Assessments:  Guidance for Industry,11/22/2016,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Final,No,,FDA-2012-D-0880
Non-Inferiority Clinical Trials,PDF (473.9 KB)PDF (473.9 KB) of Non-Inferiority Clinical Trials,11/08/2016,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2010-D-0075
Medical Device Reporting for Manufacturers :  Guidance for Industry and Food and Drug Administration Staff,PDF (366.22 KB)PDF (366.22 KB) of Medical Device Reporting for Manufacturers :  Guidance for Industry and Food and Drug Administration Staff,11/08/2016,Center for Devices and Radiological Health,"Postmarket, Adverse Event Reporting System (FAERS), Adverse Event Reporting",Final,No,,FDA-2013-D-0743
Clinical Considerations for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes:  Guidance for Industry and Food and Drug Administration Staff,PDF (176.87 KB)PDF (176.87 KB) of Clinical Considerations for Investigational Device Exemptions (IDEs) for Neurological Devices Targeting Disease Progression and Clinical Outcomes:  Guidance for Industry and Food and Drug Administration Staff,11/07/2016,Center for Devices and Radiological Health,"Premarket, Advisory Committees, 510(k), Premarket Approval (PMA), HUD/HDE, Clinical - Medical, Good Clinical Practice (GCP), Labeling, Safety - Issues, Errors, and Problems, Laser Notice, Neurological",Final,No,06/05/2016,FDA-2016-D-0539
"CVM GFI #241 Small Entity Compliance Guide – What You Need to Know About the FDA Regulation: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (21 CFR Part 507)","PDF (237.57 KB)PDF (237.57 KB) of CVM GFI #241 Small Entity Compliance Guide – What You Need to Know About the FDA Regulation: Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Food for Animals (21 CFR Part 507)",11/01/2016,Center for Veterinary Medicine,Animal Feed,Final,No,,FDA-2011-N-0922
Guidance for Industry: Submitting Forms for Food Canning Establishment Registration and Food Process Filing to FDA in Electronic or Paper Format,PDF (122.72 KB)PDF (122.72 KB) of Guidance for Industry: Submitting Forms for Food Canning Establishment Registration and Food Process Filing to FDA in Electronic or Paper Format,11/01/2016,Human Foods Program,"Registration, Canned Foods",Final,No,,FDA-2013-D-1622
"Revised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products Who Have Received Human-Derived Clotting Factor Concentrates:  Guidance for Industry","PDF (55.24 KB)PDF (55.24 KB) of Revised Recommendations for Determining Eligibility of Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products Who Have Received Human-Derived Clotting Factor Concentrates:  Guidance for Industry",11/01/2016,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2016-D-3750
"Small Entity Compliance Guide: What You Need to Know About Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food","PDF (313.99 KB)PDF (313.99 KB) of Small Entity Compliance Guide: What You Need to Know About Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food",10/31/2016,Human Foods Program,,Final,No,,FDA-2011-N-0920
Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization:  Guidance for Industry and Food and Drug Administration Staff,PDF (384.46 KB)PDF (384.46 KB) of Labeling for Permanent Hysteroscopically-Placed Tubal Implants Intended for Sterilization:  Guidance for Industry and Food and Drug Administration Staff,10/31/2016,Center for Devices and Radiological Health,"Postmarket, Biostatistics, Adverse Event Reporting System (FAERS), 510(k), Adverse Event Reporting, Labeling, Gastroenterology-Urology",Final,No,04/29/2016,FDA-2016-D-0435
"Draft Guidance for Industry: Describing a Hazard That Needs Control in Documents Accompanying the Food, as Required by Four Rules Implementing FSMA","PDF (60.3 KB)PDF (60.3 KB) of Draft Guidance for Industry: Describing a Hazard That Needs Control in Documents Accompanying the Food, as Required by Four Rules Implementing FSMA",10/30/2016,Center for Veterinary MedicineHuman Foods ProgramOffice of the Commissioner,,Draft,No,05/01/2017,FDA-2016-D-2841
Collection of Race and Ethnicity Data in Clinical Trials:  Guidance for Industry and Food and Drug Administration Staff,PDF (896.11 KB)PDF (896.11 KB) of Collection of Race and Ethnicity Data in Clinical Trials:  Guidance for Industry and Food and Drug Administration Staff,10/26/2016,"Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and ResearchOffice of the Commissioner,Office of Minority Health and Health EquityOffice of the Commissioner,Office of Women's Health","Clinical - Medical, Good Clinical Practice (GCP), Investigational Device Exemption (IDE)",Final,No,,FDA-2016-D-3561
"Low Sexual Interest, Desire, and/or Arousal in Women: Developing Drugs for Treatment Guidance for Industry","PDF (298.14 KB)PDF (298.14 KB) of Low Sexual Interest, Desire, and/or Arousal in Women: Developing Drugs for Treatment Guidance for Industry",10/25/2016,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,12/25/2016,FDA-2016-D-2817
CPG Sec. 101.100 FDA Considerations for Recommending Charges for Causing the Introduction of Violative Products into Interstate Commerce,PDF (27.22 KB)PDF (27.22 KB) of CPG Sec. 101.100 FDA Considerations for Recommending Charges for Causing the Introduction of Violative Products into Interstate Commerce,10/17/2016,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
Sunscreen Innovation Act:  Section 586C(c) Advisory Committee Process,PDF (102.97 KB)PDF (102.97 KB) of Sunscreen Innovation Act:  Section 586C(c) Advisory Committee Process,10/11/2016,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2015-D-3990
Sunscreen Innovation Act: Withdrawal of a 586A Request or Pending Request Guidance for Industry,PDF (105.1 KB)PDF (105.1 KB) of Sunscreen Innovation Act: Withdrawal of a 586A Request or Pending Request Guidance for Industry,10/11/2016,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2015-D-4012
Tropical Disease Priority Review Vouchers,PDF (274.97 KB)PDF (274.97 KB) of Tropical Disease Priority Review Vouchers,10/06/2016,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Over-the-Counter Drugs",Final,No,,FDA-2008-D-0530
Head Lice Infestation: Developing Drugs for Topical Treatment Guidance for Industry,,10/05/2016,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
Guidance for Industry:  Frequently Asked Questions About GRAS for Substances Intended for Use in Human or Animal Food,PDF (117.29 KB)PDF (117.29 KB) of Guidance for Industry:  Frequently Asked Questions About GRAS for Substances Intended for Use in Human or Animal Food,09/30/2016,Center for Veterinary MedicineHuman Foods Program,"Food & Color Additives, GRAS",Final,No,,FDA-2020-D-1908
Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry,PDF (253.13 KB)PDF (253.13 KB) of Q7 Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients Guidance for Industry,09/30/2016,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-1995-D-0288
Guidance for Industry: Use of the Term “Healthy” in the Labeling of Human Food Products,PDF (41.23 KB)PDF (41.23 KB) of Guidance for Industry: Use of the Term “Healthy” in the Labeling of Human Food Products,09/28/2016,Human Foods Program,Labeling,Final,No,,FDA-2016-D-2335
"Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry","PDF (268.36 KB)PDF (268.36 KB) of Self-Identification of Generic Drug Facilities, Sites, and Organizations; Guidance for Industry",09/23/2016,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Final,No,,FDA-2012-D-0881
CVM GFI #233 Veterinary Feed Directive Common Format Questions and Answers,PDF (834.27 KB)PDF (834.27 KB) of CVM GFI #233 Veterinary Feed Directive Common Format Questions and Answers,09/22/2016,Center for Veterinary Medicine,"Antimicrobial Resistance, Labeling, New Animal Drug Application (NADA)",Final,No,02/01/2016,FDA-2010-N-0155
Reporting of Computational Modeling Studies in Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,PDF (771.67 KB)PDF (771.67 KB) of Reporting of Computational Modeling Studies in Medical Device Submissions:  Guidance for Industry and Food and Drug Administration Staff,09/21/2016,Center for Devices and Radiological Health,"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE)",Final,No,,FDA-2013-D-1530
Qualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease Draft Guidance for Industry,PDF (32.23 KB)PDF (32.23 KB) of Qualification of Biomarker Total Kidney Volume in Studies for Treatment of Autosomal Dominant Polycystic Kidney Disease Draft Guidance for Industry,09/16/2016,Center for Drug Evaluation and Research,Drug Development Tools,Final,No,,FDA-2015-D-2843
Recommendations for Microbial Vectors Used for Gene Therapy:  Guidance for Industry,PDF (161.34 KB)PDF (161.34 KB) of Recommendations for Microbial Vectors Used for Gene Therapy:  Guidance for Industry,09/16/2016,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2015-D-3399
ANDA Submissions — Refuse to Receive for Lack of Justification of Impurity Limits:  Guidance for Industry,PDF (325.96 KB)PDF (325.96 KB) of ANDA Submissions — Refuse to Receive for Lack of Justification of Impurity Limits:  Guidance for Industry,09/14/2016,Center for Drug Evaluation and Research,"User Fees, Generic Drugs",Final,No,,FDA-2014-D-1292
Qualification of Biomarker Plasma Fibrinogen in Studies Examining Exacerbations and/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Guidance for Industry,PDF (38.52 KB)PDF (38.52 KB) of Qualification of Biomarker Plasma Fibrinogen in Studies Examining Exacerbations and/or All-Cause Mortality in Patients With Chronic Obstructive Pulmonary Disease Guidance for Industry,09/13/2016,Center for Drug Evaluation and Research,Drug Development Tools,Final,No,,FDA-2015-D-2244
Draft Guidance for Industry: Substantiation for Structure/Function Claims Made in Infant Formula Labels and Labeling,PDF (130.07 KB)PDF (130.07 KB) of Draft Guidance for Industry: Substantiation for Structure/Function Claims Made in Infant Formula Labels and Labeling,09/09/2016,Human Foods Program,"Infant Formula & Foods, Labeling",Draft,No,02/21/2017,FDA-2016-D-2241
"Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry","PDF (101.63 KB)PDF (101.63 KB) of Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Living Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",09/08/2016,Center for Biologics Evaluation and Research,"Policy Making, Tissue",Final,No,,FDA-2013-D-1143
CPG Sec. 150.200 Compliance Review of Private Laboratory Analytical Packages (PLAPs),PDF (34.49 KB)PDF (34.49 KB) of CPG Sec. 150.200 Compliance Review of Private Laboratory Analytical Packages (PLAPs),09/01/2016,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
Guidance for Industry: Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories (2016 Edition),PDF (92.38 KB)PDF (92.38 KB) of Guidance for Industry: Necessity of the Use of Food Product Categories in Food Facility Registrations and Updates to Food Product Categories (2016 Edition),09/01/2016,Center for Veterinary MedicineHuman Foods Program,"Registration,",Final,No,,FDA-2012-D-0585
"“Harmful and Potentially Harmful Constituents” in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and FDA Staff","PDF (54.46 KB)PDF (54.46 KB) of “Harmful and Potentially Harmful Constituents” in Tobacco Products as Used in Section 904(e) of the Federal Food, Drug, and Cosmetic Act:  Guidance for Industry and FDA Staff",09/01/2016,Center for Tobacco Products,,Final,No,09/01/2016,FDA-2010-D-0281
Guidance for the Submission of 510(k)s for Solid State X-ray Imaging Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (388.18 KB)PDF (388.18 KB) of Guidance for the Submission of 510(k)s for Solid State X-ray Imaging Devices:  Guidance for Industry and Food and Drug Administration Staff,09/01/2016,Center for Devices and Radiological Health,"Premarket, 510(k), Radiological Health, Radiology",Final,No,,FDA-1997-N-0389
CVM GFI #239 Human Food By-Products For Use As Animal Food,PDF (145.58 KB)PDF (145.58 KB) of CVM GFI #239 Human Food By-Products For Use As Animal Food,08/25/2016,Center for Veterinary Medicine,"Animal Feed, Current Good Manufacturing Practice (CGMP)",Draft,No,11/23/2016,FDA-2016-D-1220
"Draft Guidance for Industry: Classification of Activities as Harvesting, Packing, Holding, or Manufacturing/Processing for Farms and Facilities","PDF (256.75 KB)PDF (256.75 KB) of Draft Guidance for Industry: Classification of Activities as Harvesting, Packing, Holding, or Manufacturing/Processing for Farms and Facilities",08/25/2016,Human Foods Program,,Draft,No,02/21/2017,FDA-2016-D-2373
"Patient Preference Information - Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders","PDF (765.74 KB)PDF (765.74 KB) of Patient Preference Information - Voluntary Submission, Review in Premarket Approval Applications, Humanitarian Device Exemption Applications, and De Novo Requests, and Inclusion in Decision Summaries and Device Labeling:  Guidance for Industry, Food and Drug Administration Staff, and Other Stakeholders",08/24/2016,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,,Final,No,,FDA-2015-D-1580
Small Entity Compliance Guide: Calorie Labeling of Articles of Food in Vending Machines,PDF (447.85 KB)PDF (447.85 KB) of Small Entity Compliance Guide: Calorie Labeling of Articles of Food in Vending Machines,08/16/2016,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2011-F-0171
Draft Guidance for Industry: Calorie Labeling of Articles of Food in Vending Machines,PDF (109.07 KB)PDF (109.07 KB) of Draft Guidance for Industry: Calorie Labeling of Articles of Food in Vending Machines,08/16/2016,Human Foods Program,"Labeling, Nutrition Label",Draft,No,09/30/2016,FDA-2011-F-0171
Premarket Notification (510(k)) Submissions for Bipolar Electrosurgical Vessel Sealers for General Surgery:  Guidance for Industry and Food and Drug Administration Staff,PDF (450.4 KB)PDF (450.4 KB) of Premarket Notification (510(k)) Submissions for Bipolar Electrosurgical Vessel Sealers for General Surgery:  Guidance for Industry and Food and Drug Administration Staff,08/15/2016,Center for Devices and Radiological Health,"Premarket, 510(k), Clinical - Medical, Good Clinical Practice (GCP), Labeling, General & Plastic Surgery",Final,No,,FDA-2014-D-0218
Determining Donor Eligibility for Autologous Donors of Blood and Blood Components Intended Solely for Autologous Use - Compliance Policy:  Guidance for Industry,PDF (85.63 KB)PDF (85.63 KB) of Determining Donor Eligibility for Autologous Donors of Blood and Blood Components Intended Solely for Autologous Use - Compliance Policy:  Guidance for Industry,08/01/2016,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2016-D-2071
"Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products:  Guidance for Industry","PDF (66.85 KB)PDF (66.85 KB) of Use of Nucleic Acid Tests to Reduce the Risk of Transmission of Hepatitis B Virus from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products:  Guidance for Industry",08/01/2016,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2015-D-5073
Adaptive Designs for Medical Device Clinical Studies:  Guidance for Industry and Food and Drug Administration Staff,PDF (587.38 KB)PDF (587.38 KB) of Adaptive Designs for Medical Device Clinical Studies:  Guidance for Industry and Food and Drug Administration Staff,07/27/2016,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Good Clinical Practice (GCP), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD/HDE",Final,No,,FDA-2015-D-1439
E2C(R2) Periodic Benefit-Risk Evaluation Report – Questions and Answers,PDF (153.4 KB)PDF (153.4 KB) of E2C(R2) Periodic Benefit-Risk Evaluation Report – Questions and Answers,07/19/2016,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2012-D-0315
E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER),PDF (461.54 KB)PDF (461.54 KB) of E2C(R2) Periodic Benefit-Risk Evaluation Report (PBRER),07/18/2016,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2012-D-0315
Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (1.1 MB)PDF (1.1 MB) of Principles for Codevelopment of an In Vitro Companion Diagnostic Device with a Therapeutic Product: Draft Guidance for Industry and Food and Drug Administration Staff,07/15/2016,Center for Devices and Radiological Health,"Premarket, 510(k), Premarket Approval (PMA), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Draft,No,10/13/2016,FDA-2016-D-1703
Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn Guidance for Industry,PDF (94.11 KB)PDF (94.11 KB) of Updating ANDA Labeling After the Marketing Application for the Reference Listed Drug Has Been Withdrawn Guidance for Industry,07/11/2016,Center for Drug Evaluation and Research,Generic Drugs,Draft,No,,FDA-2016-D-1673
Guidance for Industry: FDA's Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels,PDF (99.12 KB)PDF (99.12 KB) of Guidance for Industry: FDA's Policy on Declaring Small Amounts of Nutrients and Dietary Ingredients on Nutrition Labels,07/01/2016,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2015-D-1839
"Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information:  Guidance for Industry","PDF (174.31 KB)PDF (174.31 KB) of Early Clinical Trials With Live Biotherapeutic Products: Chemistry, Manufacturing, and Control Information:  Guidance for Industry",06/30/2016,Center for Biologics Evaluation and Research,Good Clinical Practice (GCP),Final,No,,FDA-2010-D-0500
"Procedures for Evaluating Appearance Issues and Granting Authorizations for Participation in FDA Advisory Committees: Draft Guidance for the Public, FDA Advisory Committee Members, and FDA Staff","PDF (946.76 KB)PDF (946.76 KB) of Procedures for Evaluating Appearance Issues and Granting Authorizations for Participation in FDA Advisory Committees: Draft Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",06/29/2016,"Human Foods ProgramCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchCenter for Tobacco ProductsOffice of the Commissioner,Office of the Chief Scientist,National Center for Toxicological ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy","Advisory Committees,",Draft,No,06/29/2016,FDA-2016-D-1399
Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (367.42 KB)PDF (367.42 KB) of Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,06/21/2016,Center for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP), Pediatric Product Development, Premarket Approval (PMA), HUD/HDE",Final,No,09/19/2016,FDA-2015-D-1376
"CVM GFI #238 Modified Release Veterinary Parenteral Dosage Forms: Development, Evaluation, and Establishment of Specifications","PDF (164.17 KB)PDF (164.17 KB) of CVM GFI #238 Modified Release Veterinary Parenteral Dosage Forms: Development, Evaluation, and Establishment of Specifications",06/17/2016,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,03/21/2016,FDA-2015-N-4563
Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers:  Guidance for Industry,PDF (253.12 KB)PDF (253.12 KB) of Expanded Access to Investigational Drugs for Treatment Use - Questions and Answers:  Guidance for Industry,06/03/2016,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2013-D-0446
Guidance for Industry: Ingredients Declared as Evaporated Cane Juice,PDF (102.88 KB)PDF (102.88 KB) of Guidance for Industry: Ingredients Declared as Evaporated Cane Juice,05/26/2016,Human Foods Program,"Juice, Labeling",Final,No,,FDA-2009-D-0430
Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry,PDF (125.91 KB)PDF (125.91 KB) of Considerations for Use of Histopathology and Its Associated Methodologies to Support Biomarker Qualification Guidance for Industry,05/16/2016,Center for Drug Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2011-D-0872
Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products:  Guidance for Industry,PDF (93.03 KB)PDF (93.03 KB) of Requirements for the Submission of Data Needed to Calculate User Fees for Domestic Manufacturers and Importers of Tobacco Products:  Guidance for Industry,05/10/2016,Center for Tobacco Products,User Fees,Final,No,,FDA-2014-D-0917
Tobacco Product Master Files:  Guidance for Industry,PDF (153.37 KB)PDF (153.37 KB) of Tobacco Product Master Files:  Guidance for Industry,05/10/2016,Center for Tobacco Products,,Final,No,,FDA-2015-D-2325
Guidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part II,PDF (349.16 KB)PDF (349.16 KB) of Guidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part II,05/05/2016,Human Foods Program,Labeling,Final,No,,FDA-2011-F-0172
"CPG Sec 540.275 Crabmeat – Fresh and Frozen – Adulteration with Filth, Involving the Presence of Escherichia coli","PDF (19.11 KB)PDF (19.11 KB) of CPG Sec 540.275 Crabmeat – Fresh and Frozen – Adulteration with Filth, Involving the Presence of Escherichia coli",04/30/2016,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,FDA-2014-D-1842
CVM GFI #231 Distributor Labeling for New Animal Drugs,PDF (84.76 KB)PDF (84.76 KB) of CVM GFI #231 Distributor Labeling for New Animal Drugs,04/20/2016,Center for Veterinary Medicine,"Administrative / Procedural, Advertising, Labeling, New Animal Drug Application (NADA)",Final,No,11/09/2015,FDA-2015-D-3056
Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices :  Guidance for Industry and Food and Drug Administration Staff,PDF (579.46 KB)PDF (579.46 KB) of Technical Performance Assessment of Digital Pathology Whole Slide Imaging Devices :  Guidance for Industry and Food and Drug Administration Staff,04/20/2016,Center for Devices and Radiological Health,"Premarket, 510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2015-D-0230
Radiation Biodosimetry Medical Countermeasure Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (514.01 KB)PDF (514.01 KB) of Radiation Biodosimetry Medical Countermeasure Devices:  Guidance for Industry and Food and Drug Administration Staff,04/18/2016,Center for Devices and Radiological Health,"Premarket, Emergencies, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Radiological Health",Final,No,03/30/2015,FDA-2014-D-2065
Guidance for Industry: Exempt Infant Formula Production,PDF (255.08 KB)PDF (255.08 KB) of Guidance for Industry: Exempt Infant Formula Production,04/15/2016,Human Foods Program,Infant Formula & Foods,Final,No,,FDA-2014-D-0044
Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry,PDF (211.98 KB)PDF (211.98 KB) of Safety Considerations for Product Design to Minimize Medication Errors Guidance for Industry,04/12/2016,Center for Drug Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,FDA-2012-D-1005
Contents of a Complete Submission for the Evaluation of Proprietary Names,PDF (146.01 KB)PDF (146.01 KB) of Contents of a Complete Submission for the Evaluation of Proprietary Names,04/11/2016,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Labeling, Safety - Issues, Errors, and Problems",Final,No,,FDA-2008-D-0592
"CVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs","PDF (110.64 KB)PDF (110.64 KB) of CVM GFI #156 Comparability Protocols - Chemistry, Manufacturing, and Controls Information for New Animal Drugs",04/04/2016,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2016-D-0938
"CPG Sec. 690.150 Labeling and Marketing of Dog and Cat Food Diets Intended to Diagnose, Cure, Mitigate, Treat, or Prevent Diseases","PDF (91.21 KB)PDF (91.21 KB) of CPG Sec. 690.150 Labeling and Marketing of Dog and Cat Food Diets Intended to Diagnose, Cure, Mitigate, Treat, or Prevent Diseases",04/01/2016,Center for Veterinary Medicine,"Investigation & Enforcement, Labeling, Pet Food",Final,No,11/09/2012,FDA-2012-D-0755
Assessment of Radiofrequency-Induced Heating in the Magnetic Resonance (MR) Environment for Multi-Configuration Passive Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (393.81 KB)PDF (393.81 KB) of Assessment of Radiofrequency-Induced Heating in the Magnetic Resonance (MR) Environment for Multi-Configuration Passive Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,03/22/2016,Center for Devices and Radiological Health,"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), Anesthesiology , Physical Medicine, Orthopedic, Ophthalmic, Obstetrical & Gynecological, Neurological, Cardiovascular , General Hospital & Personal Use , General & Plastic Surgery , Gastroenterology-Urology , Ear, Nose & Throat , Dental , Radiology, Labeling, Safety - Issues, Errors, and Problems",Final,No,08/28/2015,FDA-2015-D-2104
CVM GFI #158 Use of Material from Deer and Elk in Animal Feed,PDF (24.46 KB)PDF (24.46 KB) of CVM GFI #158 Use of Material from Deer and Elk in Animal Feed,03/16/2016,Center for Veterinary Medicine,"Bovine Spongiform Encephalopathy (BSE), Animal Feed",Final,No,,FDA-2003-D-0432
Guidance for Industry: Acrylamide in Foods,PDF (1.28 MB)PDF (1.28 MB) of Guidance for Industry: Acrylamide in Foods,03/11/2016,Human Foods Program,,Final,No,,FDA-2013-D-0715
CVM GFI #203 Ensuring Safety of Animal Feed Maintained and Fed On-Farm,PDF (107.8 KB)PDF (107.8 KB) of CVM GFI #203 Ensuring Safety of Animal Feed Maintained and Fed On-Farm,03/09/2016,Center for Veterinary Medicine,Animal Feed,Final,No,06/03/2015,FDA-2014-D-1180
"Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Regulated Solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271:  Guidance for Industry","PDF (391.84 KB)PDF (391.84 KB) of Investigating and Reporting Adverse Reactions Related to Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Regulated Solely under Section 361 of the Public Health Service Act and 21 CFR Part 1271:  Guidance for Industry",03/08/2016,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2015-D-0309
Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails:  Guidance for Industry and Food and Drug Administration Staff,PDF (215.75 KB)PDF (215.75 KB) of Medical Devices and Clinical Trial Design for the Treatment or Improvement in the Appearance of Fungally-Infected Nails:  Guidance for Industry and Food and Drug Administration Staff,03/07/2016,Center for Devices and Radiological Health,"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE), HUD/HDE, General & Plastic Surgery , Good Clinical Practice (GCP), Labeling",Final,No,,FDA-2014-D-1849
"Environmental Assessment: Questions and Answers Regarding Drugs With Estrogenic, Androgenic, or Thyroid Activity","PDF (68.67 KB)PDF (68.67 KB) of Environmental Assessment: Questions and Answers Regarding Drugs With Estrogenic, Androgenic, or Thyroid Activity",03/04/2016,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,
"Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported Outcome Instrument for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use","PDF (50.04 KB)PDF (50.04 KB) of Evaluating Respiratory Symptoms in Chronic Obstructive Pulmonary Disease, a Patient-Reported Outcome Instrument for the Measurement of Severity of Respiratory Symptoms in Stable Chronic Obstructive Pulmonary Disease: Qualification for Exploratory Use",03/01/2016,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,
"Requirements for Transactions with First Responders under Section 582 of the Federal Food, Drug, and Cosmetic Act— Compliance Policy Guidance for Industry","PDF (88.52 KB)PDF (88.52 KB) of Requirements for Transactions with First Responders under Section 582 of the Federal Food, Drug, and Cosmetic Act— Compliance Policy Guidance for Industry",02/29/2016,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2016-D-0631
"Small Entity Compliance Guide: Alpha-Linolenic Acid, Eicosapentaenoic Acid, and Docosahexaenoic Acid Omega-3 Fatty Acids Nutrient Content Claims","PDF (134.8 KB)PDF (134.8 KB) of Small Entity Compliance Guide: Alpha-Linolenic Acid, Eicosapentaenoic Acid, and Docosahexaenoic Acid Omega-3 Fatty Acids Nutrient Content Claims",02/23/2016,Human Foods Program,Labeling,Final,No,,FDA-2016-N-0585
Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations,PDF (140.43 KB)PDF (140.43 KB) of Determining the Extent of Safety Data Collection Needed in Late Stage Premarket and Postapproval Clinical Investigations,02/19/2016,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2012-D-0096
Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry,PDF (136.19 KB)PDF (136.19 KB) of Immunogenicity-Related Considerations for Low Molecular Weight Heparin Guidance for Industry,02/18/2016,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,
Recommendations for Premarket Notifications for Lamotrigine and Zonisamide Assays:  Guidance for Industry and Food and Drug Administration Staff,PDF (130.13 KB)PDF (130.13 KB) of Recommendations for Premarket Notifications for Lamotrigine and Zonisamide Assays:  Guidance for Industry and Food and Drug Administration Staff,02/09/2016,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2010-D-0395
Applying Human Factors and Usability Engineering to Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (918.39 KB)PDF (918.39 KB) of Applying Human Factors and Usability Engineering to Medical Devices:  Guidance for Industry and Food and Drug Administration Staff,02/03/2016,Center for Devices and Radiological Health,"Postmarket, Premarket, 510(k), Premarket Approval (PMA), Anesthesiology , Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Physical Medicine, Orthopedic, Ophthalmic, Obstetrical & Gynecological, Neurological, Molecular and Clinical Genetics, Immunology & Microbiology , Cardiovascular , Hematology & Pathology , General Hospital & Personal Use , General & Plastic Surgery , Gastroenterology-Urology , Ear, Nose & Throat , Digital Health, Dental , Clinical Chemistry & Clinical Toxicology , Radiology, Labeling, Safety - Issues, Errors, and Problems",Final,No,04/03/2016,FDA-2011-D-0469
List of Highest Priority Devices for Human Factors Review: Draft Guidance for Industry and Food and Drug Administration Staff,PDF (359.16 KB)PDF (359.16 KB) of List of Highest Priority Devices for Human Factors Review: Draft Guidance for Industry and Food and Drug Administration Staff,02/03/2016,Center for Devices and Radiological Health,"Postmarket, Premarket, Labeling, Safety - Issues, Errors, and Problems, Premarket Approval (PMA), Investigational Device Exemption (IDE)",Draft,No,04/03/2016,FDA-2015-D-4599
CVM GFI #226 Target Animal Safety Data Presentation and Statistical Analysis,PDF (560.62 KB)PDF (560.62 KB) of CVM GFI #226 Target Animal Safety Data Presentation and Statistical Analysis,01/21/2016,Center for Veterinary Medicine,"Target Animal – Safety, Investigational New Animal Drug (INAD)",Final,No,06/01/2015,FDA-2015-D-0839
Implanted Blood Access Devices for Hemodialysis:  Guidance for Industry and Food and Drug Administration Staff,PDF (709.54 KB)PDF (709.54 KB) of Implanted Blood Access Devices for Hemodialysis:  Guidance for Industry and Food and Drug Administration Staff,01/21/2016,Center for Devices and Radiological Health,,Final,No,,FDA-2013-D-0749
Premarket Studies of Implantable Minimally Invasive Glaucoma Surgical (MIGS) Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (609.04 KB)PDF (609.04 KB) of Premarket Studies of Implantable Minimally Invasive Glaucoma Surgical (MIGS) Devices:  Guidance for Industry and Food and Drug Administration Staff,12/15/2015,Center for Devices and Radiological Health,"Premarket, Ophthalmic, Premarket Approval (PMA)",Final,No,05/12/2015,FDA-2015-D-0288
Premarket Notification Requirements Concerning Gowns Intended for Use in Health Care Settings:  Guidance for Industry and Food and Drug Administration Staff,PDF (318.85 KB)PDF (318.85 KB) of Premarket Notification Requirements Concerning Gowns Intended for Use in Health Care Settings:  Guidance for Industry and Food and Drug Administration Staff,12/09/2015,Center for Devices and Radiological Health,"Ebola,",Final,No,08/29/2015,FDA-2015-D-2261
CVM GFI #204 Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for use in Companion Animals,PDF (180.96 KB)PDF (180.96 KB) of CVM GFI #204 Active Controls in Studies to Demonstrate Effectiveness of a New Animal Drug for use in Companion Animals,12/01/2015,Center for Veterinary Medicine,Target Animal – Effectiveness,Final,No,,FDA-2012-D-0419
Certification Process of Designated Medical Gases,PDF (279.43 KB)PDF (279.43 KB) of Certification Process of Designated Medical Gases,11/25/2015,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-2012-D-1197
"Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use —:  Guidance for Industry","PDF (173.4 KB)PDF (173.4 KB) of Organ-Specific Warnings: Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use —:  Guidance for Industry",11/17/2015,Center for Drug Evaluation and Research,"Compliance, Current Good Manufacturing Practice (CGMP), Over-the-Counter Drugs, Pharmaceutical Quality",Final,No,,FDA-2012-D-0529
Qualification of Biomarker — Galactomannan in studies of treatments of invasive,PDF (162.39 KB)PDF (162.39 KB) of Qualification of Biomarker — Galactomannan in studies of treatments of invasive,11/13/2015,Center for Drug Evaluation and Research,Drug Development Tools,Draft,No,,FDA-2013-D-1630
Guidance for Industry: Questions and Answers on FDA’s Fortification Policy,PDF (127.24 KB)PDF (127.24 KB) of Guidance for Industry: Questions and Answers on FDA’s Fortification Policy,11/05/2015,Human Foods Program,Nutrition,Final,No,,
DSCSA Implementation: Product Tracing Requirements for Dispensers — Compliance Policy (Revised) Guidance for Industry,PDF (54.76 KB)PDF (54.76 KB) of DSCSA Implementation: Product Tracing Requirements for Dispensers — Compliance Policy (Revised) Guidance for Industry,11/02/2015,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2015-D-2270
Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment,PDF (609.36 KB)PDF (609.36 KB) of Human Immunodeficiency Virus-1 Infection: Developing Antiretroviral Drugs for Treatment,11/02/2015,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,
Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route,PDF (153.48 KB)PDF (153.48 KB) of Nonclinical Safety Evaluation of Reformulated Drug Products and Products Intended for Administration by an Alternate Route,10/28/2015,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2008-D-0142
National Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions – Small Entity Compliance Guide:  Guidance for Industry,PDF (41.92 KB)PDF (41.92 KB) of National Environmental Policy Act; Environmental Assessments for Tobacco Products; Categorical Exclusions – Small Entity Compliance Guide:  Guidance for Industry,10/26/2015,Center for Tobacco Products,Environmental Safety,Final,No,,FDA-2013-N-1282
CVM GFI #229 Evaluating the Effectiveness of New Animal Drugs for the Reduction of Pathogenic Shiga Toxin-Producing E. coli in Cattle,PDF (128.2 KB)PDF (128.2 KB) of CVM GFI #229 Evaluating the Effectiveness of New Animal Drugs for the Reduction of Pathogenic Shiga Toxin-Producing E. coli in Cattle,10/19/2015,Center for Veterinary Medicine,Target Animal – Effectiveness,Final,No,04/27/2015,FDA-2015-D-0235
"Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act","PDF (138.48 KB)PDF (138.48 KB) of Adverse Event Reporting for Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",10/08/2015,Center for Drug Evaluation and Research,"Compounding, Safety - Issues, Errors, and Problems",Final,No,05/17/2015,FDA-2014-D-2138
Integrated Summary of Effectiveness,PDF (274.45 KB)PDF (274.45 KB) of Integrated Summary of Effectiveness,10/08/2015,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2008-D-0449
Acceptability of Draft Labeling to Support Abbreviated New Drug Application Approval; Guidance for Industry,PDF (52.58 KB)PDF (52.58 KB) of Acceptability of Draft Labeling to Support Abbreviated New Drug Application Approval; Guidance for Industry,10/07/2015,Center for Drug Evaluation and Research,Generic Drugs,Draft,No,,FDA-2015-D-3378
Product Development Under the Animal Rule,PDF (573.6 KB)PDF (573.6 KB) of Product Development Under the Animal Rule,10/02/2015,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Animal Rule,Final,No,,FDA-2009-D-0007
CPG Sec 100.101 Crotalaria spp. Seeds in Grains,PDF (221.83 KB)PDF (221.83 KB) of CPG Sec 100.101 Crotalaria spp. Seeds in Grains,09/21/2015,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Draft,No,,FDA-2015-D-2994
Enforcement Policy for Certain (Provisional) Tobacco Products that FDA Finds Not Substantially Equivalent:  Guidance for Industry and Tobacco Retailers,PDF (24.78 KB)PDF (24.78 KB) of Enforcement Policy for Certain (Provisional) Tobacco Products that FDA Finds Not Substantially Equivalent:  Guidance for Industry and Tobacco Retailers,09/14/2015,Center for Tobacco Products,,Final,No,,FDA-2013-D-1600
Nonclinical Evaluation of Endocrine-Related Drug Toxicity,PDF (129.18 KB)PDF (129.18 KB) of Nonclinical Evaluation of Endocrine-Related Drug Toxicity,09/09/2015,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,
"Use of Donor Screening Tests to Test Donors of Human Cells, Tissues and Cellular and Tissue-Based Products for Infection with Treponema pallidum (Syphilis):  Guidance for Industry","PDF (175.47 KB)PDF (175.47 KB) of Use of Donor Screening Tests to Test Donors of Human Cells, Tissues and Cellular and Tissue-Based Products for Infection with Treponema pallidum (Syphilis):  Guidance for Industry",09/09/2015,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2013-D-1213
CVM GFI #225 (VICH GL53) Electronic Exchange of Documents: File Format Recommendations,PDF (113.45 KB)PDF (113.45 KB) of CVM GFI #225 (VICH GL53) Electronic Exchange of Documents: File Format Recommendations,09/01/2015,Center for Veterinary Medicine,"Electronic Submissions, New Animal Drug Application (NADA), VICH",Final,No,10/27/2014,FDA-2014-D-1177
Guidance for Industry: Colored Sea Salt,PDF (173.3 KB)PDF (173.3 KB) of Guidance for Industry: Colored Sea Salt,09/01/2015,Human Foods Program,Food & Color Additives,Final,No,,
Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products:  Guidance for Industry,PDF (120.35 KB)PDF (120.35 KB) of Design and Analysis of Shedding Studies for Virus or Bacteria-Based Gene Therapy and Oncolytic Products:  Guidance for Industry,08/27/2015,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2014-D-0852
Uncomplicated Gonorrhea: Developing Drugs for Treatment,PDF (222.06 KB)PDF (222.06 KB) of Uncomplicated Gonorrhea: Developing Drugs for Treatment,08/18/2015,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2014-D-0640
Providing Submissions in Electronic Format — Postmarketing Safety Reports for Vaccines:  Guidance for Industry,PDF (77.06 KB)PDF (77.06 KB) of Providing Submissions in Electronic Format — Postmarketing Safety Reports for Vaccines:  Guidance for Industry,08/18/2015,Center for Biologics Evaluation and Research,"Postmarket, Electronic Submissions, Safety - Issues, Errors, and Problems, Vaccines",Final,No,,FDA-2014-D-0903
Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems:  Guidance for Industry and Food and Drug Administration Staff,PDF (410.18 KB)PDF (410.18 KB) of Select Updates for Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems:  Guidance for Industry and Food and Drug Administration Staff,08/18/2015,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2013-D-0920
Endotoxin Testing Recommendations for Single-Use Intraocular Ophthalmic Devices,PDF (418.97 KB)PDF (418.97 KB) of Endotoxin Testing Recommendations for Single-Use Intraocular Ophthalmic Devices,08/17/2015,Center for Devices and Radiological Health,"Premarket, Ophthalmic",Final,No,,FDA-2014-D-0332
"Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act","PDF (74.03 KB)PDF (74.03 KB) of Guidance For Entities Considering Whether to Register As Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",08/11/2015,Center for Drug Evaluation and Research,"Administrative / Procedural, Compounding",Final,No,05/17/2015,
Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs,PDF (303.33 KB)PDF (303.33 KB) of Brief Summary and Adequate Directions for Use: Disclosing Risk Information in Consumer-Directed Print Advertisements and Promotional Labeling for Prescription Drugs,08/06/2015,"Center for Veterinary MedicineCenter for Drug Evaluation and Research,Office of Regulatory PolicyCenter for Biologics Evaluation and Research",Advertising,Draft,No,10/05/2015,FDA-2004-D-0500
CVM GFI #220 Use of Nanomaterials in Food for Animals,PDF (86.3 KB)PDF (86.3 KB) of CVM GFI #220 Use of Nanomaterials in Food for Animals,08/05/2015,Center for Veterinary Medicine,"Nanotechnology, Animal Food Additives",Final,No,09/10/2014,FDA-2013-D-1009
Over-the-Counter Pediatric Oral Liquid Drug Products Containing Acetaminophen,PDF (81.71 KB)PDF (81.71 KB) of Over-the-Counter Pediatric Oral Liquid Drug Products Containing Acetaminophen,08/05/2015,Center for Drug Evaluation and Research,"Over-the-Counter Drugs, Safety - Issues, Errors, and Problems, Administrative / Procedural, Combination Products",Final,No,,FDA-2014-D-1473
CVM GFI #198 (VICH GL45) Bracketing and Matrixing Designs For Stability Testing of New Veterinary Drug Substances and Medicinal Products,PDF (141.6 KB)PDF (141.6 KB) of CVM GFI #198 (VICH GL45) Bracketing and Matrixing Designs For Stability Testing of New Veterinary Drug Substances and Medicinal Products,07/31/2015,Center for Veterinary Medicine,VICH,Final,No,,FDA-2009-D-0309
Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation:  Guidance for Industry,PDF (75.4 KB)PDF (75.4 KB) of Recommendations for Premarket Notification (510(k)) Submissions for Nucleic Acid-Based Human Leukocyte Antigen (HLA) Test Kits Used for Matching of Donors and Recipients in Transfusion and Transplantation:  Guidance for Industry,07/31/2015,Center for Biologics Evaluation and Research,"Premarket, Blood, Blood Products",Final,No,,FDA-2013-D-1358
Analytical Procedures and Methods Validation for Drugs and Biologics,PDF (133.79 KB)PDF (133.79 KB) of Analytical Procedures and Methods Validation for Drugs and Biologics,07/27/2015,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2015-N-0007
"Meetings with the Office of Orphan Products Development:  Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff","PDF (134.31 KB)PDF (134.31 KB) of Meetings with the Office of Orphan Products Development:  Guidance for Industry, Researchers, Patient Groups, and Food and Drug Administration Staff",07/09/2015,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development","Administrative / Procedural, Pediatric Product Development",Final,No,,FDA-2014-D-0313
"Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation","PDF (297.17 KB)PDF (297.17 KB) of Guidance for Industry: Questions and Answers Regarding the Final Rule, Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation",07/01/2015,Human Foods Program,"Egg/Egg Product, Transportation, Salmonella",Final,No,,FDA-2011-D-0398
Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products:  Guidance for Industry,PDF (312.74 KB)PDF (312.74 KB) of Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products:  Guidance for Industry,06/27/2015,Center for Biologics Evaluation and Research,Gene Therapy,Final,No,,FDA-2013-D-0576
Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products,PDF (76.58 KB)PDF (76.58 KB) of Allowable Excess Volume and Labeled Vial Fill Size in Injectable Drug and Biological Products,06/25/2015,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2014-D-0248
Guidance for Industry: Food Allergen Labeling Exemption Petitions and Notifications,PDF (524.85 KB)PDF (524.85 KB) of Guidance for Industry: Food Allergen Labeling Exemption Petitions and Notifications,06/19/2015,Human Foods Program,"Allergens, Labeling",Final,No,,FDA-2014-D-0052
Naming of Drug Products Containing Salt Drug Substances,PDF (209.94 KB)PDF (209.94 KB) of Naming of Drug Products Containing Salt Drug Substances,06/17/2015,Center for Drug Evaluation and Research,Labeling,Final,No,,FDA-2013-D-1566
Content and Format for Abbreviated 510(k)s for Early Growth Response 1 (EGR1) Gene Fluorescence In-Situ Hybridization (FISH) Test System for Specimen Characterization Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (330.31 KB)PDF (330.31 KB) of Content and Format for Abbreviated 510(k)s for Early Growth Response 1 (EGR1) Gene Fluorescence In-Situ Hybridization (FISH) Test System for Specimen Characterization Devices:  Guidance for Industry and Food and Drug Administration Staff,06/17/2015,Center for Devices and Radiological Health,"Premarket, 510(k), Labeling, Laboratory Tests, IVDs (In Vitro Diagnostic Devices), Molecular and Clinical Genetics, Immunology & Microbiology",Final,No,,FDA-2014-D-1242
CVM GFI #218 Cell-Based Products for Animal Use,PDF (161.91 KB)PDF (161.91 KB) of CVM GFI #218 Cell-Based Products for Animal Use,06/12/2015,Center for Veterinary Medicine,"Cellular & Gene Therapy, Investigational New Animal Drug (INAD)",Final,No,09/30/2014,FDA-2014-D-0634
CVM GFI #221 Recommendations for Preparation and Submission of Animal Food Additive Petitions,PDF (121.79 KB)PDF (121.79 KB) of CVM GFI #221 Recommendations for Preparation and Submission of Animal Food Additive Petitions,06/12/2015,Center for Veterinary Medicine,Animal Food Additives,Final,No,,FDA-2013-D-0928
"Pregnancy, Lactation, and Reproductive Potential:  Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry  (Small Entity Compliance Guide)","PDF (164.53 KB)PDF (164.53 KB) of Pregnancy, Lactation, and Reproductive Potential:  Labeling for Human Prescription Drug and Biological Products — Content and Format Guidance for Industry  (Small Entity Compliance Guide)",06/10/2015,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,
Investigational New Drug Applications Prepared and Submitted by Sponsor-Investigators,PDF (430.73 KB)PDF (430.73 KB) of Investigational New Drug Applications Prepared and Submitted by Sponsor-Investigators,05/15/2015,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-2015-D-1484
Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry,PDF (138.29 KB)PDF (138.29 KB) of Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein Product to a Reference Product Guidance for Industry,04/30/2015,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Biosimilars,Final,No,,FDA-2011-D-0602
Scientific Considerations in Demonstrating Biosimilarity to a Reference Product,PDF (169.02 KB)PDF (169.02 KB) of Scientific Considerations in Demonstrating Biosimilarity to a Reference Product,04/28/2015,Center for Drug Evaluation and Research,Biosimilars,Final,No,,FDA-2011-D-0605
Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics,PDF (343 KB)PDF (343 KB) of Clinical Trial Endpoints for the Approval of Non-Small Cell Lung Cancer Drugs and Biologics,04/22/2015,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2011-D-0432
Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval:  Guidance for Industry and Food and Drug Administration Staff,PDF (500.14 KB)PDF (500.14 KB) of Balancing Premarket and Postmarket Data Collection for Devices Subject to Premarket Approval:  Guidance for Industry and Food and Drug Administration Staff,04/13/2015,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket, Premarket, Premarket Approval (PMA)",Final,No,,FDA-2014-D-0090
CVM GFI #211 Residual Solvents in Animal Drug Products Questions and Answers,PDF (75.83 KB)PDF (75.83 KB) of CVM GFI #211 Residual Solvents in Animal Drug Products Questions and Answers,04/03/2015,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2010-D-0566
Abuse-Deterrent Opioids-Evaluation and Labeling,PDF (226.28 KB)PDF (226.28 KB) of Abuse-Deterrent Opioids-Evaluation and Labeling,04/02/2015,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2013-D-0045
Critical Path Innovation Meetings,PDF (68.37 KB)PDF (68.37 KB) of Critical Path Innovation Meetings,03/30/2015,,Administrative / Procedural,Final,No,,
Electronic Submission of Lot Distribution Reports:  Guidance for Industry,PDF (64.97 KB)PDF (64.97 KB) of Electronic Submission of Lot Distribution Reports:  Guidance for Industry,03/23/2015,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2014-D-1288
Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling :  Guidance for Industry and Food and Drug Administration Staff,PDF (804.72 KB)PDF (804.72 KB) of Reprocessing Medical Devices in Health Care Settings: Validation Methods and Labeling :  Guidance for Industry and Food and Drug Administration Staff,03/17/2015,Center for Devices and Radiological Health,"Premarket, 510(k), Premarket Approval (PMA), Investigational Device Exemption (IDE)",Final,No,,FDA-2011-D-0293
Small Entity Compliance Guide: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments,PDF (282.72 KB)PDF (282.72 KB) of Small Entity Compliance Guide: Nutrition Labeling of Standard Menu Items in Restaurants and Similar Retail Food Establishments,03/13/2015,Human Foods Program,"Labeling, Nutrition",Final,No,,FDA-2011-F-0172
CVM GFI #207 (VICH GL48) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs In Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods,PDF (303.03 KB)PDF (303.03 KB) of CVM GFI #207 (VICH GL48) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs In Food-Producing Animals: Marker Residue Depletion Studies to Establish Product Withdrawal Periods,03/09/2015,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2010-D-0166
CVM GFI #208 (VICH GL49) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies,PDF (290.89 KB)PDF (290.89 KB) of CVM GFI #208 (VICH GL49) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Validation of Analytical Methods Used in Residue Depletion Studies,03/09/2015,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2010-D-0165
"Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products:  Guidance for Industry","PDF (103.71 KB)PDF (103.71 KB) of Determining the Need for and Content of Environmental Assessments for Gene Therapies, Vectored Vaccines, and Related Recombinant Viral or Microbial Products:  Guidance for Industry",03/01/2015,Center for Biologics Evaluation and Research,Gene Therapy,Final,No,,FDA-2014-D-0663
Alcoholism:  Developing Drugs for Treatment,PDF (350.4 KB)PDF (350.4 KB) of Alcoholism:  Developing Drugs for Treatment,02/12/2015,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2015-D-0152
Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications:  Guidance for Industry and Food and Drug Administration Staff,PDF (141.95 KB)PDF (141.95 KB) of Safety Considerations to Mitigate the Risks of Misconnections with Small-bore Connectors Intended for Enteral Applications:  Guidance for Industry and Food and Drug Administration Staff,02/11/2015,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2012-D-0630
S10 Photosafety Evaluation of Pharmaceuticals,PDF (255.89 KB)PDF (255.89 KB) of S10 Photosafety Evaluation of Pharmaceuticals,01/27/2015,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2013-D-0068
DSCSA Implementation: Product Tracing Requirements — Compliance Policy,PDF (55.76 KB)PDF (55.76 KB) of DSCSA Implementation: Product Tracing Requirements — Compliance Policy,12/31/2014,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2014-D-2254
Minimizing Risk for Children's Toy Laser Products:   Guidance for Industry and Food and Drug Administration Staff,PDF (58.93 KB)PDF (58.93 KB) of Minimizing Risk for Children's Toy Laser Products:   Guidance for Industry and Food and Drug Administration Staff,12/19/2014,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2012-D-1092
"Providing Regulatory Submissions in Electronic Format — Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act","PDF (81.47 KB)PDF (81.47 KB) of Providing Regulatory Submissions in Electronic Format — Submissions Under Section 745A(a) of the Federal Food, Drug, and Cosmetic Act",12/18/2014,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2014-D-1953
"CPG Sec 540.275 (Draft) Crabmeat - Fresh and Frozen - Adulteration with Filth, Involving the Presence of Escherichia coli","PDF (53.66 KB)PDF (53.66 KB) of CPG Sec 540.275 (Draft) Crabmeat - Fresh and Frozen - Adulteration with Filth, Involving the Presence of Escherichia coli",12/16/2014,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Draft,No,,FDA-2014-D-1842
Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,PDF (91.12 KB)PDF (91.12 KB) of Patient Counseling Information Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,12/10/2014,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2013-D-1067
DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers,PDF (94.17 KB)PDF (94.17 KB) of DSCSA Implementation: Annual Reporting by Prescription Drug Wholesale Distributors and Third-Party Logistics Providers,12/09/2014,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-2014-D-2083
SUPAC: Manufacturing Equipment Addendum,PDF (212.88 KB)PDF (212.88 KB) of SUPAC: Manufacturing Equipment Addendum,12/02/2014,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Draft,No,,FDA-2013-D-0295
Infusion Pumps Total Product Life Cycle:  Guidance for Industry and FDA Staff,PDF (577.19 KB)PDF (577.19 KB) of Infusion Pumps Total Product Life Cycle:  Guidance for Industry and FDA Staff,12/02/2014,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2010-D-0194
Recommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex:  Guidance for Industry and Food and Drug Administration Staff,PDF (75.67 KB)PDF (75.67 KB) of Recommendations for Labeling Medical Products to Inform Users that the Product or Product Container is not Made with Natural Rubber Latex:  Guidance for Industry and Food and Drug Administration Staff,12/02/2014,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2013-D-0168
CPG Sec 540.700 Labeling of Processed and Blended Seafood Products Made Primarily with Fish Protein,PDF (17.8 KB)PDF (17.8 KB) of CPG Sec 540.700 Labeling of Processed and Blended Seafood Products Made Primarily with Fish Protein,12/01/2014,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture:  Final Guidance,PDF (390.87 KB)PDF (390.87 KB) of Changes to an Approved Application: Biological Products: Human Blood and Blood Components Intended for Transfusion or for Further Manufacture:  Final Guidance,12/01/2014,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-1999-D-3528
"Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act","PDF (71.02 KB)PDF (71.02 KB) of Registration for Human Drug Compounding Outsourcing Facilities Under Section 503B of the Federal Food, Drug, and Cosmetic Act",11/24/2014,Center for Drug Evaluation and Research,"Administrative / Procedural, Compounding",Final,No,,FDA-2013-N-1429
Design Considerations for Devices Intended for Home Use:  Guidance for Industry and Food and Drug Administration Staff,PDF (522.91 KB)PDF (522.91 KB) of Design Considerations for Devices Intended for Home Use:  Guidance for Industry and Food and Drug Administration Staff,11/24/2014,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2012-D-1161
Vaginal Microbicides:Development for the Prevention of HIV Infection PDF,PDF (352.3 KB)PDF (352.3 KB) of Vaginal Microbicides:Development for the Prevention of HIV Infection PDF,11/19/2014,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2012-D-1120
Molecular Diagnostic Instruments with Combined Functions:  Guidance for Industry and Food and Drug Administration Staff,PDF (424.7 KB)PDF (424.7 KB) of Molecular Diagnostic Instruments with Combined Functions:  Guidance for Industry and Food and Drug Administration Staff,11/12/2014,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Final,No,,FDA-2013-D-0258
Specification of the Unique Facility Identifier (UFI) System for Drug Establishment,PDF (61.12 KB)PDF (61.12 KB) of Specification of the Unique Facility Identifier (UFI) System for Drug Establishment,11/06/2014,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2013-D-0984
New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products,PDF (351.45 KB)PDF (351.45 KB) of New Chemical Entity Exclusivity Determinations for Certain Fixed-Combination Drug Products,10/16/2014,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2013-D-1675
Distinguishing Medical Device Recalls from Medical Device Enhancements:  Guidance for Industry and Food and Drug Administration Staff,PDF (359.71 KB)PDF (359.71 KB) of Distinguishing Medical Device Recalls from Medical Device Enhancements:  Guidance for Industry and Food and Drug Administration Staff,10/15/2014,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2013-D-0114
CVM GFI #143 (VICH GL30) Pharmacovigilance of Veterinary Medicinal Products: Controlled List of Terms,PDF (149.17 KB)PDF (149.17 KB) of CVM GFI #143 (VICH GL30) Pharmacovigilance of Veterinary Medicinal Products: Controlled List of Terms,10/09/2014,Center for Veterinary Medicine,"Adverse Event Reporting, VICH",Final,No,,FDA-2002-D-0268
CVM GFI #224 (Supplement to VICH GL52) Supplemental Examples For Illustrating Statistical Concepts Described in the VICH In Vivo Bioequivalence Guidance GL52,PDF (131.25 KB)PDF (131.25 KB) of CVM GFI #224 (Supplement to VICH GL52) Supplemental Examples For Illustrating Statistical Concepts Described in the VICH In Vivo Bioequivalence Guidance GL52,09/24/2014,Center for Veterinary Medicine,"Generic Animal Drugs, Generic Drugs, New Animal Drug Application (NADA), VICH",Final,No,11/24/2014,FDA-2014-D-1352
Custom Device Exemption:  Guidance for Industry and Food and Drug Administration Staff,PDF (521.97 KB)PDF (521.97 KB) of Custom Device Exemption:  Guidance for Industry and Food and Drug Administration Staff,09/24/2014,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2013-D-1601
Highly Multiplexed Microbiological/Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (798.55 KB)PDF (798.55 KB) of Highly Multiplexed Microbiological/Medical Countermeasure In Vitro Nucleic Acid Based Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,08/27/2014,Center for Devices and Radiological Health,"Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2012-D-1057
Evaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff,PDF (940.93 KB)PDF (940.93 KB) of Evaluation of Sex-Specific Data in Medical Device Clinical Studies - Guidance for Industry and Food and Drug Administration Staff,08/22/2014,Center for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP)",Final,No,,FDA-2011-D-0817
"Unique Device Identifier System: Frequently Asked Questions, Vol. 1 :  Guidance for Industry and Food and Drug Administration Staff","PDF (462.01 KB)PDF (462.01 KB) of Unique Device Identifier System: Frequently Asked Questions, Vol. 1 :  Guidance for Industry and Food and Drug Administration Staff",08/20/2014,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Labeling, UDI",Final,No,,FDA-2020-D-0957
"FDA Decisions for Investigational Device Exemption Clinical Investigations:  Guidance for Sponsors, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff","PDF (630.79 KB)PDF (630.79 KB) of FDA Decisions for Investigational Device Exemption Clinical Investigations:  Guidance for Sponsors, Clinical Investigators, Institutional Review Boards, and Food and Drug Administration Staff",08/19/2014,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE)",Final,No,,FDA-2011-D-0790
Immunogenicity Assessment for Therapeutic Protein Products,PDF (241.55 KB)PDF (241.55 KB) of Immunogenicity Assessment for Therapeutic Protein Products,08/14/2014,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Clinical - Medical, Pharmaceutical Quality",Final,No,,FDA-2013-D-0092
Unique Device Identification System: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,PDF (419.86 KB)PDF (419.86 KB) of Unique Device Identification System: Small Entity Compliance Guide:  Guidance for Industry and Food and Drug Administration Staff,08/13/2014,Center for Devices and Radiological Health,Labeling,Final,No,,FDA-2011-D-0790
Upper Facial Lines:  Developing Botulinum Toxin Drug Products,,08/06/2014,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2014-D-0968
In Vitro Companion Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,PDF (159.23 KB)PDF (159.23 KB) of In Vitro Companion Diagnostic Devices:  Guidance for Industry and Food and Drug Administration Staff,08/06/2014,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2011-D-0215
Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act,PDF (99.35 KB)PDF (99.35 KB) of Reference Product Exclusivity for Biological Products Filed Under Section 351(a) of the PHS Act,08/04/2014,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Biosimilars",Draft,No,,FDA-2013-D-1165
CVM GFI #200 SECG for Designation of New Animal Drugs for Minor Uses or Minor Species,PDF (71.19 KB)PDF (71.19 KB) of CVM GFI #200 SECG for Designation of New Animal Drugs for Minor Uses or Minor Species,07/29/2014,Center for Veterinary Medicine,Minor Use/ Minor Species (MUMS),Final,No,,FDA-2010-D-0432
CVM GFI #201 SECG for The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species,PDF (72.54 KB)PDF (72.54 KB) of CVM GFI #201 SECG for The Index of Legally Marketed Unapproved New Animal Drugs for Minor Species,07/29/2014,Center for Veterinary Medicine,Minor Use/ Minor Species (MUMS),Final,No,,FDA-2010-D-0435
The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]:  Guidance for Industry and Food and Drug Administration Staff,PDF (843.9 KB)PDF (843.9 KB) of The 510(k) Program: Evaluating Substantial Equivalence in Premarket Notifications [510(k)]:  Guidance for Industry and Food and Drug Administration Staff,07/28/2014,Center for Devices and Radiological Health,"Premarket, 510(k), Administrative / Procedural",Final,No,,FDA-2011-D-0652
Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act,PDF (113.9 KB)PDF (113.9 KB) of Reporting Drug Sample Information Under Section 6004 of the Affordable Care Act,07/11/2014,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Draft,No,,FDA-2014-D-0829
Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention,PDF (364.01 KB)PDF (364.01 KB) of Neglected Tropical Diseases of the Developing World: Developing Drugs for Treatment or Prevention,07/07/2014,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2011-D-0587
"Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance","PDF (84.64 KB)PDF (84.64 KB) of Pharmacy Compounding of Human Drug Products Under Section 503A of the Federal Food, Drug, and Cosmetic Act Guidance",07/02/2014,Center for Drug Evaluation and Research,"Administrative / Procedural, Compounding",Final,No,,FDA-2013-D-1444
"Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that Are Color Additives","PDF (201.31 KB)PDF (201.31 KB) of Guidance for Industry: Assessing the Effects of Significant Manufacturing Process Changes, Including Emerging Technologies, on the Safety and Regulatory Status of Food Ingredients and Food Contact Substances, Including Food Ingredients that Are Color Additives",06/27/2014,Human Foods Program,"Food & Color Additives, Ingredients, Food Contact Substances (FCS)",Final,No,,FDA-2011-D-0490
Small Entity Compliance Guide: Gluten-Free Labeling of Foods,PDF (78.21 KB)PDF (78.21 KB) of Small Entity Compliance Guide: Gluten-Free Labeling of Foods,06/26/2014,Human Foods Program,"Allergens, Labeling",Final,No,,FDA-2005-N-0404
Guidance for Industry: Safety of Nanomaterials in Cosmetic Products,PDF (130.65 KB)PDF (130.65 KB) of Guidance for Industry: Safety of Nanomaterials in Cosmetic Products,06/24/2014,"Office of the Commissioner,Office of the Chief Scientist",,Final,No,,FDA-2011-D-0489
Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology:  Guidance for Industry,PDF (111.45 KB)PDF (111.45 KB) of Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology:  Guidance for Industry,06/23/2014,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","Premarket, Food & Color Additives, Records",Final,No,,FDA-2010-D-0530
Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices - Guidance for Industry and Food and Drug Administration Staff,PDF (77.94 KB)PDF (77.94 KB) of Criteria for Significant Risk Investigations of Magnetic Resonance Diagnostic Devices - Guidance for Industry and Food and Drug Administration Staff,06/19/2014,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Drug Master Files: Guidelines,,06/18/2014,Center for Drug Evaluation and Research,Pharmaceutical Quality,Final,No,,FDA-2014-D-0397
Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices,,06/18/2014,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Advertising,Draft,No,,FDA-2014-D-0397
Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices,PDF (176.42 KB)PDF (176.42 KB) of Internet/Social Media Platforms with Character Space Limitations— Presenting Risk and Benefit Information for Prescription Drugs and Medical Devices,06/18/2014,Center for Drug Evaluation and Research,Advertising,Draft,No,,FDA-2014-D-0397
Q4B Annex 6: Uniformity of Dosage Units General Chapter,PDF (53.18 KB)PDF (53.18 KB) of Q4B Annex 6: Uniformity of Dosage Units General Chapter,06/16/2014,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2009-D-0011
Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products—Recommended Practices,PDF (94.88 KB)PDF (94.88 KB) of Distributing Scientific and Medical Publications on Risk Information for Approved Prescription Drugs and Biological Products—Recommended Practices,06/11/2014,Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-2014-D-0758
"Guidance for Industry: Demonstration of the Quality Factor Requirements Under 21 CFR 106.96(i) for ""Eligible"" Infant Formulas","PDF (135.65 KB)PDF (135.65 KB) of Guidance for Industry: Demonstration of the Quality Factor Requirements Under 21 CFR 106.96(i) for ""Eligible"" Infant Formulas",06/10/2014,Human Foods Program,Infant Formula & Foods,Final,No,,FDA-2014-D-0033
CPG Sec 100.250 Food Facility Registration (Human and Animal Food),PDF (98.12 KB)PDF (98.12 KB) of CPG Sec 100.250 Food Facility Registration (Human and Animal Food),06/01/2014,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,FDA-2013-D-0126
Expedited Programs for Serious Conditions | Drugs and Biologics,PDF (494.14 KB)PDF (494.14 KB) of Expedited Programs for Serious Conditions | Drugs and Biologics,05/30/2014,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2013-D-0575
CVM GFI #79 Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by CVM,PDF (139.26 KB)PDF (139.26 KB) of CVM GFI #79 Dispute Resolution Procedures for Science-Based Decisions on Products Regulated by CVM,05/29/2014,Center for Veterinary Medicine,Administrative / Procedural,Final,No,,FDA-2003-D-0307
"Considerations When Transferring Clinical Investigation Oversight to Another IRB:  Guidance for IRBs, Clinical Investigators, and Sponsors","PDF (157.26 KB)PDF (157.26 KB) of Considerations When Transferring Clinical Investigation Oversight to Another IRB:  Guidance for IRBs, Clinical Investigators, and Sponsors",05/23/2014,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research",Good Clinical Practice (GCP),Final,No,,FDA-2011-D-0835
"ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers","PDF (124.21 KB)PDF (124.21 KB) of ANDAs: Stability Testing of Drug Substances and Products, Questions and Answers",05/15/2014,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2014-D-0547
CVM GFI #219 (VICH GL51) Statistical Evaluation of Stability Data,PDF (221.15 KB)PDF (221.15 KB) of CVM GFI #219 (VICH GL51) Statistical Evaluation of Stability Data,05/13/2014,Center for Veterinary Medicine,VICH,Final,No,,FDA-2012-D-0288
Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia:  Developing Drugs for Treatment,PDF (119.83 KB)PDF (119.83 KB) of Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia:  Developing Drugs for Treatment,05/06/2014,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2010-D-0589
Providing Information about Pediatric Uses of Medical Devices:  Guidance for Industry and FDA Staff,PDF (370.53 KB)PDF (370.53 KB) of Providing Information about Pediatric Uses of Medical Devices:  Guidance for Industry and FDA Staff,05/01/2014,Center for Devices and Radiological Health,"Premarket, Pediatric Product Development",Final,No,,FDA-2013-D-0117
"Guidance for Industry: FDA Records Access Authority Under Sections 414 and 704 of the Federal Food, Drug, & Cosmetic Act","PDF (82.97 KB)PDF (82.97 KB) of Guidance for Industry: FDA Records Access Authority Under Sections 414 and 704 of the Federal Food, Drug, & Cosmetic Act",04/04/2014,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,Records,Final,No,,FDA-2011-D-0674
Small Entity Compliance Guide: What You Need to Know About Establishment and Maintenance of Records,PDF (90.59 KB)PDF (90.59 KB) of Small Entity Compliance Guide: What You Need to Know About Establishment and Maintenance of Records,04/04/2014,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,Records,Final,No,,FDA-2013-N-1421
Types of Communication During the Review of Medical Device Submissions:  Guidance for Industry and FDA Staff,PDF (133.87 KB)PDF (133.87 KB) of Types of Communication During the Review of Medical Device Submissions:  Guidance for Industry and FDA Staff,04/04/2014,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2013-D-0147
"CPG Sec 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products- Hypoglycin A Toxin","PDF (17.18 KB)PDF (17.18 KB) of CPG Sec 550.050 Canned Ackee, Frozen Ackee, and Other Ackee Products- Hypoglycin A Toxin",04/01/2014,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations,PDF (88.18 KB)PDF (88.18 KB) of Interpreting Sameness of Monoclonal Antibody Products Under the Orphan Drug Regulations,04/01/2014,Center for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1999-D-0178
"The Meaning of ""Spouse"" and ""Family"" in FDA's Regulations after the Supreme Court's Ruling in United States v. Windsor: Questions and Answers:  Guidance for Industry, Consumers, and FDA Staff","PDF (37.72 KB)PDF (37.72 KB) of The Meaning of ""Spouse"" and ""Family"" in FDA's Regulations after the Supreme Court's Ruling in United States v. Windsor: Questions and Answers:  Guidance for Industry, Consumers, and FDA Staff",03/31/2014,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","Administrative / Procedural, Food & Color Additives",Final,No,,FDA-2014-D-0261
Medical Device Tracking :  Guidance for Industry and FDA Staff,PDF (291.45 KB)PDF (291.45 KB) of Medical Device Tracking :  Guidance for Industry and FDA Staff,03/27/2014,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Premarket Assessment of Pediatric Medical Devices:  Guidance for Industry and FDA Staff,PDF (161.96 KB)PDF (161.96 KB) of Premarket Assessment of Pediatric Medical Devices:  Guidance for Industry and FDA Staff,03/24/2014,Center for Devices and Radiological Health,"Premarket, Pediatric Product Development",Final,No,,FDA-2003-D-0367
Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations,PDF (804.84 KB)PDF (804.84 KB) of Bioavailability and Bioequivalence Studies Submitted in NDAs or INDs — General Considerations,03/18/2014,Center for Drug Evaluation and Research,Biopharmaceutics,Draft,No,,FDA-2014-D-0204
Chronic Fatigue Syndrome/Myalgic Encephalomyelitis:  Developing Drug Products for Treatment,PDF (337.45 KB)PDF (337.45 KB) of Chronic Fatigue Syndrome/Myalgic Encephalomyelitis:  Developing Drug Products for Treatment,03/11/2014,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2014-D-0264
CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports,PDF (298.36 KB)PDF (298.36 KB) of CMC Postapproval Manufacturing Changes To Be Documented in Annual Reports,03/05/2014,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2010-D-0283
"BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry","PDF (378.54 KB)PDF (378.54 KB) of BLA for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry",03/01/2014,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2006-D-0157
"IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry and FDA Staff","PDF (119.68 KB)PDF (119.68 KB) of IND Applications for Minimally Manipulated, Unrelated Allogeneic Placental/Umbilical Cord Blood Intended for Hematopoietic and Immunologic Reconstitution in Patients with Disorders Affecting the Hematopoietic System:  Guidance for Industry and FDA Staff",03/01/2014,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2009-D-0490
Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6/2/06,PDF (166.83 KB)PDF (166.83 KB) of Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV-1 Resistance Data: Attachment to the Guidance: Draft Draft Guidance: This draft guidance updates the final guidance posted 6/2/06,02/28/2014,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Draft,No,,FDA-2014-D-0180
"Public Availability of Advisory Committee Members' Financial Interest Information and Waivers:  Guidance for the Public, FDA Advisory Committee Members, and FDA Staff","PDF (93.78 KB)PDF (93.78 KB) of Public Availability of Advisory Committee Members' Financial Interest Information and Waivers:  Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",02/28/2014,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy","Advisory Committees, Food & Color Additives",Final,No,,
The Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification,PDF (1.65 MB)PDF (1.65 MB) of The Electronic Transmission of Individual Case Safety Reports Implementation Guide — Data Elements and Message Specification,02/27/2014,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,
"Questions and Answers about eMDR - Electronic Medical Device Reporting - Guidance for Industry, User Facilities and FDA Staff","PDF (147.41 KB)PDF (147.41 KB) of Questions and Answers about eMDR - Electronic Medical Device Reporting - Guidance for Industry, User Facilities and FDA Staff",02/13/2014,Center for Devices and Radiological Health,"Adverse Event Reporting System (FAERS), Adverse Event Reporting",Final,No,,FDA-2008-N-0393
Providing Regulatory Submissions in Electronic Format--Receipt Date:  Guidance for Industry,PDF (218.46 KB)PDF (218.46 KB) of Providing Regulatory Submissions in Electronic Format--Receipt Date:  Guidance for Industry,02/10/2014,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2007-D-0077
"Guidance for Industry: Considerations Regarding Substances Added to Foods, Including Beverages and Dietary Supplements","PDF (108.06 KB)PDF (108.06 KB) of Guidance for Industry: Considerations Regarding Substances Added to Foods, Including Beverages and Dietary Supplements",01/14/2014,Human Foods Program,Ingredients,Final,No,,FDA-2009-D-0542
Guidance for Industry: Distinguishing Liquid Dietary Supplements from Beverages,PDF (202.31 KB)PDF (202.31 KB) of Guidance for Industry: Distinguishing Liquid Dietary Supplements from Beverages,01/14/2014,Human Foods Program,,Final,No,,FDA-2009-D-0542
Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics,PDF (117.65 KB)PDF (117.65 KB) of Fulfilling Regulatory Requirements for Postmarketing Submissions of Interactive Promotional Media for Prescription Human and Animal Drugs and Biologics,01/14/2014,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Antimicrobial Resistance,Draft,No,,FDA-2013-N-1430
Community-Acquired Bacterial Pneumonia:  Developing Drugs for Treatment,PDF (166.24 KB)PDF (166.24 KB) of Community-Acquired Bacterial Pneumonia:  Developing Drugs for Treatment,01/10/2014,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2009-D-0136
Attachement - Qualification Process for Drug Development Tools: Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease,PDF (79.89 KB)PDF (79.89 KB) of Attachement - Qualification Process for Drug Development Tools: Qualification of Exacerbations of Chronic Pulmonary Disease Tool for Measurement of Symptoms of Acute Bacterial Exacerbation of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease,01/10/2014,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2013-D-1630
Dear Health Care Provider Letters: Improving Communication of Important Safety Information,PDF (340.42 KB)PDF (340.42 KB) of Dear Health Care Provider Letters: Improving Communication of Important Safety Information,01/02/2014,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2010-D-0319
Guidance for Industry: Dear Manufacturer Letter Regarding Changes to FDA's Administration of Process Filings (Forms FDA 2541a and FDA 2541c) for Acidified Foods and Low-Acid Canned Foods,PDF (104.95 KB)PDF (104.95 KB) of Guidance for Industry: Dear Manufacturer Letter Regarding Changes to FDA's Administration of Process Filings (Forms FDA 2541a and FDA 2541c) for Acidified Foods and Low-Acid Canned Foods,12/31/2013,Human Foods Program,Canned Foods,Final,No,,
CVM GFI #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,PDF (115.35 KB)PDF (115.35 KB) of CVM GFI #213 New Animal Drugs and New Animal Drug Combination Products Administered in or on Medicated Feed or Drinking Water of Food-Producing Animals: Recommendations for Drug Sponsors for Voluntarily Aligning Product Use Conditions with GFI #209,12/12/2013,Center for Veterinary Medicine,"Antimicrobial Resistance, New Animal Drug Application (NADA)",Final,No,,FDA-2011-D-0889
FDA's Strategy on Antimicrobial Resistance - Questions and Answers,,12/10/2013,Center for Veterinary Medicine,Antimicrobial Resistance,Final,No,,FDA-2010-D-0094
"CPG Sec. 460.200 Pharmacy Compounding (Withdrawn December 4, 2013)",,12/03/2013,,"Investigation & Enforcement,",Final,No,,
Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only:  Guidance for Industry and FDA Staff,PDF (195.23 KB)PDF (195.23 KB) of Distribution of In Vitro Diagnostic Products Labeled for Research Use Only or Investigational Use Only:  Guidance for Industry and FDA Staff,11/25/2013,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Good Clinical Practice (GCP), Investigational Device Exemption (IDE), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2011-D-0305
"Design Considerations for Pivotal Clinical Investigations for Medical Devices:  Guidance for Industry, Clinical Investigators, Institutional Review Boards and FDA Staff","PDF (402.07 KB)PDF (402.07 KB) of Design Considerations for Pivotal Clinical Investigations for Medical Devices:  Guidance for Industry, Clinical Investigators, Institutional Review Boards and FDA Staff",11/07/2013,Center for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP), Investigational Device Exemption (IDE)",Final,No,,FDA-2011-D-0567
Preclinical Assessment of Investigational Cellular and Gene Therapy Products:  Guidance for Industry,PDF (165.31 KB)PDF (165.31 KB) of Preclinical Assessment of Investigational Cellular and Gene Therapy Products:  Guidance for Industry,11/01/2013,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2012-D-1038
Acute Bacterial Skin and Skin Structure Infections:  Developing Drugs for Treatment,PDF (266.74 KB)PDF (266.74 KB) of Acute Bacterial Skin and Skin Structure Infections:  Developing Drugs for Treatment,10/23/2013,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2013-D-1181
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions: Annex 14: Bacterial Endotoxins Test General Chapter,PDF (96.23 KB)PDF (96.23 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions: Annex 14: Bacterial Endotoxins Test General Chapter,10/23/2013,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2010-D-0343
"Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies:  Guidance for Industry and Food and Drug Administration Staff","PDF (1.34 MB)PDF (1.34 MB) of Investigational Device Exemptions (IDEs) for Early Feasibility Medical Device Clinical Studies, Including Certain First in Human (FIH) Studies:  Guidance for Industry and Food and Drug Administration Staff",10/01/2013,Center for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP), Investigational Device Exemption (IDE)",Final,No,,FDA-2011-D-0787
CVM GFI #223 Small Entity Compliance Guide Declaring Color Additives in Animal Foods,PDF (47.67 KB)PDF (47.67 KB) of CVM GFI #223 Small Entity Compliance Guide Declaring Color Additives in Animal Foods,09/27/2013,Center for Veterinary Medicine,Animal Feed,Final,No,,FDA-2013-D-1088
Electronic Source Data in Clinical Investigations:  Guidance for Industry,PDF (190.31 KB)PDF (190.31 KB) of Electronic Source Data in Clinical Investigations:  Guidance for Industry,09/18/2013,Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2010-D-0643
"Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND:  Guidance for Clinical Investigators, Sponsors, and IRBs","PDF (305.09 KB)PDF (305.09 KB) of Investigational New Drug Applications (INDs) - Determining Whether Human Research Studies Can Be Conducted Without an IND:  Guidance for Clinical Investigators, Sponsors, and IRBs",09/10/2013,Human Foods ProgramCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,FDA-2010-D-0503
Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act,PDF (192.6 KB)PDF (192.6 KB) of Guidance for Industry: Questions and Answers Regarding Adverse Event Reporting and Recordkeeping for Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act,09/01/2013,Human Foods Program,Adverse Event Reporting,Final,No,,FDA-2007-D-0372
"IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed:  Guidance for IRBs, Clinical Investigators, and Sponsors","PDF (47.44 KB)PDF (47.44 KB) of IRB Responsibilities for Reviewing the Qualifications of Investigators, Adequacy of Research Sites, and the Determination of Whether an IND/IDE is Needed:  Guidance for IRBs, Clinical Investigators, and Sponsors",08/27/2013,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and Research","Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2012-D-0847
Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents:  Guidance for Industry,PDF (288.44 KB)PDF (288.44 KB) of Compliance with Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco To Protect Children and Adolescents:  Guidance for Industry,08/22/2013,Center for Tobacco Products,"Cigarettes, Smokeless, Snuff, Chewing",Final,No,08/22/2013,FDA-2010-D-0277
Radio Frequency Wireless Technology in Medical Devices - Guidance for Industry and FDA Staff,PDF (138.76 KB)PDF (138.76 KB) of Radio Frequency Wireless Technology in Medical Devices - Guidance for Industry and FDA Staff,08/14/2013,Center for Devices and Radiological Health,"Premarket, Digital Health",Final,No,,FDA-2006-D-0300
Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring:  Guidance for Industry,PDF (382.77 KB)PDF (382.77 KB) of Oversight of Clinical Investigations — A Risk-Based Approach to Monitoring:  Guidance for Industry,08/07/2013,"Office of Inspections and InvestigationsCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","Investigation & Enforcement, Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2011-D-0597
"Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act","PDF (117.89 KB)PDF (117.89 KB) of Safety Labeling Changes -- Implementation of Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act",07/30/2013,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Device & Drug Safety,Final,No,,FDA-2011-D-0164
Providing Submissions in Electronic Format – Postmarket Non-Expedited ICSRs Technical Questions and Answers,PDF (103.51 KB)PDF (103.51 KB) of Providing Submissions in Electronic Format – Postmarket Non-Expedited ICSRs Technical Questions and Answers,07/24/2013,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2013-D-0755
CPG Sec  690.800 Compliance Policy Guide Salmonella in Food for Animals,PDF (42.07 KB)PDF (42.07 KB) of CPG Sec  690.800 Compliance Policy Guide Salmonella in Food for Animals,07/01/2013,Center for Veterinary Medicine,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2010-D-0378
Heparin for Drug and Medical Device Use:  Monitoring Crude Heparin for Quality:  Guidance for Industry,PDF (66.18 KB)PDF (66.18 KB) of Heparin for Drug and Medical Device Use:  Monitoring Crude Heparin for Quality:  Guidance for Industry,06/25/2013,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Devices and Radiological Health,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2012-D-0083
ANDAs: Stability Testing of Drug Substances and Products,PDF (30.34 KB)PDF (30.34 KB) of ANDAs: Stability Testing of Drug Substances and Products,06/20/2013,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2012-D-0938
Codevelopment of Two or More New Investigational Drugs for Use in Combination,PDF (91.31 KB)PDF (91.31 KB) of Codevelopment of Two or More New Investigational Drugs for Use in Combination,06/14/2013,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2010-D-0616
"Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff","PDF (152.84 KB)PDF (152.84 KB) of Technical Considerations for Pen, Jet, and Related Injectors Intended for Use with Drugs and Biological Products:  Guidance for Industry and FDA Staff",06/07/2013,"Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products","Administrative / Procedural, Combination Products",Final,No,,FDA-2009-D-0179
Draft Guidance for Industry: Cosmetic Good Manufacturing Practices,PDF (77.92 KB)PDF (77.92 KB) of Draft Guidance for Industry: Cosmetic Good Manufacturing Practices,06/01/2013,"Office of the Commissioner,Office of the Chief Scientist",Current Good Manufacturing Practice (CGMP),Draft,No,,
Rheumatoid Arthritis: Developing Drug Products for Treatment,PDF (176.46 KB)PDF (176.46 KB) of Rheumatoid Arthritis: Developing Drug Products for Treatment,05/31/2013,Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Clinical - Medical,Draft,No,,FDA-2013-D-0571
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Annex 13: Bulk Density and Tapped Density of Powders General Chapter,PDF (93.51 KB)PDF (93.51 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Annex 13: Bulk Density and Tapped Density of Powders General Chapter,05/28/2013,Center for Drug Evaluation and Research,ICH-Quality,Final,No,,
Annex 13 Bulk Density and Tapped Density of Powders General Chapter,PDF (93.51 KB)PDF (93.51 KB) of Annex 13 Bulk Density and Tapped Density of Powders General Chapter,05/23/2013,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,,Final,No,,
"The Open Public Hearing at FDA Advisory Committee Meetings:  Guidance for the Public, FDA Advisory Committee Members, and FDA Staff","PDF (68.71 KB)PDF (68.71 KB) of The Open Public Hearing at FDA Advisory Committee Meetings:  Guidance for the Public, FDA Advisory Committee Members, and FDA Staff",05/15/2013,Office of the Commissioner,"Advisory Committees, Food & Color Additives",Final,No,,
Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets,PDF (501.28 KB)PDF (501.28 KB) of Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets,05/14/2013,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,FDA-2011-D-0057
Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff,PDF (1.21 MB)PDF (1.21 MB) of Assay Migration Studies for In Vitro Diagnostic Devices:  Guidance for Industry and FDA Staff,04/25/2013,Center for Devices and Radiological Health,"Premarket, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2008-D-0642
Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination:  Guidance for Industry,PDF (70.18 KB)PDF (70.18 KB) of Non-Penicillin Beta-Lactam Drugs: A CGMP Framework for Preventing Cross-Contamination:  Guidance for Industry,04/17/2013,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2011-D-0104
Self-Selection Studies for Nonprescription Drug Products,PDF (159.78 KB)PDF (159.78 KB) of Self-Selection Studies for Nonprescription Drug Products,04/11/2013,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2011-D-0620
Medical Device Classification Product Codes - Guidance for Industry and Food and Drug Administration Staff,PDF (268.79 KB)PDF (268.79 KB) of Medical Device Classification Product Codes - Guidance for Industry and Food and Drug Administration Staff,04/10/2013,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2011-D-0916
Blood Establishment Computer System Validation in the User's Facility:  Guidance for Industry,PDF (65.58 KB)PDF (65.58 KB) of Blood Establishment Computer System Validation in the User's Facility:  Guidance for Industry,04/01/2013,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2007-D-0069
"Exception from Informed Consent Requirements for Emergency Research:  Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors","PDF (340.91 KB)PDF (340.91 KB) of Exception from Informed Consent Requirements for Emergency Research:  Guidance for Institutional Review Boards, Clinical Investigators, and Sponsors",04/01/2013,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research",Good Clinical Practice (GCP),Final,No,,FDA-2006-D-0464
Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4: Draft Guidance for Industry and FDA Staff,PDF (178.04 KB)PDF (178.04 KB) of Glass Syringes for Delivering Drug and Biological Products: Technical Information to Supplement International Organization for Standardization (ISO) Standard 11040-4: Draft Guidance for Industry and FDA Staff,03/31/2013,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Draft,No,07/01/2013,FDA-2013-D-0362
Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi - Guidance for Industry and FDA Staff,PDF (177.73 KB)PDF (177.73 KB) of Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection of Antibodies to Borrelia burgdorferi - Guidance for Industry and FDA Staff,03/27/2013,Center for Devices and Radiological Health,"Premarket, Laboratory Tests",Final,No,,FDA-2008-D-0095
M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers,PDF (311.38 KB)PDF (311.38 KB) of M3(R2)Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals: Questions and Answers,03/13/2013,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2008-D-0470
"Tablet Scoring:Nomenclature, Labeling, and Data for Evaluation","PDF (55.61 KB)PDF (55.61 KB) of Tablet Scoring:Nomenclature, Labeling, and Data for Evaluation",03/13/2013,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2011-D-0595
Small Entity Compliance Guide: What You Need To Know About Administrative Detention of Foods,PDF (80.88 KB)PDF (80.88 KB) of Small Entity Compliance Guide: What You Need To Know About Administrative Detention of Foods,03/08/2013,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,,Final,No,,FDA-2011-D-0643
Investigational Device Exemption (IDE) Guidance for Retinal Prostheses:  Guidance for Industry and FDA  Staff,PDF (168.79 KB)PDF (168.79 KB) of Investigational Device Exemption (IDE) Guidance for Retinal Prostheses:  Guidance for Industry and FDA  Staff,03/06/2013,Center for Devices and Radiological Health,"Investigational Device Exemption (IDE), Ophthalmic",Final,No,,FDA-2009-D-0010
Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff,PDF (146.08 KB)PDF (146.08 KB) of Pulse Oximeters - Premarket Notification Submissions [510(k)s]: Guidance for Industry and Food and Drug Administration Staff,03/03/2013,Center for Devices and Radiological Health,"Premarket, Pediatric Product Development",Final,No,,FDA-2007-D-0205
Labeling for Human Prescription Drug and Biological Products - Implementing the PLR Content and Format Requirements,PDF (526.69 KB)PDF (526.69 KB) of Labeling for Human Prescription Drug and Biological Products - Implementing the PLR Content and Format Requirements,02/25/2013,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2005-D-0153
Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency Guidance for Submitting HCV Resistance Data -Attachment to Guidance,PDF (391.28 KB)PDF (391.28 KB) of Antiviral Product Development — Conducting and Submitting Virology Studies to the Agency Guidance for Submitting HCV Resistance Data -Attachment to Guidance,02/25/2013,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Draft,No,,FDA-2005-D-0282
Clinical Study Designs for Surgical Ablation Devices for Treatment of Atrial Fibrillation - Guidance for Industry and Food and Drug Administration Staff,PDF (169.08 KB)PDF (169.08 KB) of Clinical Study Designs for Surgical Ablation Devices for Treatment of Atrial Fibrillation - Guidance for Industry and Food and Drug Administration Staff,02/14/2013,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","Premarket,",Final,No,,FDA-2009-D-0395
CPG Sec. 390.225 Early Defects or Noncompliance - 21 CFR 1004.6,,02/03/2013,Center for Devices and Radiological Health,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
"Financial Disclosure by Clinical Investigators:  Guidance for Clinical Investigators, Industry,and FDA Staff","PDF (165.38 KB)PDF (165.38 KB) of Financial Disclosure by Clinical Investigators:  Guidance for Clinical Investigators, Industry,and FDA Staff",02/01/2013,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Good Clinical Practice (GCP), Investigational Device Exemption (IDE)",Final,No,,FDA-1999-D-0742
E3 Structure and Content of Clinical Study Reports - Questions and Answers (R1),PDF (141.13 KB)PDF (141.13 KB) of E3 Structure and Content of Clinical Study Reports - Questions and Answers (R1),01/29/2013,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,
Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling,PDF (130.55 KB)PDF (130.55 KB) of Clinical Pharmacogenomics: Premarket Evaluation in Early-Phase Clinical Studies and Recommendations for Labeling,01/28/2013,Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Clinical - Medical, Clinical - Pharmacology",Final,No,,FDA-2011-D-0082
"Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA: Draft Guidance for Industry and FDA Staff","PDF (101.18 KB)PDF (101.18 KB) of Submissions for Postapproval Modifications to a Combination Product Approved Under a BLA, NDA, or PMA: Draft Guidance for Industry and FDA Staff",01/18/2013,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Draft,No,04/01/2013,FDA-2012-D-1240
Guidance for Industry: Food Labeling Guide,PDF (8.53 MB)PDF (8.53 MB) of Guidance for Industry: Food Labeling Guide,01/01/2013,Human Foods Program,"Labeling, Nutrition Label",Final,No,,
Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies:  Guidance for Industry and Investigators,PDF (227.49 KB)PDF (227.49 KB) of Safety Reporting Requirements for INDs (Investigational New Drug Applications) and BA/BE (Bioavailability/Bioequivalence) Studies:  Guidance for Industry and Investigators,12/20/2012,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Generic Drugs, Good Clinical Practice (GCP), Safety - Issues, Errors, and Problems",Final,No,,FDA-2010-D-0482
Safety Reporting Requirements for INDs and BA/BE Studies:  Guidance for Industry and Investigators,PDF (35.12 KB)PDF (35.12 KB) of Safety Reporting Requirements for INDs and BA/BE Studies:  Guidance for Industry and Investigators,12/20/2012,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Generic Drugs, Good Clinical Practice (GCP), Safety - Issues, Errors, and Problems",Final,No,,FDA-2010-D-0482
Labeling and Effectiveness Testing: Sunscreen Drug Products for Over-The-Counter Human Use — Small Entity Compliance Guide:  Guidance for Industry,,12/06/2012,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,
Limiting the Use of Certain Phthalates as Excipients in CDER-Regulated Products:  Guidance for Industry,,12/06/2012,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2012-D-1135
FDA Oversight of PET Drug Products -- Questions and Answers,PDF (498.96 KB)PDF (498.96 KB) of FDA Oversight of PET Drug Products -- Questions and Answers,12/03/2012,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs,PDF (368.85 KB)PDF (368.85 KB) of Investigational New Drug Applications for Positron Emission Tomography (PET) Drugs,12/03/2012,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2012-D-0081
CVM GFI #217 Evaluating the Effectiveness of Anticoccidial Drugs in Food-Producing Animals,PDF (180.91 KB)PDF (180.91 KB) of CVM GFI #217 Evaluating the Effectiveness of Anticoccidial Drugs in Food-Producing Animals,11/20/2012,Center for Veterinary Medicine,Target Animal – Effectiveness,Final,No,,FDA-2011-D-0784
Q11 Development and Manufacture of Drug Substances,PDF (708.32 KB)PDF (708.32 KB) of Q11 Development and Manufacture of Drug Substances,11/20/2012,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,
"Labeling for Bronchodilators: Cold, Cough, Allergy, Bronchodilator, And Antiasthmatic Drug Products for Over-the-Counter Human Use (Small Entity Compliance Guide):  Guidance for Industry",,11/15/2012,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,
The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems:  Guidance for Industry and Food and Drug Administration Staff,PDF (688.74 KB)PDF (688.74 KB) of The Content of Investigational Device Exemption (IDE) and Premarket Approval (PMA) Applications for Artificial Pancreas Device Systems:  Guidance for Industry and Food and Drug Administration Staff,11/09/2012,Center for Devices and Radiological Health,"Premarket, Premarket Approval (PMA), Investigational Device Exemption (IDE)",Final,No,,FDA-2011-D-0464
Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect - 21 CFR 1003.11,PDF (44.63 KB)PDF (44.63 KB) of Compliance Policy Guide Sec. 390.200 Determination by Secretary that Product Fails to Comply or has Defect - 21 CFR 1003.11,11/01/2012,Center for Devices and Radiological Health,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
CPG Sec. 420.500 *Interference with Compendial Tests* (revised 11/14/2012),PDF (90.51 KB)PDF (90.51 KB) of CPG Sec. 420.500 *Interference with Compendial Tests* (revised 11/14/2012),11/01/2012,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
"CPG Sec 550.050 (Draft) Canned Ackee, Frozen Ackee, and Other Ackee Products – Hypoglycin A Toxin","PDF (22.47 KB)PDF (22.47 KB) of CPG Sec 550.050 (Draft) Canned Ackee, Frozen Ackee, and Other Ackee Products – Hypoglycin A Toxin",11/01/2012,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Draft,No,,
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs  - Questions and Answers (R1),,10/11/2012,,ICH-Efficacy,Final,No,,
Acute Bacterial Sinusitis — Developing Antimicrobial Drugs for Treatment,PDF (479.82 KB)PDF (479.82 KB) of Acute Bacterial Sinusitis — Developing Antimicrobial Drugs for Treatment,10/05/2012,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,
Guidance for Industry Acute Bacterial Sinusitis: Developing Drugs for Treatment,PDF (479.82 KB)PDF (479.82 KB) of Guidance for Industry Acute Bacterial Sinusitis: Developing Drugs for Treatment,10/04/2012,Center for Drug Evaluation and Research,Pediatric Product Development,Final,No,,
Acute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment,PDF (143.52 KB)PDF (143.52 KB) of Acute Bacterial Exacerbations of Chronic Bronchitis in Patients with Chronic Obstructive Pulmonary Disease: Developing Antimicrobial Drugs for Treatment,10/01/2012,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2008-D-0419
"Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus:  Final Guidance for Industry","PDF (187.47 KB)PDF (187.47 KB) of Use of Nucleic Acid Tests on Pooled and Individual Samples From Donors of Whole Blood and Blood Components, Including Source Plasma, to Reduce the Risk of Transmission of Hepatitis B Virus:  Final Guidance for Industry",10/01/2012,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2011-D-0799
Guidance for Industry: Acute Bacterial Otitis Media: Developing Drugs for Treatment,PDF (116.59 KB)PDF (116.59 KB) of Guidance for Industry: Acute Bacterial Otitis Media: Developing Drugs for Treatment,09/30/2012,Center for Drug Evaluation and Research,,Final,No,,
Acute Bacterial Exacerbations of Chronic Bronchitis in Patients With Chronic Obstructive Pulmonary Disease:  Acute Bacterial Exacerbations of Chronic Bronchitis in Patients,,09/27/2012,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2008-D-0419
Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion:  Final Guidance for Industry,PDF (226.54 KB)PDF (226.54 KB) of Pre-Storage Leukocyte Reduction of Whole Blood and Blood Components Intended for Transfusion:  Final Guidance for Industry,09/01/2012,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2001-D-0254
"Q8, Q9, & Q10 Questions and Answers -- Appendix:  Q&As from Training Sessions (Q8, Q9, & Q10 Points to Consider)","PDF (262.52 KB)PDF (262.52 KB) of Q8, Q9, & Q10 Questions and Answers -- Appendix:  Q&As from Training Sessions (Q8, Q9, & Q10 Points to Consider)",08/13/2012,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,
Guidance for Industry:  Suicidal Ideation and Behavior:  Prospective Assessment of Occurrence in Clinical Trials,PDF (421.53 KB)PDF (421.53 KB) of Guidance for Industry:  Suicidal Ideation and Behavior:  Prospective Assessment of Occurrence in Clinical Trials,08/13/2012,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,
CPG Sec. 490.200 Parametric Release of Parenteral Drug Products Terminally Sterilized by Moist Heat,,07/01/2012,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
Pyrogen and Endotoxins Testing: Questions and Answers,PDF (173.71 KB)PDF (173.71 KB) of Pyrogen and Endotoxins Testing: Questions and Answers,06/28/2012,Center for Veterinary MedicineHuman Foods ProgramCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Investigation & Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,
Guidance for Industry:  Pyrogen and Endotoxins Testing: Questions and Answers,,06/27/2012,Center for Drug Evaluation and Research,Pharmaceutical Quality,Final,No,,
"""Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications""","PDF (118.75 KB)PDF (118.75 KB) of ""Toll-Free Number Labeling and Related Requirements for Over-the-Counter and Prescription Drugs Marketed With Approved Applications""",06/15/2012,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2012-D-0544
Irritable Bowel Syndrome -- Clinical Evaluation of Products for Treatment,PDF (317.13 KB)PDF (317.13 KB) of Irritable Bowel Syndrome -- Clinical Evaluation of Products for Treatment,06/14/2012,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2010-D-0146
S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use,PDF (427.35 KB)PDF (427.35 KB) of S2(R1) Genotoxicity Testing and Data Interpretation for Pharmaceuticals Intended for Human Use,06/07/2012,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2008-D-0178
S6(R1) Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals,,05/18/2012,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-2009-D-0573
Size of Beads in Drug Products Labeled for Sprinkle Rev.1:  Guidance for Industry,PDF (147.91 KB)PDF (147.91 KB) of Size of Beads in Drug Products Labeled for Sprinkle Rev.1:  Guidance for Industry,05/16/2012,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2011-D-0021
Small Entity Compliance Guide: Establishing an Allowable Level for di (2-ethylhexyl)phthalate in Bottled Water,PDF (60.41 KB)PDF (60.41 KB) of Small Entity Compliance Guide: Establishing an Allowable Level for di (2-ethylhexyl)phthalate in Bottled Water,05/01/2012,Human Foods Program,Bottled Water,Final,No,,FDA-2012-D-0316
CVM GFI #209 The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals,PDF (256.08 KB)PDF (256.08 KB) of CVM GFI #209 The Judicious Use of Medically Important Antimicrobial Drugs in Food-Producing Animals,04/13/2012,Center for Veterinary Medicine,Antimicrobial Resistance,Final,No,,FDA-2010-D-0094
Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography,PDF (155.82 KB)PDF (155.82 KB) of Media Fills for Validation of Aseptic Preparations for Positron Emission Tomography,04/11/2012,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2011-D-0691
Modified Risk Tobacco Product Applications: Draft Guidance for Industry,PDF (977.02 KB)PDF (977.02 KB) of Modified Risk Tobacco Product Applications: Draft Guidance for Industry,04/03/2012,Center for Tobacco Products,Modified Risk Tobacco Product (MRTP),Draft,No,06/04/2012,FDA-2012-D-0071
"Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry","PDF (313.12 KB)PDF (313.12 KB) of Reporting Harmful and Potentially Harmful Constituents in Tobacco Products and Tobacco Smoke Under Section 904(a)(3) of the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Industry",04/03/2012,Center for Tobacco Products,,Draft,No,04/03/2012,FDA-2012-D-0049
"CVM GFI #216 Chemistry, Manufacturing, and Controls (CMC) Information - Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use","PDF (78.44 KB)PDF (78.44 KB) of CVM GFI #216 Chemistry, Manufacturing, and Controls (CMC) Information - Fermentation-Derived Intermediates, Drug Substances, and Related Drug Products for Veterinary Medicinal Use",03/08/2012,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2011-D-0112
Guidance for Industry: Testing for Salmonella Species in Human Foods and Direct-Human-Contact Animal Foods,PDF (75.56 KB)PDF (75.56 KB) of Guidance for Industry: Testing for Salmonella Species in Human Foods and Direct-Human-Contact Animal Foods,03/08/2012,Center for Veterinary MedicineHuman Foods Program,Salmonella,Final,No,,FDA-2011-D-0091
E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers,PDF (84.94 KB)PDF (84.94 KB) of E7 Studies in Support of Special Populations; Geriatrics; Questions and Answers,03/01/2012,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2009-D-0528
FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions:  Guidance for Industry and FDA Staff,PDF (108.02 KB)PDF (108.02 KB) of FDA Acceptance of Foreign Clinical Studies Not Conducted Under an IND: Frequently Asked Questions:  Guidance for Industry and FDA Staff,03/01/2012,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research","Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,
"IRB Continuing Review After Clinical Investigation Approval:  Guidance for IRBs, Clinical Investigators, and Sponsors","PDF (144.99 KB)PDF (144.99 KB) of IRB Continuing Review After Clinical Investigation Approval:  Guidance for IRBs, Clinical Investigators, and Sponsors",02/27/2012,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2009-D-0605
"Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c):  Guidance for Sponsors, Investigators, and Institutional Review Boards","PDF (56.28 KB)PDF (56.28 KB) of Questions and Answers on Informed Consent Elements, 21 CFR § 50.25(c):  Guidance for Sponsors, Investigators, and Institutional Review Boards",02/01/2012,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy",Good Clinical Practice (GCP),Final,No,,
"CPG Sec. 400.210, Radiofrequency Identification Feasibility Studies and Pilot Programs for Drugs",,01/31/2012,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"Guidance for Industry: Questions and Answers Regarding Establishment and Maintenance of Records By Persons Who Manufacture, Process, Pack, Transport, Distribute, Receive, Hold, or Import Food (Edition 5)","PDF (334.4 KB)PDF (334.4 KB) of Guidance for Industry: Questions and Answers Regarding Establishment and Maintenance of Records By Persons Who Manufacture, Process, Pack, Transport, Distribute, Receive, Hold, or Import Food (Edition 5)",01/31/2012,Human Foods Program,"Import, Packaging, Records, Transportation",Final,No,,FDA-2011-D-0598
Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices,PDF (302.29 KB)PDF (302.29 KB) of Responding to Unsolicited Requests for Off-Label Information About Prescription Drugs and Medical Devices,12/30/2011,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Veterinary Medicine,Administrative / Procedural,Draft,No,,FDA-2011-D-0868
"Guidance for Industry: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation","PDF (853.05 KB)PDF (853.05 KB) of Guidance for Industry: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Storage, and Transportation",12/28/2011,Human Foods Program,"Egg/Egg Product, Salmonella, Transportation",Final,No,,FDA-2010-D-0313
General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases:  Guidance for Industry,PDF (57.63 KB)PDF (57.63 KB) of  General Principles for the Development of Vaccines to Protect Against Global Infectious Diseases:  Guidance for Industry,12/01/2011,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-2011-D-0855
"Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry","PDF (621.08 KB)PDF (621.08 KB) of Current Good Tissue Practice (CGTP) and Additional Requirements for Manufacturers of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",12/01/2011,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA–2008–D–0659
Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage:  Guidance for Industry,PDF (156.52 KB)PDF (156.52 KB) of Preparation of IDEs and INDs for Products Intended to Repair or Replace Knee Cartilage:  Guidance for Industry,12/01/2011,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2007-D-0020
Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals,PDF (137.2 KB)PDF (137.2 KB) of Nonclinical Evaluation of Late Radiation Toxicity of Therapeutic Radiopharmaceuticals,11/28/2011,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,
Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS),PDF (91.2 KB)PDF (91.2 KB) of Medication Guides — Distribution Requirements and Inclusion in Risk Evaluation and Mitigation Strategies (REMS),11/18/2011,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,
"Q8, Q9, and Q10 Questions and Answers","PDF (184.96 KB)PDF (184.96 KB) of Q8, Q9, and Q10 Questions and Answers",11/17/2011,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,
Requalification Method for Reentry of Donors Who Test Hepatitis B Surface Antigen (HBsAg) Positive Following a Recent Vaccination against Hepatitis B Virus Infection:  Guidance for Industry,PDF (44.45 KB)PDF (44.45 KB) of Requalification Method for Reentry of Donors Who Test Hepatitis B Surface Antigen (HBsAg) Positive Following a Recent Vaccination against Hepatitis B Virus Infection:  Guidance for Industry,11/01/2011,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2008-D-0263
"Guidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, Process, or Ship Fresh Cantaloupe","PDF (1.43 MB)PDF (1.43 MB) of Guidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, Process, or Ship Fresh Cantaloupe",10/31/2011,Human Foods Program,Fruit/Fruit Product,Final,No,,
Guidance for Industry: Evaluating the Safety of Flood-affected Food Crops for Human Consumption,,10/24/2011,Human Foods Program,"Emergencies,",Final,No,,FDA-2011-D-0733
"Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format","PDF (101.67 KB)PDF (101.67 KB) of Warnings and Precautions, Contraindications, and Boxed Warning Sections of Labeling for Human Prescription Drug and Biological Products — Content and Format",10/12/2011,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2011-D-0694
Incorporation of  Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting:  Guidance for Industry,PDF (73.65 KB)PDF (73.65 KB) of Incorporation of  Physical-Chemical Identifiers into Solid Oral Dosage Form Drug Products for Anticounterfeiting:  Guidance for Industry,10/11/2011,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2009-D-0212
Guidance for Industry: Implementation of the Fee Provisions of Section 107 of the FDA Food Safety Modernization Act,,10/06/2011,Office of Inspections and Investigations,"User Fees,",Final,No,,FDA-2011-D-0721
Clinical Considerations for Therapeutic Cancer Vaccines:  Guidance for Industry,PDF (75.13 KB)PDF (75.13 KB) of Clinical Considerations for Therapeutic Cancer Vaccines:  Guidance for Industry,10/01/2011,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy, Vaccines, Good Clinical Practice (GCP)",Final,No,,FDA-2009-D-0427
CVM GFI #215 Target Animal Safety & Effectiveness Protocol Development & Submission,PDF (62.96 KB)PDF (62.96 KB) of CVM GFI #215 Target Animal Safety & Effectiveness Protocol Development & Submission,09/29/2011,Center for Veterinary Medicine,"Target Animal – Effectiveness, Target Animal – Safety",Final,No,,FDA-2011-D-0023
Time and Extent Applications for Nonprescription Drug Products,PDF (241.46 KB)PDF (241.46 KB) of Time and Extent Applications for Nonprescription Drug Products,09/29/2011,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2004-D-0438
Applications for Premarket Review of New Tobacco Products: Draft Guidance for Industry,PDF (233.44 KB)PDF (233.44 KB) of Applications for Premarket Review of New Tobacco Products: Draft Guidance for Industry,09/28/2011,Center for Tobacco Products,PreMarket,Draft,No,09/27/2011,FDA-2011-D-0212
"User Fee Waivers, Reductions, and Refunds for Drug and Biological Products","PDF (152.59 KB)PDF (152.59 KB) of User Fee Waivers, Reductions, and Refunds for Drug and Biological Products",09/27/2011,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"User Fees,",Final,No,,FDA-2011-D-0108
Reproductive and Developmental Toxicities -- Integrating Study Results to Assess Concerns,PDF (391.57 KB)PDF (391.57 KB) of Reproductive and Developmental Toxicities -- Integrating Study Results to Assess Concerns,09/23/2011,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-1999-N-0082
CVM GFI #205 (VICH GL46) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals:  Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK),PDF (209.51 KB)PDF (209.51 KB) of CVM GFI #205 (VICH GL46) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals:  Metabolism Study to Determine the Quantity and Identify the Nature of Residues (MRK),09/15/2011,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2010-D-8228
CVM GFI #206 (VICH GL47) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals,PDF (137.74 KB)PDF (137.74 KB) of CVM GFI #206 (VICH GL47) Studies to Evaluate the Metabolism and Residue Kinetics of Veterinary Drugs in Food-Producing Animals: Comparative Metabolism Studies in Laboratory Animals,09/15/2011,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2010-D-8229
Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products: Draft Guidance for Industry,PDF (209.38 KB)PDF (209.38 KB) of Submission of Warning Plans for Cigarettes and Smokeless Tobacco Products: Draft Guidance for Industry,09/09/2011,Center for Tobacco Products,Warning plans,Draft,No,11/08/2011,FDA-2011-D-0480
"PET Drug Applications - Content and Format for NDAs and ANDAs:  Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011","PDF (614.24 KB)PDF (614.24 KB) of PET Drug Applications - Content and Format for NDAs and ANDAs:  Attachment I: Sample formats for chemistry, manufacturing, and controls (CMC) sections_2011",09/01/2011,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2000-D-1542
Guidance for Industry:  Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient,PDF (89 KB)PDF (89 KB) of Guidance for Industry:  Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Pistachio-Derived Product as an Ingredient,08/31/2011,Human Foods Program,"Nuts & Nut Products, Salmonella",Final,No,,FDA-2009-D-0271
PET Drug Applications - Content and Format for NDAs and ANDAs_2011,PDF (429.23 KB)PDF (429.23 KB) of PET Drug Applications - Content and Format for NDAs and ANDAs_2011,08/31/2011,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
E2F Development Safety Update Report,PDF (272.25 KB)PDF (272.25 KB) of E2F Development Safety Update Report,08/23/2011,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2008-D-0386
Exculpatory Language in Informed Consent,PDF (112.4 KB)PDF (112.4 KB) of Exculpatory Language in Informed Consent,08/19/2011,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Draft,No,11/01/2011,HHS-OPHS-2011-0014
Residual Drug in Transdermal and Related Drug Delivery Systems:  Guidance for Industry,PDF (43.68 KB)PDF (43.68 KB) of Residual Drug in Transdermal and Related Drug Delivery Systems:  Guidance for Industry,08/17/2011,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2010-D-0246
Guidance for Industry: What You Need to Know About Prior Notice of Imported Food Shipments,,08/15/2011,Office of Inspections and InvestigationsHuman Foods Program,Import,Final,No,,FDA-2011-N-0179
"E16 Biomarkers Related to Drug or Biotechnology Product Development:  Context, Structure, and Format of Qualification Submissions","PDF (111.49 KB)PDF (111.49 KB) of E16 Biomarkers Related to Drug or Biotechnology Product Development:  Context, Structure, and Format of Qualification Submissions",08/11/2011,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2009-D-0324
PET Drugs--Current Good Manufacturing Practice (CGMP); Small Entity Compliance Guide,PDF (228.68 KB)PDF (228.68 KB) of PET Drugs--Current Good Manufacturing Practice (CGMP); Small Entity Compliance Guide,08/05/2011,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2011-D-0541
Availability of FDA’s eSubmitter Program for Regulatory Submissions from Licensed Blood Establishments:  Guidance for Industry,PDF (29.04 KB)PDF (29.04 KB) of Availability of FDA’s eSubmitter Program for Regulatory Submissions from Licensed Blood Establishments:  Guidance for Industry,08/01/2011,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2011-D-0579
Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses - Guidance for Industry and FDA Staff,PDF (289.02 KB)PDF (289.02 KB) of Establishing the Performance Characteristics of In Vitro Diagnostic Devices for the Detection or Detection and Differentiation of Influenza Viruses - Guidance for Industry and FDA Staff,07/14/2011,Center for Devices and Radiological Health,Pediatric Product Development,Final,No,,FDA-2008-D-0095
Q4B Annex 7 (R2): Dissolution Test General Chapter,PDF (101.62 KB)PDF (101.62 KB) of Q4B Annex 7 (R2): Dissolution Test General Chapter,06/24/2011,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2009-D-0012
Topical Acne Drug Products for Over-the-Counter Human Use--Revision of Labeling and Classification of Benzoyl Peroxide as Safe and Effective:  Guidance for Industry,PDF (122.51 KB)PDF (122.51 KB) of Topical Acne Drug Products for Over-the-Counter Human Use--Revision of Labeling and Classification of Benzoyl Peroxide as Safe and Effective:  Guidance for Industry,06/21/2011,Center for Drug Evaluation and Research,"Labeling, Over-the-Counter Drugs",Final,No,,FDA-2011-D-0404
"Donors of Blood and Blood Components: Notification of Donor Deferral, Small Entity Compliance Guide:  Guidance for Industry","PDF (44.98 KB)PDF (44.98 KB) of Donors of Blood and Blood Components: Notification of Donor Deferral, Small Entity Compliance Guide:  Guidance for Industry",06/01/2011,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-1998-N-1016
Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications,PDF (137.06 KB)PDF (137.06 KB) of Submission of Summary Bioequivalence Data for Abbreviated New Drug Applications,05/06/2011,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,FDA-2009-D-0126
Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products,PDF (594.59 KB)PDF (594.59 KB) of Dosage Delivery Devices for Orally Ingested OTC Liquid Drug Products,05/05/2011,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2009-D-0322
How to Write a Request for Designation (RFD):  Guidance for Industry,PDF (89.81 KB)PDF (89.81 KB) of How to Write a Request for Designation (RFD):  Guidance for Industry,04/14/2011,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Final,No,,FDA-2011-D-0214
Influenza: Developing Drugs for Treatment and/or Prophylaxis,PDF (417.45 KB)PDF (417.45 KB) of Influenza: Developing Drugs for Treatment and/or Prophylaxis,04/13/2011,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2009-D-0044
"Postmarketing Studies and  Clinical Trials—Implementation  of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry","PDF (335.12 KB)PDF (335.12 KB) of Postmarketing Studies and  Clinical Trials—Implementation  of Section 505(o)(3) of the Federal Food, Drug, and Cosmetic Act Guidance for Industry",04/12/2011,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Device & Drug Safety,Final,No,,FDA-2009-D-0283
"""Computer Crossmatch"" (Computerized Analysis of the Compatibility between the Donor's Cell Type and the Recipient's Serum or Plasma Type); :  Guidance for Industry","PDF (77.86 KB)PDF (77.86 KB) of ""Computer Crossmatch"" (Computerized Analysis of the Compatibility between the Donor's Cell Type and the Recipient's Serum or Plasma Type); :  Guidance for Industry",04/01/2011,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2007-D-0019
Guidance for Industry: Questions and Answers About the Food Additive or Color Additive Petition Process,,03/31/2011,Human Foods Program,Food & Color Additives,Final,No,,FDA-2020-D-1917
Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims,PDF (229.31 KB)PDF (229.31 KB) of Hypertension Indication: Drug Labeling for Cardiovascular Outcome Claims,03/15/2011,Center for Drug Evaluation and Research,Labeling,Final,No,,FDA-2008-D-0150
Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products,PDF (234.89 KB)PDF (234.89 KB) of Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products,03/15/2011,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,05/31/2020,FDA-2009-D-0568
Planning for the Effects of High Absenteeism to Ensure Availability of Medically Necessary Drug Products,,03/14/2011,,Administrative / Procedural,Final,No,,
Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence - Guidance for Industry and FDA Staff,PDF (258.23 KB)PDF (258.23 KB) of Clinical Investigations of Devices Indicated for the Treatment of Urinary Incontinence - Guidance for Industry and FDA Staff,03/07/2011,Center for Devices and Radiological Health,"Premarket, Pediatric Product Development",Final,No,,FDA-2008-D-0457
"Guidance for Industry: Letter to Firms that Grow, Harvest, Sort, Pack, or Ship Fresh Cilantro",,03/01/2011,Human Foods Program,"Vegetable Products, Produce",Final,No,,
CPG Sec. 335.700 Surgeons' Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure,PDF (17.19 KB)PDF (17.19 KB) of CPG Sec. 335.700 Surgeons' Gloves and Patient Examination Gloves; Defects - Criteria for Direct Reference Seizure,03/01/2011,Center for Devices and Radiological Health,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
Sample formats for Form FDA 356h_2011,PDF (601.16 KB)PDF (601.16 KB) of Sample formats for Form FDA 356h_2011,02/02/2011,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-2000-D-1542
Process Validation: General Principles and Practices:  Guidance for Industry,PDF (371.9 KB)PDF (371.9 KB) of Process Validation: General Principles and Practices:  Guidance for Industry,01/25/2011,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2008-D-0559
Potency Tests for Cellular and Gene Therapy Products:  Final Guidance for Industry:,PDF (121.48 KB)PDF (121.48 KB) of Potency Tests for Cellular and Gene Therapy Products:  Final Guidance for Industry:,01/01/2011,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2008-D-0520
CPG Sec 527.300 Microbial Contaminants & Alkaline Phosphatase Activity,PDF (103.81 KB)PDF (103.81 KB) of CPG Sec 527.300 Microbial Contaminants & Alkaline Phosphatase Activity,12/23/2010,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Dairy",Final,No,02/21/2010,FDA-2009-D-0466
"Small Entity Compliance Guide: Current Good Manufacturing Practice in Manufacturing, Packaging, Labeling, or Holding Operations for Dietary Supplements",,12/16/2010,Human Foods Program,"Labeling, Packaging",Final,No,,FDA-2010-D-0605
CPG Sec 510.800 Beverages-Serving Size Labeling,,12/01/2010,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
CPG Sec 527.300 Dairy Products - Microbial Contaminants & Alkaline Phosphatase Activity,PDF (99.92 KB)PDF (99.92 KB) of CPG Sec 527.300 Dairy Products - Microbial Contaminants & Alkaline Phosphatase Activity,12/01/2010,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"“Lookback” for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV:  Guidance for Industry","PDF (182.57 KB)PDF (182.57 KB) of “Lookback” for Hepatitis C Virus (HCV): Product Quarantine, Consignee Notification, Further Testing, Product Disposition, and Notification of Transfusion Recipients Based on Donor Test Results Indicating Infection with HCV:  Guidance for Industry",12/01/2010,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-1999-D-0002
Antibacterial Drug Products: Use of Noninferiority Studies to Support Approval,PDF (82.6 KB)PDF (82.6 KB) of Antibacterial Drug Products: Use of Noninferiority Studies to Support Approval,11/29/2010,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2007-D-0150
ANDAs: Impurities in Drug Products:  Guidance for Industry,PDF (154.52 KB)PDF (154.52 KB) of ANDAs: Impurities in Drug Products:  Guidance for Industry,11/29/2010,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2010-D-0584
Blood Lancet Labeling - Guidance for Industry and Food and Drug Administration Staff,PDF (39.59 KB)PDF (39.59 KB) of Blood Lancet Labeling - Guidance for Industry and Food and Drug Administration Staff,11/28/2010,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2010-D-0590
"Guidance for Industry: Safety of Imported Traditional Pottery Intended for Use with Food and the Use of the Term ""Lead Free"" in the Labeling of Pottery/Proper Identification of Ornamental and Decorative Ceramicware",,11/22/2010,Human Foods Program,"Import, Labeling, Lead",Final,No,,FDA-2010-D-0571
"Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application:  Guidance for Industry","PDF (41.82 KB)PDF (41.82 KB) of Recommendations for Blood Establishments: Training of Back-Up Personnel, Assessment of Blood Donor Suitability and Reporting Certain Changes to an Approved Application:  Guidance for Industry",11/01/2010,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2009-D-0533
Cellular Therapy for Cardiac Disease:  Guidance for Industry,PDF (199.9 KB)PDF (199.9 KB) of  Cellular Therapy for Cardiac Disease:  Guidance for Industry,10/01/2010,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2009-D-0132
Guidance for Industry: Food Additive Petition Expedited Review,,09/30/2010,Human Foods Program,Food & Color Additives,Final,No,,FDA-2020-D-1918
Addition of URLs to Electronic Product Labeling:  Guidance for Industry and FDA Staff,PDF (32.85 KB)PDF (32.85 KB) of Addition of URLs to Electronic Product Labeling:  Guidance for Industry and FDA Staff,09/29/2010,Center for Devices and Radiological Health,"Postmarket, Labeling",Final,No,,FDA-2020-D-0957
Q4B Annex 10: Polyacrylamide Gel Electrophoresis General Chapter,PDF (57.26 KB)PDF (57.26 KB) of Q4B Annex 10: Polyacrylamide Gel Electrophoresis General Chapter,09/12/2010,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2009-D-0342
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 11: Capillary Electrophoresis General Chapter,PDF (92.92 KB)PDF (92.92 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 11: Capillary Electrophoresis General Chapter,09/03/2010,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2009-D-0579
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 12: Analytical Sieving General Chapter,PDF (87.38 KB)PDF (87.38 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the ICH Regions Annex 12: Analytical Sieving General Chapter,09/02/2010,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2009-D-0579
Impact-Resistant Lenses: Questions and Answers:  Guidance for Industry and FDA Staff,PDF (135.12 KB)PDF (135.12 KB) of Impact-Resistant Lenses: Questions and Answers:  Guidance for Industry and FDA Staff,09/02/2010,Center for Devices and Radiological Health,,Final,No,,FDA-2007-D-0367
"Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use — Small Entity Compliance Guide","PDF (176.31 KB)PDF (176.31 KB) of Organ-Specific Warnings:  Internal Analgesic, Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use — Small Entity Compliance Guide",08/17/2010,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,
Contact Lens Care Products Labeling:  Guidance for Industry and Food and Drug Administration Staff,PDF (109.95 KB)PDF (109.95 KB) of Contact Lens Care Products Labeling:  Guidance for Industry and Food and Drug Administration Staff,08/15/2010,Center for Devices and Radiological Health,"Premarket, 510(k), Ophthalmic",Final,No,,FDA-2020-D-0957
"CVM GFI #169 Drug Substance Chemistry, Manufacturing, and Controls Information","PDF (362.59 KB)PDF (362.59 KB) of CVM GFI #169 Drug Substance Chemistry, Manufacturing, and Controls Information",08/06/2010,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2003-D-0243
Label Comprehension Studies for Nonprescription Drug Products,PDF (147.74 KB)PDF (147.74 KB) of Label Comprehension Studies for Nonprescription Drug Products,08/03/2010,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2009-D-0181
Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application,PDF (429.19 KB)PDF (429.19 KB) of Radioactive Drug Research Committee: Human Research Without An Investigational New Drug Application,08/02/2010,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2009-D-0125
Guidance for Industry and FDA: Advisory Levels for Deoxynivalenol (DON) in Finished Wheat Products for Human Consumption and Grains and Grain By-Products used for Animal Feed,,07/07/2010,Center for Veterinary MedicineHuman Foods Program,"Animal Feed, Grain/Grain Product",Final,No,,
Guidance for Industry: Recommendations for Submission of Chemical and Technological Data for Food Additive Petitions and GRAS Notices for Enzyme Preparations,PDF (100.85 KB)PDF (100.85 KB) of Guidance for Industry: Recommendations for Submission of Chemical and Technological Data for Food Additive Petitions and GRAS Notices for Enzyme Preparations,06/30/2010,Human Foods Program,"Food & Color Additives, GRAS",Final,No,,
In Vitro Diagnostic (IVD) Device Studies - Frequently Asked Questions:  Guidance for Industry and FDA Staff,PDF (352.1 KB)PDF (352.1 KB) of In Vitro Diagnostic (IVD) Device Studies - Frequently Asked Questions:  Guidance for Industry and FDA Staff,06/25/2010,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Good Clinical Practice (GCP), Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2007-D-0076
Systemic Lupus Erythematosus --Developing Medical Products for Treatment,PDF (167.92 KB)PDF (167.92 KB) of Systemic Lupus Erythematosus --Developing Medical Products for Treatment,06/22/2010,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2010-D-0249
Individual Product Bioequivalence Recommendations for Specific Products,PDF (80 KB)PDF (80 KB) of Individual Product Bioequivalence Recommendations for Specific Products,06/10/2010,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,FDA-2007-D-0433
"Use of “Light,” “Mild,” “Low,” or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products:  Guidance for Industry and FDA Staff","PDF (161.55 KB)PDF (161.55 KB) of Use of “Light,” “Mild,” “Low,” or Similar Descriptors in the Label, Labeling, or Advertising of Tobacco Products:  Guidance for Industry and FDA Staff",06/10/2010,Center for Tobacco Products,Labeling,Final,No,06/10/2010,FDA-2010-D-0282
"Frequently Asked Questions – Statement of Investigator (Form FDA 1572):  Guidance for Sponsors, Clinical Investigators, and IRBs","PDF (105.19 KB)PDF (105.19 KB) of Frequently Asked Questions – Statement of Investigator (Form FDA 1572):  Guidance for Sponsors, Clinical Investigators, and IRBs",06/04/2010,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research","Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2008-D-0406
"FDA Inspections of Clinical Investigators:  Guidance For IRBs, Clinical Investigators, and Sponsors","PDF (58.54 KB)PDF (58.54 KB) of FDA Inspections of Clinical Investigators:  Guidance For IRBs, Clinical Investigators, and Sponsors",06/01/2010,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,
Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2),PDF (171.3 KB)PDF (171.3 KB) of Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007 (Edition 2),05/25/2010,Center for Veterinary MedicineHuman Foods Program,Reportable Food Registry,Draft,No,07/26/2010,FDA-2009-D-0260
"Orientación preliminar de la industria: Preguntas y respuestas sobre el Registro de productos sanitarios en productos agroalimentarios, según establecido por la Ley de Enmiendas a la Alimentación y Medicamentos (FDA), 2007 (Edición 2)",,05/23/2010,Human Foods Program,Reportable Food Registry,Draft,No,07/26/2010,FDA-2009-D-0260
Chinese Translation of Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry Edition 2 (???????????2007?????????????????? 2010?5?),PDF (241.15 KB)PDF (241.15 KB) of Chinese Translation of Draft Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry Edition 2 (???????????2007?????????????????? 2010?5?),05/23/2010,Human Foods Program,Reportable Food Registry,Draft,No,07/26/2010,FDA-2009-D-0260
Guide pour l’industrie: Questions et réponses concernant le Registre de denrées alimentaires à signaler Reportable Food Registry (RFR) tel qu’établi par le Food and Drug Administration Amendments Act de 2007 (FDAAA) (2ème édition),PDF (122.08 KB)PDF (122.08 KB) of Guide pour l’industrie: Questions et réponses concernant le Registre de denrées alimentaires à signaler Reportable Food Registry (RFR) tel qu’établi par le Food and Drug Administration Amendments Act de 2007 (FDAAA) (2ème édition),05/23/2010,Human Foods Program,Reportable Food Registry,Draft,No,07/26/2010,FDA-2009-D-0260
Guidance for Industry: Use of Water by Food Manufacturers in Areas Subject to a Boil-Water Advisory,,05/13/2010,Human Foods Program,"Emergencies,",Final,No,,FDA-2010-D-0236
Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco:  Guidance for Industry and FDA Staff,PDF (56.92 KB)PDF (56.92 KB) of Enforcement Policy Concerning Certain Regulations Restricting the Sale and Distribution of Cigarettes and Smokeless Tobacco:  Guidance for Industry and FDA Staff,05/07/2010,Center for Tobacco Products,"Cigarettes, Smokeless, Snuff, Chewing",Final,No,05/07/2011,FDA-2010-D-0189
Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody to Hepatitis B Core Antigen (Anti-HBc):  Guidance for Industry,PDF (86.38 KB)PDF (86.38 KB) of Requalification Method for Reentry of Blood Donors Deferred Because of Reactive Test Results for Antibody to Hepatitis B Core Antigen (Anti-HBc):  Guidance for Industry,05/01/2010,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2008-D-0263
Guidance for Industry: Sanitary Transportation of Food,,04/29/2010,Human Foods Program,"Sanitation, Transportation",Final,No,,FDA-2020-D-1920
Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and FDA Staff,PDF (552.2 KB)PDF (552.2 KB) of Non-Clinical Engineering Tests and Recommended Labeling for Intravascular Stents and Associated Delivery Systems - Guidance for Industry and FDA Staff,04/17/2010,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"Small Entity Compliance Guide: Prevention of Salmonella Enteritidis in Shell Eggs During Production, Transportation, and Storage",,04/13/2010,Human Foods Program,"Egg/Egg Product, Transportation, Salmonella",Final,No,,FDA-2010-D-0183
Q4B Annex 9: Tablet Friability General Chapter,PDF (67.76 KB)PDF (67.76 KB) of Q4B Annex 9: Tablet Friability General Chapter,04/05/2010,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2009-D-0343
Small Entity Compliance Guide: Bottled Water and Total Coliform and E. coli,,03/26/2010,Human Foods Program,"Bottled Water , E. coli",Final,No,,FDA-2010-D-0141
French Translation of Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal (Soumission d’un rapport concernant plusieurs usines auprès du portail électronique d’enregistrement des denrées alimentaires),,03/25/2010,Center for Veterinary MedicineHuman Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal as Established by the Food and Drug Administration Amendments Act of 2007,,03/25/2010,Human Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
Orientación preliminar para la industria: Presentación de Informe para múltiples instalaciones al Portal electrónico de incidentes,,03/25/2010,Center for Veterinary MedicineHuman Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
CVM GFI #192 Anesthetics for Companion Animals,PDF (176.54 KB)PDF (176.54 KB) of CVM GFI #192 Anesthetics for Companion Animals,03/25/2010,Center for Veterinary Medicine,Target Animal – Safety,Final,No,,FDA-2008-D-0623
CPG Sec 540.375 Canned Salmon - Adulteration Involving Decomposition (Withdrawn 3/22/2010),,03/21/2010,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals,PDF (169.33 KB)PDF (169.33 KB) of S9 Nonclinical Evaluation for Anticancer Pharmaceuticals,03/08/2010,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2009-D-0006
S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers,PDF (536.49 KB)PDF (536.49 KB) of S9 Nonclinical Evaluation for Anticancer Pharmaceuticals--Questions and Answers,03/08/2010,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,11/16/2016,FDA-2009-D-0006
Draft Guidance for Industry: Providing Regulatory Submissions in Electronic or Paper Format to the Office of Food Additive Safety,PDF (813.15 KB)PDF (813.15 KB) of Draft Guidance for Industry: Providing Regulatory Submissions in Electronic or Paper Format to the Office of Food Additive Safety,03/01/2010,Human Foods Program,Food & Color Additives,Draft,No,,
Chinese Translation of Guidance for Industry: Submitting a Report for Multiple Facilities to the Reportable Food Electronic Portal (?????????????????????????????),,02/28/2010,Center for Veterinary MedicineHuman Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages:  Guidance for Industry,PDF (60.67 KB)PDF (60.67 KB) of Standards for Securing the Drug Supply Chain - Standardized Numerical Identification for Prescription Drug Packages:  Guidance for Industry,02/28/2010,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchOffice of the Commissioner,Labeling,Final,No,,
Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes:  Guidance for Industry,PDF (72.71 KB)PDF (72.71 KB) of Submission of Documentation in Applications for Parametric Release of Human and Veterinary Drug Products Terminally Sterilized by Moist Heat Processes:  Guidance for Industry,02/26/2010,Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Microbiology, Pharmaceutical Quality",Final,No,,FDA-2008-D-0391
Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials (PDF Version),PDF (341.52 KB)PDF (341.52 KB) of Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials (PDF Version),02/05/2010,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2006-D-0410
Guidance for the Use of Bayesian Statistics in Medical Device Clinical Trials,,02/04/2010,"Office of the Commissioner,Office of Clinical Policy and Programs","Biostatistics,",Final,No,,
Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications:  Guidance for Industry,PDF (311.98 KB)PDF (311.98 KB) of Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications:  Guidance for Industry,02/01/2010,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-2006-D-0223
The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 – Current Good Manufacturing Practice (CGMP):  Guidance for Industry,PDF (127.37 KB)PDF (127.37 KB) of The Use of Mechanical Calibration of Dissolution Apparatus 1 and 2 – Current Good Manufacturing Practice (CGMP):  Guidance for Industry,01/27/2010,Center for Drug Evaluation and Research,Current Good Manufacturing Practice (CGMP),Final,No,,FDA-2007-D-0420
M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals,PDF (325.22 KB)PDF (325.22 KB) of M3(R2) Nonclinical Safety Studies for the Conduct of Human Clinical Trials and Marketing Authorization for Pharmaceuticals,01/21/2010,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2008-D-0470
New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products:  Guidance for Industry,PDF (159.33 KB)PDF (159.33 KB) of New Contrast Imaging Indication Considerations for Devices and Approved Drug and Biological Products:  Guidance for Industry,01/06/2010,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination ProductsCenter for Drug Evaluation and ResearchCenter for Devices and Radiological Health",Combination Products,Final,No,,FDA-2008-D-0525
Q4B Annex 5: Disintegration Test General Chapter,PDF (68.62 KB)PDF (68.62 KB) of Q4B Annex 5: Disintegration Test General Chapter,12/23/2009,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2008-D-0399
General Questions and Answers on the Ban of Cigarettes that Contain Certain Characterizing Flavors (Edition 2):  Guidance to Industry and FDA Staff,PDF (30.93 KB)PDF (30.93 KB) of General Questions and Answers on the Ban of Cigarettes that Contain Certain Characterizing Flavors (Edition 2):  Guidance to Industry and FDA Staff,12/23/2009,Center for Tobacco Products,"Cigarettes, Flavored",Final,No,,FDA-2009-N-0449
Q4B Annex 8: Sterility Test General Chapter,PDF (68.49 KB)PDF (68.49 KB) of Q4B Annex 8: Sterility Test General Chapter,12/22/2009,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2009-D-0013
S6(R1) Addendum: Preclinical Safety Evaluation of Biotechnology:  Guidance for Industry,PDF (181.06 KB)PDF (181.06 KB) of S6(R1) Addendum: Preclinical Safety Evaluation of Biotechnology:  Guidance for Industry,12/17/2009,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-2009-D-0573
S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals,PDF (181.06 KB)PDF (181.06 KB) of S6 (R1) Addendum: Preclinical Safety Evaluation of Biotechnology - Derived Pharmaceuticals,12/16/2009,,ICH-Safety,Final,No,,
PET Drug Products - Current Good Manufacturing Practice (CGMP),PDF (399.04 KB)PDF (399.04 KB) of PET Drug Products - Current Good Manufacturing Practice (CGMP),12/10/2009,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-1998-D-0025
Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims:  Guidance for Industry,PDF (295 KB)PDF (295 KB) of Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims:  Guidance for Industry,12/09/2009,Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,FDA-2006-D-0362
Residual Solvents in Drug Products Marketed in the United States:  Guidance for Industry,PDF (51.82 KB)PDF (51.82 KB) of Residual Solvents in Drug Products Marketed in the United States:  Guidance for Industry,11/25/2009,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2008-D-0413
Q8(R2) Pharmaceutical Development,PDF (401.81 KB)PDF (401.81 KB) of Q8(R2) Pharmaceutical Development,11/20/2009,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2005-D-0154
Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion:  Guidance for Industry,PDF (52.46 KB)PDF (52.46 KB) of Use of Nucleic Acid Tests to Reduce the Risk of Transmission of West Nile Virus from Donors of Whole Blood and Blood Components Intended for Transfusion:  Guidance for Industry,11/06/2009,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2008-D-0263
SPL Standard for Content of Labeling Technical Qs & As,PDF (57.92 KB)PDF (57.92 KB) of SPL Standard for Content of Labeling Technical Qs & As,10/28/2009,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Electronic Submissions,",Draft,No,,FDA-2009-D-0355
"Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects:  Guidance for Industry","PDF (163.4 KB)PDF (163.4 KB) of Investigator Responsibilities — Protecting the Rights, Safety, and Welfare of Study Subjects:  Guidance for Industry",10/23/2009,Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,
Guidance for Industry: Letter Regarding Point of Purchase Food Labeling,,10/21/2009,Human Foods Program,"Labeling, Nutrition",Final,No,,FDA-2020-D-1921
Labeling for Human Prescription Drug and Biological Products — Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information,PDF (65.5 KB)PDF (65.5 KB) of Labeling for Human Prescription Drug and Biological Products — Determining Established Pharmacologic Class for Use in the Highlights of Prescribing Information,10/19/2009,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2007-D-0302
Helicobacter pylori-Associated Duodenal Ulcer Disease in Adults:  Developing Drugs for Treatment,PDF (147.7 KB)PDF (147.7 KB) of Helicobacter pylori-Associated Duodenal Ulcer Disease in Adults:  Developing Drugs for Treatment,10/05/2009,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Draft,No,,FDA-2009-D-0447
"The Scope of the Prohibition Against Marketing a Tobacco Product in Combination with Another Article or Product Regulated under the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Manufacturers, Retailers, Importers and FDA Staff","PDF (30.08 KB)PDF (30.08 KB) of The Scope of the Prohibition Against Marketing a Tobacco Product in Combination with Another Article or Product Regulated under the Federal Food, Drug, and Cosmetic Act: Draft Guidance for Manufacturers, Retailers, Importers and FDA Staff",09/29/2009,Center for Tobacco Products,,Draft,No,09/30/2009,FDA-2009-D-0470
End-of-Phase 2A Meetings,PDF (163.2 KB)PDF (163.2 KB) of End-of-Phase 2A Meetings,09/18/2009,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2008-D-0514
Chinese Translation of the Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry (???????????2007??????????????????),,09/09/2009,Human Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
French Translation of Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry (Questions et Réponses relatives au Registre des aliments à signaler),,09/09/2009,Human Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Administration Amendments Act of 2007,,09/09/2009,Human Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
Guidance for Industry: Questions and Answers Regarding the Reportable Food Registry as Established by the Food and Drug Adminstration Amendments Act of 2007 - Appendix,,09/09/2009,Human Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
"Preguntas y respuestas sobre el Registro de incidentes sanitarios en productos agroalimentarios, según lo establecido por la Ley de Enmiendas de la Administración de Medicamentos y Alimentos de 2007",,09/09/2009,Human Foods Program,Reportable Food Registry,Final,No,,FDA-2009-D-0260
Guidance for Industry: Questions and Answers Regarding the Labeling of Dietary Supplements as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act,,09/01/2009,Human Foods Program,,Final,No,,FDA-2007-D-0209
Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act:  Questions and Answers,PDF (405.32 KB)PDF (405.32 KB) of Labeling of Nonprescription Human Drug Products Marketed Without an Approved Application as Required by the Dietary Supplement and Nonprescription Drug Consumer Protection Act:  Questions and Answers,09/01/2009,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2007-D-0429
Considerations for Allogeneic Pancreatic Islet Cell Products:  Guidance for Industry,PDF (143.76 KB)PDF (143.76 KB) of Considerations for Allogeneic Pancreatic Islet Cell Products:  Guidance for Industry,09/01/2009,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2008-D-0293
Pharmaceutical Components at Risk for Melamine Contamination:  Guidance for Industry,PDF (136.64 KB)PDF (136.64 KB) of Pharmaceutical Components at Risk for Melamine Contamination:  Guidance for Industry,08/06/2009,Center for Veterinary MedicineCenter for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2009-D-0354
Drug-Induced Liver Injury: Premarketing Clinical Evaluation,PDF (205.82 KB)PDF (205.82 KB) of Drug-Induced Liver Injury: Premarketing Clinical Evaluation,07/29/2009,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Safety - Issues, Errors, and Problems",Final,No,,FDA-2008-D-0128
Nucleic Acid Testing  to Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products:  Guidance for Industry,PDF (57.38 KB)PDF (57.38 KB) of   Nucleic Acid Testing  to Reduce the Possible Risk of Parvovirus B19 Transmission by Plasma-Derived Products:  Guidance for Industry,07/28/2009,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2008-D-0379
Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application,PDF (279.87 KB)PDF (279.87 KB) of Postmarketing Adverse Event Reporting for Nonprescription Human Drug Products Marketed Without an Approved Application,07/17/2009,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2007-D-0434
ANDAs: Impurities in Drug Substances:  Guidance for Industry,PDF (48.11 KB)PDF (48.11 KB) of ANDAs: Impurities in Drug Substances:  Guidance for Industry,07/15/2009,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1998-D-0021
CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations,PDF (58.73 KB)PDF (58.73 KB) of CVM GFI #70 Small Entities Compliance Guide for Feeders of Ruminant Animals Without On-Farm Feed Mixing Operations,07/13/2009,Center for Veterinary Medicine,"Bovine Spongiform Encephalopathy (BSE), Animal Feed, Current Good Manufacturing Practice (CGMP)",Final,No,,
Frequently Asked Questions - IRB Registration:  Guidance for Institutional Review Boards (IRBs),PDF (48.34 KB)PDF (48.34 KB) of Frequently Asked Questions - IRB Registration:  Guidance for Institutional Review Boards (IRBs),07/09/2009,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,FDA-2009-D-0312
"Guidance for Industry: Color Additive Petitions - FDA Recommendations for Submission of Chemical and Technological Data on Color Additives for Food, Drugs, Cosmetics, or Medical Devices",,07/01/2009,Human Foods Program,Food & Color Additives,Final,No,,
Medication Guides — Adding a Toll-Free Number for Reporting Adverse Events,PDF (66.81 KB)PDF (66.81 KB) of Medication Guides — Adding a Toll-Free Number for Reporting Adverse Events,06/08/2009,Center for Drug Evaluation and Research,"Administrative / Procedural, Safety - Issues, Errors, and Problems",Final,No,,FDA-2009-D-0217
Small Entity Compliance Guide: Bottled Water and Residual Disinfectants and Disinfection Byproducts,,06/01/2009,Human Foods Program,Bottled Water,Final,No,,FDA-2009-D-0224
Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing,PDF (103.33 KB)PDF (103.33 KB) of Providing Regulatory Submissions in Electronic Format – Drug Establishment Registration and Drug Listing,06/01/2009,Center for Drug Evaluation and ResearchCenter for Veterinary Medicine,"Electronic Submissions,",Final,No,,FDA-2005-N-0464
Presenting Risk Information in Prescription Drug and Medical Device Promotion,PDF (932.59 KB)PDF (932.59 KB) of Presenting Risk Information in Prescription Drug and Medical Device Promotion,05/27/2009,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Advertising,Draft,No,,FDA-2008-D-0253
"Small Entity Compliance Guide: Health Claims on Calcium and Osteoporosis; and Calcium, Vitamin D, and Osteoporosis",,05/15/2009,Human Foods Program,Labeling,Final,No,,FDA-2009-D-0209
Labeling OTC Human Drug Products; Small Entity Compliance Guide:  Guidance for Industry,PDF (269.87 KB)PDF (269.87 KB) of Labeling OTC Human Drug Products; Small Entity Compliance Guide:  Guidance for Industry,05/13/2009,Center for Drug Evaluation and Research,"Compliance, Over-the-Counter Drugs",Final,No,,FDA-2004-D-0122
CPG Sec 110.310 Prior Notice of Imported Food Under the Public Health Security and Bioterrorism Preparedness and Response Act of 2002,,05/06/2009,Center for Veterinary MedicineOffice of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Import",Final,No,,FDA-2007-D-0487
CVM GFI #195 Small Entities Compliance Guide For Renderers—Substances Prohibited From Use In Animal Food Or Feed,PDF (250.9 KB)PDF (250.9 KB) of CVM GFI #195 Small Entities Compliance Guide For Renderers—Substances Prohibited From Use In Animal Food Or Feed,05/06/2009,Center for Veterinary Medicine,"Bovine Spongiform Encephalopathy (BSE),",Final,No,,FDA-2008-D-0597
Questions and Answers on Current Good Manufacturing Practice Questions and Answers on Current Good Manufacturing Practice Requirements | General Provisions,,04/30/2009,Center for Drug Evaluation and Research,,Final,No,,FDA-2017-D-6821
Small Entity Compliance Guide: Declaration by Name on the Label of All Foods and Cosmetic Products that Contain Cochineal Extract and Carmine,,04/30/2009,Human Foods Program,"Food & Color Additives, Labeling",Final,No,,FDA-2009-D-0198
Small Entity Compliance Guide: Bottled Water and Arsenic,,04/29/2009,Human Foods Program,"Arsenic, Bottled Water",Final,No,,FDA-2009-D-0196
Small Entity Compliance Guide: Bottled Water and Uranium,,04/29/2009,Human Foods Program,Bottled Water,Final,No,,FDA-2009-D-0195
CVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products,PDF (395.36 KB)PDF (395.36 KB) of CVM GFI #185 (VICH GL43) Target Animal Safety for Veterinary Pharmaceutical Products,04/24/2009,Center for Veterinary Medicine,"Target Animal – Safety, VICH",Final,No,,FDA-2007-D-0430
Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document,PDF (97.96 KB)PDF (97.96 KB) of Integrated Summaries of Effectiveness and Safety: Location Within the Common Technical Document,04/21/2009,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2007-D-0031
Q10 Pharmaceutical Quality System,PDF (273.92 KB)PDF (273.92 KB) of Q10 Pharmaceutical Quality System,04/08/2009,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2007-D-0370
Q4B Annex 4A: Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter,PDF (68.81 KB)PDF (68.81 KB) of Q4B Annex 4A: Microbiological Examination of Non-Sterile Products: Microbial Enumeration Tests General Chapter,04/08/2009,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2008-D-0396
Q4B Annex 4B: Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Chapter,PDF (69.05 KB)PDF (69.05 KB) of Q4B Annex 4B: Microbiological Examination of Non-Sterile Products: Tests for Specified Micro-organisms General Chapter,04/08/2009,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2008-D-0398
Q4B Annex 4C: Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter,PDF (57.38 KB)PDF (57.38 KB) of Q4B Annex 4C: Microbiological Examination of Non-Sterile Products: Acceptance Criteria for Pharmaceutical Preparations and Substances for Pharmaceutical Use General Chapter,04/08/2009,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2008-D-0400
Guidance for Industry: Recommendations for Submission of Chemical and Technological Data for Direct Food Additive Petitions,,03/22/2009,Human Foods Program,Food & Color Additives,Final,No,,FDA-2020-D-1922
CVM GFI #149 (VICH GL33) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing,PDF (171.13 KB)PDF (171.13 KB) of CVM GFI #149 (VICH GL33) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: General Approach to Testing,03/17/2009,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2002-D-0186
Guidance for Industry: Measures to Address the Risk for Contamination by Salmonella Species in Food Containing a Peanut-Derived Product as an Ingredient,,03/11/2009,Human Foods Program,"Nuts & Nut Products, Salmonella",Final,No,,FDA-2009-D-0060
Guidance for Industry: 1991 Letter to Seafood Manufacturers Regarding the Fraudulent Practice of Including Glaze (ice) as Part of the Weight of Frozen Seafood,,02/18/2009,Human Foods Program,Seafood/Seafood Product,Final,No,,FDA-2020-D-1923
Guidance for Industry: Referral Program from the Food and Drug Administration to the National Oceanic and Atmospheric Administration Seafood Inspection Program for the Certification of Fish and Fishery Products for Export to the European Union and the European Free Trade Association,,02/11/2009,Human Foods Program,"Export, Seafood/Seafood Product",Final,No,,FDA-2004-D-0043
Animal Models — Essential Elements to Address Efficacy Under the Animal Rule_09,PDF (28.2 KB)PDF (28.2 KB) of Animal Models — Essential Elements to Address Efficacy Under the Animal Rule_09,02/05/2009,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,None found
Guidance for Industry: Evidence-Based Review System for the Scientific Evaluation of Health Claims,,01/16/2009,Human Foods Program,Labeling,Final,No,,FDA-2007-D-0371
"Adverse Event Reporting to IRBs — Improving Human Subject Protection:  Guidance for Clinical Investigators, Sponsors, and IRBs","PDF (56.53 KB)PDF (56.53 KB) of Adverse Event Reporting to IRBs — Improving Human Subject Protection:  Guidance for Clinical Investigators, Sponsors, and IRBs",01/14/2009,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research","Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2007-D-0202
Q4B Annex 3: Test for Particulate Contamination: Subvisible Particles General Chapter,PDF (992.85 KB)PDF (992.85 KB) of Q4B Annex 3: Test for Particulate Contamination: Subvisible Particles General Chapter,01/09/2009,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2007-D-0306
"Guidance for Industry: Substantiation for Dietary Supplement Claims Made Under Section 403(r) (6) of the Federal Food, Drug, and Cosmetic Act",,01/05/2009,Human Foods Program,Labeling,Final,No,,FDA-2004-D-0303
Labeling OTC Human Drug Products -- Questions and Answers,PDF (598.82 KB)PDF (598.82 KB) of Labeling OTC Human Drug Products -- Questions and Answers,01/05/2009,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2004-D-0437
CPG Sec 540.370 Fish and Fishery Products - Decomposition,PDF (21.62 KB)PDF (21.62 KB) of CPG Sec 540.370 Fish and Fishery Products - Decomposition,01/01/2009,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
Radiation Safety Considerations for X-Ray Equipment Designed for Hand-Held Use,PDF (163.6 KB)PDF (163.6 KB) of Radiation Safety Considerations for X-Ray Equipment Designed for Hand-Held Use,12/23/2008,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","Postmarket,",Final,No,,FDA-2020-D-0957
Orally Disintegrating Tablets:  Guidance for Industry,PDF (51.6 KB)PDF (51.6 KB) of Orally Disintegrating Tablets:  Guidance for Industry,12/16/2008,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2007-D-0365
Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process:  Guidance for Industry and FDA Staff,PDF (660.23 KB)PDF (660.23 KB) of Modifications to Devices Subject to Premarket Approval (PMA) - The PMA Supplement Decision-Making Process:  Guidance for Industry and FDA Staff,12/11/2008,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological Health,"Premarket, Premarket Approval (PMA)",Final,No,,FDA-2007-D-0025
CVM GFI #5 Drug Stability Guidelines,PDF (384.72 KB)PDF (384.72 KB) of CVM GFI #5 Drug Stability Guidelines,12/09/2008,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2020-D-1385
Guidance for Industry: Dear Manufacturer Letter Regarding Front-of-Package Symbols,,12/01/2008,Human Foods Program,Labeling,Final,No,,FDA-2020-D-1924
Cooperative Manufacturing Arrangements for Licensed Biologics:  Guidance for Industry,PDF (74.63 KB)PDF (74.63 KB) of Cooperative Manufacturing Arrangements for Licensed Biologics:  Guidance for Industry,11/28/2008,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-1999-D-0128
PDUFA Pilot Project: Proprietary Name Review - Concept Paper,PDF (186.4 KB)PDF (186.4 KB) of PDUFA Pilot Project: Proprietary Name Review - Concept Paper,10/07/2008,Center for Drug Evaluation and Research,,Final,No,,FDA-2008-N-0281
"Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials:  Guidance for Sponsors, Clinical Investigators, and IRBs","PDF (74.79 KB)PDF (74.79 KB) of Data Retention When Subjects Withdraw from FDA-Regulated Clinical Trials:  Guidance for Sponsors, Clinical Investigators, and IRBs",10/01/2008,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,FDA-2008-D-0576
S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals,PDF (184.53 KB)PDF (184.53 KB) of S1C(R2) Dose Selection for Carcinogenicity Studies of Pharmaceuticals,09/17/2008,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,
Animal Models — Essential Elements to Address Efficacy Under the Animal Rule - Concept Paper,PDF (28.21 KB)PDF (28.21 KB) of Animal Models — Essential Elements to Address Efficacy Under the Animal Rule - Concept Paper,09/09/2008,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,None found
Clinical Study Designs for Catheter Ablation Devices for Treatment of Atrial Flutter:  Guidance for Industry and FDA Staff,PDF (86.12 KB)PDF (86.12 KB) of Clinical Study Designs for Catheter Ablation Devices for Treatment of Atrial Flutter:  Guidance for Industry and FDA Staff,08/05/2008,Center for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP)",Final,No,,FDA-2020-D-0957
Voting Procedures for Advisory Committee Meetings:  Guidance for FDA Advisory Committee Members and FDA Staff,PDF (36.7 KB)PDF (36.7 KB) of Voting Procedures for Advisory Committee Meetings:  Guidance for FDA Advisory Committee Members and FDA Staff,08/01/2008,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy","Advisory Committees, Food & Color Additives",Final,No,,
Preparation and Public Availability  of Information Given to Advisory Committee Members:  Guidance for Industry,PDF (169.24 KB)PDF (169.24 KB) of Preparation and Public Availability  of Information Given to Advisory Committee Members:  Guidance for Industry,08/01/2008,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy","Advisory Committees, Food & Color Additives",Final,No,,
CPG Sec 540.575 Fish - Fresh and Frozen - Adulteration Involving Decomposition (Withdrawn 7/18/2008),,07/18/2008,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
Small Entity Compliance Guide: Nutrient Content Claims Definition for “High Potency” and Definition for “Antioxidant” for Use in Nutrient Content Claims for Dietary Supplements and Conventional Foods,,07/18/2008,Human Foods Program,Labeling,Final,No,,FDA-1995-N-0400
Small Entity Compliance Guide: Final Rule Declaring Dietary Supplements Containing Ephedrine Alkaloids Adulterated Because They Present an Unreasonable Risk,,07/17/2008,Human Foods Program,,Final,No,,FDA-1995-N-0054
Small Entity Compliance Guide: Standard of Identity for White Chocolate,,07/16/2008,Human Foods Program,Chocolate/Cocoa Product,Final,No,,FDA-2008-N-0361
Current Good Manufacturing Practice for Phase 1 Investigational Drugs:  Guidance for Industry,PDF (91.58 KB)PDF (91.58 KB) of Current Good Manufacturing Practice for Phase 1 Investigational Drugs:  Guidance for Industry,07/14/2008,Office of Regulatory AffairsCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Investigation & Enforcement, Current Good Manufacturing Practice (CGMP), Good Clinical Practice (GCP), Pharmaceutical Quality",Final,No,,FDA-2005-D-0157
Intravascular Administration Sets Premarket Notification Submissions [510(k)]:  Guidance for Industry and FDA Staff,PDF (317.03 KB)PDF (317.03 KB) of Intravascular Administration Sets Premarket Notification Submissions [510(k)]:  Guidance for Industry and FDA Staff,07/11/2008,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Surveillance and Detention Without Physical Examination of Condoms:  Guidance for Industry and FDA Staff,PDF (81.04 KB)PDF (81.04 KB) of Surveillance and Detention Without Physical Examination of Condoms:  Guidance for Industry and FDA Staff,07/11/2008,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2000-D-0137
Surveillance and Detention Without Physical Examination of Surgeons' and/or Patient Examination Gloves:  Guidance for Industry and FDA Staff,PDF (79.52 KB)PDF (79.52 KB) of Surveillance and Detention Without Physical Examination of Surgeons' and/or Patient Examination Gloves:  Guidance for Industry and FDA Staff,07/11/2008,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2000-D-0186
"CPG Sec 560.700 - Processing of Imported Frozen Products of Multiple Sizes (e.g., Shrimp, Prawns, Etc.) (Withdrawn 6/6/2008)",,06/06/2008,Human Foods Program,"Investigation & Enforcement, Import",Final,No,,
Q3A(R) Impurities in New Drug Substances,PDF (54.73 KB)PDF (54.73 KB) of Q3A(R) Impurities in New Drug Substances,06/06/2008,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,
Indexing Structured Product Labeling,PDF (51.21 KB)PDF (51.21 KB) of Indexing Structured Product Labeling,06/02/2008,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,FDA-2007-D-0364
"Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency:  Guidance for Industry","PDF (75.91 KB)PDF (75.91 KB) of Safety, Efficacy, and Pharmacokinetic Studies to Support Marketing of Immune Globulin Intravenous (Human) as Replacement Therapy for Primary Humoral Immunodeficiency:  Guidance for Industry",06/01/2008,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2005-D-0208
Hemodialysis Blood Tubing Sets - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,PDF (110.19 KB)PDF (110.19 KB) of Hemodialysis Blood Tubing Sets - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,04/23/2008,Center for Devices and Radiological Health,510(k),Final,No,,FDA-2020-D-0957
"Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests:  Guidance for Industry","PDF (62.69 KB)PDF (62.69 KB) of Certain Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) Recovered from Donors Who Were Tested for Communicable Diseases Using Pooled Specimens or Diagnostic Tests:  Guidance for Industry",04/16/2008,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2007-D-0070
Investigational Device Exemptions (IDEs) for Devices Indicated for Nocturnal Home Hemodialysis:  Guidance for Industry and FDA Staff,PDF (196.53 KB)PDF (196.53 KB) of Investigational Device Exemptions (IDEs) for Devices Indicated for Nocturnal Home Hemodialysis:  Guidance for Industry and FDA Staff,04/15/2008,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE)",Final,No,,FDA-2020-D-0957
Preparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs:  Guidance for Industry and FDA Staff,PDF (241.1 KB)PDF (241.1 KB) of Preparation and Review of Investigational Device Exemption Applications (IDEs) for Total Artificial Discs:  Guidance for Industry and FDA Staff,04/11/2008,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE), Orthopedic",Final,No,,FDA-2020-D-0957
E15 Pharmacogenomics Definitions and Sample Coding,PDF (53.27 KB)PDF (53.27 KB) of E15 Pharmacogenomics Definitions and Sample Coding,04/08/2008,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2008-D-0199
"Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs):  Guidance for FDA Reviewers and Sponsors","PDF (160.29 KB)PDF (160.29 KB) of  Content and Review of Chemistry, Manufacturing, and Control (CMC) Information for Human Somatic Cell Therapy Investigational New Drug Applications (INDs):  Guidance for FDA Reviewers and Sponsors",04/01/2008,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2008-D-0206
Guidance for Industry: A Labeling Guide for Restaurants and Retail Establishments Selling Away-From-Home Foods - Part I,,03/31/2008,Human Foods Program,"Labeling, Retail Food Protection",Final,No,,
"CPG Sec 500.500 Guidance Levels for 3-MCPD (3-chloro-1,2-propanediol) in Acid-Hydrolyzed Protein and Asian-Style Sauces","PDF (25.9 KB)PDF (25.9 KB) of CPG Sec 500.500 Guidance Levels for 3-MCPD (3-chloro-1,2-propanediol) in Acid-Hydrolyzed Protein and Asian-Style Sauces",03/14/2008,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Ingredients",Final,No,,
Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards of Fresh-cut Fruits and Vegetables,,02/25/2008,Human Foods Program,"Fruit/Fruit Product , Vegetable Products, Produce, Sanitation",Final,No,,FDA-2008-D-0108
Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products:  Guidance for Industry,PDF (64.2 KB)PDF (64.2 KB) of Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products:  Guidance for Industry,02/25/2008,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket, Administrative / Procedural",Final,No,,FDA-2008-D-0060
Q4B Annex I: Residue on Ignition/Sulphated Ash General Chapter,PDF (58.33 KB)PDF (58.33 KB) of Q4B Annex I: Residue on Ignition/Sulphated Ash General Chapter,02/21/2008,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2008-D-0083
Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions,PDF (54.51 KB)PDF (54.51 KB) of Q4B Evaluation and Recommendation of Pharmacopoeial Texts for Use in the International Conference on Harmonisation Regions,02/20/2008,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2008-D-0081
Coronary and Carotid Embolic Protection Devices - Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,PDF (155.34 KB)PDF (155.34 KB) of Coronary and Carotid Embolic Protection Devices - Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,02/15/2008,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
CPG Sec 555.320 Listeria monocytogenes,,02/01/2008,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Draft,No,,
Medical Glove Guidance Manual:  Guidance for Industry and FDA Staff,PDF (770.76 KB)PDF (770.76 KB) of Medical Glove Guidance Manual:  Guidance for Industry and FDA Staff,01/22/2008,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
CVM GFI #179 Use of Animal Clones and Clone Progeny for Human Food and Animal Feed,PDF (51.58 KB)PDF (51.58 KB) of CVM GFI #179 Use of Animal Clones and Clone Progeny for Human Food and Animal Feed,01/15/2008,Center for Veterinary Medicine,"Biotechnology,",Final,No,,FDA-2008-N-0033
The Review and Inspection of Premarket Approval Application Manufacturing Information and Operations:  Guidance for Industry and FDA Staff,PDF (158.84 KB)PDF (158.84 KB) of The Review and Inspection of Premarket Approval Application Manufacturing Information and Operations:  Guidance for Industry and FDA Staff,01/08/2008,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
CPG Sec 575.100 Draft Revision - Pesticide Chemical Residues in Food - Enforcement Criteria,PDF (807.66 KB)PDF (807.66 KB) of CPG Sec 575.100 Draft Revision - Pesticide Chemical Residues in Food - Enforcement Criteria,01/01/2008,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Draft,No,,
Guidance for Industry: Preparation of Premarket Submissions for Food Contact Substances (Chemistry Recommendations),,12/01/2007,Human Foods Program,"Food & Color Additives, Ingredients",Final,No,,FDA-2020-D-1925
Collection of Platelets by Automated Methods:  Guidance for Industry and FDA Review Staff,PDF (153.01 KB)PDF (153.01 KB) of  Collection of Platelets by Automated Methods:  Guidance for Industry and FDA Review Staff,12/01/2007,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2005-D-0013
CVM GFI #92 (VICH GL10(R)) Impurities In New Veterinary Drug Substances,PDF (149.87 KB)PDF (149.87 KB) of CVM GFI #92 (VICH GL10(R)) Impurities In New Veterinary Drug Substances,11/26/2007,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-1999-D-0064
CVM GFI #73 (VICH GL3(R)) Stability Testing of New Veterinary Drug Substances and Medicinal Products,PDF (227.8 KB)PDF (227.8 KB) of CVM GFI #73 (VICH GL3(R)) Stability Testing of New Veterinary Drug Substances and Medicinal Products,11/21/2007,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-2006-D-0299
CVM GFI #93 (VICH GL11(R)) Impurities in New Veterinary Medicinal Products,PDF (133.55 KB)PDF (133.55 KB) of CVM GFI #93 (VICH GL11(R)) Impurities in New Veterinary Medicinal Products,11/21/2007,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-1999-D-0048
"Adequate and Appropriate Donor Screening Tests for Hepatitis B; Hepatitis B Surface Antigen (HBsAg) Assays Used to Test Donors of Whole Blood and Blood Components, Including Source Plasma and Source Leukocytes:  Guidance for Industry","PDF (27.28 KB)PDF (27.28 KB) of  Adequate and Appropriate Donor Screening Tests for Hepatitis B; Hepatitis B Surface Antigen (HBsAg) Assays Used to Test Donors of Whole Blood and Blood Components, Including Source Plasma and Source Leukocytes:  Guidance for Industry",11/21/2007,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2002-D-0175
Considerations for Plasmid DNA Vaccines for Infectious Disease Indications:  Guidance for Industry,PDF (87.65 KB)PDF (87.65 KB) of Considerations for Plasmid DNA Vaccines for Infectious Disease Indications:  Guidance for Industry,11/01/2007,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-2005-D-0211
Role of HIV Drug Resistance Testing in Antiretroviral Drug Development,PDF (238.03 KB)PDF (238.03 KB) of Role of HIV Drug Resistance Testing in Antiretroviral Drug Development,10/31/2007,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2004-D-0242
Inspection and Field Testing of Radiation-Emitting Electronic Products: Attachment A,,10/30/2007,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health","Postmarket,",Final,No,,FDA-2020-D-0957
Inspection and Field Testing of Radiation-Emitting Electronic Products: Attachment C: Specific Instructions for Sunlamp Product Inspections and Tests,,10/30/2007,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",,Final,No,,FDA-2020-D-0957
Biological Indicator (BI) Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,PDF (189.01 KB)PDF (189.01 KB) of Biological Indicator (BI) Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,10/04/2007,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Guidance for Industry: Food Security Preventive Measures for Importers and Filers,,10/01/2007,Human Foods Program,"Import, Defense & Security",Final,No,,FDA-2020-D-1926
Guidance for Industry: Food Security Preventive Measures Guidance for  Retail Food Stores and Food Service Establishments,,10/01/2007,Human Foods Program,"Defense & Security, Retail Food Protection",Final,No,,FDA-2020-D-1927
"Guidance for Industry: Food Security Preventive Measures Guidance for Dairy Farms, Bulk Milk Transporters, Bulk Milk Transfer Stations and Fluid Milk Processors",,10/01/2007,Human Foods Program,Milk/Milk Product,Final,No,,FDA-2020-D-1928
CVM GFI #178 Recommended Design and Evaluation of Effectiveness Studies for Swine Respiratory Disease Claims,PDF (139.98 KB)PDF (139.98 KB) of CVM GFI #178 Recommended Design and Evaluation of Effectiveness Studies for Swine Respiratory Disease Claims,10/01/2007,Center for Veterinary Medicine,Animal Feed,Final,No,,FDA-2006-D-0479
"Guidance for Industry: Food Security Preventive Measures Guidance for Food Producers, Processors, and Transporters",,09/30/2007,Human Foods Program,Transportation,Final,No,,FDA-2020-D-1929
Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials:  Guidance for Industry,PDF (114.01 KB)PDF (114.01 KB) of Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials:  Guidance for Industry,09/27/2007,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-2005-D-0272
Procedures for Renewal and Amendment of Certain Laser Light Show Variances (Laser Notice 55),PDF (230.36 KB)PDF (230.36 KB) of Procedures for Renewal and Amendment of Certain Laser Light Show Variances (Laser Notice 55),09/24/2007,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",,Final,No,,FDA-2020-D-0957
Compliance Guide for Cabinet X-Ray Systems,PDF (624.92 KB)PDF (624.92 KB) of Compliance Guide for Cabinet X-Ray Systems,09/18/2007,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",,Final,No,,FDA-2020-D-0957
Non-clinical Information for Femoral Stem Prostheses:  Guidance for Industry and FDA Staff,PDF (156.85 KB)PDF (156.85 KB) of Non-clinical Information for Femoral Stem Prostheses:  Guidance for Industry and FDA Staff,09/17/2007,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions:  Guidance for Industry and FDA Staff,PDF (138.61 KB)PDF (138.61 KB) of Commercially Distributed Analyte Specific Reagents (ASRs): Frequently Asked Questions:  Guidance for Industry and FDA Staff,09/13/2007,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Good Clinical Practice (GCP)",Final,No,,FDA-2006-D-0357
Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Sugar Free Claims,,09/03/2007,Human Foods Program,Labeling,Final,No,,FDA-2020-D-1930
Manufacturing Biological Intermediates and Biological Drug Substances Using Spore-Forming Microorganisms:  Guidance for Industry,PDF (156.61 KB)PDF (156.61 KB) of Manufacturing Biological Intermediates and Biological Drug Substances Using Spore-Forming Microorganisms:  Guidance for Industry,09/01/2007,Center for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2003-N-0096
Pharmacogenomic Data Submissions — Companion Guidance,PDF (211.18 KB)PDF (211.18 KB) of Pharmacogenomic Data Submissions — Companion Guidance,08/28/2007,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-2007-D-0136
"Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products:  Guidance for Industry","PDF (502.42 KB)PDF (502.42 KB) of Eligibility Determination for Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products:  Guidance for Industry",08/08/2007,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2004-D-0225
Writing Dear Doctor Letters for Recalls of Implantable Cardioverter Defibrillators (ICDs):  Guidance for Industry and FDA Staff,PDF (144.9 KB)PDF (144.9 KB) of Writing Dear Doctor Letters for Recalls of Implantable Cardioverter Defibrillators (ICDs):  Guidance for Industry and FDA Staff,07/19/2007,Center for Devices and Radiological Health,"Postmarket, Radiological Health",Final,No,,FDA-2020-D-0957
"ANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information:  Guidance for Industry","PDF (109.51 KB)PDF (109.51 KB) of ANDAs:Pharmaceutical Solid Polymorphism: Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",07/09/2007,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality",Final,No,,FDA-2004-D-0182
Guidance for Industry and Other Stakeholders: Redbook 2000 :  Toxicological Principles for the Safety Assessment of Food Ingredients,,07/02/2007,Human Foods Program,"Food & Color Additives, Ingredients",Final,No,,
Redbook 2000: I Introduction,,07/01/2007,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: III Recommended Toxicity Studies,,07/01/2007,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.1. Short-Term Tests for Genetic Toxicity,,07/01/2007,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.5.a. Chronic Toxicity Studies with Rodents,,07/01/2007,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.7. Combined Chronic Toxicity/Carcinogenicity Studies with Rodents,,07/01/2007,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.8. In-Utero Exposure Phase for Addition to Carcinogenicity Studies or Chronic Toxicity Studies with Rodents,,07/01/2007,Human Foods Program,Food & Color Additives,Final,No,,
"Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry and FDA Staff","PDF (28.52 KB)PDF (28.52 KB) of Devices Used to Process Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry and FDA Staff",07/01/2007,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Final,No,,FDA-2020-D-1407
Bundling Multiple Devices or Multiple Indications in a Single Submission:  Guidance for Industry and FDA Staff,PDF (439.01 KB)PDF (439.01 KB) of Bundling Multiple Devices or Multiple Indications in a Single Submission:  Guidance for Industry and FDA Staff,06/22/2007,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket,",Final,No,,FDA-2003-D-0376
Pre-Clinical and Clinical Studies for Neurothrombectomy Devices:  Guidance for Industry and FDA Staff,PDF (118.87 KB)PDF (118.87 KB) of Pre-Clinical and Clinical Studies for Neurothrombectomy Devices:  Guidance for Industry and FDA Staff,06/18/2007,Center for Devices and Radiological Health,"Premarket, Good Clinical Practice (GCP)",Final,No,,FDA-2020-D-0957
Guidance for Industry: Refrigerated Carrot Juice and Other Refrigerated Low-Acid Juices,,06/05/2007,Human Foods Program,Juice,Final,No,,FDA-2007-D-0030
CPG Sec. 130.300  FDA Access to Results of Quality Assurance Program Audits and Inspections,,06/01/2007,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
Redbook 2000: IV.B.4. Statistical Considerations in Toxicity Studies,,06/01/2007,Human Foods Program,Food & Color Additives,Final,No,,
Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs:  Guidance for Industry,PDF (56.11 KB)PDF (56.11 KB) of Informed Consent Recommendations for Source Plasma Donors Participating in Plasmapheresis and Immunization Programs:  Guidance for Industry,06/01/2007,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2006-D-0350
Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines:  Guidance for Industry,PDF (187.68 KB)PDF (187.68 KB) of Clinical Data Needed to Support the Licensure of Pandemic Influenza Vaccines:  Guidance for Industry,05/31/2007,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-2006-D-0351
Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines:  Guidance for Industry,PDF (165.68 KB)PDF (165.68 KB) of Clinical Data Needed to Support the Licensure of Seasonal Inactivated Influenza Vaccines:  Guidance for Industry,05/31/2007,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-2006-D-0222
"CVM GFI #83 Chemistry, Manufacturing and Controls Changes to Approved NADA/ANADA","PDF (162.29 KB)PDF (162.29 KB) of CVM GFI #83 Chemistry, Manufacturing and Controls Changes to Approved NADA/ANADA",05/30/2007,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), New Animal Drug Application (NADA)",Final,No,,FDA-1999-D-0011
CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds,PDF (94.14 KB)PDF (94.14 KB) of CVM GFI #137 Analytical Methods Description for Type C Medicated Feeds,05/08/2007,Center for Veterinary Medicine,"Animal Feed, Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2006-D-0231
Small Business Nutrition Labeling Exemption Guidance,,05/07/2007,Human Foods Program,Labeling,Final,No,,
Dental Handpieces - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,PDF (115.81 KB)PDF (115.81 KB) of Dental Handpieces - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,05/02/2007,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
CVM GFI #136 Protocols for the Conduct of Method Transfer Studies for Type C Medicated Feed Assay Methods,PDF (105.42 KB)PDF (105.42 KB) of CVM GFI #136 Protocols for the Conduct of Method Transfer Studies for Type C Medicated Feed Assay Methods,04/26/2007,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2006-D-0230
CVM GFI #150 Concerns Related to the use of Clove Oil as an Anesthetic for Fish,PDF (40.75 KB)PDF (40.75 KB) of CVM GFI #150 Concerns Related to the use of Clove Oil as an Anesthetic for Fish,04/24/2007,Center for Veterinary Medicine,Aquaculture,Final,No,,FDA-2020-D-1442
Approval of Alternate Means of Labeling for Laser Products (Laser Notice 53),PDF (31.62 KB)PDF (31.62 KB) of Approval of Alternate Means of Labeling for Laser Products (Laser Notice 53),03/22/2007,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",,Final,No,,FDA-2020-D-0957
Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff,PDF (336.84 KB)PDF (336.84 KB) of Statistical Guidance on Reporting Results from Studies Evaluating Diagnostic Tests - Guidance for Industry and FDA Staff,03/12/2007,Center for Devices and Radiological Health,"Biostatistics,",Final,No,,FDA-2020-D-0957
CVM GFI #183 Animal Drug User Fees: Fees Exceed Costs Waiver/Reduction,PDF (117.49 KB)PDF (117.49 KB) of CVM GFI #183 Animal Drug User Fees: Fees Exceed Costs Waiver/Reduction,03/09/2007,Center for Veterinary Medicine,"User Fees,",Final,No,,FDA-2006-D-0361
Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children,PDF (82.43 KB)PDF (82.43 KB) of Orally Inhaled and Intranasal Corticosteroids: Evaluation of the Effects on Growth in Children,03/06/2007,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,FDA-2001-D-0137
Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry,PDF (123.98 KB)PDF (123.98 KB) of Complementary and Alternative Medicine Products and their Regulation by the Food and Drug Administration: Draft Guidance for Industry,02/27/2007,Human Foods ProgramCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,"Premarket, Administrative / Procedural, Food & Color Additives",Draft,No,03/01/2006,FDA-2006-D-0102
"Guidance for Industry and FDA: Letter to Industry, State and Local Food Regulators and Inspectors Regarding  Web-based ALERT Training",,02/22/2007,Human Foods Program,,Final,No,,
User Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR,PDF (45.96 KB)PDF (45.96 KB) of User Fee Waivers for FDC and Co-Packaged HIV Drugs for PEPFAR,02/08/2007,Center for Drug Evaluation and Research,"User Fees,",Final,No,,FDA-2005-D-0083
"CPG Sec 540.600 Fish, Shellfish, Crustaceans and other Aquatic Animals - Fresh, Frozen or Processed - Methyl Mercury",,02/06/2007,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
Guidance for Industry and FDA: Dear Manufacturer Letter Regarding Food Labeling,,01/01/2007,Human Foods Program,Labeling,Final,No,,FDA-1998-N-0050
"Process for Handling Referrals to FDA Under 21 CFR 50.54 - Additional Safeguards for Children in Clinical Investigations:  Guidance for Clinical Investigators, Institutional Review Boards and Sponsors","PDF (115.95 KB)PDF (115.95 KB) of Process for Handling Referrals to FDA Under 21 CFR 50.54 - Additional Safeguards for Children in Clinical Investigations:  Guidance for Clinical Investigators, Institutional Review Boards and Sponsors",12/01/2006,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","Good Clinical Practice (GCP), Pediatric Product Development",Final,No,,
Guidance for Industry: Lead in Candy Likely To Be Consumed Frequently by Small Children:  Recommended Maximum Level and Enforcement Policy,,11/24/2006,Human Foods Program,"Candy/Gum (without chocolate), Lead",Final,No,,FDA-2005-D-0084
"Decorative, Non-corrective Contact Lenses:  Guidance for Industry, FDA Staff, Eye Care Professionals, and Consumers","PDF (55.32 KB)PDF (55.32 KB) of Decorative, Non-corrective Contact Lenses:  Guidance for Industry, FDA Staff, Eye Care Professionals, and Consumers",11/24/2006,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Prescription Drug Marketing Act (PDMA) Requirements- Questions and Answers,PDF (111.75 KB)PDF (111.75 KB) of Prescription Drug Marketing Act (PDMA) Requirements- Questions and Answers,11/15/2006,Center for Drug Evaluation and Research,"Compliance,",Final,No,,FDA-1992-N-0056
CVM GFI #35 Bioequivalence Guidance,PDF (181.84 KB)PDF (181.84 KB) of CVM GFI #35 Bioequivalence Guidance,11/08/2006,Center for Veterinary Medicine,"Generic Animal Drugs, Generic Drugs",Final,No,,FDA-1994-D-0317
Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components,PDF (115.19 KB)PDF (115.19 KB) of Biological Product Deviation Reporting for Licensed Manufacturers of Biological Products Other than Blood and Blood Components,10/19/2006,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2001-D-0008
CPG Sec. 100.550 Status and Responsibilities of Contract Sterilizers Engaged in the Sterilization of Drugs and Devices,,10/02/2006,Center for Devices and Radiological HealthOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations,PDF (362.89 KB)PDF (362.89 KB) of Quality Systems Approach to Pharmaceutical Current Good Manufacturing Practice Regulations,10/02/2006,Center for Veterinary MedicineOffice of Regulatory AffairsCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Investigation & Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2004-D-0300
"Public Availability of Labeling Changes in ""Changes Being Effected"" Supplements","PDF (25.91 KB)PDF (25.91 KB) of Public Availability of Labeling Changes in ""Changes Being Effected"" Supplements",09/20/2006,Center for Drug Evaluation and Research,Labeling,Draft,No,,FDA-2006-D-0038
Keratome and Replacement Keratome Blades Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,PDF (113.6 KB)PDF (113.6 KB) of Keratome and Replacement Keratome Blades Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,09/18/2006,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Compliance with 21 CFR Part 1271.150(c)(1) – Manufacturing Arrangements:  Guidance for Industry,PDF (45.62 KB)PDF (45.62 KB) of Compliance with 21 CFR Part 1271.150(c)(1) – Manufacturing Arrangements:  Guidance for Industry,09/08/2006,Center for Biologics Evaluation and Research,"Compliance, Tissue",Final,No,,
Early Development Considerations for Innovative Combination Products:  Guidance for Industry  and FDA Staff,PDF (129.58 KB)PDF (129.58 KB) of Early Development Considerations for Innovative Combination Products:  Guidance for Industry  and FDA Staff,09/01/2006,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Final,No,,FDA-2020-D-1455
Implementing a Collection Program for Source Plasma Containing Disease-Associated and Other Immunoglobulin (IgG) Antibodies:  Guidance for Industry,PDF (42.09 KB)PDF (42.09 KB) of Implementing a Collection Program for Source Plasma Containing Disease-Associated and Other Immunoglobulin (IgG) Antibodies:  Guidance for Industry,08/08/2006,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2005-D-0014
Q3B(R) Impurities in New Drug Products (Revision 3),PDF (133.64 KB)PDF (133.64 KB) of Q3B(R) Impurities in New Drug Products (Revision 3),08/04/2006,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-1996-D-0048 (Revision 1)
Guidance for Industry: Estimating Dietary Intake of Substances in Food,,08/01/2006,Human Foods Program,"Food & Color Additives, Ingredients",Final,No,,
CVM GFI #141 (VICH GL28) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing,PDF (82.76 KB)PDF (82.76 KB) of CVM GFI #141 (VICH GL28) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Carcinogenicity Testing,07/27/2006,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2001-D-0101
CVM GFI #147 (VICH GL31) Studies to Evaluate the Safety of Residues of  Veterinary Drugs in Human Food: Repeat-Dose (90 Day) Toxicity Testing,PDF (102.13 KB)PDF (102.13 KB) of CVM GFI #147 (VICH GL31) Studies to Evaluate the Safety of Residues of  Veterinary Drugs in Human Food: Repeat-Dose (90 Day) Toxicity Testing,07/27/2006,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2002-D-0091
CVM GFI #148 (VICH GL32) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Developmental Toxicity Testing,PDF (52.06 KB)PDF (52.06 KB) of CVM GFI #148 (VICH GL32) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Developmental Toxicity Testing,07/27/2006,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2002-D-0090
CVM GFI #160 (VICH GL37) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (Chronic) Toxicity Testing,PDF (75.3 KB)PDF (75.3 KB) of CVM GFI #160 (VICH GL37) Studies to Evaluate the Safety of Residues of Veterinary Drugs in Human Food: Repeat-Dose (Chronic) Toxicity Testing,07/27/2006,Center for Veterinary Medicine,"Human Food Safety, VICH",Final,No,,FDA-2003-D-0372
Useful Written Consumer Medication Information (CMI),PDF (278.35 KB)PDF (278.35 KB) of Useful Written Consumer Medication Information (CMI),07/18/2006,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2005-D-0397
CPG Sec. 608.100  Human-Labeled Drugs Distributed and Used in Animal  Medicine (Withdrawn 7/7/2006),,07/07/2006,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 616.100  Streptomycin Residues in Cattle Tissues (Withdrawn 7/7/2006),,07/06/2006,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs, Human Food Safety",Final,No,,
Guidance for Industry: Recommendations for the Early Food Safety Evaluation of New Non-Pesticidal Proteins Produced by New Plant Varieties Intended for Food Use,,06/19/2006,Human Foods Program,Bioengineering / GMOs,Final,No,,FDA-2004-D-0044
CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances,PDF (277.27 KB)PDF (277.27 KB) of CVM GFI #176 (VICH GL39) Specifications: Test Procedures and Acceptance Criteria for New Veterinary Drug Substances and New Medicinal Products: Chemical Substances,06/14/2006,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-2005-D-0336
CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products,PDF (286.03 KB)PDF (286.03 KB) of CVM GFI #177 (VICH GL40) Test Procedures/Acceptance Criteria for New Biotechnological/Biological Veterinary Medicinal Products,06/14/2006,Center for Veterinary Medicine,VICH,Final,No,,FDA-2005-D-0028
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency,PDF (100.47 KB)PDF (100.47 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency,06/05/2006,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2005-D-0282
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency : Guidance for Submitting Influenza Resistance Data,PDF (107.75 KB)PDF (107.75 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency : Guidance for Submitting Influenza Resistance Data,06/02/2006,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2005-D-0282
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency:  Guidance for Submitting HCV Resistance Data,PDF (128.2 KB)PDF (128.2 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency:  Guidance for Submitting HCV Resistance Data,06/02/2006,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HBV Resistance Data,PDF (84.75 KB)PDF (84.75 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HBV Resistance Data,06/02/2006,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,FDA-2005-D-0183
Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data,PDF (116.53 KB)PDF (116.53 KB) of Antiviral Product Development--Conducting and Submitting Virology Studies to the Agency: Guidance for Submitting HIV Resistance Data,06/02/2006,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,None found
Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment,PDF (105.62 KB)PDF (105.62 KB) of Chronic Cutaneous Ulcer and Burn Wounds -- Developing Products for Treatment,06/02/2006,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2000-D-0037
Guidance for Industry: Summary Table of Recommended Toxicological Testing for Additives Used in Food,,06/01/2006,Human Foods Program,Food & Color Additives,Final,No,,FDA-2020-D-1936
"CVM GFI #126 BACPAC I-Intermediates in Drug Substance Synthesis Bulk Actives Postapproval Changes: Chemistry, Manufacturing, and Controls Documentation","PDF (134.14 KB)PDF (134.14 KB) of CVM GFI #126 BACPAC I-Intermediates in Drug Substance Synthesis Bulk Actives Postapproval Changes: Chemistry, Manufacturing, and Controls Documentation",06/01/2006,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2021-D-0610
Guidance for Industry: Appendix C of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,,05/16/2006,Human Foods Program,Food & Color Additives,Final,No,,
Guidance for Industry: Appendix D of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,,05/16/2006,Human Foods Program,Food & Color Additives,Final,No,,
Guidance for Industry: Appendix E of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN (40 CFR 1508.27),,05/16/2006,Human Foods Program,Food & Color Additives,Final,No,,
Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,,05/16/2006,Human Foods Program,Food & Color Additives,Final,No,,FDA-2003-D-0087
Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN - Attachment 1,,05/16/2006,Human Foods Program,Food & Color Additives,Final,No,,
Guidance for Industry: Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN - Attachment 2,,05/16/2006,Human Foods Program,Food & Color Additives,Final,No,,
Guidance for Industry: FDA's Implementation of Qualified Health Claims,,05/12/2006,Human Foods Program,Labeling,Final,No,,
Guidance for Industry: Appendix A of Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,,05/01/2006,Human Foods Program,Food & Color Additives,Final,No,,
Guidance for Industry: Appendix B for Preparing a Claim of Categorical Exclusion or an Environmental Assessment for Submission to CFSAN,,05/01/2006,Human Foods Program,Food & Color Additives,Final,No,,
Guidance for Industry: Preparing a Color Additive Petition for Submission to the Center for Food Safety and Applied Nutrition for Color Additives Used in or on Contact Lenses,,05/01/2006,Human Foods Program,Food & Color Additives,Final,No,,
CVM GFI #117 (VICH GL24) Management of Adverse Event Reports (AER's),PDF (121.27 KB)PDF (121.27 KB) of CVM GFI #117 (VICH GL24) Management of Adverse Event Reports (AER's),05/01/2006,Center for Veterinary Medicine,"Adverse Event Reporting, VICH",Draft,No,,FDA-2000-D-0136
"Compliance with Section 301 of the Medical Device User Fee and Modernization Act of 2002, as amended – Prominent and Conspicuous Mark of Manufacturers on Single-Use Devices:  Guidance for Industry and FDA Staff","PDF (250 KB)PDF (250 KB) of Compliance with Section 301 of the Medical Device User Fee and Modernization Act of 2002, as amended – Prominent and Conspicuous Mark of Manufacturers on Single-Use Devices:  Guidance for Industry and FDA Staff",05/01/2006,Center for Devices and Radiological Health,"Postmarket, User Fees, Labeling",Final,No,,FDA-2005-D-0156
"Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable :  Guidance for Sponsors, Institutional Review Boards, and Food and Drug Administration Staff","PDF (368.81 KB)PDF (368.81 KB) of Guidance on Informed Consent for In Vitro Diagnostic Device Studies Using Leftover Human Specimens that are Not Individually Identifiable :  Guidance for Sponsors, Institutional Review Boards, and Food and Drug Administration Staff",04/25/2006,"Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Office of Blood Research and Review","Premarket, Good Clinical Practice (GCP)",Final,No,,FDA-2006-D-0095
S8 Immunotoxicity Studies for Human Pharmaceuticals,PDF (72.49 KB)PDF (72.49 KB) of S8 Immunotoxicity Studies for Human Pharmaceuticals,04/12/2006,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2005-D-0398
Redbook 2000: IV.C.1.c Mouse Lymphoma Thymidine Kinase Gene Mutation Assay,,04/01/2006,Human Foods Program,Food & Color Additives,Final,No,,
Establishment and Operation of Clinical Trial Data Monitoring Committees:  Guidance for Clinical Trial Sponsors,PDF (395.28 KB)PDF (395.28 KB) of Establishment and Operation of Clinical Trial Data Monitoring Committees:  Guidance for Clinical Trial Sponsors,03/28/2006,Center for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,FDA-2001-D-0219
Dental Curing Lights - Premarket Notification [510(k)]:  Guidance for Industry and FDA Staff,PDF (193.97 KB)PDF (193.97 KB) of Dental Curing Lights - Premarket Notification [510(k)]:  Guidance for Industry and FDA Staff,03/27/2006,Center for Devices and Radiological Health,"Premarket, 510(k), Dental",Final,No,,FDA-2020-D-0957
Tonometers - Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,PDF (232.63 KB)PDF (232.63 KB) of Tonometers - Premarket Notification [510(k)] Submissions :  Guidance for Industry and FDA Staff,03/27/2006,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Using a Centralized IRB Review Process in Multicenter Clinical Trials:  Guidance for Industry,PDF (734.96 KB)PDF (734.96 KB) of Using a Centralized IRB Review Process in Multicenter Clinical Trials:  Guidance for Industry,03/16/2006,"Office of Regulatory AffairsOffice of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research","Investigation & Enforcement, Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2005-D-0443
Nonclinical Safety Evaluation of Drug or Biologic Combinations,PDF (99.71 KB)PDF (99.71 KB) of Nonclinical Safety Evaluation of Drug or Biologic Combinations,03/15/2006,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,2005D-0004
Prescription Drug Marketing Act — Donation of Prescription Drug Samples to Free Clinics,PDF (37.79 KB)PDF (37.79 KB) of Prescription Drug Marketing Act — Donation of Prescription Drug Samples to Free Clinics,03/14/2006,Center for Drug Evaluation and Research,"Compliance,",Final,No,,FDA-2002-D-0092
Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment:  Guidance for Industry and FDA Staff,PDF (978.13 KB)PDF (978.13 KB) of Hospital Bed System Dimensional and Assessment Guidance to Reduce Entrapment:  Guidance for Industry and FDA Staff,03/10/2006,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2004-D-0499
Internal Radioactive Contamination —Development of Decorporation Agents,PDF (176.7 KB)PDF (176.7 KB) of Internal Radioactive Contamination —Development of Decorporation Agents,03/02/2006,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2005-D-0025
Guidance for Industry: Frequently Asked Questions about FDA's Regulation of Infant Formula,,03/01/2006,Human Foods Program,Infant Formula & Foods,Final,No,,FDA-2020-D-1937
Using Electronic Means to Distribute Certain Product Information:  Guidance for Industry,,02/28/2006,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","Administrative / Procedural, Food & Color Additives",Final,No,,
Draft Guidance for Industry and FDA Staff: Whole Grain Label Statements,,02/17/2006,Human Foods Program,Labeling,Draft,No,04/18/2006,FDA-2006-D-0298
Reports on the Status of Postmarketing Study Commitments — Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997,PDF (455.98 KB)PDF (455.98 KB) of Reports on the Status of Postmarketing Study Commitments — Implementation of Section 130 of the Food and Drug Administration Modernization Act of 1997,02/16/2006,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-1999-N-0098
Nonclinical Safety Evaluation of Pediatric Drug Products,PDF (478.84 KB)PDF (478.84 KB) of Nonclinical Safety Evaluation of Pediatric Drug Products,02/15/2006,Center for Drug Evaluation and Research,"Pediatric Product Development, Pharmacology/Toxicology",Final,No,,2003D-0001
Pharmacogenetic Tests and Genetic Tests for Heritable Markers:  Guidance for Industry and FDA Staff,PDF (66.47 KB)PDF (66.47 KB) of Pharmacogenetic Tests and Genetic Tests for Heritable Markers:  Guidance for Industry and FDA Staff,02/09/2006,Center for Devices and Radiological HealthCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Premarket,",Final,No,,FDA-2006-D-0232
Providing Regulatory Submissions in Electronic Format Orphan-Drug and Humanitarian Use Device Designation Requests and Related Submissions: Draft Draft Guidance for Industry,PDF (128.17 KB)PDF (128.17 KB) of Providing Regulatory Submissions in Electronic Format Orphan-Drug and Humanitarian Use Device Designation Requests and Related Submissions: Draft Draft Guidance for Industry,02/01/2006,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Orphan Products Development",Administrative / Procedural,Draft,No,,FDA-2006-D-0159
Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications:  Guidance for Industry,PDF (53.02 KB)PDF (53.02 KB) of  Considerations for Developmental Toxicity Studies for Preventive and Therapeutic Vaccines for Infectious Disease Indications:  Guidance for Industry,02/01/2006,Center for Biologics Evaluation and Research,"Pediatric Product Development, Vaccines",Final,No,,FDA-2000-D-0029
Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,PDF (51.79 KB)PDF (51.79 KB) of Adverse Reactions Section of Labeling for Human Prescription Drug and Biological Products — Content and Format,01/24/2006,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Labeling,Final,No,,FDA-2005-D-0153
Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format:  Guidance for Industry,PDF (126.9 KB)PDF (126.9 KB) of Clinical Studies Section of Labeling for Human Prescription Drug and Biological Products — Content and Format:  Guidance for Industry,01/24/2006,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Good Clinical Practice (GCP), Labeling",Final,No,,FDA-2000-D-0074
"Exploratory IND Studies:  Guidance for Industry, Investigators, and Reviewers","PDF (219.74 KB)PDF (219.74 KB) of Exploratory IND Studies:  Guidance for Industry, Investigators, and Reviewers",01/12/2006,Center for Drug Evaluation and Research,"Good Clinical Practice (GCP), Pharmacology/Toxicology",Final,No,,
Formal Dispute Resolution:  Scientific and Technical Issues Related to Pharmaceutical CGMP,PDF (266.83 KB)PDF (266.83 KB) of Formal Dispute Resolution:  Scientific and Technical Issues Related to Pharmaceutical CGMP,01/11/2006,Center for Veterinary MedicineOffice of Regulatory AffairsCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Investigation & Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2003-D-0369
CVM GFI #166 (VICH GL38) Environmental Impact Assessments (EIA's) for Veterinary Medicinal Products (VMP’s) - Phase II,PDF (427.09 KB)PDF (427.09 KB) of CVM GFI #166 (VICH GL38) Environmental Impact Assessments (EIA's) for Veterinary Medicinal Products (VMP’s) - Phase II,01/09/2006,Center for Veterinary Medicine,"Environmental Safety, VICH",Final,No,,FDA-2004-D-0273
CVM GFI #123 Development of Data Supporting Approval of NSAIDS for Use in Animals,PDF (52.46 KB)PDF (52.46 KB) of CVM GFI #123 Development of Data Supporting Approval of NSAIDS for Use in Animals,01/05/2006,Center for Veterinary Medicine,"Target Animal – Effectiveness, Target Animal – Safety",Final,No,,FDA-2004-D-0372
Exemption from Reporting and Recordkeeping Requirements for Low Power Laser Products (Laser Notice 54):  Guidance for Industry and FDA Staff,PDF (455.32 KB)PDF (455.32 KB) of Exemption from Reporting and Recordkeeping Requirements for Low Power Laser Products (Laser Notice 54):  Guidance for Industry and FDA Staff,01/05/2006,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Recommended Approaches to Integration of Genetic Toxicology Study Results,PDF (189.87 KB)PDF (189.87 KB) of Recommended Approaches to Integration of Genetic Toxicology Study Results,01/04/2006,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2004-D-0374
Redbook 2000: IV.C.6. Carcinogenicity Studies with Rodents,,01/01/2006,Human Foods Program,Food & Color Additives,Final,No,,
"FDA Institutional Review Board Inspections:  Guidance For IRBs, Clinical Investigators, and Sponsors","PDF (37.77 KB)PDF (37.77 KB) of FDA Institutional Review Board Inspections:  Guidance For IRBs, Clinical Investigators, and Sponsors",01/01/2006,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,
"Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors","PDF (266.36 KB)PDF (266.36 KB) of Frequently Asked Questions About Medical Devices:  Guidance For IRBs, Clinical Investigators, and Sponsors",01/01/2006,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research",Good Clinical Practice (GCP),Final,No,,FDA-2006-D-0031
"Significant Risk and Nonsignificant Risk Medical Device Studies:  Guidance For IRBs, Clinical Investigators, and Sponsors","PDF (214.72 KB)PDF (214.72 KB) of Significant Risk and Nonsignificant Risk Medical Device Studies:  Guidance For IRBs, Clinical Investigators, and Sponsors",01/01/2006,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical PracticeCenter for Devices and Radiological Health","Good Clinical Practice (GCP), Investigational Device Exemption (IDE)",Final,No,,FDA-2006-D-0031
"CPG Sec 500.200 Food Additives -""GRAS""",,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Ingredients",Final,No,,
CPG Sec 500.425 Use of Color Additives in Paper and Paperboard Intended for Use with Food,,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Ingredients",Final,No,,
CPG Sec 500.450 Volatile N-Nitrosamines in Rubber Baby Bottle Nipples,,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Ingredients",Final,No,,
"CPG Sec 505.100 Bakery Products, Candy - ""Catch-All"" or ""Shotgun"" Ingredients Declaration",,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Bakery Product/Mix",Final,No,,
"CPG Sec 510.150 Apple Juice, Apple Juice Concentrates, and Apple Juice Products - Adulteration with Patulin",,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
CPG Sec 510.400 Dealcoholized Wine and Malt Beverages - Labeling,,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
CPG Sec 510.600 Dimethylnitrosamine in Malt Beverages,,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
"CPG Sec 515.775 Cocoa Powder, Press Cake - Adulteration with Insect and Rodent Filth",,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Chocolate/Cocoa Product",Final,No,,
CPG Sec 540.420 Raw Breaded Shrimp - Microbiological Criteria for Evaluating Compliance with Current Good Manufacturing Practice Regulations,,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
"CPG Sec 540.500 Tuna, Sable, Salmon, Shad-Smoked Cured, Adulteration Involving Food Additives, Sodium Nitrite",,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
"CPG Sec 540.650 Uneviscerated Fish Products that are Salt-cured, Dried, or Smoked (Revised)",,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seeds",Final,No,,
"CPG Sec 560.600 Clams, Mussels, Oysters; Fresh or Frozen - Adulteration by Bacteriological Contamination",,11/29/2005,Office of Inspections and Investigations,"Investigation & Enforcement, Import",Final,No,,
CPG Sec 562.200 Foods - FPLA Compliance,,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 562.300 Foods - Net Weight,,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 562.550 Safety and Labeling of Waxed (Coated) Fruits and Vegetables,,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 565.100 FDA Jurisdiction Over Meat and Poultry Products,,11/29/2005,Office of Inspections and Investigations,"Investigation & Enforcement, Meat/Meat Products & Poultry",Final,No,,
CPG Sec 570.700 Mixed Nuts - Misbranding Involving Food Standards,,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,
CPG Sec 587.100 Label Declaration of Certification-Exempt Color Additives,,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Food & Color Additives",Final,No,,
CPG Sec 590.500 Packaging Technologies and Tamper-Resistant Packaging Requirements for Cosmetic Products,,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"Guidance for Industry and FDA Staff: Guidance for Records Access Authority Provided in Title III, Subtitle A, of the Public Health Security and Bioterrorism Preparedness and Response Act of 2002",,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,Records,Final,No,,FDA-2004-G-0002
CPG Sec 510.500 Green Coffee Beans - Adulteration with Insects; Mold,PDF (12.51 KB)PDF (12.51 KB) of CPG Sec 510.500 Green Coffee Beans - Adulteration with Insects; Mold,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
"CPG Sec 515.750 Cocoa Beans - Adulteration by Mold, Insect Infestation, and Mammalian Excreta","PDF (10.63 KB)PDF (10.63 KB) of CPG Sec 515.750 Cocoa Beans - Adulteration by Mold, Insect Infestation, and Mammalian Excreta",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Chocolate/Cocoa Product",Final,No,,
CPG Sec 525.150 Bay (Laurel) Leaves - Adulteration by Insect Filth; Mold; Mammalian Excreta,PDF (10.25 KB)PDF (10.25 KB) of CPG Sec 525.150 Bay (Laurel) Leaves - Adulteration by Insect Filth; Mold; Mammalian Excreta,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
"CPG Sec 525.200 Capsicum Pods, Ground Capsicums Excluding Paprika, Ground Paprika - Adulteration with Insect and Rodent Filth, Mold, Mammalian Excreta","PDF (11.41 KB)PDF (11.41 KB) of CPG Sec 525.200 Capsicum Pods, Ground Capsicums Excluding Paprika, Ground Paprika - Adulteration with Insect and Rodent Filth, Mold, Mammalian Excreta",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.250 Cloves - Adulteration with Stems,PDF (8.82 KB)PDF (8.82 KB) of CPG Sec 525.250 Cloves - Adulteration with Stems,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.300 Condimental Seeds Other than Fennel Seeds and Sesame Seeds - Adulteration by Mammalian Excreta,PDF (9.13 KB)PDF (9.13 KB) of CPG Sec 525.300 Condimental Seeds Other than Fennel Seeds and Sesame Seeds - Adulteration by Mammalian Excreta,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.325 Cumin Seed - Adulteration with Sand and Grit,PDF (8.88 KB)PDF (8.88 KB) of CPG Sec 525.325 Cumin Seed - Adulteration with Sand and Grit,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.330 Curry Powder - Adulteration by Insect and Rodent Filth,PDF (9.43 KB)PDF (9.43 KB) of CPG Sec 525.330 Curry Powder - Adulteration by Insect and Rodent Filth,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.350 Fennel Seed - Adulteration by Mammalian Excreta; Insects,PDF (9.67 KB)PDF (9.67 KB) of CPG Sec 525.350 Fennel Seed - Adulteration by Mammalian Excreta; Insects,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.375 Whole Ginger - Adulteration with Insect Filth; Mold; Mammalian Excreta,PDF (9.75 KB)PDF (9.75 KB) of CPG Sec 525.375 Whole Ginger - Adulteration with Insect Filth; Mold; Mammalian Excreta,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
"CPG Sec 525.500 Leafy Spices, Other than Bay Leaves - Whole Oregano Leaves, Whole Marjoram, Whole Sage Leaves and Whole Thyme Leaves - Adulteration with Insect Filth; Mold; Mammalian Excreta","PDF (10.7 KB)PDF (10.7 KB) of CPG Sec 525.500 Leafy Spices, Other than Bay Leaves - Whole Oregano Leaves, Whole Marjoram, Whole Sage Leaves and Whole Thyme Leaves - Adulteration with Insect Filth; Mold; Mammalian Excreta",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.550 Mace - Adulteration with Insect Filth; Mold; Foreign Matter; Mammalian Excreta,PDF (10.35 KB)PDF (10.35 KB) of CPG Sec 525.550 Mace - Adulteration with Insect Filth; Mold; Foreign Matter; Mammalian Excreta,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.600 Whole and Ground Nutmeg - Adulteration with Insect Filth; Mold; Rodent Filth,PDF (10.27 KB)PDF (10.27 KB) of CPG Sec 525.600 Whole and Ground Nutmeg - Adulteration with Insect Filth; Mold; Rodent Filth,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.625 Whole and Ground Pepper - Adulteration with Insect & Rodent Filth; Mold; Mammalian Excreta; Foreign Matter,PDF (11.26 KB)PDF (11.26 KB) of CPG Sec 525.625 Whole and Ground Pepper - Adulteration with Insect & Rodent Filth; Mold; Mammalian Excreta; Foreign Matter,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.700 Sesame Seeds - Adulteration with Insect Filth; Decomposition; Mammalian Excreta; Foreign Matter,PDF (10.59 KB)PDF (10.59 KB) of CPG Sec 525.700 Sesame Seeds - Adulteration with Insect Filth; Decomposition; Mammalian Excreta; Foreign Matter,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
"CPG Sec 525.850 Whole Plant (Unprocessed) Oregano, Crushed Oregano & Ground Oregano - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta","PDF (11.82 KB)PDF (11.82 KB) of CPG Sec 525.850 Whole Plant (Unprocessed) Oregano, Crushed Oregano & Ground Oregano - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
"CPG Sec 525.900 Whole Plant (Unprocessed) Marjoram, Unground (Processed) Marjoram & Ground Marjoram - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta","PDF (12.13 KB)PDF (12.13 KB) of CPG Sec 525.900 Whole Plant (Unprocessed) Marjoram, Unground (Processed) Marjoram & Ground Marjoram - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
"CPG Sec 525.925 Whole Plant (Unprocessed) Thyme, Unground (Processed) Thyme & Ground Thyme - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta","PDF (12.21 KB)PDF (12.21 KB) of CPG Sec 525.925 Whole Plant (Unprocessed) Thyme, Unground (Processed) Thyme & Ground Thyme - Adulteration by Insect & Rodent Filth; Mold; Mammalian Excreta",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
"CPG Sec 525.950 Whole Plant (Unprocessed) Sage, and Ground Sage - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta","PDF (11.59 KB)PDF (11.59 KB) of CPG Sec 525.950 Whole Plant (Unprocessed) Sage, and Ground Sage - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 527.100 Butter - Adulteration Involving Insufficient Fat Content,PDF (15.26 KB)PDF (15.26 KB) of CPG Sec 527.100 Butter - Adulteration Involving Insufficient Fat Content,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dairy",Final,No,,
CPG Sec 527.225 Cheese - Misbranding Due to Moisture and Fat,PDF (11.48 KB)PDF (11.48 KB) of CPG Sec 527.225 Cheese - Misbranding Due to Moisture and Fat,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Dairy",Final,No,,
CPG Sec 535.100 Oleomargarine - Misbranding Due to Insufficient Fat,PDF (9.88 KB)PDF (9.88 KB) of CPG Sec 535.100 Oleomargarine - Misbranding Due to Insufficient Fat,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Oils",Final,No,,
CPG Sec 537.100 Eggs and Egg Products - Frozen - Adulteration Involving Decomposition,PDF (10.26 KB)PDF (10.26 KB) of CPG Sec 537.100 Eggs and Egg Products - Frozen - Adulteration Involving Decomposition,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Egg/Egg Product",Final,No,,
"CPG Sec 540.590 Fish - Fresh and Frozen, as Listed - Adulteration by Parasites","PDF (11.85 KB)PDF (11.85 KB) of CPG Sec 540.590 Fish - Fresh and Frozen, as Listed - Adulteration by Parasites",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
"CPG Sec 545.300 Foods, Rail Car Sanitation - Adulteration","PDF (12.92 KB)PDF (12.92 KB) of CPG Sec 545.300 Foods, Rail Car Sanitation - Adulteration",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 545.400 Pottery (Ceramics); Import and Domestic - Cadmium Contamination,PDF (14.65 KB)PDF (14.65 KB) of CPG Sec 545.400 Pottery (Ceramics); Import and Domestic - Cadmium Contamination,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 545.450 Pottery (Ceramics); Import and Domestic - Lead Contamination,PDF (17.67 KB)PDF (17.67 KB) of CPG Sec 545.450 Pottery (Ceramics); Import and Domestic - Lead Contamination,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 545.500 Silver-Plated Hollowware - Lead Contamination,PDF (14.47 KB)PDF (14.47 KB) of CPG Sec 545.500 Silver-Plated Hollowware - Lead Contamination,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 545.600 Cinnamon-Flavored Toothpicks,PDF (8.93 KB)PDF (8.93 KB) of CPG Sec 545.600 Cinnamon-Flavored Toothpicks,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
"CPG Sec 550.100 Apple Butter - Adulteration with Mold; Rodent Filth, Insect","PDF (10.52 KB)PDF (10.52 KB) of CPG Sec 550.100 Apple Butter - Adulteration with Mold; Rodent Filth, Insect",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 550.150 Apricots - Canned - Adulteration with Insects,PDF (9.54 KB)PDF (9.54 KB) of CPG Sec 550.150 Apricots - Canned - Adulteration with Insects,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.155 Apricot, Peach and Pear Nectars and Purees - Adulteration with Mold","PDF (11.59 KB)PDF (11.59 KB) of CPG Sec 550.155 Apricot, Peach and Pear Nectars and Purees - Adulteration with Mold",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
"CPG Sec 550.200 Drupelet Berries (Blackberries, Raspberries, Etc.) - Common or Usual Names of Varieties; Canned and Frozen - Adulteration with Rot and Insects","PDF (15.51 KB)PDF (15.51 KB) of CPG Sec 550.200 Drupelet Berries (Blackberries, Raspberries, Etc.) - Common or Usual Names of Varieties; Canned and Frozen - Adulteration with Rot and Insects",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.225 Cherries Brined, Fresh, Canned and Frozen - Adulteration Involving Rot and Insect","PDF (9.65 KB)PDF (9.65 KB) of CPG Sec 550.225 Cherries Brined, Fresh, Canned and Frozen - Adulteration Involving Rot and Insect",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.230 Cherries, Canned - Misbranding Involving Food Standards","PDF (12.42 KB)PDF (12.42 KB) of CPG Sec 550.230 Cherries, Canned - Misbranding Involving Food Standards",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.300 Dates and Date Material; Imported and Domestic - Adulteration Involving Mold, Insect Excreta, Sour, Dirty, Worthless and Pits","PDF (22.01 KB)PDF (22.01 KB) of CPG Sec 550.300 Dates and Date Material; Imported and Domestic - Adulteration Involving Mold, Insect Excreta, Sour, Dirty, Worthless and Pits",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.350 Figs; Fig Paste - Adulteration Involving Insect Infestation; Mold, Dirt","PDF (10.24 KB)PDF (10.24 KB) of CPG Sec 550.350 Figs; Fig Paste - Adulteration Involving Insect Infestation; Mold, Dirt",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.500 Lingon Berries, Canned - Adulteration by Insects","PDF (9.45 KB)PDF (9.45 KB) of CPG Sec 550.500 Lingon Berries, Canned - Adulteration by Insects",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 550.600 Olives - Adulteration Involving Pits; Rot; Insect Infestation,PDF (14.61 KB)PDF (14.61 KB) of CPG Sec 550.600 Olives - Adulteration Involving Pits; Rot; Insect Infestation,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.655 Peaches, Canned - Misbranding Involving Food Standards","PDF (13.61 KB)PDF (13.61 KB) of CPG Sec 550.655 Peaches, Canned - Misbranding Involving Food Standards",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.685 Pineapple, Canned; Imported and Domestic - Misbranding Involving Food Standards","PDF (16.26 KB)PDF (16.26 KB) of CPG Sec 550.685 Pineapple, Canned; Imported and Domestic - Misbranding Involving Food Standards",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.690 Plums, Canned - Adulteration with Rot","PDF (9.43 KB)PDF (9.43 KB) of CPG Sec 550.690 Plums, Canned - Adulteration with Rot",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.700 Dried Prunes, Dehydrated Low Moisture Prunes, and Pitted Prunes - Adulteration Involving Insects; Decomposition; Dirt; Pits; and Pit Fragments","PDF (11.29 KB)PDF (11.29 KB) of CPG Sec 550.700 Dried Prunes, Dehydrated Low Moisture Prunes, and Pitted Prunes - Adulteration Involving Insects; Decomposition; Dirt; Pits; and Pit Fragments",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.750 Raisins - Adulteration Involving Mold, Sand, Grit, & Insects","PDF (9.93 KB)PDF (9.93 KB) of CPG Sec 550.750 Raisins - Adulteration Involving Mold, Sand, Grit, & Insects",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 550.800 Standardized Canned Fruit - Misbranding Involving Improper Declaration of Packing Medium,PDF (10.36 KB)PDF (10.36 KB) of CPG Sec 550.800 Standardized Canned Fruit - Misbranding Involving Improper Declaration of Packing Medium,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.850 Strawberries; Frozen, Whole, or Sliced - Adulteration with Sand, Mold","PDF (10.12 KB)PDF (10.12 KB) of CPG Sec 550.850 Strawberries; Frozen, Whole, or Sliced - Adulteration with Sand, Mold",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 555.250 Statement of Policy for Labeling and Preventing Cross-contact of Common Food Allergens,PDF (24.45 KB)PDF (24.45 KB) of CPG Sec 555.250 Statement of Policy for Labeling and Preventing Cross-contact of Common Food Allergens,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
CPG Sec 555.880 Guidance Levels for Radionuclides in Domestic and Imported Foods,PDF (26.41 KB)PDF (26.41 KB) of CPG Sec 555.880 Guidance Levels for Radionuclides in Domestic and Imported Foods,11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Import",Final,No,,
CPG Sec 560.200 Country of Origin Labeling,PDF (13.81 KB)PDF (13.81 KB) of CPG Sec 560.200 Country of Origin Labeling,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Import",Final,No,,
CPG Sec 570.300 Peanut Butter - Adulteration with Filth; Grit,PDF (12.54 KB)PDF (12.54 KB) of CPG Sec 570.300 Peanut Butter - Adulteration with Filth; Grit,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,
"CPG Sec 570.350 Peanuts, Shelled and Unshelled - Adulteration with Filth and Reject Nuts","PDF (11.77 KB)PDF (11.77 KB) of CPG Sec 570.350 Peanuts, Shelled and Unshelled - Adulteration with Filth and Reject Nuts",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,
"CPG Sec 570.425 Tree Nuts - Adulteration Involving Rejects (Insect Infestation, Moldy, Rancid, Otherwise Decomposed, Blanks, and Shriveled)","PDF (17.86 KB)PDF (17.86 KB) of CPG Sec 570.425 Tree Nuts - Adulteration Involving Rejects (Insect Infestation, Moldy, Rancid, Otherwise Decomposed, Blanks, and Shriveled)",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,
"CPG Sec 570.450 Tree Nuts - Adulteration with Filth, Involving the Presence of the Organism Escherichia coli","PDF (13.08 KB)PDF (13.08 KB) of CPG Sec 570.450 Tree Nuts - Adulteration with Filth, Involving the Presence of the Organism Escherichia coli",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,
CPG Sec 580.100 Food Storage and Warehousing-Adulteration-Filth (Domestic and Import),PDF (27.04 KB)PDF (27.04 KB) of CPG Sec 580.100 Food Storage and Warehousing-Adulteration-Filth (Domestic and Import),11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
"CPG Sec 585.200 Beets, Canned - Adulteration with Rot","PDF (8.87 KB)PDF (8.87 KB) of CPG Sec 585.200 Beets, Canned - Adulteration with Rot",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.275 Brussels Sprouts, Frozen - Adulteration by Insects","PDF (9.37 KB)PDF (9.37 KB) of CPG Sec 585.275 Brussels Sprouts, Frozen - Adulteration by Insects",11/29/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.300 Corn, Sweet; Canned - Adulteration by Corn Ear Worms, Corn Borers","PDF (9.91 KB)PDF (9.91 KB) of CPG Sec 585.300 Corn, Sweet; Canned - Adulteration by Corn Ear Worms, Corn Borers",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.400 Cowpeas (Black-Eyed Peas); Canned (Succulent Peas) - Adulteration by Insects,PDF (9.81 KB)PDF (9.81 KB) of CPG Sec 585.400 Cowpeas (Black-Eyed Peas); Canned (Succulent Peas) - Adulteration by Insects,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.475 Canned Green Beans and Canned Wax Beans - Misbranding Involving Food Standards,PDF (16.69 KB)PDF (16.69 KB) of CPG Sec 585.475 Canned Green Beans and Canned Wax Beans - Misbranding Involving Food Standards,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.575 Peas and Beans; Dried - Adulteration Involving Storage, Insect Damage, Rocks","PDF (14.46 KB)PDF (14.46 KB) of CPG Sec 585.575 Peas and Beans; Dried - Adulteration Involving Storage, Insect Damage, Rocks",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.775 Spinach, Canned or Frozen - Adulteration Involving Insects, Decomposition","PDF (11.95 KB)PDF (11.95 KB) of CPG Sec 585.775 Spinach, Canned or Frozen - Adulteration Involving Insects, Decomposition",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.825 Sweet Potatoes - Dyeing of Yellow and Red Varieties,PDF (13.53 KB)PDF (13.53 KB) of CPG Sec 585.825 Sweet Potatoes - Dyeing of Yellow and Red Varieties,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 587.300 Color Additives,PDF (9.33 KB)PDF (9.33 KB) of CPG Sec 587.300 Color Additives,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Food & Color Additives",Final,No,,
CPG Sec 590.300 Direct Reference Authority for Pseudomonas Contamination of Cosmetics Used in the Eye Area,PDF (9.57 KB)PDF (9.57 KB) of CPG Sec 590.300 Direct Reference Authority for Pseudomonas Contamination of Cosmetics Used in the Eye Area,11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"CPG Sec 590.400 Natural Bristle Brushes (i.e., Hair Brushes, Shaving Brushes) - Nit Contamination","PDF (9.28 KB)PDF (9.28 KB) of CPG Sec 590.400 Natural Bristle Brushes (i.e., Hair Brushes, Shaving Brushes) - Nit Contamination",11/29/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 520.300 Acidified Low-Acid Canned Foods - Adulteration Due to High pH,,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Canned Foods",Final,No,,
CPG Sec 525.100 Whole & Ground Allspice - Adulteration by Mold; Insect & Rodent Filth,,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.575 Prepared Mustard - Composition,,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 525.800 Tomato Sauce or Tomato Hot Sauce Labeling,,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 527.250 Cheese & Cheese Products - Misbranding Involving Net Contents,,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dairy",Final,No,,
CPG Sec 527.350 Eggnog; Egg Nog Flavored Milk - Common or Usual Names,,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dairy",Final,No,,
"CPG Sec 527.400 Whole Milk, Lowfat Milk, Skim Milk - Aflatoxin M1",,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dairy",Final,No,,
CPG Sec 530.500 Wheat Germ Containing Non-Wheat Germ Tissue,,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
"CPG Sec 540.200 Chubs, Hot Process Smoked with Added Nitrite - Adulteration Involving Food Additives, Sodium Nitrite",,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
"CPG Sec 540.250 Clams, Mussels, Oysters, Fresh, Frozen or Canned - Paralytic Shellfish Poison",,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
"CPG Sec 540.410 Shrimp - Frozen, Raw, Breaded or Lightly Breaded, Misbranding Involving Non-Compliance with Standards",,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
"CPG Sec 550.475 Jellies, Nonstandardized",,11/28/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 550.605 Olives Stuffed with Minced Pimentos - Labeling,,11/28/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.650 Peaches, Canned, Frozen - Adulteration Due to Insects and Mold",,11/28/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 578.500 Dimethylnitrosamine (DMNA) in Barley Malt,,11/28/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Grain/Grain Product",Final,No,,
"CPG Sec 585.325 Corn on the Cob, Canned - Quantity of Contents Declaration",,11/28/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.500 Mushrooms, Canned or Dried (Freeze-Dried or Dehydrated) - Adulteration Involving Maggots, Mites, Decomposition",,11/28/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.750 Sauerkraut - Definition; Adulteration by Thrips,,11/28/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec. 160.100 Regulatory Actions and Small Business,,11/28/2005,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 585.875 Tomatoes - Canned - Misbranding Involving Food Standards (Peel),PDF (10.64 KB)PDF (10.64 KB) of CPG Sec 585.875 Tomatoes - Canned - Misbranding Involving Food Standards (Peel),11/25/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.890 Tomato Products - Adulteration with Drosophila Fly Eggs and Maggots,PDF (11.29 KB)PDF (11.29 KB) of CPG Sec 585.890 Tomato Products - Adulteration with Drosophila Fly Eggs and Maggots,11/25/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.900 Tomato Products - Adulteration with Mold,PDF (20.94 KB)PDF (20.94 KB) of CPG Sec 585.900 Tomato Products - Adulteration with Mold,11/25/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CVM GFI #135 Validation of Analytical Procedures for Type C Medicated Feeds,PDF (106.96 KB)PDF (106.96 KB) of CVM GFI #135 Validation of Analytical Procedures for Type C Medicated Feeds,11/07/2005,Center for Veterinary Medicine,"Animal Feed, Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2004-D-0370
Applicability of the Performance Standard for High-Intensity Mercury Vapor Discharge Lamps (21 CFR 1040.30),PDF (31.82 KB)PDF (31.82 KB) of Applicability of the Performance Standard for High-Intensity Mercury Vapor Discharge Lamps (21 CFR 1040.30),11/05/2005,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",,Final,No,,FDA-2020-D-0957
"Guidance for Industry: Notice to Growers, Food Manufacturers, Food Warehouse Managers, and Transporters of Food Products on Decontamination of Transport Vehicles",,11/01/2005,Human Foods Program,Transportation,Final,No,,FDA-2005-D-0337
Dental Composite Resin Devices - Premarket Notification [510(k)] Submissions -  Guidance for Industry and FDA Staff,,10/25/2005,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals,PDF (51.75 KB)PDF (51.75 KB) of S7B Nonclinical Evaluation of the Potential for Delayed Ventricular Repolarization (QT Interval Prolongation) by Human Pharmaceuticals,10/20/2005,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-2004-D-0366
E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs,PDF (97.84 KB)PDF (97.84 KB) of E14 Clinical Evaluation of QT/QTc Interval Prolongation and Proarrhythmic Potential for Non-Antiarrhythmic Drugs,10/11/2005,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2004-D-0241
Letter to State Regulatory Agencies and Firms That Produce Treated (but not Pasteurized) and Untreated Juice and Cider,,09/22/2005,Human Foods Program,Juice,Final,No,,FDA-2020-D-1938
"Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays:  Guidance for Industry and FDA Staff","PDF (175.75 KB)PDF (175.75 KB) of Review Criteria for Assessment of C-Reactive Protein (CRP), High Sensitivity C-Reactive Protein (hsCRP) and Cardiac C-Reactive Assays:  Guidance for Industry and FDA Staff",09/22/2005,Center for Devices and Radiological Health,"Postmarket, Cardiovascular",Final,No,,FDA-2020-D-0957
How to Comply with the Pediatric Research Equity Act,PDF (115.53 KB)PDF (115.53 KB) of How to Comply with the Pediatric Research Equity Act,09/07/2005,Center for Drug Evaluation and Research,"Administrative / Procedural, Pediatric Product Development",Draft,No,,
M5International Conference on Harmonisation; Draft Guidance on M5 Data Elements and Standards for Drug Dictionaries,PDF (405.51 KB)PDF (405.51 KB) of M5International Conference on Harmonisation; Draft Guidance on M5 Data Elements and Standards for Drug Dictionaries,09/06/2005,Center for Drug Evaluation and Research,ICH-Multidisciplinary,Draft,No,,FDA-2005-D-0459
Medical Devices with Sharps Injury Prevention Features -  Guidance for Industry and FDA Staff,PDF (216.97 KB)PDF (216.97 KB) of Medical Devices with Sharps Injury Prevention Features -  Guidance for Industry and FDA Staff,08/08/2005,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,PDF (702.04 KB)PDF (702.04 KB) of Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers,07/28/2005,,Pharmacology/Toxicology,Final,No,,
Menstrual Tampons and Pads: Information for Premarket Notification Submissions (510(k)s) -  Guidance for Industry and FDA Staff,PDF (303.32 KB)PDF (303.32 KB) of Menstrual Tampons and Pads: Information for Premarket Notification Submissions (510(k)s) -  Guidance for Industry and FDA Staff,07/26/2005,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Nonclinical Pharmacology/Toxicology Development of Topical Drugs Intended to Prevent the Transmission of Sexually Transmitted Diseases (STD) and/or for the Development of Drugs Intended to Act as Vaginal Contraceptives,,06/30/2005,,Pharmacology/Toxicology,Final,No,,
Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process,PDF (58.1 KB)PDF (58.1 KB) of Q5E Comparability of Biotechnological/Biological Products Subject to Changes in Their Manufacturing Process,06/30/2005,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2004-D-0440
Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection:  Guidance for Industry,PDF (39.62 KB)PDF (39.62 KB) of Assessing Donor Suitability and Blood and Blood Product Safety in Cases of Known or Suspected West Nile Virus Infection:  Guidance for Industry,06/23/2005,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2005-D-0139
CPG Sec. 315.100 Illegal Interstate Commercial Shipment of Dentures (CPG retitled and revised 5/19/2005),PDF (97.34 KB)PDF (97.34 KB) of CPG Sec. 315.100 Illegal Interstate Commercial Shipment of Dentures (CPG retitled and revised 5/19/2005),05/19/2005,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Dental",Final,No,,FDA-2020-D-0957
Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients,PDF (229.53 KB)PDF (229.53 KB) of Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients,05/19/2005,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2002-D-0188
"Guidance for Industry: Channels of Trade Policy for Commodities With Residues of Pesticide Chemicals, for Which Tolerances Have Been Revoked, Suspended, or Modified by the Environmental Protection Agency Pursuant to Dietary Risk Considerations",,05/18/2005,Human Foods Program,Pesticide,Final,No,,FDA-2003-D-0430
CPG Sec 560.400 Imported Milk and Cream - Federal Import Milk Act,PDF (23.28 KB)PDF (23.28 KB) of CPG Sec 560.400 Imported Milk and Cream - Federal Import Milk Act,05/12/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Import",Final,No,,
"CPG Sec 525.225 - Whole Cassia or Whole Cinnamon, Ground Cinnamon - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta","PDF (11.84 KB)PDF (11.84 KB) of CPG Sec 525.225 - Whole Cassia or Whole Cinnamon, Ground Cinnamon - Adulteration by Insect and Rodent Filth; Mold; Mammalian Excreta",05/01/2005,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
"CPG Sec 555.425  Foods, Adulteration Involving hard or Sharp Foreign Objects","PDF (15.56 KB)PDF (15.56 KB) of CPG Sec 555.425  Foods, Adulteration Involving hard or Sharp Foreign Objects",05/01/2005,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
Evaluating the Risks of Drug Exposure in Human Pregnancies,PDF (3.08 MB)PDF (3.08 MB) of Evaluating the Risks of Drug Exposure in Human Pregnancies,04/27/2005,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
CPG Sec. 100.700  GWQAP Pre-Award Evaluation - Inadequate Information to Evaluate Prospective Supplier,,04/24/2005,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
Providing Regulatory Submissions in Electronic Format — Content of Labeling,PDF (42.75 KB)PDF (42.75 KB) of Providing Regulatory Submissions in Electronic Format — Content of Labeling,04/21/2005,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Electronic Submissions,",Final,No,,
Guidance for Industry: Templates for Reporting Toxicology Data,,04/11/2005,Human Foods Program,Food & Color Additives,Final,No,,FDA-2020-D-1941
CPG Sec. 390.300 Assessment of Civil Penalties Against Manufacturers and Importers of Electronic Products,,04/01/2005,,"Investigation & Enforcement, Administrative / Procedural",Final,No,,
Guidance for Industry: Pre-Petition Consultations for Food Additives and Color Additives,,04/01/2005,Human Foods Program,"Food & Color Additives, Ingredients",Final,No,,FDA-2020-D-1944
Guidance for Industry: Submitting Requests under 21 CFR 170.39 Threshold of Regulation for Substances Used in Food-Contact Articles,,04/01/2005,Human Foods Program,"Food & Color Additives, Ingredients",Final,No,,FDA-2013-N-0730
E2E Pharmacovigilance Planning,PDF (99.67 KB)PDF (99.67 KB) of E2E Pharmacovigilance Planning,04/01/2005,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2004-D-0245
Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products,PDF (701.94 KB)PDF (701.94 KB) of Guidance for Review Staff and Industry Good Review Management Principles and Practices for PDUFA Products,04/01/2005,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,,
Guidance for Industry: Dietary Supplement Labeling Guide,,03/31/2005,Human Foods Program,Labeling,Final,No,,FDA-2004-D-0544
Development and Use of Risk Minimization Action Plans:  Guidance for Industry,PDF (128.07 KB)PDF (128.07 KB) of Development and Use of Risk Minimization Action Plans:  Guidance for Industry,03/29/2005,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,FDA-2004-D-0441
Premarketing Risk Assessment:  Guidance for Industry,PDF (129.5 KB)PDF (129.5 KB) of Premarketing Risk Assessment:  Guidance for Industry,03/29/2005,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,FDA-2004-D-0121
Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment:  Guidance for Industry,PDF (225.83 KB)PDF (225.83 KB) of Good Pharmacovigilance Practices and Pharmacoepidemiologic Assessment:  Guidance for Industry,03/24/2005,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,FDA-2004-D-0041
E2B(M) Questions and Answers,PDF (61.07 KB)PDF (61.07 KB) of E2B(M) Questions and Answers,03/09/2005,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1996-D-0168
CPG Sec. 390.400 Examples of Electronic Products Subject to the Reporting Requirements Under 21 CFR 1000.15(a),,03/01/2005,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Administrative / Procedural",Final,No,,FDA-2020-D-0957
"Pharmacogenomic Data Submissions; Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601","PDF (63.39 KB)PDF (63.39 KB) of Pharmacogenomic Data Submissions; Examples of Voluntary Submissions or Submissions Required Under 21 CFR 312, 314, or 601",03/01/2005,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
Pharmacogenomic Data Submissions:  Guidance for Industry,PDF (179.08 KB)PDF (179.08 KB) of Pharmacogenomic Data Submissions:  Guidance for Industry,03/01/2005,Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2003-D-0031
CPG Sec. 396.300 Defective Suntanning Booths and Bed,,02/28/2005,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 398.100 Definition of General Purpose Radiographic X-Ray System - 21 CFR 1020.30(b),,02/28/2005,Office of Regulatory AffairsCenter for Devices and Radiological Health,"Investigation & Enforcement, Radiology",Final,No,,FDA-2020-D-0957
CPG Sec. 398.325 Regulatory Actions Against Assemblers Noncompliant Diagnostic X-Ray Equipment,,02/28/2005,,"Investigation & Enforcement,",Final,No,,
"CPG Sec. 398.700 Reloaders of X-ray Tube Housing Assemblies; Applicability of Medical Device Establishment Registration, Device Listing and Biennial Inspection",,02/28/2005,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 310.210 Blood Pressure Measurement Devices (Sphygmomanometers) - Accuracy,PDF (63.87 KB)PDF (63.87 KB) of CPG Sec. 310.210 Blood Pressure Measurement Devices (Sphygmomanometers) - Accuracy,02/18/2005,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,FDA-2005-D-0029
"Information for Healthcare Organizations about FDA's ""Guidance for Industry: Cybersecurity for Networked Medical Devices Containing Off-The-Shelf (OTS) Software""",,02/08/2005,Center for Devices and Radiological Health,Digital Health,Final,No,,FDA-2020-D-0957
CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA),PDF (51.92 KB)PDF (51.92 KB) of CVM GFI #173 Animal Drug Sponsor Fees Under the Animal Drug User Fee Act (ADUFA),02/07/2005,Center for Veterinary Medicine,"User Fees,",Final,No,,FDA-2004-D-0181
CVM GFI #173 Appendix for the Animal Drug Sponsor Fees Under ADUFA,PDF (43.8 KB)PDF (43.8 KB) of CVM GFI #173 Appendix for the Animal Drug Sponsor Fees Under ADUFA,02/07/2005,Center for Veterinary Medicine,"User Fees,",Final,No,,FDA-2004-D-0181
Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention,PDF (112.67 KB)PDF (112.67 KB) of Gingivitis: Development and Evaluation of Drugs for Treatment or Prevention,01/28/2005,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Draft,No,,
Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (OTS) Software:  Guidance for Industry,PDF (147.75 KB)PDF (147.75 KB) of Cybersecurity for Networked Medical Devices Containing Off-the-Shelf (OTS) Software:  Guidance for Industry,01/14/2005,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Guidance for Industry: Labeling for Cosmetics Containing Alpha Hydroxy Acids,,01/10/2005,"Office of the Commissioner,Office of the Chief Scientist","Ingredients, Labeling",Final,No,,FDA-2000-P-0063
Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees:  Guidance for Industry,PDF (211.49 KB)PDF (211.49 KB) of Submitting Separate Marketing Applications and Clinical Data for Purposes of Assessing User Fees:  Guidance for Industry,01/03/2005,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"User Fees,",Final,No,,FDA-2001-D-0134
M4:  The CTD -- General Questions and Answers,PDF (44.82 KB)PDF (44.82 KB) of M4:  The CTD -- General Questions and Answers,12/22/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,
Clinical Data Presentations for Orthopedic Device Applications -  Guidance for Industry and FDA Staff,PDF (538.18 KB)PDF (538.18 KB) of Clinical Data Presentations for Orthopedic Device Applications -  Guidance for Industry and FDA Staff,12/01/2004,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
M4: The CTD -- Efficacy Questions and Answers,PDF (165.46 KB)PDF (165.46 KB) of M4: The CTD -- Efficacy Questions and Answers,12/01/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,
Changes to an Approved NDA or ANDA; Specifications – Use of Enforcement Discretion for Compendial Changes:  Guidance for Industry,PDF (24.22 KB)PDF (24.22 KB) of Changes to an Approved NDA or ANDA; Specifications – Use of Enforcement Discretion for Compendial Changes:  Guidance for Industry,11/22/2004,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-2004-D-0179
CVM GFI #122 Manufacture and Labeling of Raw Meat Foods for Companion and Captive Noncompanion Carnivores and Omnivores,PDF (94.47 KB)PDF (94.47 KB) of CVM GFI #122 Manufacture and Labeling of Raw Meat Foods for Companion and Captive Noncompanion Carnivores and Omnivores,11/09/2004,Center for Veterinary Medicine,Animal Feed,Final,No,,FDA-2002-D-0148
CPG Sec. 130.400  Use of Microfiche and/or Microfilm for Method of Records Retention,,11/07/2004,Office of Regulatory Affairs,"Investigation & Enforcement, Records",Final,No,,
"Pharmacokinetics in Pregnancy — Study Design, Data Analysis, and Impact on Dosing and Labeling","PDF (324.06 KB)PDF (324.06 KB) of Pharmacokinetics in Pregnancy — Study Design, Data Analysis, and Impact on Dosing and Labeling",11/01/2004,Center for Drug Evaluation and Research,Clinical - Pharmacology,Draft,No,,FDA-2004-D-0459
"Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry","PDF (33.12 KB)PDF (33.12 KB) of Recommendations for Obtaining a Labeling Claim for Communicable Disease Donor Screening Tests Using Cadaveric Blood Specimens from Donors of Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps):  Guidance for Industry",11/01/2004,Center for Biologics Evaluation and Research,"Labeling, Tissue",Final,No,,FDA-2005-D-0273
Clinical Trial Considerations: Vertebral Augmentation Devices to Treat Spinal Insufficiency Fractures -  Guidance for Industry and FDA Staff,,10/23/2004,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of  of HIV-1 and HCV:  Guidance for Industry,PDF (54.21 KB)PDF (54.21 KB) of  Use of Nucleic Acid Tests on Pooled and Individual Samples from Donors of Whole Blood and Blood Components (including Source Plasma and Source Leukocytes) to Adequately and Appropriately Reduce the Risk of Transmission of  of HIV-1 and HCV:  Guidance for Industry,10/21/2004,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2001-D-0095
"PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance:  Guidance for Industry","PDF (210.76 KB)PDF (210.76 KB) of PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance:  Guidance for Industry",10/04/2004,Center for Veterinary MedicineOffice of Regulatory AffairsCenter for Drug Evaluation and Research,"Investigation & Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2003-D-0032
Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice:  Guidance for Industry,PDF (734.22 KB)PDF (734.22 KB) of Sterile Drug Products Produced by Aseptic Processing — Current Good Manufacturing Practice:  Guidance for Industry,10/04/2004,Office of Regulatory AffairsCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Investigation & Enforcement, Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-2003-D-0145
Guidance for Industry: Recommendations to Processors of Apple Juice or Cider on the Use of Ozone for Pathogen Reduction Purposes,,10/01/2004,Human Foods Program,Juice,Final,No,,FDA-2004-D-0531
"FDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information:  Guidance for Industry","PDF (32.78 KB)PDF (32.78 KB) of FDA Review of Vaccine Labeling Requirements for Warnings, Use Instructions, and Precautionary Information:  Guidance for Industry",10/01/2004,Center for Biologics Evaluation and Research,"Pediatric Product Development, Vaccines",Final,No,,FDA-2004-D-0286
Class II Special Controls Guidance Document: Serological Assays for the Detection of Beta-Glucan (PDF version),PDF (55.39 KB)PDF (55.39 KB) of Class II Special Controls Guidance Document: Serological Assays for the Detection of Beta-Glucan (PDF version),09/23/2004,,"Premarket,",Final,No,,
The Use of Clinical Holds Following Clinical Investigator Misconduct:  Guidance for Industry and Clinical Investigators,PDF (37.48 KB)PDF (37.48 KB) of The Use of Clinical Holds Following Clinical Investigator Misconduct:  Guidance for Industry and Clinical Investigators,09/02/2004,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2002-D-0053
Independent Consultants for Biotechnology Clinical Trial Protocols:  Guidance for Industry,PDF (39.87 KB)PDF (39.87 KB) of Independent Consultants for Biotechnology Clinical Trial Protocols:  Guidance for Industry,08/19/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-2003-D-0288
Calcium DTPA and Zinc DTPA Drug Products-Submitting a New Drug Application,PDF (168.17 KB)PDF (168.17 KB) of Calcium DTPA and Zinc DTPA Drug Products-Submitting a New Drug Application,08/13/2004,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,None found
Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments,PDF (270.68 KB)PDF (270.68 KB) of Developing Medical Imaging Drug and Biological Products Part 1: Conducting Safety Assessments,06/22/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-1998-D-0035
Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications,PDF (231.4 KB)PDF (231.4 KB) of Developing Medical Imaging Drug and Biological Products Part 2: Clinical Indications,06/22/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-1998-D-0035
"Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies","PDF (307.06 KB)PDF (307.06 KB) of Developing Medical Imaging Drug and Biological Products Part 3: Design, Analysis, and Interpretation of Clinical Studies",06/22/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-1998-D-0035
CPG Sec. 690.300  Canned Pet Food (Withdrawn 4/30/2019),,06/10/2004,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Pet Food",Final,No,,
M4: The CTD -- Quality Questions and Answers /Location Issues,PDF (85.61 KB)PDF (85.61 KB) of M4: The CTD -- Quality Questions and Answers /Location Issues,06/09/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,FDA-2002-D-0261
Q1E Evaluation of Stability Data,PDF (220.51 KB)PDF (220.51 KB) of Q1E Evaluation of Stability Data,06/08/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2002-D-0180
"Medical Device User Fee and Modernization Act of 2002, Validation Data in Premarket Notification Submissions (510(k)s) for Reprocessed Single-Use Medical Devices:  Guidance for Industry and FDA Staff","PDF (133.23 KB)PDF (133.23 KB) of Medical Device User Fee and Modernization Act of 2002, Validation Data in Premarket Notification Submissions (510(k)s) for Reprocessed Single-Use Medical Devices:  Guidance for Industry and FDA Staff",06/02/2004,Center for Devices and Radiological Health,"User Fees, 510(k)",Final,No,,FDA-2003-D-0309
Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System (PDF version),PDF (64.19 KB)PDF (64.19 KB) of Class II Special Controls Guidance Document: Immunomagnetic Circulating Cancer Cell Selection and Enumeration System (PDF version),05/11/2004,,"Premarket,",Final,No,,
Submission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product:  Guidance for Industry and FDA Staff,PDF (101.25 KB)PDF (101.25 KB) of Submission and Resolution of Formal Disputes Regarding the Timeliness of Premarket Review of a Combination Product:  Guidance for Industry and FDA Staff,05/03/2004,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Combination Products",Combination Products,Final,No,,FDA-2004-D-0502
Guidance for Industry and FDA Staff: Spinal System 510(k)s,PDF (377.97 KB)PDF (377.97 KB) of Guidance for Industry and FDA Staff: Spinal System 510(k)s,05/02/2004,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","Premarket,",Final,No,,FDA-2020-D-0957
CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance,PDF (179.67 KB)PDF (179.67 KB) of CVM GFI #144 (VICH GL27) Pre-Approval Information for Registration of New Veterinary Medicinal Products for Food-Producing Animals with Respect to Antimicrobial Resistance,04/27/2004,Center for Veterinary Medicine,"Antimicrobial Resistance, VICH",Final,No,,FDA-2003-D-0152
"Redbook 2000: VII Glossary, Acronyms and Definitions",,04/25/2004,Human Foods Program,Food & Color Additives,Final,No,,
Changes to an Approved NDA or ANDA:  Guidance for Industry,PDF (173.43 KB)PDF (173.43 KB) of Changes to an Approved NDA or ANDA:  Guidance for Industry,04/08/2004,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1999-D-0049
CPG Sec.  490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval,PDF (124.71 KB)PDF (124.71 KB) of CPG Sec.  490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval,03/12/2004,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval,PDF (124.71 KB)PDF (124.71 KB) of CPG Sec. 490.100 Process Validation Requirements for Drug Products and Active Pharmaceutical Ingredients Subject to Pre-Market Approval,03/12/2004,Center for Drug Evaluation and Research,,Final,No,,
Potassium Iodide Tablets - Shelf Life Extension,PDF (191.25 KB)PDF (191.25 KB) of Potassium Iodide Tablets - Shelf Life Extension,03/08/2004,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2003-D-0029
Surgical Masks - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,PDF (224.92 KB)PDF (224.92 KB) of Surgical Masks - Premarket Notification [510(k)] Submissions:  Guidance for Industry and FDA Staff,03/04/2004,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2003-D-0305
"Guidance for Industry: Juice Hazard Analysis Critical Control Point Hazards and Controls Guidance, First Edition",,03/03/2004,Human Foods Program,"HACCP, Juice",Final,No,,FDA-2002-D-0298
Guidance for Industry and FDA Staff: Vocal Fold Medialization Devices - Premarket Notification [510(k)] Submissions,PDF (426.72 KB)PDF (426.72 KB) of Guidance for Industry and FDA Staff: Vocal Fold Medialization Devices - Premarket Notification [510(k)] Submissions,02/12/2004,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","Premarket,",Final,No,,FDA-2020-D-0957
IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer:  Guidance for Industry,PDF (171.61 KB)PDF (171.61 KB) of IND Exemptions for Studies of Lawfully Marketed Drug or Biological Products for the Treatment of Cancer:  Guidance for Industry,01/15/2004,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,
Premarket Notification [510(k)] Submissions for Chemical Indicators - Guidance for Industry and FDA Staff,PDF (608.45 KB)PDF (608.45 KB) of Premarket Notification [510(k)] Submissions for Chemical Indicators - Guidance for Industry and FDA Staff,12/18/2003,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Q1A(R2) Stability Testing of New Drug Substances and Products,PDF (57.67 KB)PDF (57.67 KB) of Q1A(R2) Stability Testing of New Drug Substances and Products,11/21/2003,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2002-D-0222
Redbook 2000: IV. A. Introduction to Guidelines for Toxicity Studies,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.B.1. General Guidelines for Designing and Conducting Toxicity Studies,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.B.2 Guidelines for Reporting the Results of Toxicity Studies,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.1.b. In vitro Mammalian Chromosomal Aberration Test,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.3.a. Short-Term Toxicity Studies with Rodents,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.3.b. Short-Term Toxicity Studies with Non-Rodents,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.4.a. Subchronic Toxicity Studies with Rodents,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.4.b. Subchronic Toxicity Studies with Non-Rodents,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.5.b. One-Year Toxicity Studies with Non-Rodents,,11/01/2003,Human Foods Program,Food & Color Additives,Final,No,,
Small Entity Compliance Guide: Label Warning Statements for Iron-Containing Supplements and Drugs,,10/17/2003,Human Foods Program,Labeling,Final,No,,FDA-1997-D-0056
E2D Postapproval Safety Data Management: Definitions and Standards for Expedited Reporting,PDF (164.68 KB)PDF (164.68 KB) of E2D Postapproval Safety Data Management: Definitions and Standards for Expedited Reporting,09/12/2003,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-2003-D-0371
"Part 11, Electronic Records; Electronic Signatures - Scope and Application:  Guidance for Industry","PDF (43.9 KB)PDF (43.9 KB) of Part 11, Electronic Records; Electronic Signatures - Scope and Application:  Guidance for Industry",09/05/2003,Human Foods ProgramCenter for Veterinary MedicineOffice of Inspections and InvestigationsCenter for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Postmarket, Compliance, Electronic Submissions, Investigation & Enforcement, Administrative / Procedural, Current Good Manufacturing Practice (CGMP), Good Clinical Practice (GCP), Food & Color Additives",Final,No,,FDA-2003-D-0143
Information Disclosure by Manufacturers to Assemblers for Diagnostic X-ray Systems - Guidance for Industry and FDA Staff,PDF (41.73 KB)PDF (41.73 KB) of Information Disclosure by Manufacturers to Assemblers for Diagnostic X-ray Systems - Guidance for Industry and FDA Staff,09/04/2003,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2020-D-0957
Guidance for Industry: Questions and Answers on Juice HACCP Regulation (2003),,09/03/2003,Human Foods Program,"HACCP, Juice",Final,No,,FDA-2020-D-1951
"Small Entity Compliance Guide: Trans Fatty Acids in Nutrition Labeling, Nutrient Content Claims, and Health Claims",,08/20/2003,Human Foods Program,Labeling,Final,No,,FDA-2003-D-0035
IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations:  Guidance for Industry,PDF (613.57 KB)PDF (613.57 KB) of IRB Review of Stand-Alone HIPAA Authorizations Under FDA Regulations:  Guidance for Industry,08/16/2003,Office of the Commissioner,,Final,No,,FDA-2003-D-0037
"Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors - Three Additional Questions:  Guidance for Industry, FDA Staff, Third-Party and Hospital Reprocessors","PDF (2.01 MB)PDF (2.01 MB) of Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors - Three Additional Questions:  Guidance for Industry, FDA Staff, Third-Party and Hospital Reprocessors",07/16/2003,"Center for Devices and Radiological Health,Office of Communication, Information Disclosure, Training and Education",,Final,No,,FDA-2020-D-0957
Guidance for Industry: Interim Procedures for Qualified Health Claims in the Labeling of Conventional Human Food and Human Dietary Supplements,,07/11/2003,Human Foods Program,Labeling,Final,No,,FDA-2003-N-0103
Streamlining the Donor Interview Process: Recommendations for Self-Administered Questionnaires:  Guidance for Industry,PDF (48.42 KB)PDF (48.42 KB) of Streamlining the Donor Interview Process: Recommendations for Self-Administered Questionnaires:  Guidance for Industry,07/03/2003,Center for Biologics Evaluation and Research,"Application & Approvals, Blood Products",Final,No,,FDA-2002-D-0524
180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day,PDF (138.08 KB)PDF (138.08 KB) of 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day,07/01/2003,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,2003D-0325
Guidance for Industry: Standardized Training Curriculum for Application of HACCP Principles to Juice Processing,,06/13/2003,Human Foods Program,"HACCP, Juice",Final,No,,FDA-2002-D-0227
"Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate — Labeling Enforcement Policy","PDF (159.11 KB)PDF (159.11 KB) of Drug Products Containing Ensulizole, Hypromellose, Meradimate, Octinoxate, and Octisalate — Labeling Enforcement Policy",06/03/2003,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2003-D-0090
Pediatric Expertise for Advisory Panels - Guidance for Industry and FDA Staff,PDF (39.46 KB)PDF (39.46 KB) of Pediatric Expertise for Advisory Panels - Guidance for Industry and FDA Staff,06/02/2003,Center for Devices and Radiological Health,"Advisory Committees, Pediatric Product Development",Final,No,,FDA-2003-D-0147
"Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling","PDF (222.32 KB)PDF (222.32 KB) of Pharmacokinetics in Patients with Impaired Hepatic Function: Study Design, Data Analysis, and Impact on Dosing and Labeling",05/30/2003,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Pharmacology,Final,No,,FDA-1999-D-0063
"INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information:  Guidance for Industry","PDF (283.35 KB)PDF (283.35 KB) of INDs for Phase 2 and Phase 3 Studies Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",05/20/2003,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Good Clinical Practice (GCP), Pharmaceutical Quality",Final,No,,FDA-1999-D-0030
"Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications","PDF (220.68 KB)PDF (220.68 KB) of Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications",05/05/2003,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Pharmacology,Final,No,,FDA-2002-D-0177
CVM GFI #118 Mass Spectrometry for Confirmation of Identity of Animal Drug Residues,PDF (112.22 KB)PDF (112.22 KB) of CVM GFI #118 Mass Spectrometry for Confirmation of Identity of Animal Drug Residues,05/01/2003,Center for Veterinary Medicine,Human Food Safety,Final,No,,FDA-2001-D-0102
Guidance for Industry: Bulk Transport of Juice Concentrates and Certain Shelf-Stable Juices,,04/24/2003,Human Foods Program,"Juice, Transportation",Final,No,,FDA-2002-P-0302
Guidance for Industry: Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS,PDF (52.27 KB)PDF (52.27 KB) of Guidance for Industry: Recommendations for the Assessment of Donor Suitability and Blood Product Safety in Cases of Suspected Severe Acute Respiratory Syndrome (SARS) or Exposure to SARS,04/17/2003,,Blood Products,Final,No,,
"Statistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999","PDF (190.76 KB)PDF (190.76 KB) of Statistical Information from the June 1999 Draft Guidance and Statistical Information for In Vitro Bioequivalence Data Posted on August 18, 1999",04/11/2003,Center for Drug Evaluation and Research,"Biopharmaceutics, Generic Drugs",Draft,No,,
Small Entity Compliance Guide: Juice HACCP,,04/04/2003,Human Foods Program,"HACCP, Juice",Final,No,,FDA-2003-D-0283
Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action,PDF (727.41 KB)PDF (727.41 KB) of Bioavailability and Bioequivalence Studies for Nasal Aerosols and Nasal Sprays for Local Action,04/03/2003,Center for Drug Evaluation and Research,"Biopharmaceutics, Generic Drugs",Draft,No,,FDA-1999-D-0050
User Labeling for Devices that Contain Natural Rubber (21 CFR 801.437); Small Entity Compliance Guide - Guidance for Industry,PDF (40.65 KB)PDF (40.65 KB) of User Labeling for Devices that Contain Natural Rubber (21 CFR 801.437); Small Entity Compliance Guide - Guidance for Industry,04/01/2003,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
Integration of Dose-Counting Mechanisms into MDI Drug Products,PDF (124.67 KB)PDF (124.67 KB) of Integration of Dose-Counting Mechanisms into MDI Drug Products,03/13/2003,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2003-D-0285
M4: The CTD -- Safety Questions and Answers,PDF (27 KB)PDF (27 KB) of M4: The CTD -- Safety Questions and Answers,02/04/2003,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,
Prussian Blue Drug Products — Submitting a New Drug Application,PDF (158.67 KB)PDF (158.67 KB) of Prussian Blue Drug Products — Submitting a New Drug Application,02/04/2003,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-2003-D-0727
Quality System Information for Certain Premarket Application Reviews :  Guidance for Industry and FDA Staff,PDF (548 KB)PDF (548 KB) of Quality System Information for Certain Premarket Application Reviews :  Guidance for Industry and FDA Staff,02/03/2003,Center for Devices and Radiological Health,"Premarket, Premarket Approval (PMA)",Final,No,,FDA-2020-D-0957
Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms — Recommendations for Clinical Evaluation,PDF (166 KB)PDF (166 KB) of Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms — Recommendations for Clinical Evaluation,01/31/2003,Center for Drug Evaluation and Research,Clinical - Medical,Draft,No,,
Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products,PDF (30.59 KB)PDF (30.59 KB) of Q1D Bracketing and Matrixing Designs for Stability Testing of New Drug Substances and Products,01/16/2003,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-2001-D-0164
Recommendations for Deferral of Donors and Quarantine and Retrieval of Blood and Blood Products in Recent Recipients of Smallpox Vaccine (Vaccinia Virus) and Certain Contacts of Smallpox Vaccine Recipients:  Guidance for Industry,PDF (46.65 KB)PDF (46.65 KB) of Recommendations for Deferral of Donors and Quarantine and Retrieval of Blood and Blood Products in Recent Recipients of Smallpox Vaccine (Vaccinia Virus) and Certain Contacts of Smallpox Vaccine Recipients:  Guidance for Industry,12/30/2002,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-2002-D-0013
(Potassium Iodide) KI in Radiation Emergencies-Questions and Answers,PDF (161.11 KB)PDF (161.11 KB) of (Potassium Iodide) KI in Radiation Emergencies-Questions and Answers,12/23/2002,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,None found
"Guidance for Industry: Implementation of Section 403(t) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 343(t)) Regarding the Use of the Term ""Catfish""",,12/06/2002,Human Foods Program,Seafood/Seafood Product,Final,No,,FDA-2002-D-0174
Determination of Intended Use for 510(k) Devices - Guidance for CDRH Staff (Update to K98-1),PDF (275 KB)PDF (275 KB) of Determination of Intended Use for 510(k) Devices - Guidance for CDRH Staff (Update to K98-1),12/02/2002,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Food-Effect Bioavailability and Fed Bioequivalence Studies:  Guidance for Industry,PDF (216.55 KB)PDF (216.55 KB) of Food-Effect Bioavailability and Fed Bioequivalence Studies:  Guidance for Industry,12/01/2002,Center for Drug Evaluation and Research,"Biopharmaceutics, Good Clinical Practice (GCP)",Final,No,,FDA-2001-D-0040
CVM GFI #80 Evaluation the Utility of Anti-Salmonella Chemical Food Additives,PDF (78 KB)PDF (78 KB) of CVM GFI #80 Evaluation the Utility of Anti-Salmonella Chemical Food Additives,11/21/2002,Center for Veterinary Medicine,Animal Food Additives,Final,No,,FDA-1994-D-0007
"CPG Sec 555.600 Filth from Insects, Rodents, and Other Pests in Foods",,11/13/2002,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"Needlesticks -  Medical Device Reporting Guidance for User Facilities, Manufacturers, and Importers","PDF (33.84 KB)PDF (33.84 KB) of Needlesticks -  Medical Device Reporting Guidance for User Facilities, Manufacturers, and Importers",11/11/2002,Center for Devices and Radiological Health,"Adverse Event Reporting System (FAERS),",Final,No,,FDA-2020-D-0957
Draft Guidance for Industry: Regulatory Procedures Manual Chapter 9 Subchapter on Recommending Customs' Seizure and Destruction of Imported Human and Animal Food That Has Not Been Reconditioned,,11/05/2002,Center for Veterinary MedicineHuman Foods Program,Import,Draft,No,01/06/2003,FDA-2002-D309
CVM GFI #82 Development of Supplemental Applications for Approved New Animal Drugs,PDF (842.86 KB)PDF (842.86 KB) of CVM GFI #82 Development of Supplemental Applications for Approved New Animal Drugs,10/28/2002,Center for Veterinary Medicine,New Animal Drug Application (NADA),Final,No,,FDA-1999-N-1881
Guidance for Small Businesses: Submission of Comments for CFSAN Rulemaking,,10/20/2002,Human Foods Program,"Rulemaking ,",Final,No,,
Labeling OTC Human Drug Products Updating Labeling in RLDs and ANDAs,PDF (29.54 KB)PDF (29.54 KB) of Labeling OTC Human Drug Products Updating Labeling in RLDs and ANDAs,10/18/2002,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-2001-D-0135
Guidance for Industry:  Implementation of Section 10809 of the Farm Security and Investment Act of 2002 Regarding the Petition Process to Request Approval of Labeling for Foods that Have Been Treated with Irradiation,,10/07/2002,Human Foods Program,Labeling,Final,No,,FDA-2002-D-0189
Guidance for Industry: Exemptions from the Warning Label Requirement for Juice,,10/07/2002,Human Foods Program,"HACCP, Juice, Labeling",Final,No,,FDA-2001-D-0138
CVM GFI #119 How CVM Intends to Handle Deficient Submissions Filed During the Investigation of a New Animal Drug,PDF (32.96 KB)PDF (32.96 KB) of CVM GFI #119 How CVM Intends to Handle Deficient Submissions Filed During the Investigation of a New Animal Drug,08/29/2002,Center for Veterinary Medicine,Investigational New Animal Drug (INAD),Final,No,,FDA-2001-D-0011
Guidance on the Department of Defense Exemption from the FDA Performance Standard for Laser Products:  Guidance for Industry and FDA,PDF (318.25 KB)PDF (318.25 KB) of Guidance on the Department of Defense Exemption from the FDA Performance Standard for Laser Products:  Guidance for Industry and FDA,07/12/2002,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
"Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation:  Guidance for Industry","PDF (285.16 KB)PDF (285.16 KB) of Nasal Spray and Inhalation Solution, Suspension, and Spray Drug Products--Chemistry, Manufacturing, and Controls Documentation:  Guidance for Industry",07/05/2002,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1999-D-0060
Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and/or Pelvic Surgery - Guidance for Industry,PDF (332.42 KB)PDF (332.42 KB) of Guidance for Resorbable Adhesion Barrier Devices for Use in Abdominal and/or Pelvic Surgery - Guidance for Industry,06/17/2002,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance for Industry: Channels of Trade Policy for Commodities with Vinclozolin Residues,,06/12/2002,Human Foods Program,Pesticide,Final,No,,FDA-2001-D-0094
Carcinogenicity Study Protocol Submissions,PDF (29.3 KB)PDF (29.3 KB) of Carcinogenicity Study Protocol Submissions,05/23/2002,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-2000-D-1405
Container Closure Systems for Packaging Human Drugs and Biologics -- Questions and Answers:  Guidance for Industry,PDF (34.31 KB)PDF (34.31 KB) of Container Closure Systems for Packaging Human Drugs and Biologics -- Questions and Answers:  Guidance for Industry,05/01/2002,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,None found
E2BM Data Elements for Transmission Of Individual Case Safety Reports,PDF (161.56 KB)PDF (161.56 KB) of E2BM Data Elements for Transmission Of Individual Case Safety Reports,04/04/2002,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1996-D-0168
Validation of Procedures for Processing of Human Tissues Intended for Transplantation:  Guidance for Industry,PDF (16.71 KB)PDF (16.71 KB) of Validation of Procedures for Processing of Human Tissues Intended for Transplantation:  Guidance for Industry,03/08/2002,Center for Biologics Evaluation and Research,Tissue,Final,No,,FDA-2002-D-0181
Guidance for Industry: Providing Regulatory Submissions to CBER in Electronic Format -- Investigational New Drug Applications (INDs) (PDF),PDF (97.52 KB)PDF (97.52 KB) of Guidance for Industry: Providing Regulatory Submissions to CBER in Electronic Format -- Investigational New Drug Applications (INDs) (PDF),03/01/2002,,Administrative / Procedural,Final,No,,
General Principles of Software Validation:  Guidance for Industry and FDA Staff,PDF (367.23 KB)PDF (367.23 KB) of General Principles of Software Validation:  Guidance for Industry and FDA Staff,01/11/2002,Center for Devices and Radiological HealthCenter for Biologics Evaluation and Research,"Premarket, Digital Health, Good Clinical Practice (GCP)",Final,No,,FDA-1997-D-0029
Small Entity Compliance Guide on Structure/Function Claims,,01/09/2002,Human Foods Program,Labeling,Final,No,,FDA-1998-N-0071
Sterilized Convenience Kits for Clinical and Surgical Use:  Final Guidance for Industry,PDF (99.94 KB)PDF (99.94 KB) of Sterilized Convenience Kits for Clinical and Surgical Use:  Final Guidance for Industry,01/07/2002,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2020-D-0957
Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies,PDF (39.94 KB)PDF (39.94 KB) of Potassium Iodide as a Thyroid Blocking Agent in Radiation Emergencies,12/11/2001,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-2000-D-1403
CVM GFI #142 (VICH GL29) Pharmacovigilance of Veterinary Medicinal Products: Management of Periodic Summary Update Reports (PSUs),PDF (151.51 KB)PDF (151.51 KB) of CVM GFI #142 (VICH GL29) Pharmacovigilance of Veterinary Medicinal Products: Management of Periodic Summary Update Reports (PSUs),12/06/2001,Center for Veterinary Medicine,"Adverse Event Reporting, VICH",Draft,No,,FDA-2001-D-0398
Information Request and Discipline Review Letters Under the Prescription Drug User Fee Act:  Guidance for Industry,PDF (26.99 KB)PDF (26.99 KB) of Information Request and Discipline Review Letters Under the Prescription Drug User Fee Act:  Guidance for Industry,11/21/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"User Fees,",Final,No,,FDA-1999-D-1301
Guidance for Industry: Fumonisin Levels in Human Foods and Animal Feeds,,11/09/2001,Center for Veterinary MedicineHuman Foods Program,,Final,No,,
Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation — Small Entity Compliance Guide:  Guidance for Industry,PDF (17.58 KB)PDF (17.58 KB) of Sterility Requirement for Aqueous-Based Drug Products for Oral Inhalation — Small Entity Compliance Guide:  Guidance for Industry,11/07/2001,Center for Drug Evaluation and Research,,Final,No,,
Recommendations for Assessment of Donor Suitability and Blood and Blood Product Safety in Cases of Possible Exposure to Anthrax:  Guidance for Industry,PDF (37.18 KB)PDF (37.18 KB) of Recommendations for Assessment of Donor Suitability and Blood and Blood Product Safety in Cases of Possible Exposure to Anthrax:  Guidance for Industry,10/17/2001,Center for Biologics Evaluation and Research,"Application & Approvals, Blood Products",Final,No,,FDA-2001-D-0488
Cancer Drug and Biological Products - Clinical Data in Marketing Applications,PDF (118.63 KB)PDF (118.63 KB) of Cancer Drug and Biological Products - Clinical Data in Marketing Applications,10/11/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-2000-D-0100
Redbook 2000: VI.B Epidemiology,,10/01/2001,Human Foods Program,Food & Color Additives,Final,No,,
Submitting Marketing Applications According to the ICH/CTD Format: General Considerations 2001,,09/05/2001,Center for Drug Evaluation and Research,"Administrative / Procedural, ICH-Multidisciplinary",Draft,No,,FDA-2001-D-0061
Submitting Marketing Applications According to the ICH/CTD Format: General Considerations,PDF (174.62 KB)PDF (174.62 KB) of Submitting Marketing Applications According to the ICH/CTD Format: General Considerations,09/01/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, ICH-Multidisciplinary",Draft,No,,
Guidance for Industry: Questions and Answers on Juice HACCP Regulation,,08/31/2001,Human Foods Program,"HACCP, Juice",Final,No,,
Q7A Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients,,08/01/2001,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
M4: The CTD -- Quality,PDF (130.92 KB)PDF (130.92 KB) of M4: The CTD -- Quality,08/01/2001,Center for Drug Evaluation and Research,ICH-Multidisciplinary,Final,No,,
M4S: The CTD -- Safety,PDF (115.51 KB)PDF (115.51 KB) of M4S: The CTD -- Safety,08/01/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,
M4S: The CTD -- Safety Appendices,PDF (1.96 MB)PDF (1.96 MB) of M4S: The CTD -- Safety Appendices,08/01/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Multidisciplinary,Final,No,,
Labeling Recommendations for Single-Use Devices Reprocessed by Third Parties and Hospitals:  Final Guidance for Industry and FDA,PDF (45.56 KB)PDF (45.56 KB) of Labeling Recommendations for Single-Use Devices Reprocessed by Third Parties and Hospitals:  Final Guidance for Industry and FDA,07/30/2001,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Premarket Notification Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components:  Guidance for FDA Reviewers,PDF (29.88 KB)PDF (29.88 KB) of  Premarket Notification Submissions for Empty Containers for the Collection and Processing of Blood and Blood Components:  Guidance for FDA Reviewers,07/19/2001,Center for Biologics Evaluation and Research,"Application & Approvals, Blood Products",Final,No,,FDA-2007-D-0251
Premarket Notification Submissions for Blood and Plasma Warmers:  Guidance for FDA Reviewers,PDF (31.21 KB)PDF (31.21 KB) of Premarket Notification Submissions for Blood and Plasma Warmers:  Guidance for FDA Reviewers,07/19/2001,Center for Biologics Evaluation and Research,"Application & Approvals, Blood Products",Final,No,,FDA-2022-D-0484
Premarket Notification Submissions for Transfer Sets (Excluding Sterile Connecting Devices):  Guidance for FDA Reviewers,PDF (29.87 KB)PDF (29.87 KB) of Premarket Notification Submissions for Transfer Sets (Excluding Sterile Connecting Devices):  Guidance for FDA Reviewers,07/19/2001,Center for Biologics Evaluation and Research,"Application & Approvals, Blood Products",Final,No,,FDA-2022-D-0485
"Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date and Submission of New Applications","PDF (24.32 KB)PDF (24.32 KB) of Levothyroxine Sodium Products Enforcement of August 14, 2001 Compliance Date and Submission of New Applications",07/13/2001,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
S7A Safety Pharmacology Studies for Human Pharmaceuticals,PDF (44.06 KB)PDF (44.06 KB) of S7A Safety Pharmacology Studies for Human Pharmaceuticals,07/13/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-2000-D-0274
Revised Recommendations Regarding Invalidation of Test Results of Licensed and 510(k) Cleared Bloodborne Pathogen Assays Used to Test Donors:  Guidance for Industry,PDF (32.91 KB)PDF (32.91 KB) of Revised Recommendations Regarding Invalidation of Test Results of Licensed and 510(k) Cleared Bloodborne Pathogen Assays Used to Test Donors:  Guidance for Industry,07/11/2001,Center for Biologics Evaluation and Research,"Application & Approvals, Blood Products",Final,No,,FDA-1999-D-0743
CVM GFI #104 Content and Format of Effectiveness and Target Animal Safety Technical Sections and Final Study Reports For Submission,PDF (173.8 KB)PDF (173.8 KB) of CVM GFI #104 Content and Format of Effectiveness and Target Animal Safety Technical Sections and Final Study Reports For Submission,07/10/2001,Center for Veterinary Medicine,"New Animal Drug Application (NADA), Target Animal – Effectiveness, Target Animal – Safety, Investigational New Animal Drug (INAD)",Final,No,,FDA-2021-D-0619
CVM GFI #56 Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials,PDF (60.4 KB)PDF (60.4 KB) of CVM GFI #56 Protocol Development Guideline for Clinical Effectiveness and Target Animal Safety Trials,07/10/2001,Center for Veterinary Medicine,"Environmental Safety, Target Animal – Effectiveness, Target Animal – Safety",Final,No,,FDA-2021-D-0611
Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors:  Final Guidance for Industry and FDA Staff,PDF (287.92 KB)PDF (287.92 KB) of Frequently-Asked-Questions about the Reprocessing and Reuse of Single-Use Devices by Third-Party and Hospital Reprocessors:  Final Guidance for Industry and FDA Staff,07/06/2001,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance for Industry: Refusal of Inspection or Access to HACCP Records Pertaining to the Safe and Sanitary Processing of Fish and Fishery Products,,07/01/2001,Human Foods Program,"HACCP, Records, Seafood/Seafood Product",Final,No,,FDA-2000-D-0278
Small Entity Compliance Guide: Safe Handling Statements on Labeling of Shell Eggs and the Refrigeration of Shell Eggs Held for Retail Distribution,,07/01/2001,Human Foods Program,"Egg/Egg Product, Retail Food Protection",Final,No,,FDA-2020-D-1954
"Small Entity Compliance Guide: Serving Sizes Reference Amount for Baking Powder, Baking Soda, and Pectin",,07/01/2001,Human Foods Program,"Bakery Product/Mix, Labeling, Nutrition Label",Final,No,,FDA-2020-D-1955
Information for Keratome Manufacturers Regarding LASIK - Final Guidance for Industry,PDF (209.66 KB)PDF (209.66 KB) of Information for Keratome Manufacturers Regarding LASIK - Final Guidance for Industry,06/20/2001,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2020-D-0957
Changes or Modifications During the Conduct of a Clinical Investigation; Final Guidance for Industry and CDRH Staff,PDF (506.78 KB)PDF (506.78 KB) of Changes or Modifications During the Conduct of a Clinical Investigation; Final Guidance for Industry and CDRH Staff,05/28/2001,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE)",Final,No,,FDA-2020-D-0957
"Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; (Laser Notice 51)","PDF (211.08 KB)PDF (211.08 KB) of Responsibilities of Laser Light Show Projector Manufacturers, Dealers, and Distributors; (Laser Notice 51)",05/26/2001,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",,Final,No,,FDA-2020-D-0957
E10 Choice of Control Group and Related Issues in Clinical Trials,PDF (93.22 KB)PDF (93.22 KB) of E10 Choice of Control Group and Related Issues in Clinical Trials,05/14/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1999-D-1874
CVM GFI #85 (VICH GL9) Good Clinical Practice,PDF (355.95 KB)PDF (355.95 KB) of CVM GFI #85 (VICH GL9) Good Clinical Practice,05/09/2001,Center for Veterinary Medicine,"Target Animal – Effectiveness, Target Animal – Safety, VICH",Final,No,,FDA-1999-D-0754
"Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals","PDF (135.48 KB)PDF (135.48 KB) of Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of Pharmaceuticals",05/08/2001,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Draft,No,,FDA-2001-D-0043
"IND Meetings for Human Drugs and Biologics Chemistry, Manufacturing, and Controls Information:  Guidance for Industry","PDF (30.12 KB)PDF (30.12 KB) of IND Meetings for Human Drugs and Biologics Chemistry, Manufacturing, and Controls Information:  Guidance for Industry",05/01/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,
Guidance on Medical Device Patient Labeling:  Final Guidance for Industry and FDA Staff,PDF (333.25 KB)PDF (333.25 KB) of Guidance on Medical Device Patient Labeling:  Final Guidance for Industry and FDA Staff,04/19/2001,Center for Devices and Radiological Health,Labeling,Final,No,,FDA-2000-D-0067
"Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities - FDA Public Health Advisory:  Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities","PDF (18.7 KB)PDF (18.7 KB) of Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities - FDA Public Health Advisory:  Guidance for Hospitals, Nursing Homes, and Other Health Care Facilities",04/05/2001,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,
CVM GFI #99 (VICH GL17) Testing of New Biotechnological/Biological Products,PDF (118.25 KB)PDF (118.25 KB) of CVM GFI #99 (VICH GL17) Testing of New Biotechnological/Biological Products,03/26/2001,Center for Veterinary Medicine,"Biotechnology, Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-2021-D-0612
Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines: Draft Guidance for Industry,PDF (380.54 KB)PDF (380.54 KB) of Postmarketing Safety Reporting for Human Drug and Biological Products Including Vaccines: Draft Guidance for Industry,03/12/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Safety - Issues, Errors, and Problems, Vaccines",Draft,No,,FDA-2001-D-0506
Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing,PDF (27.48 KB)PDF (27.48 KB) of Levothyroxine Sodium Tablets - In Vivo Pharmacokinetic and Bioavailability Studies and In Vitro Dissolution Testing,03/08/2001,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-1999-D-0010
CVM GFI #89 (VICH GL6) EIAs for Veterinary Medicinal Products  - Phase I,PDF (106.15 KB)PDF (106.15 KB) of CVM GFI #89 (VICH GL6) EIAs for Veterinary Medicinal Products  - Phase I,03/07/2001,Center for Veterinary Medicine,"Environmental Safety, VICH",Final,No,,FDA-1999-D-3541
Monoclonal Antibodies Used as Reagents in Drug Manufacturing,PDF (28.78 KB)PDF (28.78 KB) of Monoclonal Antibodies Used as Reagents in Drug Manufacturing,03/01/2001,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,
Early Collaboration Meetings Under the FDA Modernization Act (FDAMA); Final Guidance for Industry and for CDRH Staff,PDF (79.69 KB)PDF (79.69 KB) of Early Collaboration Meetings Under the FDA Modernization Act (FDAMA); Final Guidance for Industry and for CDRH Staff,02/27/2001,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","Premarket, Investigational Device Exemption (IDE)",Final,No,,FDA-2020-D-0957
Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods - Technical Correction February 2001:  Guidance for Industry,PDF (28.7 KB)PDF (28.7 KB) of Recommendations for Collecting Red Blood Cells by Automated Apheresis Methods - Technical Correction February 2001:  Guidance for Industry,02/13/2001,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-1998-D-0851
Clinical Development and Labeling of Anti-Infective Drug Products,PDF (5.11 MB)PDF (5.11 MB) of Clinical Development and Labeling of Anti-Infective Drug Products,02/12/2001,Center for Drug Evaluation and Research,Clinical - Antimicrobial,Final,No,,None found
Statistical Approaches to Establishing Bioequivalence,PDF (130.1 KB)PDF (130.1 KB) of Statistical Approaches to Establishing Bioequivalence,02/01/2001,Center for Drug Evaluation and Research,"Biopharmaceutics, Generic Drugs",Final,No,,01D-0027
PHS Guideline on Infectious Disease Issues in Xenotransplantation:  PHS Guideline,PDF (618.05 KB)PDF (618.05 KB) of PHS Guideline on Infectious Disease Issues in Xenotransplantation:  PHS Guideline,01/19/2001,Center for Biologics Evaluation and Research,Xenotransplantation,Final,No,,FDA-1996-M-0140
"Content of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation - Guidance for Industry and FDA Reviewers","PDF (133.33 KB)PDF (133.33 KB) of Content of Investigational Device Exemptions for Solutions for Hypothermic Flushing, Transport and Storage of Organs for Transplantation - Guidance for Industry and FDA Reviewers",01/15/2001,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE)",Final,No,,FDA-2020-D-0957
Changes to an Approved NDA or ANDA: Questions and Answers:  Guidance for Industry,PDF (35.44 KB)PDF (35.44 KB) of Changes to an Approved NDA or ANDA: Questions and Answers:  Guidance for Industry,01/01/2001,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-1999-D-0049
Q6A Specifications: Test Procedures and Acceptance Criteria for New Drug Substances and New Drug Products:  Chemical Substances,,12/29/2000,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-1997-D-0005
Labeling OTC Human Drug Products Using a Column Format,PDF (57 KB)PDF (57 KB) of Labeling OTC Human Drug Products Using a Column Format,12/19/2000,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,FDA-1999-D-1300
E11 Clinical Investigation of Medicinal Products in the Pediatric Population,PDF (60.38 KB)PDF (60.38 KB) of E11 Clinical Investigation of Medicinal Products in the Pediatric Population,12/15/2000,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"ICH-Efficacy, Pediatric Product Development",Final,No,,FDA-2000-D-0942
Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs:  Guidance for Industry,PDF (14.36 KB)PDF (14.36 KB) of Alternate Source of the Active Pharmaceutical Ingredient in Pending ANDAs:  Guidance for Industry,12/01/2000,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Generic Drugs, Pharmaceutical Quality",Final,No,,None found
Guidance for Industry: Channels of Trade Policy for Commodities with Methyl Parathion Residues,,11/30/2000,Human Foods Program,Pesticide,Final,No,,FDA-2000-D-0028
Use of Sterile Connecting Devices in Blood Bank Practices:  Guidance for Industry,PDF (38.25 KB)PDF (38.25 KB) of Use of Sterile Connecting Devices in Blood Bank Practices:  Guidance for Industry,11/22/2000,Center for Biologics Evaluation and Research,"Application & Approvals, Blood Products",Final,No,,FDA-2022-D-0486
Guidance Document for Dura Substitute Devices - Guidance for Industry,PDF (65.56 KB)PDF (65.56 KB) of Guidance Document for Dura Substitute Devices - Guidance for Industry,11/08/2000,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Submitting and Reviewing Complete Responses to Clinical Holds (Revised),PDF (25.51 KB)PDF (25.51 KB) of Submitting and Reviewing Complete Responses to Clinical Holds (Revised),10/01/2000,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Administrative / Procedural, Good Clinical Practice (GCP)",Final,No,,FDA-1998-D-0279
"Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products.  Questions and Answers:  Guidance for Industry Q&A","PDF (14.19 KB)PDF (14.19 KB) of Content and Format of INDs for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-Derived Products.  Questions and Answers:  Guidance for Industry Q&A",10/01/2000,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Pharmacology/Toxicology, Investigational New Drug Application (INDA)",Final,No,,None found
"CPG Sec. 230.110-  Registration of Blood Banks, Other Firms Collecting, Manufacturing, Preparing or Processing Human Blood or Blood Products",,08/16/2000,,"Investigation & Enforcement,",Final,No,,
Labeling for Electronic Anti-Theft Systems:  Guidance for Industry,PDF (23.05 KB)PDF (23.05 KB) of Labeling for Electronic Anti-Theft Systems:  Guidance for Industry,08/15/2000,Center for Devices and Radiological Health,"Premarket, Labeling",Final,No,,FDA-2020-D-0957
E12A Principles for Clinical Evaluation of New Antihypertensive Drugs,PDF (26.9 KB)PDF (26.9 KB) of E12A Principles for Clinical Evaluation of New Antihypertensive Drugs,08/09/2000,Center for Drug Evaluation and Research,ICH-Efficacy,Draft,No,,FDA-2000-D-0785
Guidance on Section 216 of the Food and Drug Administration Modernization Act of 1997 - Guidance for Industry and for FDA Reviewers,PDF (190.71 KB)PDF (190.71 KB) of Guidance on Section 216 of the Food and Drug Administration Modernization Act of 1997 - Guidance for Industry and for FDA Reviewers,08/08/2000,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
CPG Sec 515.700 Chocolate & Chocolate Liquor - Adulteration with Insect and Rodent Filth,PDF (10.36 KB)PDF (10.36 KB) of CPG Sec 515.700 Chocolate & Chocolate Liquor - Adulteration with Insect and Rodent Filth,08/01/2000,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Chocolate/Cocoa Product",Final,No,,
Guidance for the Submission of Premarket Notifications for Photon-Emitting Brachytherapy Sources - Guidance for Industry,PDF (84.33 KB)PDF (84.33 KB) of Guidance for the Submission of Premarket Notifications for Photon-Emitting Brachytherapy Sources - Guidance for Industry,08/01/2000,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
CPG Sec. 220.100 - IS Shipment Biologicals for Medical Emergency,,07/31/2000,,"Investigation & Enforcement, Investigational New Drug Application (INDA)",Final,No,,
CPG Sec. 270.100 Final Container Labels - Allergenic Extracts Containing Glycerin; Reporting Changes,,07/31/2000,Office of Regulatory Affairs,"Investigation & Enforcement, Allergenics",Final,No,,
Guidance for Industry: Action Levels for Poisonous or Deleterious Substances in Human Food and Animal Feed,,07/31/2000,Human Foods Program,"Animal Feed, Sanitation",Final,No,,FDA-2020-D-1956
Guidance for Over-the-Counter (OTC) Human Chorionic Gonadotropin (hCG) 510(k)s - Guidance for Industry and FDA Reviewers/Staff,PDF (63.86 KB)PDF (63.86 KB) of Guidance for Over-the-Counter (OTC) Human Chorionic Gonadotropin (hCG) 510(k)s - Guidance for Industry and FDA Reviewers/Staff,07/21/2000,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality","Premarket,",Final,No,,FDA-2020-D-0957
1-Consolidated Annual Report for a Device product line (1-CARD) - Guidance for Industry and CDRH Reviewers,PDF (124.68 KB)PDF (124.68 KB) of 1-Consolidated Annual Report for a Device product line (1-CARD) - Guidance for Industry and CDRH Reviewers,07/05/2000,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Redbook 2000: IV.B.3. Pathology Considerations in Toxicity Studies,,07/01/2000,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.1.a. Bacterial Reverse Mutation Test,,07/01/2000,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.1.d. Mammalian Erythrocyte Micronucleus Test,,07/01/2000,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.10. Neurotoxicity Studies,,07/01/2000,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.9.a.Guidelines for Reproduction Studies,,07/01/2000,Human Foods Program,Food & Color Additives,Final,No,,
Redbook 2000: IV.C.9.b. Guidelines for Developmental Toxicity Studies,,07/01/2000,Human Foods Program,Food & Color Additives,Final,No,,
CPG Sec. 100.950  International Partnership Agreements for Compliance Activities,,06/28/2000,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CVM GFI #98  Dioxin In Anti-Caking Agents In Animal Feed And Feed Ingredients,PDF (35.15 KB)PDF (35.15 KB) of CVM GFI #98  Dioxin In Anti-Caking Agents In Animal Feed And Feed Ingredients,04/12/2000,Center for Veterinary Medicine,Animal Feed,Final,No,,FDA-1999-D-2441
Guidance for Premarket Submissions of Orthokeratology Rigid Gas Permeable Contact Lenses - Guidance for Industry,PDF (291.05 KB)PDF (291.05 KB) of Guidance for Premarket Submissions of Orthokeratology Rigid Gas Permeable Contact Lenses - Guidance for Industry,04/09/2000,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Street Drug Alternatives,PDF (10.51 KB)PDF (10.51 KB) of Street Drug Alternatives,04/03/2000,Center for Drug Evaluation and Research,"Compliance,",Final,No,,FDA-2000-D-0783
"CPG Sec. 215.100 IND Filings; Completion of Applicable Portions Prior to Final Action on License Applications or License Supplements, Deleted 03/28/2000, Outdated and Obsolete",,03/27/2000,,"Investigation & Enforcement,",Final,No,,
"Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act","PDF (25.28 KB)PDF (25.28 KB) of Court Decisions, ANDA Approvals, and 180-Day Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act",03/27/2000,,Administrative / Procedural,Final,No,,
"Guidance for Manufacturers Seeking Marketing Clearance of Ear, Nose, and Throat Endoscope Sheaths Used as Protective Barriers: Guidance for Industry","PDF (80.59 KB)PDF (80.59 KB) of Guidance for Manufacturers Seeking Marketing Clearance of Ear, Nose, and Throat Endoscope Sheaths Used as Protective Barriers: Guidance for Industry",03/11/2000,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"CPG Sec. 252.110 Volume Limits for Automated Collection of Source Plasma (Obsolete, Withdrawn on 11/28/2017)",,03/05/2000,,"Investigation & Enforcement, Blood Products",Final,No,,
CVM GFI #91 (VICH GL8) Stability Testing for Medicated Premixes,PDF (47.42 KB)PDF (47.42 KB) of CVM GFI #91 (VICH GL8) Stability Testing for Medicated Premixes,03/01/2000,Center for Veterinary Medicine,"Animal Feed, Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-2021-D-0613
Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements - Guidance for Industry and for FDA Reviewers/Staff,PDF (37.99 KB)PDF (37.99 KB) of Guidance for Industry on the Testing of Metallic Plasma Sprayed Coatings on Orthopedic Implants to Support Reconsideration of Postmarket Surveillance Requirements - Guidance for Industry and for FDA Reviewers/Staff,02/01/2000,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2020-D-0957
NDAs: Impurities in Drug Substances,PDF (11.2 KB)PDF (11.2 KB) of NDAs: Impurities in Drug Substances,02/01/2000,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-1998-D-0277
"Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer:  Guidance for Industry and for FDA Reviewers","PDF (1.57 MB)PDF (1.57 MB) of Guidance Document for Premarket Notification Submissions for Nitric Oxide Delivery Apparatus, Nitric Oxide Analyzer and Nitrogen Dioxide Analyzer:  Guidance for Industry and for FDA Reviewers",01/24/2000,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-1999-D-4090
Guidance for the Content of Premarket Notifications for Penile Rigidity Implants - Guidance for Industry and for FDA Staff,PDF (105.01 KB)PDF (105.01 KB) of Guidance for the Content of Premarket Notifications for Penile Rigidity Implants - Guidance for Industry and for FDA Staff,01/15/2000,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Guidance Document for the Preparation of IDEs for Spinal Systems - Guidance for Industry and/or FDA Staff,PDF (99.71 KB)PDF (99.71 KB) of Guidance Document for the Preparation of IDEs for Spinal Systems - Guidance for Industry and/or FDA Staff,01/12/2000,Center for Devices and Radiological Health,"Labeling, Pediatric Product Development",Final,No,,FDA-2020-D-0957
Content and Format of Premarket Notification [510(k)] Submissions for Liquid Chemical Sterilants/High Level Disinfectants - Guidance for Industry and FDA Reviewers,PDF (238.24 KB)PDF (238.24 KB) of Content and Format of Premarket Notification [510(k)] Submissions for Liquid Chemical Sterilants/High Level Disinfectants - Guidance for Industry and FDA Reviewers,01/02/2000,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
"Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000","PDF (10.32 KB)PDF (10.32 KB) of Disclosure of Materials Provided to Advisory Committees in Connection with Open Advisory Committee Meetings Convened by the Center for Drug Evaluation and Research Beginning on January 1, 2000",12/22/1999,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
Applications Covered by Section 505(b)(2),PDF (41.41 KB)PDF (41.41 KB) of Applications Covered by Section 505(b)(2),12/08/1999,Center for Drug Evaluation and Research,Administrative / Procedural,Draft,No,,FDA-1999-D-0738
Guidance for Industry: Seafood HACCP Transition Guidance,,12/01/1999,Human Foods Program,"HACCP, Seafood/Seafood Product",Final,No,,FDA-1999-D-3543
Drug Master Files for Bulk Antibiotic Drug Substances:  Guidance for Industry,PDF (23.23 KB)PDF (23.23 KB) of Drug Master Files for Bulk Antibiotic Drug Substances:  Guidance for Industry,11/29/1999,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1999-D-1314
Guidance for Cardiovascular Intravascular Filter 510(k) Submissions - Guidance for Industry and FDA Staff,,11/25/1999,Center for Devices and Radiological Health,"Premarket, Cardiovascular",Final,No,,FDA-2020-D-0957
Providing Regulatory Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format - Biologics Marketing Applications:  Guidance for Industry,PDF (713.82 KB)PDF (713.82 KB) of Providing Regulatory Submissions to the Center for Biologics Evaluation and Research (CBER) in Electronic Format - Biologics Marketing Applications:  Guidance for Industry,11/01/1999,Center for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-1998-D-0850
Submission of Abbreviated Reports and Synopses in Support of Marketing Applications.,PDF (43.08 KB)PDF (43.08 KB) of Submission of Abbreviated Reports and Synopses in Support of Marketing Applications.,09/13/1999,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-1998-D-0141
CVM GFI #74 (VICH GL4 ) Stability Testing of New Veterinary Dosage Forms,PDF (78.51 KB)PDF (78.51 KB) of CVM GFI #74 (VICH GL4 ) Stability Testing of New Veterinary Dosage Forms,09/01/1999,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA -2006-D-0299
CVM GFI #75 (VICH GL5) Stability Testing-Photostability Testing of New Veterinary Drug Substances and Medicinal Products,PDF (76.02 KB)PDF (76.02 KB) of CVM GFI #75 (VICH GL5) Stability Testing-Photostability Testing of New Veterinary Drug Substances and Medicinal Products,09/01/1999,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), VICH",Final,No,,FDA-1998-D-1165
Possible Dioxin/PCB Contamination of Drug and Biological Products,PDF (7.73 KB)PDF (7.73 KB) of Possible Dioxin/PCB Contamination of Drug and Biological Products,08/23/1999,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,
Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products,PDF (54 KB)PDF (54 KB) of Q6B Specifications: Test Procedures and Acceptance Criteria for Biotechnological/Biological Products,08/18/1999,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-1998-D-0003
Consumer-Directed Broadcast Advertisements:  Guidance for Industry,PDF (25.43 KB)PDF (25.43 KB) of Consumer-Directed Broadcast Advertisements:  Guidance for Industry,08/01/1999,Center for Veterinary MedicineCenter for Drug Evaluation and Research,Advertising,Final,No,,FDA-1997-D-0048
CPG Sec. 230.140 Evaluation and Processing Post Donation Information Reports is obsolete and was withdrawn on 7/16/2018.,PDF (131.44 KB)PDF (131.44 KB) of CPG Sec. 230.140 Evaluation and Processing Post Donation Information Reports is obsolete and was withdrawn on 7/16/2018.,07/09/1999,,"Investigation & Enforcement, Blood Products",Final,No,,
Container Closure Systems for Packaging Human Drugs and Biologics:  Guidance for Industry,PDF (164.05 KB)PDF (164.05 KB) of Container Closure Systems for Packaging Human Drugs and Biologics:  Guidance for Industry,07/07/1999,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1997-D-0145
Guidance for Industry: Antimicrobial Food Additives,,06/30/1999,Human Foods Program,"Food & Color Additives, Ingredients",Final,No,,FDA-1999-D-1298
S4A Duration of Chronic Toxicity Testing in Animals (Rodent and Nonrodent Toxicity Testing),PDF (20.77 KB)PDF (20.77 KB) of S4A Duration of Chronic Toxicity Testing in Animals (Rodent and Nonrodent Toxicity Testing),06/25/1999,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-1997-D-0153
"Guidance Document for Powered Muscle Stimulator 510(k)s - Guidance for Industry, FDA Reviewers/Staff and Compliance","PDF (54.69 KB)PDF (54.69 KB) of Guidance Document for Powered Muscle Stimulator 510(k)s - Guidance for Industry, FDA Reviewers/Staff and Compliance",06/08/1999,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Fees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act,PDF (48.22 KB)PDF (48.22 KB) of Fees-Exceed-the-Costs Waivers Under the Prescription Drug User Fee Act,06/01/1999,Center for Drug Evaluation and Research,"User Fees,",Final,No,,
Efficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use:  Guidance for Industry,PDF (12.05 KB)PDF (12.05 KB) of Efficacy Studies to Support Marketing of Fibrin Sealant Products Manufactured for Commercial Use:  Guidance for Industry,05/20/1999,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-1997-D-0186
"For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h:  Guidance for Industry","PDF (94.13 KB)PDF (94.13 KB) of  For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Blood and Blood Components Intended for Transfusion or for Further Manufacture and For the Completion of the Form FDA 356h:  Guidance for Industry",05/10/1999,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,05/10/1999,FDA-1998-D-0995
Recommended Clinical Study Design for Ventricular Tachycardia Ablation,PDF (1.14 MB)PDF (1.14 MB) of Recommended Clinical Study Design for Ventricular Tachycardia Ablation,05/07/1999,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Immunotoxicity Testing Guidance,,05/05/1999,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"CPG Sec. 210.100 Deleted 4/26/99,  Outdated and Obsolete",,04/25/1999,,"Investigation & Enforcement,",Final,No,,
"On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test:  Guidance for Industry","PDF (44.57 KB)PDF (44.57 KB) of On the Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for an Allergenic Extract or Allergen Patch Test:  Guidance for Industry",04/23/1999,Center for Biologics Evaluation and Research,Allergenics,Final,No,,FDA-1998-D-1277
Preparing Notices of Availability of Investigational Medical Devices and for Recruiting Study Subjects:  Guidance for Industry and FDA Staff,PDF (25.84 KB)PDF (25.84 KB) of Preparing Notices of Availability of Investigational Medical Devices and for Recruiting Study Subjects:  Guidance for Industry and FDA Staff,03/19/1999,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE)",Final,No,,FDA-2020-D-0957
"Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Biological In Vitro Diagnostic Product:  Guidance for Industry","PDF (47.63 KB)PDF (47.63 KB) of Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Biological In Vitro Diagnostic Product:  Guidance for Industry",03/08/1999,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-1998-D-0689
Guidance on 510(k) Submissions for Keratoprostheses - Guidance for Industry and for FDA Reviewers/Staff,PDF (37.92 KB)PDF (37.92 KB) of Guidance on 510(k) Submissions for Keratoprostheses - Guidance for Industry and for FDA Reviewers/Staff,03/02/1999,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance for Dermabrasion Devices - Guidance for Industry,PDF (20.25 KB)PDF (20.25 KB) of Guidance for Dermabrasion Devices - Guidance for Industry,03/01/1999,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh - Guidance for Industry and/or for FDA Reviewers/Staff and/or Compliance,PDF (35.51 KB)PDF (35.51 KB) of Guidance for the Preparation of a Premarket Notification Application for a Surgical Mesh - Guidance for Industry and/or for FDA Reviewers/Staff and/or Compliance,03/01/1999,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
"Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)","PDF (369.2 KB)PDF (369.2 KB) of Clinical Development Programs for Drugs, Devices, and Biological Products for the Treatment of Rheumatoid Arthritis (RA)",02/17/1999,Center for Drug Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-1996-D-0004
"For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Plasma-Derived Biological Products, Animal Plasma or Serum-Derived Products:  Guidance for Industry:","PDF (39.77 KB)PDF (39.77 KB) of For the Submission of Chemistry, Manufacturing and Controls and Establishment Description Information for Human Plasma-Derived Biological Products, Animal Plasma or Serum-Derived Products:  Guidance for Industry:",02/17/1999,Center for Biologics Evaluation and Research,Blood Products,Final,No,,FDA-1998-D-0405
Providing Regulatory Submissions in Electronic Format; General Considerations,PDF (54.31 KB)PDF (54.31 KB) of Providing Regulatory Submissions in Electronic Format; General Considerations,01/28/1999,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Electronic Submissions,",Final,No,,
Premarket Notification [510(k)] Submissions for Testing for Skin Sensitization To Chemicals In Natural Rubber Products - Guidance for Industry and FDA Reviewers/Staff,PDF (40.48 KB)PDF (40.48 KB) of Premarket Notification [510(k)] Submissions for Testing for Skin Sensitization To Chemicals In Natural Rubber Products - Guidance for Industry and FDA Reviewers/Staff,01/12/1999,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product:  Guidance for Industry","PDF (92.87 KB)PDF (92.87 KB) of Content and Format of Chemistry, Manufacturing and Controls Information and Establishment Description Information for a Vaccine or Related Product:  Guidance for Industry",01/05/1999,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-1998-D-0854
"Small Entity Compliance Guide: Statement of Identity, Nutrition Labeling and Ingredient Labeling of Dietary Supplements",,01/03/1999,Human Foods Program,Labeling,Final,No,,FDA-2020-D-1959
Guidance for Industry: Questions and Answers on HACCP Regulation for Fish and Fishery Products,,01/01/1999,Human Foods Program,"HACCP, Seafood/Seafood Product",Final,No,,FDA-2020-D-1960
"CPG Sec. 205.100 Deleted 12/21/98, Obsolete",,12/20/1998,,"Investigation & Enforcement,",Final,No,,
Guidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and PET) and Nuclear Tomography Systems :  Guidance for Industry,PDF (97.38 KB)PDF (97.38 KB) of Guidance for the Submission of Premarket Notifications for Emission Computed Tomography Devices and Accessories (SPECT and PET) and Nuclear Tomography Systems :  Guidance for Industry,12/02/1998,Center for Devices and Radiological Health,"Premarket, Radiology",Final,No,,FDA-2020-D-0957
FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products,PDF (58.39 KB)PDF (58.39 KB) of FDA Approval of New Cancer Treatment Uses for Marketed Drug and Biological Products,12/01/1998,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,
Variations in Drug Products that May Be Included in a Single ANDA,PDF (106.73 KB)PDF (106.73 KB) of Variations in Drug Products that May Be Included in a Single ANDA,12/01/1998,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,FDA-2021-D-0385
Guidance for the Submission of Premarket Notifications For Radionuclide Dose Calibrators - Guidance for Industry,PDF (47.65 KB)PDF (47.65 KB) of Guidance for the Submission of Premarket Notifications For Radionuclide Dose Calibrators - Guidance for Industry,11/19/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Non-Automated Sphygmomanometer (Blood Pressure Cuff) Guidance - Version 1 - Guidance for Industry,PDF (53.08 KB)PDF (53.08 KB) of Non-Automated Sphygmomanometer (Blood Pressure Cuff) Guidance - Version 1 - Guidance for Industry,11/18/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Aqueous Shunts - 510(k) Submissions - Guidance for Industry and for FDA Reviewers/Staff,PDF (57.2 KB)PDF (57.2 KB) of Aqueous Shunts - 510(k) Submissions - Guidance for Industry and for FDA Reviewers/Staff,11/15/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
CPG Sec. 675.400 Rendered Animal Feed Ingredients (Withdrawn 4/30/2019),,11/12/1998,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,
Protection of Human Subjects: Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) Through an Expedited Review Procedure:  Guidance for Institutional Review Boards and Clinical Investigators,PDF (126.43 KB)PDF (126.43 KB) of Protection of Human Subjects: Categories of Research That May Be Reviewed by the Institutional Review Board (IRB) Through an Expedited Review Procedure:  Guidance for Institutional Review Boards and Clinical Investigators,11/09/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","Clinical Trials, Good Clinical Practice (GCP)",Final,No,03/10/1998,FDA-1997-N-0257
FDA Animal Products Database Data Entry Form,PDF (106.72 KB)PDF (106.72 KB) of FDA Animal Products Database Data Entry Form,11/06/1998,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Cardiac Monitor Guidance (including Cardiotachometer and Rate Alarm) - Guidance for Industry,PDF (80.92 KB)PDF (80.92 KB) of Cardiac Monitor Guidance (including Cardiotachometer and Rate Alarm) - Guidance for Industry,11/04/1998,Center for Devices and Radiological Health,"Premarket, Cardiovascular",Final,No,,FDA-2020-D-0957
Diagnostic ECG Guidance (Including Non-Alarming ST Segment Measurement) - Guidance for Industry,PDF (82.31 KB)PDF (82.31 KB) of Diagnostic ECG Guidance (Including Non-Alarming ST Segment Measurement) - Guidance for Industry,11/04/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
General/Specific Intended Use - Guidance for Industry,PDF (75.67 KB)PDF (75.67 KB) of General/Specific Intended Use - Guidance for Industry,11/03/1998,Center for Devices and Radiological Health,"Premarket, Pediatric Product Development",Final,No,,FDA-2020-D-0957
Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards for Fresh Fruits and Vegetables,PDF (98.28 KB)PDF (98.28 KB) of Guidance for Industry: Guide to Minimize Microbial Food Safety Hazards for Fresh Fruits and Vegetables,10/25/1998,Human Foods Program,"Fruit/Fruit Product , Vegetable Products",Final,No,,FDA-1997-N-0152
Noise Claims in Hearing Aid Labeling - Guidance for Industry,PDF (144.98 KB)PDF (144.98 KB) of Noise Claims in Hearing Aid Labeling - Guidance for Industry,10/20/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance Document For Nonprescription Sunglasses - Guidance for Industry,PDF (71.93 KB)PDF (71.93 KB) of Guidance Document For Nonprescription Sunglasses - Guidance for Industry,10/08/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Submitting Debarment Certification Statements,PDF (143.85 KB)PDF (143.85 KB) of Submitting Debarment Certification Statements,10/02/1998,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and ResearchCenter for Veterinary Medicine,Administrative / Procedural,Draft,No,,FDA-1998-D-0556
Implementation of Section 120 of the Food and Drug Administration Modernization Act of 1997-Advisory Committees,PDF (62.13 KB)PDF (62.13 KB) of Implementation of Section 120 of the Food and Drug Administration Modernization Act of 1997-Advisory Committees,10/01/1998,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
Guidance Document for Powered Suction Pump 510(k)s - Guidance for Industry and FDA Reviewers/Staff,PDF (35.4 KB)PDF (35.4 KB) of Guidance Document for Powered Suction Pump 510(k)s - Guidance for Industry and FDA Reviewers/Staff,09/29/1998,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
CPG Sec. 615.100  Extralabel Use of New Animal Drugs in Food Producing Animals - Revoked on 09/24/1998 (63 FR 51074),,09/24/1998,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
Q5D Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products; Availability,PDF (52.35 KB)PDF (52.35 KB) of Q5D Quality of Biotechnological/Biological Products: Derivation and Characterization of Cell Substrates Used for Production of Biotechnological/Biological Products; Availability,09/21/1998,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-1997-D-0098
E9 Statistical Principles for Clinical Trials,PDF (109.86 KB)PDF (109.86 KB) of E9 Statistical Principles for Clinical Trials,09/16/1998,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1997-D-0508
How to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1):  Guidance for Industry,PDF (82.14 KB)PDF (82.14 KB) of How to Complete the Vaccine Adverse Event Reporting System Form (VAERS-1):  Guidance for Industry,09/09/1998,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-2022-D-0487
"OTC Denture Cushions, Pads, Reliners, Repair Kits, and Partially Fabricated Denture Kits - Guidance for Industry and FDA Staff","PDF (93.73 KB)PDF (93.73 KB) of OTC Denture Cushions, Pads, Reliners, Repair Kits, and Partially Fabricated Denture Kits - Guidance for Industry and FDA Staff",08/17/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2017-P-5124
Accidental Radioactive Contamination of Human Food and Animal Feeds:  Recommendations for State and Local Agencies,PDF (231.36 KB)PDF (231.36 KB) of Accidental Radioactive Contamination of Human Food and Animal Feeds:  Recommendations for State and Local Agencies,08/13/1998,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
Revised Procedures for Adding Lens Finishing Laboratories to Approved Premarket Approval Applications for Class III Rigid Gas Permeable Contact Lenses for Extended Wear - Guidance for Industry and FDA Staff,PDF (46.55 KB)PDF (46.55 KB) of Revised Procedures for Adding Lens Finishing Laboratories to Approved Premarket Approval Applications for Class III Rigid Gas Permeable Contact Lenses for Extended Wear - Guidance for Industry and FDA Staff,08/10/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Environmental Assessment of Human Drug and Biologics Applications:  Guidance for Industry,PDF (187.76 KB)PDF (187.76 KB) of Environmental Assessment of Human Drug and Biologics Applications:  Guidance for Industry,07/27/1998,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1998-D-0278
Latex Condoms for Men - Information for 510(k) Premarket Notifications: Use of Consensus Standards for Abbreviated Submissions:  Guidance for Industry,PDF (145.88 KB)PDF (145.88 KB) of Latex Condoms for Men - Information for 510(k) Premarket Notifications: Use of Consensus Standards for Abbreviated Submissions:  Guidance for Industry,07/23/1998,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Uniform Contraceptive Labeling - Guidance for Industry,PDF (93.67 KB)PDF (93.67 KB) of Uniform Contraceptive Labeling - Guidance for Industry,07/22/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Women and Minorities Guidance Requirements,PDF (30.17 KB)PDF (30.17 KB) of Women and Minorities Guidance Requirements,07/20/1998,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,
Slit Lamp Guidance - Guidance for Industry,PDF (60.65 KB)PDF (60.65 KB) of Slit Lamp Guidance - Guidance for Industry,07/07/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
CVM GFI #76 Questions and Answers BSE Feed Regulations,PDF (152.28 KB)PDF (152.28 KB) of CVM GFI #76 Questions and Answers BSE Feed Regulations,07/01/1998,Center for Veterinary Medicine,"Bovine Spongiform Encephalopathy (BSE), Current Good Manufacturing Practice (CGMP)",Final,No,,
"Repeal of Section 507 of the Federal Food, Drug and Cosmetic Act _1","PDF (84.7 KB)PDF (84.7 KB) of Repeal of Section 507 of the Federal Food, Drug and Cosmetic Act _1",06/15/1998,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-1998-D-0864
Guidance for Industry: Notification of a Health Claim or Nutrient Content Claim Based on an Authoritative Statement of a Scientific Body,,06/11/1998,Human Foods Program,Labeling,Final,No,,FDA-1998-D-0102
E5 Ethnic Factors in the Acceptability of Foreign Clinical Data,PDF (79.19 KB)PDF (79.19 KB) of E5 Ethnic Factors in the Acceptability of Foreign Clinical Data,06/10/1998,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1997-D-0360
Guidance Document For Washers And Washer-Disinfectors Intended For Processing Reusable Medical Devices,,06/01/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act","PDF (77.08 KB)PDF (77.08 KB) of 180-Day Generic Drug Exclusivity Under the Hatch-Waxman Amendments to the Federal Food, Drug, and Cosmetic Act",06/01/1998,Center for Drug Evaluation and Research,"Administrative / Procedural, Generic Drugs",Final,No,,FDA-1998-D-101c
"Supplements to Approved Applications for Class III Medical Devices: Use of Published Literature, Use of Previously Submitted Materials, and Priority Review :  Guidance for Industry",,05/19/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.,PDF (129.17 KB)PDF (129.17 KB) of Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products.,05/15/1998,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-1997-D-0027
CVM GFI #72 GMP'S For Medicated Feed Manufacturers Not Required to Register and be Licensed with FDA,PDF (56.67 KB)PDF (56.67 KB) of CVM GFI #72 GMP'S For Medicated Feed Manufacturers Not Required to Register and be Licensed with FDA,05/01/1998,Center for Veterinary Medicine,"Animal Feed, Current Good Manufacturing Practice (CGMP)",Final,No,,
"Standards for the Prompt Review of Efficacy Supplements, Including Priority Efficacy Supplements :  Guidance for Industry","PDF (75.79 KB)PDF (75.79 KB) of Standards for the Prompt Review of Efficacy Supplements, Including Priority Efficacy Supplements :  Guidance for Industry",05/01/1998,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,98-0276
PAC-ATLS: Postapproval Changes - Analytical Testing Laboratory Sites:  Guidance for Industry,PDF (76.47 KB)PDF (76.47 KB) of PAC-ATLS: Postapproval Changes - Analytical Testing Laboratory Sites:  Guidance for Industry,04/28/1998,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1998-D-1157
Guidance For The Content Of Premarket Notifications For Esophageal And Tracheal Prostheses - Guidance For Industry,PDF (52.1 KB)PDF (52.1 KB) of Guidance For The Content Of Premarket Notifications For Esophageal And Tracheal Prostheses - Guidance For Industry,04/27/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
National Uniformity for Nonpresciption Drugs - Ingredient Listing for OTC Drugs,PDF (73.83 KB)PDF (73.83 KB) of National Uniformity for Nonpresciption Drugs - Ingredient Listing for OTC Drugs,04/09/1998,Center for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-1998-D-1007
Q3C: Appendix 5,PDF (216.11 KB)PDF (216.11 KB) of Q3C: Appendix 5,03/18/1998,Center for Drug Evaluation and Research,ICH-Quality,Final,No,,None found
Q3C: Appendix 4,PDF (120.43 KB)PDF (120.43 KB) of Q3C: Appendix 4,03/18/1998,Center for Drug Evaluation and Research,ICH-Quality,Draft,No,,
Q3C: Appendix 6,PDF (127.67 KB)PDF (127.67 KB) of Q3C: Appendix 6,03/18/1998,Center for Drug Evaluation and Research,ICH-Quality,Draft,No,,
Local Anesthetics--Clinical Evaluation,,03/02/1998,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
FDA Requirements for Approval of Drugs to Treat Non-Small Cell Lung Cancer,PDF (1.56 MB)PDF (1.56 MB) of FDA Requirements for Approval of Drugs to Treat Non-Small Cell Lung Cancer,03/02/1998,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
Good Laboratory Practice Regulations Questions and Answers,PDF (2.19 MB)PDF (2.19 MB) of Good Laboratory Practice Regulations Questions and Answers,03/02/1998,Center for Drug Evaluation and Research,"Compliance, Current Good Manufacturing Practice (CGMP)",Final,No,,
Guidance for the Development of Vaginal Contraceptive Drugs (NDA),PDF (465.1 KB)PDF (465.1 KB) of Guidance for the Development of Vaginal Contraceptive Drugs (NDA),03/02/1998,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
Oncologic Drugs Advisory Committee Discussion on FDA Requirements or Approval of New Drugs for Treatment of Colon and Rectal Cancer,PDF (1.51 MB)PDF (1.51 MB) of Oncologic Drugs Advisory Committee Discussion on FDA Requirements or Approval of New Drugs for Treatment of Colon and Rectal Cancer,03/02/1998,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
Psychoactive Drugs in Infants and Children--Clinical Evaluation,PDF (17.9 MB)PDF (17.9 MB) of Psychoactive Drugs in Infants and Children--Clinical Evaluation,03/02/1998,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,
Reference Guide for the Nonclinical Toxicity Studies of Antivial Drugs Indicated for the Treatment of N/A Non-Life Threatening Disease Evaluation of Drug Toxicity Prior to Phase I Clinical Studies,PDF (836.93 KB)PDF (836.93 KB) of Reference Guide for the Nonclinical Toxicity Studies of Antivial Drugs Indicated for the Treatment of N/A Non-Life Threatening Disease Evaluation of Drug Toxicity Prior to Phase I Clinical Studies,03/02/1998,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,
"Supplement to 10/11/1984 letter about policies, procedures and implementation of the Act (Q&A format)","PDF (740.37 KB)PDF (740.37 KB) of Supplement to 10/11/1984 letter about policies, procedures and implementation of the Act (Q&A format)",03/02/1998,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,
Third of a series of letters regarding the implementation of the Act,PDF (393.27 KB)PDF (393.27 KB) of Third of a series of letters regarding the implementation of the Act,03/02/1998,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,FDA-2011-D-0595
Guidance for Industry: Guide for Developing and Using Data Bases for Nutrition Labeling,,03/01/1998,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2020-D-1961
Guidance for Human Somatic Cell Therapy and Gene Therapy:  Guidance for Industry,PDF (93.25 KB)PDF (93.25 KB) of Guidance for Human Somatic Cell Therapy and Gene Therapy:  Guidance for Industry,03/01/1998,Center for Biologics Evaluation and Research,"Cellular & Gene Therapy, Gene Therapy",Final,No,,FDA-2009-D-0132-0016
S1B Testing for Carcinogenicity of Pharmaceuticals,PDF (144.62 KB)PDF (144.62 KB) of S1B Testing for Carcinogenicity of Pharmaceuticals,02/23/1998,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,FDA-1996-D-0010
Guidance on PMA Interactive Procedures for Day-100 Meetings and Subsequent Deficiencies - for Use by CDRH and Industry,PDF (12.58 KB)PDF (12.58 KB) of Guidance on PMA Interactive Procedures for Day-100 Meetings and Subsequent Deficiencies - for Use by CDRH and Industry,02/18/1998,Center for Devices and Radiological Health,"Premarket, Administrative / Procedural, Premarket Approval (PMA)",Final,No,,FDA-2020-D-0957
"Procedures for Class II Device Exemptions from Premarket Notification, Guidance for Industry and CDRH Staff","PDF (20.6 KB)PDF (20.6 KB) of Procedures for Class II Device Exemptions from Premarket Notification, Guidance for Industry and CDRH Staff",02/18/1998,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2017-N-1129
CVM GFI #67 Small Entities Compliance Guide for Renderers,PDF (65.79 KB)PDF (65.79 KB) of CVM GFI #67 Small Entities Compliance Guide for Renderers,02/01/1998,Center for Veterinary Medicine,"Bovine Spongiform Encephalopathy (BSE), Current Good Manufacturing Practice (CGMP)",Final,No,,
"CVM GFI #68  Small Entities Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors","PDF (65.92 KB)PDF (65.92 KB) of CVM GFI #68  Small Entities Compliance Guide for Protein Blenders, Feed Manufacturers, and Distributors",02/01/1998,Center for Veterinary Medicine,"Bovine Spongiform Encephalopathy (BSE), Current Good Manufacturing Practice (CGMP)",Final,No,,
CVM GFI #69  Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations,PDF (62 KB)PDF (62 KB) of CVM GFI #69  Small Entities Compliance Guide for Feeders of Ruminant Animals with On-Farm Feed Mixing Operations,02/01/1998,Center for Veterinary Medicine,"Bovine Spongiform Encephalopathy (BSE), Animal Feed",Final,No,,
Cooperative Research:  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Emergency Use of an Investigational Drug or Biologic:  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Evaluation of Gender Differences in Clinical Investigations:  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Institutional Review Boards Frequently Asked Questions:  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice","Good Clinical Practice (GCP), Pediatric Product Development",Final,No,,
Non-local IRB Review :  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Recruiting Study Subjects:  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Screening Tests Prior to Study Enrollment:  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Sponsor - Investigator - IRB Interrelationship:  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Use of Investigational Products When Subjects Enter a Second Institution:  Guidance for Institutional Review Boards and Clinical Investigators,,01/01/1998,"Office of the Commissioner,Office of Clinical Policy and Programs,Office of Clinical Policy,Office of Good Clinical Practice",Good Clinical Practice (GCP),Final,No,,
Q3C Impurities: Residual Solvents_2011,PDF (40.56 KB)PDF (40.56 KB) of Q3C Impurities: Residual Solvents_2011,12/24/1997,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-1997-D-0381
Industry-Supported Scientific and Educational Activites,PDF (428.5 KB)PDF (428.5 KB) of Industry-Supported Scientific and Educational Activites,12/03/1997,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy","Administrative / Procedural, Advertising",Final,No,,92N-0434
S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals,PDF (131.49 KB)PDF (131.49 KB) of S2B Genotoxicity: A Standard Battery for Genotoxicity Testing of Pharmaceuticals,11/21/1997,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-1997-D-0199
Direct Final Rule Procedures:  Guidance for FDA and Industry,,11/20/1997,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Policy",Administrative / Procedural,Final,No,,
S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals,PDF (137.18 KB)PDF (137.18 KB) of S6 Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals,11/18/1997,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-1997-D-0265
Industry Supported Scientific and Educational Activities:  Guidance for Industry,PDF (428.5 KB)PDF (428.5 KB) of Industry Supported Scientific and Educational Activities:  Guidance for Industry,11/01/1997,"Office of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of PolicyCenter for Veterinary Medicine",Administrative / Procedural,Final,No,,FDA-1992-N-0007
"SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation:  Guidance for Industry","PDF (214.71 KB)PDF (214.71 KB) of SUPAC-MR: Modified Release Solid Oral Dosage Forms Scale-Up and Postapproval Changes: Chemistry, Manufacturing, and Controls; In Vitro Dissolution Testing and In Vivo Bioequivalence Documentation:  Guidance for Industry",10/06/1997,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1997-D-0507
Guidance for Industry: Consultation Procedures under FDA's 1992 Statement of Policy for Foods Derived from New Plant Varieties,,10/01/1997,Human Foods Program,,Final,No,,
"Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations","PDF (170.47 KB)PDF (170.47 KB) of Extended Release Oral Dosage Forms: Development, Evaluation, and Application of In Vitro/In Vivo Correlations",09/01/1997,Center for Drug Evaluation and Research,Biopharmaceutics,Final,No,,
Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report,PDF (95.35 KB)PDF (95.35 KB) of Postmarketing Adverse Experience Reporting for Human Drug and Licensed Biological Products: Clarification of What to Report,08/27/1997,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,Clinical - Medical,Final,No,,FDA-1997-D-0445
Dissolution Testing of Immediate Release Solid Oral Dosage Forms,PDF (129.83 KB)PDF (129.83 KB) of Dissolution Testing of Immediate Release Solid Oral Dosage Forms,08/25/1997,Center for Drug Evaluation and Research,Biopharmaceutics,Final,No,,FDA-1997-D-0187
Expiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron:  Guidance for Industry,PDF (88.67 KB)PDF (88.67 KB) of Expiration Dating and Stability Testing of Solid Oral Dosage Form Drugs Containing Iron:  Guidance for Industry,07/09/1997,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,FDA-1997-D-0489
Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products,PDF (32.75 KB)PDF (32.75 KB) of Changes to an Approved Application for Specified Biotechnology and Specified Synthetic Biological Products,07/01/1997,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1995-D-0101
Kit Certification for 510(k)s,,06/30/1997,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Convenience Kits Interim Regulatory Guidance,PDF (31.23 KB)PDF (31.23 KB) of Convenience Kits Interim Regulatory Guidance,05/19/1997,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Q2B Validation of Analytical Procedures: Methodology,PDF (132.18 KB)PDF (132.18 KB) of Q2B Validation of Analytical Procedures: Methodology,05/19/1997,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-1996-D-0169
Q1C Stability Testing for New Dosage Forms,PDF (101.12 KB)PDF (101.12 KB) of Q1C Stability Testing for New Dosage Forms,05/09/1997,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-2013-S-0610
"SUPAC-SS: Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation:  Guidance for Industry","PDF (117.66 KB)PDF (117.66 KB) of SUPAC-SS: Nonsterile Semisolid Dosage Forms; Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls; In Vitro Release Testing and In Vivo Bioequivalence Documentation:  Guidance for Industry",05/01/1997,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,FDA-1997-D-0380
"Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies:  Guidance for Industry","PDF (80.89 KB)PDF (80.89 KB) of Guidance for Industry for the Evaluation of Combination Vaccines for Preventable Diseases: Production, Testing and Clinical Studies:  Guidance for Industry",04/10/1997,Center for Biologics Evaluation and Research,Vaccines,Final,No,,FDA-1997-N-0454
Design Control Guidance For Medical Device Manufacturers:  Guidance for Industry,PDF (178.93 KB)PDF (178.93 KB) of Design Control Guidance For Medical Device Manufacturers:  Guidance for Industry,03/11/1997,Center for Devices and Radiological Health,Good Clinical Practice (GCP),Final,No,,FDA-2020-D-0957
Non-Invasive Blood Pressure (NIBP) Monitor Guidance,,03/09/1997,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use,PDF (1011.66 KB)PDF (1011.66 KB) of Points to Consider in the Manufacture and Testing of Monoclonal Antibody Products for Human Use,02/28/1997,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,,Final,No,,FDA-1994-D-0318
Proposed Approach to Regulation of Cellular and Tissue-Based Products,PDF (452.22 KB)PDF (452.22 KB) of Proposed Approach to Regulation of Cellular and Tissue-Based Products,02/28/1997,Center for Biologics Evaluation and Research,,Final,No,04/17/1997,FDA-1997-N-0207
Guidance on Labeling of Foods That Need Refrigeration by Consumers,PDF (99.77 KB)PDF (99.77 KB) of Guidance on Labeling of Foods That Need Refrigeration by Consumers,02/24/1997,Human Foods Program,Labeling,Final,No,,FDA-1996-D-0012
Reviewers Guidance Checklist For Orthopedic External Fixation Devices Version #5,PDF (37.12 KB)PDF (37.12 KB) of Reviewers Guidance Checklist For Orthopedic External Fixation Devices Version #5,02/20/1997,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
510(K) Information Needed for Hydroxyapatite Coated Orthopedic Implants,,02/19/1997,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
SUPAC-IR Questions and Answers about SUPAC-IR Guidance,,02/18/1997,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,
Third Party Review Guidance for Phacofragmentation System Device Premarket Notification (510(k)),PDF (149.04 KB)PDF (149.04 KB) of Third Party Review Guidance for Phacofragmentation System Device Premarket Notification (510(k)),01/31/1997,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Third Party Review Guidance For Vitreous Aspiration and Cutting Device Premarket Notification (510(k)),,01/30/1997,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
General Considerations for the Clinical Evaluation of Drugs,PDF (1.37 MB)PDF (1.37 MB) of General Considerations for the Clinical Evaluation of Drugs,01/01/1997,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
"CPG Sec 540.400 Shrimp - Fresh or Frozen, Raw, Headless, Peeled or Breaded (Revoked 12/24/96)",,12/23/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 :  Guidance for Industry,PDF (527.72 KB)PDF (527.72 KB) of  Guidance for Industry: Exports Under the FDA Export Reform and Enhancement Act of 1996 :  Guidance for Industry,12/01/1996,Center for Veterinary MedicineCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,,Final,No,,
Prospective Manufacturers of Barrier Devices Used During Oral Sex for STD Protection,PDF (79.74 KB)PDF (79.74 KB) of Prospective Manufacturers of Barrier Devices Used During Oral Sex for STD Protection,10/30/1996,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality",,Final,No,,FDA-2020-D-0957
Checklist of Information Usually Submitted in an Investigational Device Exemptions (IDE) Application for Refractive Surgery Lasers [excimer],,10/09/1996,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE)",Final,No,,FDA-2020-D-0957
Emitted Laser Beam as Emission Indicator for Class II and Class IIIa Laser Products (Laser Notice 49),PDF (58.9 KB)PDF (58.9 KB) of Emitted Laser Beam as Emission Indicator for Class II and Class IIIa Laser Products (Laser Notice 49),09/05/1996,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Identification Labels for Certain Class I Laser Products (Laser Notice 48),PDF (86.6 KB)PDF (86.6 KB) of Identification Labels for Certain Class I Laser Products (Laser Notice 48),09/05/1996,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",,Final,No,,FDA-2020-D-0957
Single Dose Acute Toxicity Testing for Pharmaceuticals,PDF (62.7 KB)PDF (62.7 KB) of Single Dose Acute Toxicity Testing for Pharmaceuticals,08/26/1996,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,FDA-1992-N-0026
CPG Sec 540.100 Capelin - Prohibited from Being Labeled as Smelt (Revoked 8/23/96),,08/22/1996,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 540.300 Crabmeat - Product Name (Revoked 8/23/96),,08/22/1996,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 540.350 Common or Usual Names for Crustaceans (Revoked 8/23/96),,08/22/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
CPG Sec 110.900 Imported Products - Lack of English Labeling,,08/20/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Labeling",Final,No,,
Variance from Manufacturer Report Number Format - No. 5,,08/11/1996,Center for Devices and Radiological Health,"Postmarket,",Final,No,,FDA-2020-D-0957
"CPG Sec 500.300 ""Approved by FDA"" - Use of Phrase Objectionable in Marketing or Labeling of a Food Additive",,08/01/1996,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Ingredients",Final,No,,
"CPG Sec 505.400 Chow Mein Noodles, Chinese Noodles and Other Oriental Noodles (Labeling)",,08/01/1996,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Bakery Product/Mix",Final,No,,
CPG Sec 510.450 Labeling - Diluted Wines and Cider with Less Than 7% Alcohol,,08/01/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
CPG Sec 510.700 Fortification of Standardized Juices,,08/01/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
CPG Sec 515.200 Malt Extract; Malt Syrup; Malted Cereal Syrup; Liquid Malt; Dried Malt,,08/01/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Candy/Gum (without chocolate)",Final,No,,
CPG Sec. 654.300  Chloramphenicol as an Unapproved New Animal Drug - Direct Reference Seizure Authority (Withdrawn 2/20/2020),,08/01/1996,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs, Unapproved Animal Drugs",Final,No,,
CPG Sec. 690.600  Rodent Contaminated Pet Foods - *Direct Reference  Seizure Authority* (Withdrawn 2/20/2020),,08/01/1996,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Pet Food",Final,No,,
CPG Sec 500.250 Food Additives - Labeling Directions Necessary for Safe Use:  CPG Sec 500.250 Food Additives,,08/01/1996,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Ingredients",Final,No,,
CPG Sec 505.500 Macaroni and Noodle Products - Adulteration Involving Insect Fragments and Rodent Hairs,PDF (12 KB)PDF (12 KB) of CPG Sec 505.500 Macaroni and Noodle Products - Adulteration Involving Insect Fragments and Rodent Hairs,08/01/1996,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Bakery Product/Mix",Final,No,,
CPG Sec 527.200 Cheese & Cheese Products - Adulteration with Filth,PDF (12.21 KB)PDF (12.21 KB) of CPG Sec 527.200 Cheese & Cheese Products - Adulteration with Filth,08/01/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dairy",Final,No,,
CPG Sec 585.675 Popcorn - Adulteration with Rodent Filth and Field Corn,PDF (10.94 KB)PDF (10.94 KB) of CPG Sec 585.675 Popcorn - Adulteration with Rodent Filth and Field Corn,08/01/1996,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use","PDF (69.41 KB)PDF (69.41 KB) of Guidance for Industry for the Submission of Chemistry, Manufacturing, and Controls Information for a Therapeutic Recombinant DNA-Derived Product or a Monoclonal Antibody Product for In Vivo Use",08/01/1996,Center for Biologics Evaluation and ResearchCenter for Drug Evaluation and Research,Administrative / Procedural,Final,No,,FDA-1996-D-0071
CPG Sec 527.500 Malted Milk,,07/31/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dairy",Final,No,,
CPG Sec 527.600 Use of DDVP (dichlorvos) Strips in Milkhouses and Milkrooms,,07/31/1996,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dairy",Final,No,,
CPG Sec. 160.500  Answering Inquiries on Status of Criminal Referrals,,07/31/1996,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 160.750  Drug and Device Products (Including Biologics and Animal Drugs) Found in Violation of GMPRs - Reconditioning,,07/31/1996,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
"Recommendations for the Quarantine and Disposition of Units from Prior Collections from Donors with Repeatedly Reactive Screening Tests for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human T-Lymphotropic Virus Type I (HTLV-I)","PDF (28.56 KB)PDF (28.56 KB) of Recommendations for the Quarantine and Disposition of Units from Prior Collections from Donors with Repeatedly Reactive Screening Tests for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) and Human T-Lymphotropic Virus Type I (HTLV-I)",07/19/1996,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2022-D-0497
Variance from Manufacturer Report Number Format [MDR letter],,07/15/1996,Center for Devices and Radiological Health,"Adverse Event Reporting System (FAERS),",Final,No,,FDA-2020-D-0957
E3 Structure and Content of Clinical Study Reports,PDF (239.72 KB)PDF (239.72 KB) of E3 Structure and Content of Clinical Study Reports,07/01/1996,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1995-D-0201
E4 Dose-Response Information to Support Drug Registration,PDF (49.35 KB)PDF (49.35 KB) of E4 Dose-Response Information to Support Drug Registration,07/01/1996,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1993-D-0183
Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products,PDF (70.17 KB)PDF (70.17 KB) of Q5C Quality of Biotechnological Products: Stability Testing of Biotechnological/Biological Products,07/01/1996,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,
Effective Visual Control of Laser Projections (Laser Notice 47),PDF (147.45 KB)PDF (147.45 KB) of Effective Visual Control of Laser Projections (Laser Notice 47),06/06/1996,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
Suggested Format For IDE Progress Report,,05/31/1996,Center for Devices and Radiological Health,"Premarket, Investigational Device Exemption (IDE)",Final,No,,FDA-2020-D-0957
"Additional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV):  Memorandum to Registered Blood and Plasma Establishments","PDF (13.24 KB)PDF (13.24 KB) of Additional Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV):  Memorandum to Registered Blood and Plasma Establishments",05/16/1996,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2022-D-0498
S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals,PDF (123.21 KB)PDF (123.21 KB) of S2A Specific Aspects of Regulatory Genotoxicity Tests for Pharmaceuticals,04/24/1996,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-1994-D-0134
Medical Device Reporting for User Facilities,PDF (313.13 KB)PDF (313.13 KB) of Medical Device Reporting for User Facilities,04/01/1996,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
"Demonstration of Comparability of Human Biological Products, Including Therapeutic Biotechnology-derived Products",,03/31/1996,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,
Additional Recommendations for Donor Screening With a Licensed Test for HIV-1 Antigen:  Memorandum to Registered Blood and Plasma Establishments,PDF (43.42 KB)PDF (43.42 KB) of Additional Recommendations for Donor Screening With a Licensed Test for HIV-1 Antigen:  Memorandum to Registered Blood and Plasma Establishments,03/14/1996,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2022-D-0499
Thermal Endometrial Ablation Devices (Submission Guidance for an IDE),,03/13/1996,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Hysteroscopes and Gynecology Laparoscopes - Submission Guidance for a 510(k),PDF (1.15 MB)PDF (1.15 MB) of Hysteroscopes and Gynecology Laparoscopes - Submission Guidance for a 510(k),03/07/1996,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Q1B Photostability Testing of New Drug Substances and Products,PDF (339.22 KB)PDF (339.22 KB) of Q1B Photostability Testing of New Drug Substances and Products,03/07/1996,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Draft,No,,
S1A The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals,PDF (99.78 KB)PDF (99.78 KB) of S1A The Need for Long-term Rodent Carcinogenicity Studies of Pharmaceuticals,03/01/1996,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,FDA-1996-D-0010
Q5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products,PDF (108.58 KB)PDF (108.58 KB) of Q5B Quality of Biotechnological Products: Analysis of the Expression Construct in Cells Used for Production of r-DNA Derived Protein Products,02/23/1996,Center for Drug Evaluation and Research,ICH-Quality,Final,No,,FDA-1995-D-0245
All Holders of Approved Variances For Laser Light Shows and Displays (Laser Notice 46),PDF (123.16 KB)PDF (123.16 KB) of All Holders of Approved Variances For Laser Light Shows and Displays (Laser Notice 46),12/11/1995,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",Radiological Health,Final,No,,FDA-2020-D-0957
Donor Deferral Due to Red Blood Cell Loss During Collection of Source Plasma by Automated Plasmapheresis,PDF (118.98 KB)PDF (118.98 KB) of Donor Deferral Due to Red Blood Cell Loss During Collection of Source Plasma by Automated Plasmapheresis,12/04/1995,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2022-D-0500
"SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation","PDF (59.87 KB)PDF (59.87 KB) of SUPAC-IR: Immediate-Release Solid Oral Dosage Forms: Scale-Up and Post-Approval Changes: Chemistry, Manufacturing and Controls, In Vitro Dissolution Testing, and In Vivo Bioequivalence Documentation",11/01/1995,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,
"Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products:  Guidance for Industry","PDF (42.07 KB)PDF (42.07 KB) of Content and Format of Investigational New Drug Applications (INDs) for Phase 1 Studies of Drugs, Including Well-Characterized, Therapeutic, Biotechnology-derived Products:  Guidance for Industry",11/01/1995,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Clinical - Medical, Pharmacology/Toxicology, Investigational New Drug Application (INDA)",Final,No,,FDA-1995-D-0251
Addendum to: Guidance on Premarket Notification [510(k)] Submissions for Sterilizers Intended for Use in Health Care Facilities,,09/18/1995,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
User Instruction for Medical Products (Laser Notice 44),PDF (122.52 KB)PDF (122.52 KB) of User Instruction for Medical Products (Laser Notice 44),08/11/1995,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen:  Memorandum to All Registered Blood Establishments,PDF (28.72 KB)PDF (28.72 KB) of Recommendations for Donor Screening with a Licensed Test for HIV-1 Antigen:  Memorandum to All Registered Blood Establishments,08/08/1995,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2022-D-0501
Hysteroscopic and Laparoscopic Insufflators: Submission Guidance for a 510(k),,07/31/1995,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance Document for the Preparation of Premarket Notification [510(K)] Applications for Exercise Equipment,PDF (30.5 KB)PDF (30.5 KB) of Guidance Document for the Preparation of Premarket Notification [510(K)] Applications for Exercise Equipment,07/25/1995,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Heating and Cooling Devices,PDF (14.05 KB)PDF (14.05 KB) of Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Heating and Cooling Devices,07/25/1995,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Mechanical and Powered Wheelchairs, and Motorized Three-Wheeled Vehicles","PDF (19.46 KB)PDF (19.46 KB) of Guidance Document for the Preparation of Premarket Notification [510(k)] Applications for Mechanical and Powered Wheelchairs, and Motorized Three-Wheeled Vehicles",07/25/1995,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
FDA Guidance Document Concerning Use of Pilot Manufacturing Facilities for the Development and Manufacture of Biological Products,PDF (30.62 KB)PDF (30.62 KB) of FDA Guidance Document Concerning Use of Pilot Manufacturing Facilities for the Development and Manufacture of Biological Products,07/11/1995,Center for Biologics Evaluation and Research,Administrative / Procedural,Final,No,,FDA-1995-D-0149
Testing Guidance for Male Condoms Made From New Material (Non-Latex),,06/28/1995,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"Guidance for Industry: Letter to Manufacturers, Importers, and Distributors of Imported Candy and Candy Wrappers",,06/13/1995,Human Foods Program,"Candy/Gum (without chocolate), Import, Lead",Final,No,,FDA-2020-D-2006
CPG Sec 100.900  International Memoranda of Understanding,,06/06/1995,Center for Veterinary MedicineHuman Foods ProgramOffice of Inspections and InvestigationsCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and ResearchCenter for Tobacco Products,"Investigation & Enforcement,",Final,No,,
Topical Dermatologic Corticosteroids: in Vivo Bioequivalence,PDF (2.59 MB)PDF (2.59 MB) of Topical Dermatologic Corticosteroids: in Vivo Bioequivalence,06/02/1995,Center for Drug Evaluation and Research,"Biopharmaceutics, Generic Drugs",Final,No,,FDA-2021-D-0384
Guidance on the Content and Organization of a Premarket Notification for a Medical Laser,PDF (71.58 KB)PDF (71.58 KB) of Guidance on the Content and Organization of a Premarket Notification for a Medical Laser,05/31/1995,Center for Devices and Radiological Health,"Premarket, Radiology",Final,No,,FDA-2020-D-0957
"Guidance Document for Testing Non-Articulating, 'Mechanically Locked', Modular Implant Components","PDF (50.71 KB)PDF (50.71 KB) of Guidance Document for Testing Non-Articulating, 'Mechanically Locked', Modular Implant Components",04/30/1995,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Revised Recommendations for Red Blood Cell Immunization Programs for Source Plasma Donors:  Memorandum to Licensed Establishments,PDF (2.67 MB)PDF (2.67 MB) of Revised Recommendations for Red Blood Cell Immunization Programs for Source Plasma Donors:  Memorandum to Licensed Establishments,03/14/1995,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2013-S-0611
"CPG 230.130- Adequate Space for Determination of Donor Suitability (Obsolete, Withdrawn on 7/16/2018)",,03/01/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec 120.500 Health Fraud - Factors in Considering Regulatory Action,,03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,FDA-2012-E-0163
CPG Sec 500.400 Use of Calcium Chloride as a Drying Agent in Such Products as Packaged Potato Chips and Peanuts,,03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Ingredients",Final,No,,
CPG Sec 515.400 Raw Sugar,,03/01/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Candy/Gum (without chocolate)",Final,No,,
CPG Sec 515.600 Candied Citron - Labeling,,03/01/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Candy/Gum (without chocolate)",Final,No,,
"CPG Sec 587.200 Uncertified or Delisted Colors in Foods for Export -  (e.g., FD&C Red #2)",,03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Food & Color Additives",Final,No,,
"CPG Sec. 231.100-  *Platelets, Pooled* is obsolete and was withdrawn on 7/16/2018.",,03/01/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec. 231.120-  Time Period for Separation of Platelets from Platelet-Rich Plasma When Preparing *Platelets* and Fresh Frozen Plasma* is obsolete and was withdrawn on 7/16/2018.,,03/01/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec. 231.130-  Storage of *Platelets* [ ] for up to five (5) Days is obsolete and was withdrawn on 7/16/2018.,,03/01/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec. 345.300 Menstrual Sponges,,03/01/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Physical Medicine",Final,No,,FDA-2020-D-0957
CPG Sec. 355.300 Ion Generating Devices,,03/01/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Radiological Health",Final,No,,FDA-2020-D-0957
CPG Sec. 370.100 Cytotoxic Testing for Allergic Diseases,,03/01/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Clinical Chemistry & Clinical Toxicology",Final,No,,FDA-2020-D-0957
CPG Sec. 390.425 Records and Reports; Applicability - 21 CFR 1002.1,,03/01/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Records",Final,No,,FDA-2020-D-0957
CPG Sec. 391.200 Warning Statement in Advertisements for High-Intensity Mercury Vapor Discharge Lamps that are not Self-Extinguishing (21 CFR 1040.30(e)(3)*),,03/01/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Advertising",Final,No,,FDA-2020-D-0957
"CPG Sec. 393.200 Laser(s) as Medical Devices for Facelift, Wrinkle Removal, Acupuncture, Auricular Stimulation, etc. (CPG 7133.21)",,03/01/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
CPG Sec. 400.200 Consistent Application of CGMP Determinations,,03/01/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 400.500 Identical or Similar Product Names,,03/01/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement, Labeling",Final,No,,None found
CPG Sec. 430.400 Urinary Preparations - Misbranding - Lack of Rx Legend and Claims,,03/01/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 450.200 Drugs - General Provisions and Administrative Procedures for Recognition as Safe and Effective,,03/01/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 450.300 OTC Drugs - General Provisions and Administrative Procedures for Marketing Combination Products,,03/01/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 456.100 Non-Rx Drugs Anti-Obesity Preparations,,03/01/1995,Center for Drug Evaluation and Research,,Final,No,,None found
CPG Sec. 457.100 Pangamic Acid and Pangamic Acid Products Unsafe for Food and Drug Use,,03/01/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 608.500  Illegal Sales of Veterinary Prescription Drugs Direct Reference Authority for *Warning* Letter Issuance (Withdrawn 2/20/2020),,03/01/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec. 625.300  Unapproved New Animal Drugs - Follow-up Action to Approved Warning Letter - Direct Reference Seizure Authority (Withdrawn 2/20/2020),,03/01/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs, Unapproved Animal Drugs",Final,No,,
CPG Sec. 625.500  Failure to Register *and/or Drug List* (Withdrawn 2/20/2020),,03/01/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Registration, Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec 515.100 Confectionery - Use of Non-Nutritive Substances as Ingredients,PDF (16.2 KB)PDF (16.2 KB) of CPG Sec 515.100 Confectionery - Use of Non-Nutritive Substances as Ingredients,03/01/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Candy/Gum (without chocolate)",Final,No,,
CPG Sec 525.425 Hops - Adulteration Involving Aphid Infestation,PDF (8.77 KB)PDF (8.77 KB) of CPG Sec 525.425 Hops - Adulteration Involving Aphid Infestation,03/01/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
"CPG Sec 525.825 Vinegar, Definitions - Adulteration with Vinegar Eels","PDF (15.1 KB)PDF (15.1 KB) of CPG Sec 525.825 Vinegar, Definitions - Adulteration with Vinegar Eels",03/01/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 550.235 Cherry Jam - Adulteration with Mold,PDF (8.68 KB)PDF (8.68 KB) of CPG Sec 550.235 Cherry Jam - Adulteration with Mold,03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.250 Citrus Fruit Juices, Canned - Adulteration with Fly Filth and Mold","PDF (10.23 KB)PDF (10.23 KB) of CPG Sec 550.250 Citrus Fruit Juices, Canned - Adulteration with Fly Filth and Mold",03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 550.260 Cranberry Sauce - Adulteration with Mold,PDF (8.83 KB)PDF (8.83 KB) of CPG Sec 550.260 Cranberry Sauce - Adulteration with Mold,03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 550.270 Currants - Adulteration Involving Wormy Fruits,PDF (8.77 KB)PDF (8.77 KB) of CPG Sec 550.270 Currants - Adulteration Involving Wormy Fruits,03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.450 Jam, Black Currant - Adulteration with Mold","PDF (8.77 KB)PDF (8.77 KB) of CPG Sec 550.450 Jam, Black Currant - Adulteration with Mold",03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.590 Cloudberries (Multer Berries), Canned - Adulteration by Insects","PDF (8.89 KB)PDF (8.89 KB) of CPG Sec 550.590 Cloudberries (Multer Berries), Canned - Adulteration by Insects",03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 550.680 Pineapple, Canned; Pineapple Juice - Adulteration with Mold","PDF (9.34 KB)PDF (9.34 KB) of CPG Sec 550.680 Pineapple, Canned; Pineapple Juice - Adulteration with Mold",03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
"CPG Sec 555.300 Foods, Except Dairy Products - Adulteration with Salmonella","PDF (10.78 KB)PDF (10.78 KB) of CPG Sec 555.300 Foods, Except Dairy Products - Adulteration with Salmonella",03/01/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
CPG Sec 575.100 Pesticide Residues in Food and Feed - Enforcement Criteria,PDF (68.52 KB)PDF (68.52 KB) of CPG Sec 575.100 Pesticide Residues in Food and Feed - Enforcement Criteria,03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Pesticide",Final,No,,
"CPG Sec 585.225 Black-Eyed Peas (Cow Peas, Field Peas); Dried-Adulteration with Lygus Bug Damage","PDF (11.03 KB)PDF (11.03 KB) of CPG Sec 585.225 Black-Eyed Peas (Cow Peas, Field Peas); Dried-Adulteration with Lygus Bug Damage",03/01/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec. 250.500-  Plasma Brokers - Registration and Compliance with Good Manufacturing Practices is obsolete and was withdrawn on 7/16/2018.,PDF (132.7 KB)PDF (132.7 KB) of CPG Sec. 250.500-  Plasma Brokers - Registration and Compliance with Good Manufacturing Practices is obsolete and was withdrawn on 7/16/2018.,03/01/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec. 300.400 Contamination of Devices Labeled as Sterile,PDF (62.53 KB)PDF (62.53 KB) of CPG Sec. 300.400 Contamination of Devices Labeled as Sterile,03/01/1995,Office of Regulatory AffairsCenter for Devices and Radiological Health,"Investigation & Enforcement, Labeling",Final,No,,FDA-2020-D-0957
CPG Sec. 345.100 Condoms; Defects - Criteria for Direct Reference Seizure,PDF (73.78 KB)PDF (73.78 KB) of CPG Sec. 345.100 Condoms; Defects - Criteria for Direct Reference Seizure,03/01/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Administrative / Procedural",Final,No,,FDA-2020-D-0957
CPG Sec. 355.200 Electrical Muscle Stimulators,PDF (62.43 KB)PDF (62.43 KB) of CPG Sec. 355.200 Electrical Muscle Stimulators,03/01/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
CPG Sec. 398.350 Regulatory Actions Against Assemblers of X-ray Equipment that Fail to File Reports of Assembly,PDF (67.05 KB)PDF (67.05 KB) of CPG Sec. 398.350 Regulatory Actions Against Assemblers of X-ray Equipment that Fail to File Reports of Assembly,03/01/1995,,"Investigation & Enforcement, Radiology",Final,No,,
"CPG Sec. 400.100 Drugs, Human - Failure to Register","PDF (60.89 KB)PDF (60.89 KB) of CPG Sec. 400.100 Drugs, Human - Failure to Register",03/01/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 448.100 Reconditioning of New Drugs Which Do Not Have Approved NDAs/ANDAs,PDF (70.36 KB)PDF (70.36 KB) of CPG Sec. 448.100 Reconditioning of New Drugs Which Do Not Have Approved NDAs/ANDAs,03/01/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 480.300 Lack of Expiration Date of Stability Data,PDF (66.71 KB)PDF (66.71 KB) of CPG Sec. 480.300 Lack of Expiration Date of Stability Data,03/01/1995,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 480.300 Lack of Expiration Date of Stability Data,PDF (66.71 KB)PDF (66.71 KB) of CPG Sec. 480.300 Lack of Expiration Date of Stability Data,03/01/1995,Center for Drug Evaluation and Research,,Final,No,,
E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions,PDF (17 KB)PDF (17 KB) of E1A The Extent of Population Exposure to Assess Clinical Safety: For Drugs Intended for Long-term Treatment of Non-Life-Threatening Conditions,03/01/1995,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1994-D-0267
E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting,PDF (48.84 KB)PDF (48.84 KB) of E2A Clinical Safety Data Management: Definitions and Standards for Expedited Reporting,03/01/1995,Center for Drug Evaluation and Research,ICH-Efficacy,Final,No,,FDA-1993-D-0128
Q2A Text on Validation of Analytical Procedures,PDF (24.76 KB)PDF (24.76 KB) of Q2A Text on Validation of Analytical Procedures,03/01/1995,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Quality,Final,No,,FDA-1994-D-0401
S3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies,PDF (45.65 KB)PDF (45.65 KB) of S3A Toxicokinetics: The Assessment of Systemic Exposure in Toxicity Studies,03/01/1995,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Safety,Final,No,,
S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies,PDF (13.92 KB)PDF (13.92 KB) of S3B Pharmacokinetics: Guidance for Repeated Dose Tissue Distribution Studies,03/01/1995,Center for Drug Evaluation and Research,ICH-Safety,Final,No,,
CPG Sec 515.425 Sugar - Water Damaged - Reconditioning,,02/28/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Candy/Gum (without chocolate)",Final,No,,
"CPG Sec 520.100 Canned Foods, Use of the Term ""Solid Pack""",,02/28/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Canned Foods, Fruit/Fruit Product",Final,No,,
CPG Sec 525.400 Hollandaise Sauce - Common or Usual Name,,02/28/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 550.400 Grenadine,,02/28/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 555.650 Reconditioning Foods by Diversion for Animal Feed,,02/28/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
CPG Sec 562.400 Foreign Language Declarations on Food Labels,,02/28/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 578.600 Unapproved Additives for Exported Grains,,02/28/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Grain/Grain Product",Final,No,,
CPG Sec. 150.500 Analytical Methodology Used by FDA - Drugs,,02/28/1995,Human Foods ProgramOffice of Inspections and InvestigationsCenter for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 231.110-  Quality Control Testing of *Platelets* [ ] and Cryoprecipitated Antihemophilic Factor [ ],,02/28/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
"CPG Sec. 250.100 Source Plasma – Guidelines for Informed Consent Forms (Obsolete, Withdrawn on 11/28/2017)",,02/28/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
"CPG Sec. 252.100 Source Plasma - Regulatory Action Based on Overbleeding (Obsolete, Withdrawn on 11/28/2017)",,02/28/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec. 253.100- Use of Units of *Plasma and Fresh Frozen Plasma* Which Have Been Thawed,,02/28/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
"CPG Sec. 254.100 Source Plasma - Use of Units from Donors Subsequently Found to be Reactive to a Serologic Test for Syphilis (Obsolete, Withdrawn on 11/28/2017)",,02/28/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
"CPG Sec. 255.100 Quantitative Testing for Serum Proteins in Plasmapheresis Donors (Obsolete, Withdrawn on 11/28/2017)",,02/28/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
"CPG Sec. 256.100 Plasmapheresis - 48-hour Period Between Plasmapheresis Procedures (Obsolete, Withdrawn on 11/28/2017)",,02/28/1995,,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec. 300.300 Ineffective Devices - 502(f)(I) Labeling Requirements,,02/28/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Labeling",Final,No,,FDA-2020-D-0957
CPG Sec. 310.100 Pacemaker Reuse,,02/28/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Cardiovascular",Final,No,,FDA-2020-D-0957
CPG Sec. 394.100 Retention of Microwave Oven Test Records,,02/28/1995,,"Investigation & Enforcement, Records",Final,No,,
CPG Sec. 396.100 Applicability of the Sunlamp Performance Standard To UVA Tanning Products,,02/28/1995,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 396.200 Exemption for Certain Sunlamp Product Purchaser Records,,02/28/1995,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 396.400 Policy on Warned on Sunlamp Products,,02/28/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Labeling",Final,No,,FDA-2020-D-0957
CPG Sec. 398.200 Hazardous Diagnostic X-ray Systems,,02/28/1995,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Radiology",Final,No,,FDA-2020-D-0957
CPG Sec. 398.300 Registration of Assemblers of  Diagnostic X-Ray Systems as Device Manufacturers,,02/28/1995,Office of Regulatory AffairsCenter for Devices and Radiological Health,"Investigation & Enforcement, Radiology",Final,No,,FDA-2020-D-0957
CPG Sec. 398.375 Obligations of Factory-based Manufacturers and Assemblers of Diagnostic X-ray Equipment Under the Performance Standard for Diagnostic X-ray Equipment,,02/28/1995,,"Investigation & Enforcement, Radiology",Final,No,,
CPG Sec. 398.600 Certification and Identification of X-ray Components - Sections 1010.2 and 1020.30(e),,02/28/1995,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 480.100 Requirements for Expiration Dating and Stability Testing,,02/28/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 480.200 Expiration Dating of Unit Dose Repackaged Drugs,,02/28/1995,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,07/30/2020,
CPG Sec. 607.100 -  Adequate Directions for Use (Species Designation) - Animal Drugs and Veterinary Devices,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Devices, Animal Drugs, Labeling",Final,No,,FDA-2021-D-0629
CPG Sec. 608.300  Lay Use of *Animal Capture and Euthanasia* Drugs (Withdrawn 2/20/2020),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec. 637.100  Plastic Containers for Injectable Animal Drugs (Withdrawn 2/20/2020),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec. 638.100  Process Validation Requirements for Drug Products Subject to Pre-Market Approval,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec. 640.100  Anthelmintics (Withdrawn 2/20/2020),,02/28/1995,"Center for Veterinary MedicineOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Global Policy and Strategy","Investigation & Enforcement, Anthelmintics",Final,No,,
CPG Sec. 641.100  *Products for Control of Fleas and Ticks* Containing a Pesticide (Withdrawn 2/20/2020),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 642.100  *Drugs for Odor Control and Conception in Pet Animals*,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,FDA-2021-D-0630
CPG Sec. 643.100  Oral Iron Products for Baby Pigs (Withdrawn 2/20/2020),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 650.100  Animal Drugs for Euthanasia (Withdrawn 5/23/2024),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,FDA-2021-D-0631
CPG Sec. 654.100  Dimethyl Sulfoxide (DMSO) for Animal Use (Withdrawn 2/20/2020),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec. 654.200  Teat Dips and Udder Washes for Dairy Cows and Goats,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,FDA-2021-D-0632
CPG Sec. 665.100  Common or Usual Names for Animal Feed Ingredients (Withdrawn 1/6/2025),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed, Labeling",Final,No,,FDA-2021-D-0633
CPG Sec. 665.200  Checklist Labeling for Custom Mixed Medicated Feeds (Withdrawn 7/23/2019),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Labeling, Medicated Feed",Final,No,,
CPG Sec. 670.500  Ammoniated Cottonseed Meal - Interpretation of 21 CFR,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0634
CPG Sec. 675.100  Diversion of Contaminated Food for Animal Use,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0635
CPG Sec. 675.200  Diversion of Adulterated Food to Acceptable Animal Feed Use,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0636
CPG Sec. 675.300  Moisture Damaged Grain,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0637
CPG Sec. 680.500  Unsafe Contamination of Animal Feed from Drug Carryover (Withdrawn 1/30/2023),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0638
"CPG Sec. 680.600  Sequencing as a Means to Prevent Unsafe Drug   Contamination in the Production, Storage, and Distribution of Feeds (Withdrawn 1/30/2023)",,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0639
CPG Sec. 685.100  Recycled Animal Waste,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0640
CPG Sec. 687.500  Silage Ingredients,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0641
CPG Sec. 689.100  Direct-Fed Microbial Products,,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0642
CPG Sec. 690.100  Nutritional Supplements for Companion Animals (Withdrawn 2/20/2020),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,
CPG Sec.140.500 Metric Declarations of Quantity of Contents on Product Labels,,02/28/1995,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec.625.400 Reconditioning of New Animal Drugs Seized Under Section 501(a)(5) (Withdrawn 2/20/2020),,02/28/1995,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,
CPG Sec 275.100 Immune Milk (Withdrawn 1/30/2020) :  CPG Sec 275.100 Immune Milk,,02/28/1995,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
Guidance Document For The Preparation of Premarket Notification For Ceramic Ball Hip Systems,PDF (36.84 KB)PDF (36.84 KB) of Guidance Document For The Preparation of Premarket Notification For Ceramic Ball Hip Systems,01/09/1995,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
CVM GFI #57 Preparation and Submission of Veterinary Master Files,PDF (109.53 KB)PDF (109.53 KB) of CVM GFI #57 Preparation and Submission of Veterinary Master Files,01/01/1995,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC)",Final,No,,FDA-2021-D-0617
Checklist for Mechanical Lithotripters and Stone Dislodgers used in Gastroenterology and Urology,PDF (14.79 KB)PDF (14.79 KB) of Checklist for Mechanical Lithotripters and Stone Dislodgers used in Gastroenterology and Urology,11/01/1994,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products:  Guidance for Industry,PDF (57.36 KB)PDF (57.36 KB) of Submission Documentation for Sterilization Process Validation in Applications for Human and Veterinary Drug Products:  Guidance for Industry,11/01/1994,Center for Veterinary MedicineCenter for Drug Evaluation and Research,"Microbiology, Pharmaceutical Quality",Final,No,,
510(k) Checklist for Sterile Lubricating Jelly Used With Transurethral Surgical Instruments,,09/18/1994,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance for the Content of Premarket Notifications for Conventional and Antimicrobial Foley Catheters,,09/11/1994,Center for Devices and Radiological Health,"Premarket, Antimicrobial Resistance",Final,No,,FDA-2020-D-0957
Format and Content for the CMC Section of an Annual Report,PDF (29.3 KB)PDF (29.3 KB) of Format and Content for the CMC Section of an Annual Report,09/01/1994,Center for Drug Evaluation and Research,"Chemistry, Manufacturing, and Controls (CMC), Pharmaceutical Quality",Final,No,,
Guidance for the Preparation of a Premarket Notification for Extended Laparoscopy Devices (ELD),PDF (11.56 KB)PDF (11.56 KB) of Guidance for the Preparation of a Premarket Notification for Extended Laparoscopy Devices (ELD),08/29/1994,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
CPG Sec. 634.100  Drugs Packaged for Infusion or Injection of Food-Producing Animals (Withdrawn 2/20/2020),,08/22/1994,"Center for Veterinary MedicineOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Global Policy and Strategy","Investigation & Enforcement, Animal Drugs",Final,No,,
E7 Studies in Support of Special Populations: Geriatrics,PDF (24.71 KB)PDF (24.71 KB) of E7 Studies in Support of Special Populations: Geriatrics,08/01/1994,Center for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,ICH-Efficacy,Final,No,,
Points to Consider for Cervical Cytology Devices,PDF (660.62 KB)PDF (660.62 KB) of Points to Consider for Cervical Cytology Devices,07/25/1994,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Guidance for the Content of Premarket Notifications for Urine Drainage Bags,PDF (500.32 KB)PDF (500.32 KB) of Guidance for the Content of Premarket Notifications for Urine Drainage Bags,06/07/1994,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
"CVM GFI #55 Supportive Data for Cat Food Labels Bearing ""Reduces Urinary pH Claims:  Protocol Development",,05/31/1994,Center for Veterinary Medicine,Animal Feed,Final,No,,FDA-1994-D-0230
CVM GFI #53  Evaluation of the Utility of Food Additives in Diet Fed to Aquatic Animals,,04/30/1994,Center for Veterinary Medicine,"Animal Food Additives, Aquaculture",Final,No,,FDA-2021-D-0618
Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone Or Bone Cement,PDF (26.73 KB)PDF (26.73 KB) of Guidance Document for Testing Orthopedic Implants with Modified Metallic Surfaces Apposing Bone Or Bone Cement,04/27/1994,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"Letter - Manufacturers, Distributors and Importers of Condom Products (included in Condom Packet 398) :  Letter - Manufacturers, Distributors and Importers of Condom Products","PDF (74.51 KB)PDF (74.51 KB) of Letter - Manufacturers, Distributors and Importers of Condom Products (included in Condom Packet 398) :  Letter - Manufacturers, Distributors and Importers of Condom Products",02/23/1994,Center for Devices and Radiological Health,"Postmarket, Premarket,",Final,No,,FDA-2020-D-0957
Manufacturers/Assemblers of Diagnostic X-ray Systems: Enforcement Policy for Positive-Beam Limitation (PBL) Requirements in 21 CFR 1020.31(g) :,PDF (321.29 KB)PDF (321.29 KB) of Manufacturers/Assemblers of Diagnostic X-ray Systems: Enforcement Policy for Positive-Beam Limitation (PBL) Requirements in 21 CFR 1020.31(g) :,10/13/1993,Center for Devices and Radiological Health,"Postmarket, Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
Guidance on the Content and Format of Premarket Notification [510(k)] Submissions for Sharps Containers,PDF (296.78 KB)PDF (296.78 KB) of Guidance on the Content and Format of Premarket Notification [510(k)] Submissions for Sharps Containers,10/01/1993,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Guidance for Industry: Guidelines for Determining Metric Equivalents of Household Measures,,09/30/1993,Human Foods Program,"Labeling, Nutrition Label",Final,No,,FDA-2020-D-1977-0001
"Reviewer Guidance for Nebulizers, Metered Dose Inhalers, Spacers and Actuators",,09/30/1993,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
"Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)","PDF (18.91 KB)PDF (18.91 KB) of Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)",08/05/1993,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2013-S-0612
1993 Draft Redbook II,,08/01/1993,Human Foods Program,Food & Color Additives,Draft,No,,
"Guidance on Premarket Notification [510(k)] Submissions for Automated Endoscope Washers, Washer/Disinfectors, and Disinfectors Intended for Use in Health Care Facilities","PDF (954.92 KB)PDF (954.92 KB) of Guidance on Premarket Notification [510(k)] Submissions for Automated Endoscope Washers, Washer/Disinfectors, and Disinfectors Intended for Use in Health Care Facilities",08/01/1993,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Guidance on Premarket Notification [510(k)] Submissions for Surgical Gowns and Surgical Drapes,PDF (635.1 KB)PDF (635.1 KB) of Guidance on Premarket Notification [510(k)] Submissions for Surgical Gowns and Surgical Drapes,08/01/1993,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
CVM GFI #45 Guideline for Uniform Labeling of Drugs for Dairy and Beef Cattle,,07/31/1993,Center for Veterinary Medicine,Labeling,Final,No,,FDA-2021-D-0620
Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products,PDF (39.83 KB)PDF (39.83 KB) of Recommendations Regarding License Amendments and Procedures for Gamma Irradiation of Blood Products,07/22/1993,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2013-S-0613
Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs:  Guidance for Industry,PDF (1.83 MB)PDF (1.83 MB) of Study and Evaluation of Gender Differences in the Clinical Evaluation of Drugs:  Guidance for Industry,07/22/1993,Center for Drug Evaluation and Research,"Clinical - Medical, Good Clinical Practice (GCP)",Final,No,,FDA-1993-D-0184
CPG Sec. 615.200  Proper Drug Use and Residue Avoidance by Non-Veterinarians,,07/08/1993,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs, Human Food Safety",Final,No,,FDA-2021-D-0643
Beam Attenuators and Emission Indicators for Class II and IIIa Laser Systems (Laser Notice 43),PDF (90.36 KB)PDF (90.36 KB) of Beam Attenuators and Emission Indicators for Class II and IIIa Laser Systems (Laser Notice 43),06/07/1993,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
"Letter to Industry, Powered Wheelchair Manufacturers from RMJohnson","PDF (47.17 KB)PDF (47.17 KB) of Letter to Industry, Powered Wheelchair Manufacturers from RMJohnson",05/10/1993,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
CPG Sec. 680.100  Tracers in Animal Feed (Withdrawn 10/19/2022),,04/04/1993,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,
Guidance on the Content of Premarket Notification [510(K)] Submissions for Hypodermic Single Lumen Needles,,03/31/1993,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Guidance on the Content of Premarket Notification [510(K)] Submissions for Piston Syringes,,03/31/1993,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance on Premarket Notification 510(k) for Sterilizers Intended for Use in Health Care Facilities,PDF (843.41 KB)PDF (843.41 KB) of Guidance on Premarket Notification 510(k) for Sterilizers Intended for Use in Health Care Facilities,03/01/1993,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
Guidance on the Content of Premarket Notification [510(K)] Submissions for Clinical Electronic Thermometers,,02/28/1993,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance for the Content of Premarket Notifications for Biopsy Devices Used in Gastroenterology and Urology,,02/09/1993,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Guidance for the Content of Premarket Notifications for Ureteral Stents,,02/09/1993,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Volume Limits for Automated Collection of Source Plasma,PDF (30.16 KB)PDF (30.16 KB) of Volume Limits for Automated Collection of Source Plasma,11/04/1992,Center for Biologics Evaluation and Research,"Blood, Blood Products, Device & Drug Safety",Final,No,,FDA-2013-S-0613
Preparation of Investigational New Drug Products (Human and Animal):  Guidance for Industry,PDF (795.48 KB)PDF (795.48 KB) of Preparation of Investigational New Drug Products (Human and Animal):  Guidance for Industry,11/01/1992,Center for Drug Evaluation and Research,"Current Good Manufacturing Practice (CGMP), Pharmaceutical Quality",Final,No,,
CPG Sec. 625.600  Orders for Post-Approval Record Reviews,,06/24/1992,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs, Records",Final,No,,
CPG Sec. 681.100  Order for Post-Approval Record Reviews (Withdrawn 2/20/2020),,06/24/1992,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed, Records",Final,No,,
CPG Sec. 470.100 Orders for Post-Approval Record Reviews,PDF (67.35 KB)PDF (67.35 KB) of CPG Sec. 470.100 Orders for Post-Approval Record Reviews,06/24/1992,,"Investigation & Enforcement,",Final,No,,
Compliance Guide for Laser Products (FDA 86-8260),PDF (211.25 KB)PDF (211.25 KB) of Compliance Guide for Laser Products (FDA 86-8260),06/01/1992,"Center for Devices and Radiological Health,Office of Product Evaluation and Quality,Office of In Vitro Diagnostics and Radiological Health",Radiological Health,Final,No,,FDA-2020-D-0957
Statement of Policy - Foods Derived from New Plant Varieties,,05/29/1992,Human Foods Program,Bioengineering / GMOs,Final,No,,
CPG Sec. 450.500 Tamper-Resistant Packaging Requirements for Certain Over-the-Counter Human Drug Products,,05/21/1992,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
Review Criteria For Premarket Approval of In Vitro Diagnostic Devices for Detection of Antibodies to Parvovirus B19,PDF (697.97 KB)PDF (697.97 KB) of Review Criteria For Premarket Approval of In Vitro Diagnostic Devices for Detection of Antibodies to Parvovirus B19,05/15/1992,Center for Devices and Radiological Health,"Premarket, Laboratory Tests, IVDs (In Vitro Diagnostic Devices)",Final,No,,FDA-2020-D-0957
Development of New Stereoisomeric Drugs,,05/01/1992,Center for Drug Evaluation and Research,,Final,No,,
CPG Sec. 420.100 Adulteration of Drugs Under Section 501(b) and 501(c) of the Act. *Direct Reference Seizure Authority for Adulterated Drugs Under Section 501(b)*,PDF (71.02 KB)PDF (71.02 KB) of CPG Sec. 420.100 Adulteration of Drugs Under Section 501(b) and 501(c) of the Act. *Direct Reference Seizure Authority for Adulterated Drugs Under Section 501(b)*,05/01/1992,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
"Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)","PDF (673.83 KB)PDF (673.83 KB) of Revised Recommendations for Testing Whole Blood, Blood Components, Source Plasma and Source Leukocytes for Antibody to Hepatitis C Virus Encoded Antigen (Anti-HCV)",04/23/1992,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2013-S-0613
Guideline for Postmarketing Reporting of Adverse Drug Experiences,PDF (3.63 MB)PDF (3.63 MB) of Guideline for Postmarketing Reporting of Adverse Drug Experiences,03/01/1992,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,FDA-1985-D-0044
FDA Recommendations Concerning Testing for Antibody to Hepatitis B Core Antigen (Anti-HBc),PDF (17.81 KB)PDF (17.81 KB) of FDA Recommendations Concerning Testing for Antibody to Hepatitis B Core Antigen (Anti-HBc),09/10/1991,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2013-S-0613
"CPG Sec. 120.100  Fraud, Untrue Statements of Material Facts, Bribery, and Illegal Gratuities",,06/30/1991,"Office of Regulatory AffairsCenter for Drug Evaluation and Research,Office of Regulatory Policy","Investigation & Enforcement,",Final,No,,
CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects,PDF (64.91 KB)PDF (64.91 KB) of CPG Sec. 335.800 Clinical Thermometer - Adulteration; Misbranding Defects,05/31/1991,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Administrative / Procedural",Final,No,,FDA-2020-D-0957
Shelf Life of Medical Devices,PDF (1.75 MB)PDF (1.75 MB) of Shelf Life of Medical Devices,04/01/1991,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Device Labeling Guidance #G91-1 (Blue Book Memo),,03/07/1991,Center for Devices and Radiological Health,"Premarket, Labeling",Final,No,,FDA-2020-D-0957
Quality Assurance Guidelines for Hemodialysis Devices,PDF (12.72 MB)PDF (12.72 MB) of Quality Assurance Guidelines for Hemodialysis Devices,02/01/1991,Center for Devices and Radiological Health,Gastroenterology-Urology,Final,No,,FDA-2020-D-0957
CPG Sec. 446.100 Regulatory Action Regarding Approved New Drugs and Antibiotic Drug Products Subjected to Additional Processing or other Manipulations,,01/18/1991,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
"Continuation of a series of letters communicating interim and informal generic drug policy and guidance. Availability of Policy and Procedure Guides, and further operational changes to the generic drug review program",,06/01/1990,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,
Format and Content of the Microbiology Section of an Application*:  Guidance for Industry,PDF (545.53 KB)PDF (545.53 KB) of Format and Content of the Microbiology Section of an Application*:  Guidance for Industry,01/01/1990,Center for Drug Evaluation and Research,"Microbiology, Pharmaceutical Quality",Final,No,,
Clarification of Compliance Requirements for Certain Manufacturers Who Incorporate Certified Class I Laser Products into Their Products (Laser Notice 42),PDF (57.9 KB)PDF (57.9 KB) of Clarification of Compliance Requirements for Certain Manufacturers Who Incorporate Certified Class I Laser Products into Their Products (Laser Notice 42),12/18/1989,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
Review of FDA's Implementation of the Drug Export Amendments of 1986,PDF (2 MB)PDF (2 MB) of Review of FDA's Implementation of the Drug Export Amendments of 1986,11/01/1989,Center for Veterinary MedicineCenter for Drug Evaluation and ResearchCenter for Biologics Evaluation and Research,"Compliance, Current Good Manufacturing Practice (CGMP)",Final,No,,
Study of Drugs Likely to be used in the Elderly,PDF (1.18 MB)PDF (1.18 MB) of Study of Drugs Likely to be used in the Elderly,11/01/1989,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
CPG Sec 540.450 *Imitation Breaded Shrimp*,,10/30/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
CPG Sec 540.550 Kipper and Kipper Unsplit - Definitions,,10/30/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
"CPG Sec 540.150 Caviar, Use of Term - Labeling",,10/29/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
"CPG Sec 540.390 Canned Shrimp - Labeling, Size Designations and Corresponding Counts",,10/29/1989,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
CPG Sec 560.250 Imports - Importer can be Required to Reveal Identity of Ingredients,,09/19/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Import",Final,No,,
Labeling - Regulatory Requirements for Medical Devices (FDA 89-4203),PDF (2.98 MB)PDF (2.98 MB) of Labeling - Regulatory Requirements for Medical Devices (FDA 89-4203),09/01/1989,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
CPG Sec 100.200 FDA Jurisdiction Over Products Composed of Interstate Ingredients,,08/31/1989,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Food & Color Additives",Final,No,,
"CPG Sec 100.600 Status of Facial Tissues, Paper Napkins, Paper Towels and Similar Paper Products",,08/30/1989,Human Foods ProgramOffice of Inspections and InvestigationsCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
"CPG Sec. 100.500 - Common Carrier as a Relabeler, Repacker, Reprocessor, etc.",,08/30/1989,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 100.800  Guaranties Over Printed Signatures,,08/30/1989,Office of Regulatory Affairs,"Investigation & Enforcement, Records",Final,No,,
CPG Sec. 110.200  Export of FDA Regulated Products from U.S. Foreign Trade Zones,,08/30/1989,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
"CPG Sec. 110.600  FDA Authority Over Products of Foreign Origin Located in Foreign Trade Zones, Bonded Warehouses or on Bonded Carriers",,08/30/1989,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 110.700  Seizures by the U.S. Customs Service of Prohibited Articles of Foreign Origin Not Intended for Entry into the United States,,08/30/1989,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 130.200  Inspection of Firms when Legal Action is Pending,,08/30/1989,,"Investigation & Enforcement, Food & Color Additives",Final,No,,
CPG Sec. 140.100  Seizure of Books that Constitute Misleading Labeling,,08/30/1989,Office of Regulatory Affairs,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec. 160.300  Requests for Records Under Section 703,,08/30/1989,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 160.400  *Section 305 Meeting* Before Report of Criminal Violation,,08/30/1989,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 400.700 Drug Product Entries in Periodic Publications,,08/01/1989,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 160.700 Reconditioning of Foods Adulterated Under 402(a)(4),,07/20/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"CPG Sec 560.300 Reconditioning of Imported, Insect Infested, Insect Damaged or Moldy Coffee Beans",,07/19/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Import",Final,No,,
CPG Sec 560.350 Coffee and Cocoa Bean Sweeps,,07/19/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Import",Final,No,,
CPG Sec 560.100 Importation of Unlabeled Foods - Exemption Under *21 CFR 101.100(d)*,,07/18/1989,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Import",Final,No,,
Metaproterenol Sulfate and Albuterol Metered Dose Inhalers In Vitro,PDF (743.81 KB)PDF (743.81 KB) of Metaproterenol Sulfate and Albuterol Metered Dose Inhalers In Vitro,06/27/1989,Center for Drug Evaluation and Research,Biopharmaceutics,Final,No,,
CPG Sec. 690.500  Uncooked Meat for Animal Food (Withdrawn 4/30/2019),,05/23/1989,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,
Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 1 ),PDF (925.48 KB)PDF (925.48 KB) of Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 1 ),03/01/1989,Center for Devices and Radiological Health,Radiology,Final,No,,FDA-2018-D-4115
Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 2),PDF (1.08 MB)PDF (1.08 MB) of Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 2),03/01/1989,Center for Devices and Radiological Health,Radiology,Final,No,,FDA-2018-D-4115
Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 3),PDF (1.08 MB)PDF (1.08 MB) of Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (Part 3),03/01/1989,Center for Devices and Radiological Health,,Final,No,,FDA-2018-D-4115
Clarification of Radiation Control Regulations for Diagnostic X-Ray Equipment (FDA 89-8221),,02/28/1989,,Radiology,Final,No,,
CPG Sec 562.100 Acetic Acid - Use in Foods - Labeling of Foods in Which Used,,02/01/1989,Human Foods Program,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 562.600 Preservatives; Use in Nonstandardized Foods; Label Declaration,,02/01/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 562.700 Labeling of Food Bearing Residues of Pesticide Chemicals,,02/01/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 562.750 Labeling of Food Articles Distributed Solely in Puerto Rico,,02/01/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 562.800 Vending Machine Food - Labeling,,02/01/1989,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Labeling",Final,No,,
"CPG Sec 555.550 Foods, Standardized; Enriched or Fortified - Adulteration Involving Misbranding - Potency","PDF (9.24 KB)PDF (9.24 KB) of CPG Sec 555.550 Foods, Standardized; Enriched or Fortified - Adulteration Involving Misbranding - Potency",02/01/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"CPG Sec 555.850 Water Damaged Food Products in Screw-Top, Crimped-Cap and Similar Containers","PDF (11.42 KB)PDF (11.42 KB) of CPG Sec 555.850 Water Damaged Food Products in Screw-Top, Crimped-Cap and Similar Containers",02/01/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
Guidance for Oxygen Conserving Device 510(k) Review 73 BZD 868.5905 Non-continuous Ventilator Class II,PDF (99.57 KB)PDF (99.57 KB) of Guidance for Oxygen Conserving Device 510(k) Review 73 BZD 868.5905 Non-continuous Ventilator Class II,02/01/1989,Center for Devices and Radiological Health,"Premarket, 510(k)",Final,No,,FDA-2020-D-0957
CPG Sec 555.100 Alcohol; Use of Synthetic Alcohol in Foods,,01/31/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"CPG Sec 555.750 Seeds for Sprouting Prior to Food Use, i.e., Dried Mung Beans, Alfalfa Seeds, Etc.",,01/31/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"CPG Sec 555.800 Polysorbates 20, 40, 60, 65, 80, 85 - Common or Usual Names",,01/31/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 555.875 Water in Food Products (Ingredient or Adulterant),,01/31/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"CPG Sec 562.650 ""Processing"" - Use of Term in Section 405 of the FD&C Act",,01/31/1989,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 570.550 Reconditioning - Tree Nuts Contaminated with E. coli,,12/09/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,
CPG Sec 585.100 Artichoke; Jerusalem Artichoke - Common or Usual Name,,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.525: Mushroom Mycelium - Fitness for Food; Labeling,,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.600 Peas and Carrots, Labeling of Canned Mixture",,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.625 Canned Peas - Label Designation of Sizes,,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.650 Canned Pimentos and Red Sweet Peppers - Seeds Should be Removed,,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.710 Potato Chips, Ingredients - Labeling",,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.725 ""Pumpkin"" - Labeling Articles Made from Certain Varieties of Squash",,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.800 Squash Seeds - Labeling as Pumpkin Seeds,,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.850 Sweet Potatoes - Sirup Pack,,12/08/1988,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement,",Final,No,,
"CPG Sec 585.150 Asparagus, Canned or Frozen - Adulteration with Insect Filth","PDF (9.84 KB)PDF (9.84 KB) of CPG Sec 585.150 Asparagus, Canned or Frozen - Adulteration with Insect Filth",12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.260 Broccoli, Frozen - Adulteration with Insects","PDF (8.85 KB)PDF (8.85 KB) of CPG Sec 585.260 Broccoli, Frozen - Adulteration with Insects",12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 585.350 Corn Husks (for Tamales) - Adulteration with Filth,PDF (8.76 KB)PDF (8.76 KB) of CPG Sec 585.350 Corn Husks (for Tamales) - Adulteration with Filth,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
"CPG Sec 585.450 Greens, Canned - Adulteration by Mildew","PDF (8.82 KB)PDF (8.82 KB) of CPG Sec 585.450 Greens, Canned - Adulteration by Mildew",12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Spices, Flavors &  Salts",Final,No,,
CPG Sec 585.700 Potato Chips - Adulteration with Rot,PDF (8.71 KB)PDF (8.71 KB) of CPG Sec 585.700 Potato Chips - Adulteration with Rot,12/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Vegetable Products",Final,No,,
CPG Sec 570.100 Jordan Almonds - Common or Usual Name,,12/02/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,
"CPG Sec 570.250 Cashews, Insect Infested - Reconditioning",,12/02/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Nuts & Nut Products",Final,No,,
CPG Sec. 350.100 Packaging Technologies and Tamper-Resistant Packaging Requirements for Contact Lens Solutions and Tablets,,11/21/1988,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
CPG Sec 510.100 Beverage Bases,,11/01/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
"Seventh of a series of letters about the Act providing guidance on the ""130-day exclusivity"" provision of section 505(j)(4)(B)(iv) of the FD&C",,07/29/1988,Center for Drug Evaluation and Research,Generic Drugs,Final,No,,
Format and Content of the Clinical and Statistical Sections of an Application,PDF (1.09 MB)PDF (1.09 MB) of Format and Content of the Clinical and Statistical Sections of an Application,07/01/1988,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
CPG Sec 545.200 Confectionery Decorations (Nutritive and Non-Nutritive),,06/27/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 578.200 Corn Meal - Adulteration by Insect and Rodent Filth,PDF (10.3 KB)PDF (10.3 KB) of CPG Sec 578.200 Corn Meal - Adulteration by Insect and Rodent Filth,06/06/1988,Human Foods Program,"Investigation & Enforcement, Grain/Grain Product",Final,No,,
CPG Sec 578.300 Wheat - Adulteration by Insect and Rodent filth,PDF (12.18 KB)PDF (12.18 KB) of CPG Sec 578.300 Wheat - Adulteration by Insect and Rodent filth,06/06/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Grain/Grain Product",Final,No,,
"CPG Sec 515.800 Labeling of Products Purporting to be ""Chocolate"" or ""Chocolate Flavored""",,05/12/1988,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Chocolate/Cocoa Product",Final,No,,
CPG Sec. 160.200  FDA Use of Income Tax Information from IRS in Compliance Activity,,04/20/1988,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 150.100  Requests for Portions of Intermediate or End Products Resulting from FDA Sample Analysis,,03/22/1988,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
"CPG Sec 505.200 ""Butter"" Featured in Product Name",,03/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Bakery Product/Mix",Final,No,,
"CPG Sec 505.300 ""Butter-Nut"" Bread",,03/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Bakery Product/Mix",Final,No,,
"CPG Sec 505.350 Honey Bread, Honey Buns",,03/08/1988,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Bakery Product/Mix",Final,No,,
Guide for Establishing and Maintaining a Calibration Constancy Intercomparison System for Microwave Oven Compliance Survey Instruments (FDA 88-8264)] (PDF Only),PDF (826.14 KB)PDF (826.14 KB) of Guide for Establishing and Maintaining a Calibration Constancy Intercomparison System for Microwave Oven Compliance Survey Instruments (FDA 88-8264)] (PDF Only),03/01/1988,,Radiological Health,Final,No,,
Quality Control Guide for Sunlamp Products (FDA 88-8234),PDF (4.17 MB)PDF (4.17 MB) of Quality Control Guide for Sunlamp Products (FDA 88-8234),03/01/1988,Center for Devices and Radiological Health,"Tanning Lamps, Booths & Beds",Final,No,,FDA-2020-D-0957
CPG Sec 578.450 Wheat Flour-Adulteration with Insect Fragments and Rodent Hairs,PDF (10.09 KB)PDF (10.09 KB) of CPG Sec 578.450 Wheat Flour-Adulteration with Insect Fragments and Rodent Hairs,12/31/1987,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Grain/Grain Product",Final,No,,
Recommendations for the Management of Donor and Units that are Initially Reactive for Hepatitis B Surface Antigen (HBsAg),PDF (204.4 KB)PDF (204.4 KB) of Recommendations for the Management of Donor and Units that are Initially Reactive for Hepatitis B Surface Antigen (HBsAg),12/02/1987,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2013-S-0613
CPG Sec 565.200 Red Meat Adulterated with PCBs,,11/10/1987,Office of Inspections and Investigations,"Investigation & Enforcement, Meat/Meat Products & Poultry",Final,No,,
Class II and IIIA Laser Light Show Projectors and Shows (Laser Notice 40),PDF (194.21 KB)PDF (194.21 KB) of Class II and IIIA Laser Light Show Projectors and Shows (Laser Notice 40),10/29/1987,Center for Devices and Radiological Health,"Laser Notice, Laser Notice",Final,No,,FDA-2020-D-0957
CPG Sec. 160.600  Payment of Expert Witnesses,,10/15/1987,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 460.600 Content Uniformity Testing of Tablets and Capsules,,10/02/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec 567.200 Pork and Beans and Similar Bean Products - Labeling,,10/01/1987,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec. 325.100 Karaya Gum Powder and Related Devices for Use by Ostomates,,09/24/1987,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Safety - Issues, Errors, and Problems",Final,No,,FDA-2020-D-0957
CPG Sec. 345.200 Diaphragms - Rx Devices,,09/24/1987,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Labeling",Final,No,,FDA-2020-D-0957
CPG Sec. 300.100 Inspection of Manufacturers of Device Components,,09/23/1987,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
CPG Sec. 300.600 Commercial Distribution with Regard to Premarket Notification (Section 510(k)),,09/23/1987,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
CPG Sec. 320.100 Ear Piercing Devices,,09/23/1987,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
CPG Sec. 410.100 *Finished Dosage Form Drug Products in Bulk Containers - Applications of Current Good Manufacturing Practice Regulations*,,09/04/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 425.100 Computerized Drug Processing; CGMP Applicability to Hardware and Software*,,09/04/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 425.200 Computerized Drug Processing; Vendor Responsibility,,09/04/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 425.400 Computerized Drug Processing; Input/Output Checking,,09/04/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
"CPG Sec. 425.500 Computerized Drug Processing; Identification of ""Persons"" on Batch Production and Control Records",,09/04/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
"CPG Sec 567.100 Antipasto, Common or Usual Name",,09/01/1987,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
"CPG Sec 567.300 *Bouillon, Bouillon Cubes, Granulated Bouillon*",,09/01/1987,Human Foods Program,"Investigation & Enforcement,",Final,No,,
"CPG Sec. 100.100  Responsibility for Reporting Possible or Potential Violations of Laws Administered by FDA, Regulations Issued by FDA, Other Possible or Potential Hazards to the Public Health",,09/01/1987,,"Investigation & Enforcement, Administrative / Procedural, Food & Color Additives",Final,No,,
CPG Sec. 100.300  *Non-FDA Regulated Products Involving Communicable Disease Hazards*,,09/01/1987,,"Investigation & Enforcement, Food & Color Additives, Safety - Issues, Errors, and Problems",Final,No,,
CPG Sec. 100.350  FDA Jurisdiction on Indian Reservations,,08/31/1987,,"Investigation & Enforcement, Food & Color Additives",Final,No,,
User Instructions - Multi Axis Workstations (Laser Notice 39),PDF (101.68 KB)PDF (101.68 KB) of User Instructions - Multi Axis Workstations (Laser Notice 39),06/24/1987,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
CPG Sec. 655.100  Devices for Use in Animals,,06/01/1987,"Center for Veterinary MedicineOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Global Policy and Strategy","Investigation & Enforcement, Animal Devices",Final,No,,
CPG Sec. 655.300  Barking Dog Collar (Withdrawn 2/20/2020),,06/01/1987,"Center for Veterinary MedicineOffice of the Commissioner,Office of Policy, Legislation, and International Affairs,Office of Global Policy and Strategy","Investigation & Enforcement, Animal Devices",Final,No,,
CPG Sec. 655.400  The Status of Syringes and Needles for Animal Use (Withdrawn 2/20/2020),,06/01/1987,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Devices",Final,No,,
Color Additive Petitions - Medical Devices,PDF (90.74 KB)PDF (90.74 KB) of Color Additive Petitions - Medical Devices,06/01/1987,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Master Files Part III - Guidance on Scientific and Technical Information,PDF (317.65 KB)PDF (317.65 KB) of Master Files Part III - Guidance on Scientific and Technical Information,06/01/1987,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
CPG Sec. 400.335 Fructose-Containing Drugs,,05/22/1987,Office of Regulatory Affairs,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec. 430.300 Labeling Shipping Containers of Drugs,,05/22/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 450.400 Labeling and Distribution of OTC Drugs in Vending Machines,,05/22/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 454.100 OTC Ear Drop Preparations,,05/22/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
"CPG Sec. 455.100 Inert Glandular Preparations *(OTC)*, Inadequate Full Disclosure and Claims",,05/22/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 460.450 Status of Mail-Order Filling of Prescriptions,,05/21/1987,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 425.300 Computerized Drug Processing; Source Code for Process Control Application Programs,,04/15/1987,,"Investigation & Enforcement,",Final,No,,
"All U.S. Condom Manufacturers, Importers and Repackagers","PDF (93.76 KB)PDF (93.76 KB) of All U.S. Condom Manufacturers, Importers and Repackagers",04/07/1987,Center for Devices and Radiological Health,"Postmarket, Premarket,",Final,No,,FDA-2020-D-0957
Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application,PDF (519.21 KB)PDF (519.21 KB) of Format and Content of the Human Pharmacokinetics and Bioavailability Section of an Application,02/01/1987,Center for Drug Evaluation and Research,Clinical - Pharmacology,Final,No,,
"Formatting, Assembling and Submitting New Drug and Antibiotic Applications*","PDF (1.7 MB)PDF (1.7 MB) of Formatting, Assembling and Submitting New Drug and Antibiotic Applications*",02/01/1987,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
GUIDELINE FOR SUBMITTING SUPPORTING DOCUMENTATION IN DRUG APPLICATIONS FOR THE MANUFACTURE OF DRUG PRODUCTS,PDF (739.87 KB)PDF (739.87 KB) of GUIDELINE FOR SUBMITTING SUPPORTING DOCUMENTATION IN DRUG APPLICATIONS FOR THE MANUFACTURE OF DRUG PRODUCTS,02/01/1987,Center for Drug Evaluation and Research,,Final,No,,FDA-1985-D-0033
Summary for New Drug and Antibiotic Applications--Format and Content of the Summary for New Drug and Antibiotic Applications,PDF (1.25 MB)PDF (1.25 MB) of Summary for New Drug and Antibiotic Applications--Format and Content of the Summary for New Drug and Antibiotic Applications,02/01/1987,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
Format and Content of the Nonclinical Pharmacology/Toxicology Section of an Application*:  Guidance for Industry,PDF (1.27 MB)PDF (1.27 MB) of Format and Content of the Nonclinical Pharmacology/Toxicology Section of an Application*:  Guidance for Industry,02/01/1987,Center for Drug Evaluation and Research,Pharmacology/Toxicology,Final,No,,
Policy on Lamp Compatibility (sunlamps),PDF (65.83 KB)PDF (65.83 KB) of Policy on Lamp Compatibility (sunlamps),09/02/1986,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
CPG Sec 590.600 Wigs Compliance Policy Guide 7128.05,,09/01/1986,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 605.100 - Use of Statements Regarding NADA Approval by FDA in  Labeling and Advertising of New Animal Drugs (Withdrawn 2/20/2020),,08/31/1986,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs, Labeling",Final,No,,
CPG Sec. 680.200  CGMP Regulations for Medicated Feeds - Daily Inventory Requirements (Withdrawn 2/20/2020),,06/30/1986,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Medicated Feed",Final,No,,
CPG Sec. 670.100  Refusals of Formula Information During Inspection of Feed Mills Manufacturing Feeds Requiring Approved Medicated Feed Applications (Withdrawn 6/30/2020),,05/31/1986,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Medicated Feed",Final,No,,
CPG Sec. 670.200  Status of Vitamins and Minerals in Type B and C Medicated Feed and in Non-Medicated Feed (Withdrawn 2/20/2020),,05/31/1986,Center for Veterinary MedicineOffice of Regulatory Affairs,Medicated Feed,Final,No,,
CPG Sec. 680.400  Medicated Feeds -- Combined Batches,,05/31/1986,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Medicated Feed",Final,No,,FDA-2021-D-0644
Walk-In Workstations (Laser Notice 37),PDF (85.64 KB)PDF (85.64 KB) of Walk-In Workstations (Laser Notice 37),10/21/1985,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Policy On Maximum Timer Interval and Exposure Schedule For Sunlamp Products,PDF (182.17 KB)PDF (182.17 KB) of Policy On Maximum Timer Interval and Exposure Schedule For Sunlamp Products,08/21/1985,Center for Devices and Radiological Health,"Tanning Lamps, Booths & Beds",Final,No,,FDA-2020-D-0957
CVM GFI #23 Medicated Free Choice Feeds--Manufacturing Control,,06/30/1985,Center for Veterinary Medicine,"Chemistry, Manufacturing, and Controls (CMC), Current Good Manufacturing Practice (CGMP)",Final,No,,FDA-2021-D-0623
Policy on Warning Label Required on Sunlamp Products,PDF (71.19 KB)PDF (71.19 KB) of Policy on Warning Label Required on Sunlamp Products,06/25/1985,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
User Instruction Hazard Warnings (Laser Notice 35),PDF (62.8 KB)PDF (62.8 KB) of User Instruction Hazard Warnings (Laser Notice 35),02/05/1985,Center for Devices and Radiological Health,Laser Notice,Final,No,,FDA-2020-D-0957
Medical Laser Delivery System Interlocks (Laser Notice 34),PDF (90.27 KB)PDF (90.27 KB) of Medical Laser Delivery System Interlocks (Laser Notice 34),01/20/1985,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
CVM GFI #13  Evaluation of Effectiveness of New Animal Drugs for Use in Free-Choice Feeds-Medicated Block,,12/31/1984,Center for Veterinary Medicine,"Animal Feed, Target Animal – Effectiveness",Final,No,,FDA-2021-D-0624
Plasma Derived from Therapeutic Plasma Exchange,PDF (15.85 KB)PDF (15.85 KB) of Plasma Derived from Therapeutic Plasma Exchange,12/14/1984,Center for Biologics Evaluation and Research,"Blood, Blood Products",Final,No,,FDA-2013-S-0613
CVM GFI #38 Guideline for Effectiveness Evaluation of Topical/Otic Animal Drugs,,08/20/1984,Center for Veterinary Medicine,Target Animal – Effectiveness,Final,No,,FDA-2021-D-0625
Enforcement Policy on Marketing OTC Combination Products (CPG 7132b.16).,PDF (293.59 KB)PDF (293.59 KB) of Enforcement Policy on Marketing OTC Combination Products (CPG 7132b.16).,05/01/1984,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,
Nuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment,PDF (3.46 MB)PDF (3.46 MB) of Nuclear Pharmacy Guideline Criteria for Determining When to Register as a Drug Establishment,05/01/1984,Center for Drug Evaluation and Research,"Compliance,",Final,No,,FDA-1975-N-0008
CVM GFI #37 Evaluation of Effectiveness of New Animal Drugs for Use in Poultry Feed for Pigmentation,,02/29/1984,Center for Veterinary Medicine,"Animal Feed, Target Animal – Effectiveness",Final,No,,FDA-2021-D-0626
CPG Sec 430.100 Unit Dose Labeling for Solid and Liquid Oral Dosage Forms,,01/31/1984,"Center for Drug Evaluation and Research,Office of Pharmaceutical Quality","Investigation & Enforcement,",Final,No,,
CVM GFI #24 Drug Combinations for Use in Animals,,09/30/1983,Center for Veterinary Medicine,Target Animal – Effectiveness,Final,No,,FDA-2021-D-0627
"CPG Sec. 398.450 Applicability of Positive Beam Limitation (PBL) Requirements When PBL is Provided on ""Other than Stationary General Purpose"" Radiographic System",,07/31/1983,Center for Devices and Radiological HealthOffice of Regulatory Affairs,"Investigation & Enforcement, Radiology",Final,No,,FDA-2020-D-0957
CPG Sec. 450.550 Control and Accountability of Labeling Associated with Tamper-Resistant Packaging of Over-the-Counter Drug Products,,03/01/1983,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 682.200  The Use of Antibiotic Drug Residue By-Products in Animal Feed Feed (Withdrawn 2/20/2020),,09/30/1982,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,FDA-2021-D-0645
"CPG Sec. 615.300  Responsibility for Illegal Drug Residues in Meat, Milk and Eggs",,06/30/1982,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs, Human Food Safety",Final,No,,FDA-2021-D-0646
Clinical Evaluation of General Anesthetics,,05/01/1982,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
CPG Sec. 450.100 CGMP Enforcement Policy - OTC vs Rx Drugs,PDF (59.71 KB)PDF (59.71 KB) of CPG Sec. 450.100 CGMP Enforcement Policy - OTC vs Rx Drugs,04/01/1982,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 688.100  Unapproved Additives for Exported Grains,,01/31/1982,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed, Export",Final,No,,
Procedures for Laboratory Testing of Microwave Ovens,PDF (704.99 KB)PDF (704.99 KB) of Procedures for Laboratory Testing of Microwave Ovens,10/01/1981,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Exemption from Reporting and Record keeping Requirements for Certain Sunlamp Product Manufacturers,PDF (74.01 KB)PDF (74.01 KB) of Exemption from Reporting and Record keeping Requirements for Certain Sunlamp Product Manufacturers,09/16/1981,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
CPG Sec. 430.200 Repacking of Drug Products - Testing/Examination under CGMPs,,07/01/1981,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
Investigational Medical Laser Significant Risk Device (Laser Notice 31),PDF (116.98 KB)PDF (116.98 KB) of Investigational Medical Laser Significant Risk Device (Laser Notice 31),05/18/1981,Center for Devices and Radiological Health,Laser Notice,Final,No,,FDA-2020-D-0957
Clinical Evaluation of Antiepileptic Drugs (adults and children),PDF (1007.13 KB)PDF (1007.13 KB) of Clinical Evaluation of Antiepileptic Drugs (adults and children),01/01/1981,Center for Drug Evaluation and Research,"Clinical - Medical, Pediatric Product Development",Final,No,,
CPG Sec 500.100 Additives - Labeling with Adequate Directions for Many Uses,,10/01/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 510.200 Brandy Containing Methyl Alcohol - Food Additive,,10/01/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
"CPG Sec 510.300 Unfermented Beverages - Use of Word ""Champagne""",,10/01/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Beverage Bases/Conc/Nectar",Final,No,,
CPG Sec 515.300 Honey - Source Declaration,,10/01/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Candy/Gum (without chocolate)",Final,No,,
CPG Sec 515.350 Candy - Mixed with Trinkets and Sold in Vending Machines,,10/01/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Candy/Gum (without chocolate)",Final,No,,
"CPG Sec 515.500 Barley Sugar - Definition, and Barley Sugar Candy",,10/01/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Candy/Gum (without chocolate)",Final,No,,
CPG Sec 525.750 Spices - Definitions,,10/01/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 540.475 Snapper - Labeling,,10/01/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
CPG Sec 560.450 Imported Low-Acid Canned Foods (Manufacturer Not Registered and/or No Scheduled Process Filed),,10/01/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Import",Final,No,,
"CPG Sec 560.500 Jams, Jellies and Related Products - Imports",,10/01/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Import",Final,No,,
"CPG Sec 562.450 Identity of Foods - Use of Terms Such as Fresh, Frozen, Dried, Canned, Etc.",,10/01/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec 578.100 Starches - Common or Usual Names,,10/01/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Grain/Grain Product",Final,No,,
CPG Sec 578.350 Wheat for Human Consumption - Reconditioning,,10/01/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Grain/Grain Product",Final,No,,
CPG Sec. 110.100 Certification for Exports (Withdrawn 11/04/2021),,10/01/1980,Office of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,FDA-1996-D-0405
"CPG Sec. 400.325 Candy ""Pills"" Representation as Drug",,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 400.600 Drugs - Declaration of Quantity of Active Ingredient by Both Metric and Apothecary Systems,,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement, Labeling",Final,No,,
CPG Sec. 400.800 Collection and Charitable Distribution of Drugs,,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 400.900 Class I Recalls of Prescription Drugs,,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 420.400 Performance of Tests for Compendial Requirements on Compendial Products,,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 442.100 New Drugs - Export,,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 444.100 Recovery of Investigational New Drugs from Clinical Investigators,,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 460.100 Hospital Pharmacies - Status as Drug Manufacturer,,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 460.300 Return of Unused Prescription Drugs to Pharmacy Stock,,10/01/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,None found
CPG Sec. 690.400  Water and Gravy in Pet Food (Withdrawn 2/20/2020),,10/01/1980,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Pet Food",Final,No,,
CPG Sec 390.100 Definition of “Commerce” - 21 CFR 1000.3(d) 2,PDF (16.41 KB)PDF (16.41 KB) of CPG Sec 390.100 Definition of “Commerce” - 21 CFR 1000.3(d) 2,10/01/1980,Office of Regulatory AffairsCenter for Devices and Radiological Health,"Investigation & Enforcement,",Final,No,,
CPG Sec 555.450 Foods - Adulteration Involving Infestation and 1080 Rodenticide,PDF (8.99 KB)PDF (8.99 KB) of CPG Sec 555.450 Foods - Adulteration Involving Infestation and 1080 Rodenticide,10/01/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 555.500 All Food Sanitation (Including Bacteriological) Inspections - Classification of Establishment,PDF (10.31 KB)PDF (10.31 KB) of CPG Sec 555.500 All Food Sanitation (Including Bacteriological) Inspections - Classification of Establishment,10/01/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec 578.400 Treated Grain Seed - Mercury Residue,PDF (8.55 KB)PDF (8.55 KB) of CPG Sec 578.400 Treated Grain Seed - Mercury Residue,10/01/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Grain/Grain Product",Final,No,,
CPG 230.120- Human Blood and Blood Products as Drugs,,09/30/1980,Office of Regulatory Affairs,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec 520.200 Canned Foods - Seam Defects,,09/30/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Canned Foods",Final,No,,
CPG Sec 525.650 Labeling of Seasonings,,09/30/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dressing/Condiment",Final,No,,
CPG Sec 527.450 Milk & Milk Products Containing Penicillin,,09/30/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Dairy",Final,No,,
CPG Sec 540.285 Crabmeat Products - Labeling; Crabmeat Products with Added Fish or Other Seafood Ingredients - Labeling,,09/30/1980,Office of Inspections and InvestigationsHuman Foods Program,"Investigation & Enforcement, Seafood/Seafood Product",Final,No,,
CPG Sec 550.550 Maraschino Cherries,,09/30/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 550.575 Marmalade,,09/30/1980,Human Foods Program,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 550.625 Oranges - Artificial Coloring,,09/30/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement, Fruit/Fruit Product",Final,No,,
CPG Sec 555.200 Adulterated Food Mixed with Good Food,,09/30/1980,Human Foods ProgramOffice of Inspections and Investigations,"Investigation & Enforcement,",Final,No,,
CPG Sec. 110.500  Food and Drug Guaranty - Imports,,09/30/1980,Office of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 130.100  Inspectional Authority; Refusal to Permit Inspection.,,09/30/1980,,"Investigation & Enforcement, Food & Color Additives",Final,No,,
"CPG Sec. 251.100 Schedule of Physical Examination for Donors Receiving Immunization Injections (Obsolete, Withdrawn on 11/28/2017)",,09/30/1980,,"Investigation & Enforcement, Blood Products",Final,No,,
CPG Sec. 398.400 Automatic Adjustment of the X-ray Field Size to the Selected Spot-Film Size - 21 CFR 1020.31(g)(1),,09/30/1980,,"Investigation & Enforcement, Radiology",Final,No,,
CPG Sec. 420.200 Compendium Revisions and Deletions,,09/30/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 420.300 Changes in Compendial Specifications and NDA Supplements withdrawn on 8/30/12,,09/30/1980,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 460.400 Computerized Prescription Recordkeeping by Pharmacies,,09/30/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 460.425 Prescription Status when Telephoned to Recording Machine,,09/30/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 460.500 Prescription Drugs for Ship's Medicine Chests,,09/30/1980,Center for Drug Evaluation and Research,"Investigation & Enforcement,",Final,No,,
CPG Sec. 625.200  Availability of Bulk Chemicals for Animal Drug Use (Withdrawn 4/14/2022),,09/30/1980,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Drugs",Final,No,,FDA-2021-D-0647
CPG Sec. 655.200  Adequate Directions for Use - Animal Drugs & Veterinary Devices (Withdrawn 2/20/2020),,09/30/1980,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Devices, Animal Drugs, Labeling",Final,No,,
CPG Sec. 660.100  Failure to Register (Withdrawn 2/20/2020),,09/30/1980,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement,",Final,No,,
CPG Sec. 682.100  Use of Drug-Contaminated Products in Animal Feed (Withdrawn 2/20/2020),,09/30/1980,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Animal Feed",Final,No,,
CPG Sec. 690.200  Pet Food Labeling (Withdrawn 2/20/2020),,09/30/1980,Center for Veterinary MedicineOffice of Regulatory Affairs,"Investigation & Enforcement, Labeling, Pet Food",Final,No,,
Alternate Wording For Caution Statement (Laser Notice 30),PDF (70.66 KB)PDF (70.66 KB) of Alternate Wording For Caution Statement (Laser Notice 30),08/25/1980,Center for Devices and Radiological Health,Radiology,Final,No,,FDA-2020-D-0957
Quality Control Practices for Compliance with the Federal Mercury Vapor Lamp Performance Standard,PDF (1.81 MB)PDF (1.81 MB) of Quality Control Practices for Compliance with the Federal Mercury Vapor Lamp Performance Standard,05/01/1980,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Open Door Operation of Microwave Ovens as a Result of Oven Miswiring,PDF (178.41 KB)PDF (178.41 KB) of Open Door Operation of Microwave Ovens as a Result of Oven Miswiring,03/28/1980,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
"Exemption of Certain Lasers Used By DOE, NOAA and U.S. Dept. of Commerce (Laser Notice 25)","PDF (116.62 KB)PDF (116.62 KB) of Exemption of Certain Lasers Used By DOE, NOAA and U.S. Dept. of Commerce (Laser Notice 25)",09/14/1979,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
"Good Laboratory Practice Regulations Management Briefings, Post Conference Report, Aug 1979:  Guidance for Industry",,08/31/1979,Center for Veterinary MedicineHuman Foods ProgramOffice of Inspections and InvestigationsCenter for Biologics Evaluation and ResearchCenter for Devices and Radiological HealthCenter for Drug Evaluation and Research,"Clinical Trials, Compliance, Food & Color Additives, Investigational New Drug Application (INDA), Pharmacology/Toxicology",Final,No,,FDA-1976-N-0476-0380
General Guidelines for OTC Combination Products,PDF (270.2 KB)PDF (270.2 KB) of General Guidelines for OTC Combination Products,11/01/1978,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,
Upgrading Category III Antiperspirants to Category I (43 FR 46728-46731),PDF (582.91 KB)PDF (582.91 KB) of Upgrading Category III Antiperspirants to Category I (43 FR 46728-46731),10/01/1978,Center for Drug Evaluation and Research,Over-the-Counter Drugs,Final,No,,
Guidance ('Guidelines') for Evaluation of Hysteroscopic Sterilization Devices,PDF (19.79 KB)PDF (19.79 KB) of Guidance ('Guidelines') for Evaluation of Hysteroscopic Sterilization Devices,05/09/1978,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Laser Light Shows Subject to Laser Product Performance Standard (Laser Notice 22),PDF (154.43 KB)PDF (154.43 KB) of Laser Light Shows Subject to Laser Product Performance Standard (Laser Notice 22),11/23/1977,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Antidepressant Drugs--Clinical Evaluation,,09/01/1977,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
Hypnotic Drugs--Clinical Evaluation,PDF (1.7 MB)PDF (1.7 MB) of Hypnotic Drugs--Clinical Evaluation,09/01/1977,Center for Drug Evaluation and Research,Clinical - Medical,Final,No,,
Procedures for Field Testing Microwave Ovens,PDF (2.73 MB)PDF (2.73 MB) of Procedures for Field Testing Microwave Ovens,08/01/1977,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Warning Labels For Dye And Multiple Wavelength Lasers (Laser Notice 16),PDF (83.75 KB)PDF (83.75 KB) of Warning Labels For Dye And Multiple Wavelength Lasers (Laser Notice 16),03/02/1977,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
Review Guidelines for Oxygen Generators and Oxygen Equipment for Emergency Use,,01/01/1977,Center for Devices and Radiological Health,"Premarket,",Final,No,,FDA-2020-D-0957
Lasers Manufactured and Used In-House (Laser Notice 14),PDF (54.95 KB)PDF (54.95 KB) of Lasers Manufactured and Used In-House (Laser Notice 14),11/23/1976,Center for Devices and Radiological Health,Laser Notice,Final,No,,FDA-2020-D-0957
Manufacture and Certification of Laser Kits (Laser Notice 13),PDF (85.79 KB)PDF (85.79 KB) of Manufacture and Certification of Laser Kits (Laser Notice 13),10/14/1976,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Remote Interlock Connectors (Laser Notice 11),PDF (62.34 KB)PDF (62.34 KB) of Remote Interlock Connectors (Laser Notice 11),10/07/1976,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Certain Military Lasers Exempt From 21 CFR 1040.10 & .11 (Laser Notice 9),PDF (89.53 KB)PDF (89.53 KB) of Certain Military Lasers Exempt From 21 CFR 1040.10 & .11 (Laser Notice 9),08/23/1976,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
Viewing Optics - Sighting Telescope (Laser Notice 8),PDF (70.59 KB)PDF (70.59 KB) of Viewing Optics - Sighting Telescope (Laser Notice 8),08/05/1976,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Quality Control Practices for Compliance with the Federal Laser Performance Standard,PDF (1.07 MB)PDF (1.07 MB) of Quality Control Practices for Compliance with the Federal Laser Performance Standard,03/01/1976,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Laser Energy Source (Laser Notice 2),PDF (39.92 KB)PDF (39.92 KB) of Laser Energy Source (Laser Notice 2),11/21/1975,Center for Devices and Radiological Health,,Final,No,,FDA-2020-D-0957
Guidance for the Submission of Cabinet X-Ray System Reports Pursuant to 21-CFR 1020.40,PDF (651.51 KB)PDF (651.51 KB) of Guidance for the Submission of Cabinet X-Ray System Reports Pursuant to 21-CFR 1020.40,02/01/1975,Center for Devices and Radiological Health,Radiological Health,Final,No,,FDA-2020-D-0957
CPG Sec. 335.300 Hypnotherapy Devices - Self-Hypnotic Tape Recordings,PDF (89.52 KB)PDF (89.52 KB) of CPG Sec. 335.300 Hypnotherapy Devices - Self-Hypnotic Tape Recordings,01/01/1900,Office of Regulatory AffairsCenter for Devices and Radiological Health,"Investigation & Enforcement,",Final,No,,FDA-2020-D-0957
Chapter 1 - General,,,,"Investigation & Enforcement,",Final,No,,
Chapter 3 - Devices,,,,"Investigation & Enforcement,",Final,No,,
Chapter 4 - Human Drugs,,,,"Investigation & Enforcement,",Final,No,,
"CPG Sec. 257.100 Deferral of Source Plasma Donors Due To Red Cell Loss During Collection of Source Plasma by Automated Plasmapheresis (Obsolete, Withdrawn on 11/28/2017)",,,,"Investigation & Enforcement,",Final,No,,
"CPG Sec. 390.100 Definition of ""Commerce"" - 21 CFR 1000.3(d)",,,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 420.500 Interference with Compendial Tests,,,,"Investigation & Enforcement,",Final,No,,
CPG Sec. 460.700 Controlled Release Dosage Form Drugs - Rate of Release of Active Ingredients,,,,"Investigation & Enforcement,",Final,No,,
"Formas posológicas orales sólidas de liberación inmediata Cambios de escala y posteriores a la aprobación: documentación química, de fabricación y controles, de pruebas de disolución in vitro y bioequivalencia in vivo.",,,,,Final,No,,
"Guía para la Industria:  Formas de dosificación oral de liberación prolongada: elaboración, evaluación y aplicación de correlaciones in vitro/in vivo",,,,,Final,No,,
Guía para la Industria:  Pruebas de disolución de formas de dosificación oral sólidas de liberación inmediata.,,,,,Final,No,,
CHAPTER 48 - 7348.809 Bioresearch Monitoring,PDF (474.42 KB)PDF (474.42 KB) of CHAPTER 48 - 7348.809 Bioresearch Monitoring,,,,Final,No,,
Chapter 48 7348.809A Radioactive Drug Research Committee,PDF (537.33 KB)PDF (537.33 KB) of Chapter 48 7348.809A Radioactive Drug Research Committee,,,,Final,No,,
CPG Sec. 300.500 *Reprocessing of Single Use* Devices,PDF (86.4 KB)PDF (86.4 KB) of CPG Sec. 300.500 *Reprocessing of Single Use* Devices,,,"Investigation & Enforcement,",Final,No,,
Final In Vivo Bioavailability-Bioequivalence Studies- Analytical,PDF (664.54 KB)PDF (664.54 KB) of Final In Vivo Bioavailability-Bioequivalence Studies- Analytical,,,,Final,No,,
NEPA_Final_Guidance,PDF (41.92 KB)PDF (41.92 KB) of NEPA_Final_Guidance,,,,Final,No,,
New/Revised/Withdrawn Guidances 2014,PDF (46.79 KB)PDF (46.79 KB) of New/Revised/Withdrawn Guidances 2014,,,,Final,No,,
Sample WHO Certificate for Quality of a Pharmaceutical Product,PDF (104.47 KB)PDF (104.47 KB) of Sample WHO Certificate for Quality of a Pharmaceutical Product,,,"Investigation & Enforcement,",Final,No,,
